terms
heart failure ( class l - lll )
duration of hypertension  n ( % )
type $nmbr$ diabetes 一 no . ( % )
tofacitinib $nmbr$ mg bid [ n = $nmbr$ |
high - density lipoprotein cholesterol mean ( mg / dl ± sd )
temporary discontinuation of study drug
death  mi  idr  st  or any timi bleeding
race and ss at baseline
high intensity
prior percutaneous coronary intervention  n ( % )
pre - randomization pci
p  subgroup *
hosji fcrhypoglycemia
apixaban vs . placebo
medication use — no . ( % )
second prior mi
subarachnoid hemorrhage
total invasive cancer
acute stent thrombosis
alteplase ( n = $nmbr$ )
relative decrease > $nmbr$ %
$nmbr$ th - $nmbr$ th percentiles
number of ( % ) females
emphysema ( % )
argentina
ccq score § §
vents / patients
number of patients with
concomitant mtx —
europe / lsrael
thromboaspiration — no . ( % )
cardiac - biomarker status — no . / total no . ( % ) $
receiving insulin therapy
pulmonary embolism ± deep vein thrombosis
abdominal or perianal fistula at baseline  n ( % )
cyclosporine ( n = $nmbr$ )
geographic region - europe
indian ( indian subcontinent )
percutaneous coronary intervention
antiplatelet or anticoagulant therapy
lesion length  mean ( sd )  mm
non - q wave
continued thienopyridine n = $nmbr$ subjects
weight ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ]
left ventricular ejection fraction  % af history
single - vessel disease  n ( % )
geographic region — no . ( % )
pad lower extremities
bmi > $nmbr$ kg / m $nmbr$ ( % )
total gadolinium - enhancing lesion count  no . ( % )
fatigue
$nmbr$ to < $nmbr$ kg / m $nmbr$
st - elevation mi
azathioprine ( n = $nmbr$ )
serum uric acid ( mg / dl )
baseline mean ( sd )  % [ mmol / mol ]
cv death  ml  or stroke
atenolol ( « = $nmbr$ $nmbr$ )
previous antiarrhythmic treatment — no . ( % )
drugs used in diabetes  n ( % )
after pci
secukinumab
mean a ± sem ( % )
ppi but no aspirin
$nmbr$ mg / kg ( n = $nmbr$ )
family history of cad ( diagnosed at < $nmbr$ yr of age ) — no . ( % ) cigarette smoker — no . ( % )
trend / het . test
cv death + hf hospitalization
mepolizumab  $nmbr$ mg ( n = $nmbr$ )
medical therapy only ( n = $nmbr$ )
caucasian ethnicity
crcl at baseline < $nmbr$ ml / min
elevated hscrp > $nmbr$ mg / l  n ( % )
seizure types reported during baseline  n ( % ) a
median total cholesterol  mmol / l
mean ± sd bmi  kg / m $nmbr$
first mace
disease duration $nmbr$ to b $nmbr$ years ( n = $nmbr$ )
history of amputation — no . ( % )
lipid - lowering medication ( % )
previous hf hospitalization  n ( % )
mean lipid values  mg / dl
prior years taking warfarin
bnp  median ( iqr )  pg / ml
hba $nmbr$ ca  % ( mmol / mol )
latin america hr ( $nmbr$ % cl )
current atrial fibrillation or flutter on ecg
invasive
estimated glomerular filtration
pasi score ! * *
amiodarone  n ( % )
american indian or alaska
pooled simvastatin factorial studies
implantable cardioverter - defibrillator
varespladib ( n = $nmbr$ )
acute coronary event
ntpro - cnp ( ng / ml )
useofmedical therapyathospitaldischarge
coenzyme q $nmbr$  ^ g / ml #
dyspnoea - mmrc grade  n ( % )
triglycerides — mmol / liter
baseline ecrcl
cardiovascular history
with placebo ( n $nmbr$ $nmbr$ )
cardiovascular medications
after bronchodilation
mean $nmbr$ mwd *  m ( sd )
angiotensin - converting enzyme inhibitors / angiotensin receptor blockers
medication taken alone or in combination
etoricoxib dose
ischemic cerebrovascular disease  n ( % )
bare metal stent  n ( % )
mean age ( years ) ( s . d . )
das $nmbr$ ( esr )  mean ( sd )
absolute  litres
wml load at follow - up mri
clopidogrel ( n = $nmbr$  $nmbr$ )
ancestry ( % ) f
no p - blocker intake at randomisation ( n = $nmbr$ )
valsartan / hctz  n / n ( % )
> $nmbr$ oral agents
total chol  mg / dl
calcium channel blockers  n ( % )
bsa > $nmbr$ %  n ( % ) t
benralizumab $nmbr$ mg q $nmbr$ w ( n = $nmbr$ )
blood pressure  mean ( sd ) [ range ]  mm hg
atenolol n = $nmbr$
type of mi ( % )
mtx + non - mtx
concomitant corticosteroid use  n ( % )
estimated glomerular filtration rate ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$
mild impairment ( $nmbr$ to < $nmbr$ )
years since menopause
major cvd /
medical therapy ( n = $nmbr$ )
no . of tnfi among non - tnfi naive
use of ace inhibitor
haemorrhagic
stroke ( vs tia )
detemir / insulin glargine  %
screening prebronchodilator fev $nmbr$  l
stent plus placebo
coronary revascularization $nmbr$ days after randomization
sacubitril / valsartan
no . of prior bdmards
mean prebronchodilator fev $nmbr$ ( sd )  % predicted
paracetamol
aspirin / other antiplatelet agents  n ( % )
randomized to receive beta carotene
bsa  % *
erosion score
peripheral arterial disease  n ( % )
primary end point  no . of events / total no . ( % )
lvdd ( mm )
draining cutaneous fistula at baseline  n ( % )
tg < $nmbr$  hdl > $nmbr$ ( n = $nmbr$ )
comorbidities other than diabetes
toast classification of qualifying stroke
rasagiline  $nmbr$ mg / day
metabolic syndrome $nmbr$ baseline lipids  mg / dl
crude analysis  n ( % )
bypass surgery
missing — number / n ( % )
cholesterol  ( . $nmbr$ . $nmbr$ mmol / l )  n ( % )
right coronary
health habits
blood pressure
homa . % b  median ( ql  q $nmbr$ )  %
severity of copd  ( gold $nmbr$ )  %
prior myocardial infarction
both ptca and cabg
major cerebrovascular
hazard ratio ( $nmbr$ % cl ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )
diastolic blood pressure ( mm hg ) medications
iglar dose at randomization ( u / day )
prior cv event at randomization !
mean ± sd waist circumference  cm
risk of bleeding
cv medication  % of patients
total updrs score ( range  $nmbr$ - $nmbr$ ) 卞
atrial fibrillation  duration — no . ( % )
known duration of diabetes  yr
$nmbr$ % < hba $nmbr$ c < = $nmbr$ %
dactylitis count
previous disease :
previous dmards use  n ( % )
gly $nmbr$ . $nmbr$ gg b . i . d n / n ( % )
previous percutaneous coronary intervention
unfractionated heparin before randomisation
oad plus insulin
diabetes with target organ disease *
unknown type
beta - blocker — no . ( % )
cognitive functioning
( % ) $nmbr$ - $nmbr$
history of hyperlipidemia ( % )
evenls per $nmbr$  $nmbr$ palienl - years
fasting free fatty acids ( ^ mol / liter )
treatment after admission
rarertd antocagibtcn before andorrtzafon
intestinal area involved  n ( % ) $
ethnicity ( % )
all cardiovascular
smoking in the past year
diskus only  n
jsn score  mean $nmbr$ sd
number omega - $nmbr$ number placeb fatty acid
high - intensity statin vs medium - or low - intensity statin at randomization
score on nih stroke scale — median ( iqr )
initiation of insulin
$nmbr$ nd > $nmbr$ . $nmbr$ / < $nmbr$ . $nmbr$
cad and abi < $nmbr$ - $nmbr$ §
pioglitazone events / n ( % )
acecoumarol  no . ( % )
cigarette users
gfr ( mdrd ) ( ml / min / $nmbr$ - $nmbr$ m $nmbr$ )
bmi ( kg / m $nmbr$ ) cardiac parameters
ace inhibitor or arb at last follow - up
blood urea nitrogen ( mg / dl )
grip strength ( kg )
current smoker — no . of patients ( % )
one - third radius
psychosocial risk factors
bursitis
non - hdl - c in $nmbr$ classes
family history ol diabetes ?
age ( years ) : $nmbr$ - < $nmbr$
digital clubbing  n ( % )
death or myocardial infarction
risk reduction  %
a mini - mental state examination  omega - $nmbr$ fatty acids vs placebo
pain vas  $nmbr$ - $nmbr$ mm
smoking : ex - smoker
statin treatment
pre - bronchodilator fev $nmbr$ / fvc ratio *
prior stroke or transient ischemic attack
czp $nmbr$ mg ( n $nmbr$ $nmbr$ )
microvascular eye diseased
extent of disease  %
mean ( $nmbr$ % ci ) difference vs saxa + dapa + met
urgent coronary revascularization
caucasian simva
full analysis set
serious ae
smoking history ( ever )
uncodable
no pah therapy
standard ( n = $nmbr$ )
patent foramen ovale
laboratory values
years  mean ( sd )
hscrp < $nmbr$ . $nmbr$ mga . $nmbr$ ( $nmbr$ . $nmbr$ x $nmbr$ ( $nmbr$ . $nmbr$ )
physician ' s judgment that vka
calcium - channel blocker ( ratelowering )
left ventricular hypertrophy ( % )
randomized to aspirin use
antihypertensive  antianginal  and other cardiovascular medications
glp - $nmbr$ receptor agonist ( other than study drug )
primary renal endpoint or death
metabolic syndrome characteristics  n ( % )
mean duration of disease  years
other oral hypoglycemic drug ( s )
> $nmbr$ additional cv risk factors $nmbr$
pancolitis
death from any cause
high - density lipoprotein cholesterol  mg / l
diabetes mellitus status
fibrinolysis primary pci ( n = $nmbr$ ) ( n = $nmbr$ ) no . of patients / total no . ( % )
stool frequency subscore
psap - b ( ng / ml )
no use of $nmbr$ - asa compounds
visit $nmbr$ ldl cholesterol strata
endothelin $nmbr$ ( pg / ml )
normal ( egfr > $nmbr$ )
py = $nmbr$ . $nmbr$ )
fibrinogen
total haq  $nmbr$ - $nmbr$
mean baseline ibdq score ( sd ) § crp concentration  mg / l
dipyridamole
aspirin and other antiplatelet
positive
age [ years ] ( interaction : p = $nmbr$ . $nmbr$ )
decreased appetite
beta - blocker ( except sotalol )
geometric mean crp concentration ( mg / l )
duration of morning
hr ( enl vs lcz ) ( $nmbr$ % cl )
rf positive — number ( % )
selected medications — no . ( % )
no peripheral revascularization ( n = $nmbr$  $nmbr$ )
white / european
at least $nmbr$ flare
time to admission  min
octave sustain
lm bifurcation not treated
radial access
history of peripheral artery disease
baseline fev  ( l )
combined trials
negative
severe dysfunction
fasting c - peptide  ng / ml
aggressive ( n = $nmbr$ )
aldosterone blocker  %
management of event — no . ( % )
> $nmbr$ mg / dl chd status
serum albumin  g $nmbr$ $nmbr$
intraperitoneal
headache
left main artery
> $nmbr$ to < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a
established
gender ( % ) male / female
chondroitin sulfate ( n = $nmbr$ )
unstable angina ( biomarker negative )
american indian or native alaskan
symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !
age ( years ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ]
formoterol $nmbr$ gg bid
race or ethnic group ( % )
dihydropyridine
canakinumab
lev status  n ( % )
steroids § §
normal / mild ckd
number of stent = $nmbr$
previous medications  n ( % )
nyha class $nmbr$ - $nmbr$ : no { n = llll )
tofacitinib $nmbr$ mg twice daily n = $nmbr$
verapamil sr n = $nmbr$ no . ( % )
no prior ml or stroke
stent length per lesion  mm
chf history
anti - ccp antibody positive
oral medications
no antidiabetic drug
tofacitinib $nmbr$ mg two times a day
no . of $nmbr$ - mg acetaminophen tablets / day
acpa positive  %
timi major / minor
severity of airflow limitation ( gold $nmbr$ - $nmbr$ )  n ( % )
pooled simva
timi risk score — no . ( % ) : t
baseline dyspnea index  mean total score
number ( % ) of patients with event
atrial fibrillation onset
infarct characteristics
caucasian simva ( „ = $nmbr$ }
ticagrelor $nmbr$ mg $nmbr$ yr km %
galectin - $nmbr$ ( ng / ml )
hctz = hydrochlorothiazide . * based on wilcoxon $nmbr$ - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / $nmbr$ tests for categorical variables . t data were missing for some patients .
$nmbr$ mg clopidogrel load
intravenous dobutamine
family history of diabetes — no . ( % )
primary prevention subgroup
telmisartan ( n = $nmbr$  $nmbr$ )
ppi use ( p = $nmbr$ - $nmbr$ t )
large mi
never / rarely
medication adherence
no concomitant cortcosteroid use
severity of hypertensionb
clopidogrel  %
fev $nmbr$ percent predicted ( sd )
antidiabetic medication | |
gad positive — no . ( % ) ^
intravenous vasodilators ( % )
european trial
systemic corticosteroid use
weight  median ( interquartile range )  kg
indacaterol $nmbr$ ug versus placebo
crohn ’ s disease related surgery
peripheral arterial disease — no . ( % ) §
mases ( $nmbr$ - $nmbr$ )  mean ( sd )
duration of coronary artery disease — yr
hba $nmbr$ c  mean ( sd )  % [ mmol / mol ]
total cholesterol ( week $nmbr$ )
at least $nmbr$ severe flare
baseline / concomitant therapies
chd eze / simva ( n = $nmbr$ ]
heart failure criteria met
left atrial diameter
pulmonary function tests  % of predicted
other nsaids
rheumatic heart disease
coronary angiography and intervention
time of qualifying ecg to balloon inflation ( hrs )
time from symptoms to treatment
ratio fp / sal : sal ( $nmbr$ % ci )
coexisting conditions — no . ( % )
clopidogrel  ticlopidine  or prasugrel
crp ( mg / dl ) < $nmbr$ . $nmbr$
mean ± s . d . duration of diabetes  years
russia / georgia ( n = $nmbr$ )
fatal and nonfatal ml
hypertension ( n 二 $nmbr$ )
cv event  years
oxidative stress
age ( yrs ) < $nmbr$
no . of previous anti - tnf drugs — no . ( % )
< $nmbr$ . $nmbr$ mmol / liter apob : apoa - l ratio
former smoker  n ( % )
less than $nmbr$ %
hispanic ( n = $nmbr$ )
ischemic tvr
any albuminuria — no . ( % )
baseline ics use  n ( % )
bosentan ( n = $nmbr$ )
nitrates ( oral or topical )
left - sided disease only
third heart sound  n ( % )
other antiarrhythmics ^
psa duration  years
low molecular weight ( lmw ) heparin before randomisation
interval study drug to pci
atrial fibrillation / atrial flutter  %
a $nmbr$ + ez n = $nmbr$
initial aspirin — no . ( % )
symbol digit score
time from qualifying event to randomization
serum hdl cholesterol ( mmol / l )  mean ( sd )
pav  mean ( $nmbr$ % ci )
events treatment ( $nmbr$ )
annt or bnnh ( $nmbr$ % ci )
geographic region  %
drug - related teaes $nmbr$
atorvastatin dose
ldl - cihdl - c  mean ( sd )
prior biologic therapy ( including anti - tnfs )
left ventricular ejection fraction within previous $nmbr$ mo |
cabg or pci
ace inhibitor monotherapy
treated with cabg — no . / total no . ( % )
psoriatic arthritis pain ]
erythrocyte sedimentation rate — mm / hr | |
dose of aspirin
p - val . ( $nmbr$ )
small - artery occlusion ( lacune )
atorvastatin  n ( % )
baseline heart rate
apo b ( mg / dl ) - mean ± sd
peak procedural act — sec
extended - duration enoxaparin  n / n ( % )
total stent length
triglycerides  median ( range )
efficacy
non - stemi
mri substudy ( n = $nmbr$ )
lv mass index ( g / m $nmbr$ - $nmbr$ )
all with coenzyme q $nmbr$ ( n = $nmbr$  $nmbr$ )
serum total cholesterol  mmol / l ( sd )
visits $nmbr$ e $nmbr$
week $nmbr$ ( itt population )
puerperium
gold group d — no . ( % ) | |
atv $nmbr$ mg study protocol
aml / val $nmbr$ / $nmbr$ mg
median albumin / creatinine ratio ( g / mg )
smoking ( a )
tirofiban ( n = $nmbr$ )
time from acs to randomization ( median  iqr )
smoking pack - years
serum creatinine > $nmbr$ mmol / l  n ( % )
nonaspirin antiplatelet agent
use of concomitant lipid - modifying therapy
% stenosis  as assessed by investigator
parenteral anticoagulalion before randomization
lesions b $nmbr$ / c
median fasting insulin ( iqr ) — pu per milliliter
death or stent thrombosis
measured at home with automated device
atenolol *
neuropilin ( ng / ml )
individuals with diabetes  n = $nmbr$
basal insulin analogue : insulin
mean pulse pressure  mmhg ( s . d . ) “
oral hypoglycemic drug
antihypertensive treatment
patients with > $nmbr$ exacerbations resulting in hospital admission
ranolazine ( n = $nmbr$  $nmbr$ )
final timi flow grade post - ppci
duration of disease  median
ace inhibitor or arb at enrollment
psoriasis duration  yrs *
$nmbr$ to < $nmbr$ . $nmbr$ %
simvastatin monotherapy ( n = $nmbr$  $nmbr$ * )
timi major bleeding
small - artery occlusion
left ventricular hypertrophy — no . ( % )
laboratory findings
crp  nmol / l  median ( range )
bivariate frailty model ( statin users vs non - users )
resection performed  %
liraglutide $nmbr$ . $nmbr$ mg ls means ( n )
ada ifg
median change  %
sita $nmbr$ + pio $nmbr$
combined estimated gfr and albuminuria status
neoplasia
venous graft
mean age  y  median ( range )
body - mass index ( kg / mj ) previous diagnosis
antihyperglycemic
duration of ra ( time from symptom onset )  years
grouped region
nitrate — no . ( % )
shs  mean $nmbr$ sd
oral antidiabetes monotherapya  n ( % )
patients without ra  as  or psa ( n = $nmbr$  $nmbr$ )
treatmentofpulmonary embolismpriorto randomization
renin - angiotensin inhibitors
fev $nmbr$  litres ( post - salbutamol )  mean ( sd )
upper respiratory tract infection $nmbr$ ( $nmbr$ . $nmbr$ )
age at diagnosis  y
change in mtss ( mean )
aliskiren ( n = $nmbr$ )
number of exacerbations in last $nmbr$ months
p  all vs all
fasting plasma insulin — mu / liter
baseline albumin / creatinine ratio in $nmbr$ classes
cvd risk factors ( age > $nmbr$ )
former smoker ( n = $nmbr$ )
prior use of biologics  n ( % )
amlodipine $nmbr$ mg / v = $nmbr$
moderate or less airflow limitation
ethnic group — no . ( % ) '
any event
pain in extremity
hospitalized for asthma  n ( % ) *
sex : male ( n = $nmbr$ )
apolipoprotein b ^
abnormal angiogram
three or more drugs
data missing
heart failure nyha ii - iii
cerebrovascular disease  n ( % )
western europe hr ( $nmbr$ % cl )
biologic agents
ls mean difference ± seb
factor xa inhibitor
mean bmi  kg / m $nmbr$ ( s . d . )
anti - ischaemia agents *
exposure
mycophenolate mofetil
age when diabetes first diagnosed — yr
randomization to placebo or telmisartan
aspirin $nmbr$ clopidogrel
chd risk equivalents  n ( % )
systolic blood pressure [ mmhg ] ( interaction : p = $nmbr$ . $nmbr$ )
clinical history
ezetimibe + simvastatin ( n = $nmbr$ * )
duration of psoriasis  years
procedures for index event
killip class at admission — no . / total no . ( % )
other lipid parameters
tc / hdl - c ratio
ct or mr scan of the brain *
peri - or postmenopausal
indeterminate or unknown
ratet ( $nmbr$ % cl )
> $nmbr$ % stenosis of coronary  carotid  or lower extremity arteries
atrial fibrillation / flutter  n ( % )
hypertension — no . ( % ) hypercholesterolemia — no . ( % )
pulmonary disease
region of enrollment  n ( % ) +
baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$
statin + ezetimibe  n ( % )
ldl - c ( calculated ) *
evaluable for acr $nmbr$ at week $nmbr$  n
tertile $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pg / ml ) n = $nmbr$
ez / simva n = $nmbr$ n ( % )
event rates  %
baseline $nmbr$ - h ppg
nontrial ppi
cardiac resynchronization therapy
nyha class iii or iv ( n = $nmbr$ )
oral agents use
recurrent ischemia - urgent revascularization
rheumatoid factor positive §  n ( % )
serum p $nmbr$ np ( ^ g / liter )
investigator - reported hypoglycaemia *
diuretic — no . / total no . ( % )
interleukin - $nmbr$ ( ng / l )
non - caucasian eze / simva ( „ = $nmbr$ }
median ( q $nmbr$ : q $nmbr$ ) tgs
indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug
score of > $nmbr$ . $nmbr$ — %
weight  median ( $nmbr$ th — $nmbr$ th percentiles )  kg
$nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )
anti - cholinergics ( short - acting ) a
north america n z $nmbr$
diabetes durationa < median
discontinuations
available baseline blood specimen n
quicki
ratio of women to men — %
randomization to arterial sheath insertion
p value versus placebo
history of cardiac arrhythmia
n analysed
body mass  kg
mean cdai score
placebo plus aspirin
ii - iv ( % )
previous bowel resection performed — no . of patients ( % )
left anterior descending  n ( % )
postmenopausal hormone use
femoral neck
standard control ( n = $nmbr$ ) no . of patients ( percent )
other asian
measurements
antithrombotic / coagulant
myocardial infarction within the previous $nmbr$ yr
receiving concomitant nsaids and / or cox - $nmbr$ inhibitors
b digit symbol substitution  omega - $nmbr$ fatty acids vs placebo
post - bronchodilator ratio of fev $nmbr$ to fvc — %
statin with niacin
neither glucocorticoids nor immunosuppressive agents
anti - inflammatory drugs
i & ii : fev $nmbr$ > $nmbr$ % predicted
interval clopidogrel to pci
procedure
electrophysiological study — no . ( % ) weight — ibj
montelukast ( n = $nmbr$ )
$nmbr$ - h pmg ( mg / dl )
phenytoin
enact - $nmbr$ trial rerandomization to natalizumab ( n = $nmbr$ )
$nmbr$ bmi  kg / m
baseline ldl cholesterol
iglar ( insulin glargine l $nmbr$ u )
llv wlalil $nmbr$ statin
number of prior csdmards  n ( % )
efficacy and safety : net adverse clinical events *
glucocorticoids and immunosuppressants
heart disease risk factors
statin use at baseline
current smoker : ex - smoker ( % )
aspirin but no ppi
nsaid use — no . / total no . ( % )
dx at presentation  n ( % )
recent surgery or trauma
left anterior descending
ezetimibe $nmbr$ mg + statin ( n = $nmbr$  $nmbr$ )
coumadin
device group
glargine
safety population  n ( % )
pef  post - bronchodilator  % predicted normal
all randomized patients ( range )
permanent
tocilizumab
$nmbr$ = help needed  still independent
non - metsyn
hemoglobin  g $nmbr$ $nmbr$
level of renal impairment
soe or sue
previous stroke ortransient ischaemic attack ( % )
clopidogrel / ticlopidine
selexipag
mi type unknown ( % )
crohn ' s disease
high - sensitivity crp — mg / liter | |
prior coronary revascularization
severe teaes
any statin + other llt
arb at last follow - up
ml without st - segment elevation !
hydralazine
multivessel pci
oral anticoagulant — no . / total no . ( % )
notable abnormalities
contrast nephropathy risk score
aspirin at last follow - up
physical component
indacaterol $nmbr$ gg qd
elderly ( > $nmbr$ years )
odds ratio versus placebo ( $nmbr$ % ci )
geographic region - north america
all patients with fistulas ( n = $nmbr$ )
fev $nmbr$ / fvc ( post - albuterol )
prior medications
location of ml
use of hormone replacement therapy ( a )
versus tiotropium $nmbr$ . $nmbr$ pg
prior coronary revascularization  n ( % )
duration of infusion — hr
beta - blocker at last follow - up |
rentrop score
randomisation visit ( baseline )
gastrointestinal area involved — no . / total no . ( % )
baseline pulmonary medication  n ( % )
median serum periostin  ng / mla
multiple tnfi *
diet + pravastatin ( n = $nmbr$ )
prior coronary artery bypass graft surgery
c - peptide  median ( ql  q $nmbr$ )  nmol / l
enoxaparin
vorapaxar placebo $nmbr$ - yr %
missing data
risk reduction ( %  $nmbr$ % ci )
fastest third
gemfibrozil
cha $nmbr$ ds $nmbr$ - vasc
ezetimibe / simvastatin $nmbr$ / $nmbr$ mg ( n = $nmbr$ )
( $nmbr$ % ci ] $nmbr$
triglycerides mean ( mg / dl ± sd )
incidence rate
urinary albumin / creatinine ratio  median mg / g ( range )
minimum stent diameter
nt - probnp pg / mla ( iqr )
body mass index ( bmi )  kg / m $nmbr$
diet plus pravastatin group ( n = $nmbr$ )
duration of clopidogrel pretreatment 一 hr median
family history of coronary artery disease
sex  n ( % ) male
cv risk factor - no . ( % )
valvular disease ( % )
no corticosteroid + no imm  n
antimalarials only
tnl ultrapositive > $nmbr$ . $nmbr$ pg / l  $nmbr$ = $nmbr$
dactylitis count ( $nmbr$ - $nmbr$ )  mean ( sd )
nasal polyps
verapamil sr n = $nmbr$
continued thienopyridine n ( % )
disease - progression composite outcome !
egfrmdrd < $nmbr$ ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$  n ( % )
diarrhea
uric acid ( mg / dl )
pasi score  mean ± sd
theophylline compound
heterogeneity / trend test
disease
hispanic / latin american
isolated pulmonary embolism
middle tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl )
total cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients
geometric mean of baseline
baseline fvc  l
csf $nmbr$ s - hydroxy -
mean annualized exacerbation rate
placebo no . / total ( % )
not reported / unknown
prior therapy with tnf antagonist  n ( % )
difference from baselinea
age at randomization ( years )
never used lev
single vessel coronary artery disease *
non - sulfonylurea secretagogues
index event asymptomatic or unconfirmed
baseline medical therapy
prior corticosteroid failure only
one or more blood pressure medications  n ( % )
evomab ( n = $nmbr$ )
baseline post - bronchodilator % predicted fev  < $nmbr$ %
cardiovascular hospitalization
crohn ' s disease activity index score ]
prior use of biologic agents
relative risk reduction ( $nmbr$ % cl )
hba $nmbr$ c distribution
diuretic agent
patients treated with insulin
estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) ^ |
$nmbr$ - aminosalicylic compounds — no . ( % )
iwqol - lite physical score ( arbitrary units )
bdi total score ( baseline )
estimated * creatinine clearance < $nmbr$ mlvmin  %
low - density lipoprotein cholesterol  %
education  high school or higher
partial mayo clinic scored
prior lipid - modifying therapy
cv risk factor
mets w / o t $nmbr$ dm
other countries
smoking history — no . ( % )
other vascular disease — no . ( % )
mean — g / dl
outcome
ccbs  ( % )
sfc $nmbr$ / $nmbr$ | ig bid n = $nmbr$
cangrelor  %
losartan n = $nmbr$
laba + ics
short - acting anticholinergics
> $nmbr$ vessels with > $nmbr$ % stenosis
concomitant antihyperglycaemic drugs  n ( % )
losmapimod
history of myocardial infarction ( % )
$nmbr$ - $nmbr$ with cv disease ( n = $nmbr$ )
severely impaired
estimated creatinine clearance < $nmbr$ ml / min *
anticyclic citrullinated peptide positive ^  n ( % )
wrist fracture
mtx exposure ( mg / week )
ischaemic  n ( % )
atenolol n = $nmbr$ no . ( % )
vascular disordersb
adjusted mean change from baseline ( $nmbr$ % ci )  % [ mmol / mol ]
< $nmbr$ . $nmbr$ mmol / liter triglyceride level
previous myocardial infarction — no . ( % )
time since diagnosis of diabetesa  n ( % )
fev $nmbr$ / fvc  %  mean ( sd ) $nmbr$
> $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ )
serum albumin  g / dl
classification of af  no . ( % )
age at screening
change in sbp ( $nmbr$ months )
bronchitis
left ventricular ef  mean ( sd )  %
pde $nmbr$ inhibitor monotherapy
ischemic heart disease  %
neither pbo + statin eze + statin
impaired fasting glucose level ( n = $nmbr$ )
cancer ( n = $nmbr$ )
selected clinical characteristics  n ( % )
lumbar spine
reversibility of fev $nmbr$ ( % )
missing data — no . / total no . ( % )
insulin ( pmol / l ) t vital signs
glucose - lowering therapies
baseline heart failure severity nyha class i
selected baseline medications
endovascular — no . ( % )
aspirin - erdp ( n = $nmbr$  $nmbr$ )
previous treatment with tnf antagonist — no . ( % ) §
zotarolimus - eluting
change in nt - probnp at $nmbr$ months ( log - transformed )
low - molecular - weight
heart rate ( b . p . m . )  mean ± sd
vorapaxar group ( n = $nmbr$ )
glucose test
number of concomitant aeds  n ( % )
mean number of exacerbations ( per patient - year [ $nmbr$ % ci ] )
use $nmbr$ - asa compounds
glycemic drugs
balloon angioplasty — no . ( % )
prior history of cardiovascular disease  n ( % )
accp bleeding risk at inclusion  no . ( % ) f
angina pectoris — no . ( % )
history of systemic hypertension
angiography — no . ( % )
prasugrel
cardiovascular disease
prior congestive heart failure
post - bronchodilator reversibility fev $nmbr$ ( % ) mean ( sd )
diabetes therapy  n ( % )
low - dose aspirin use at baseline yes
medication at enrollment — no . ( % )
age  yrs  median ( $nmbr$ th  $nmbr$ th )
no . of predictors of cardiovascular risk
mean ( s . d . ) free pcsk $nmbr$  ng / ml
enrollment in lmwh
coronary angiography during the index hospital stay
primary pci ( n = $nmbr$ )
versus tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg
long - acting or short - acting nitrates
cardiovascular and respiratory
hispanic ethnic group — no . ( % ) f
placebo  n ( rate )
calcium antagonists  n ( % )
egfr  ml / min / m $nmbr$
lipid lowering medication use
opg  ( ng / ml )
final timi flow
patient ' s global assessment of disease activity  mean ( sd )
with revascularisation
antihypertensive medication or
level $nmbr$ immobility § | |
serum creatinine  limo $nmbr$ $nmbr$
central / eastern europe / russia
role physical
hba $nmbr$ c category  n ( % )
not reported in ecrf
beta - blockers ( all )  n ( % )
laba users
creatinine clearance at admission ( ml / min )
egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ )
other anticoagulant
severe impairment ( < $nmbr$ )
pre - bronchodilator fev $nmbr$ ( % predicted normal )
insulin + oad
clopidogrel ( n = $nmbr$ )
first - generation stentt
crp  mg / l : median ( range )
least square mean ( se )
preoperative heart rate ( beats per minute )
angiography during index hospitalization
allhat - llt
prior cardiovascular event — no . ( % ) - j -
baseline killip class
score on modified rankin scale — no . ( % ) §
energy / fatigue
atrial flutter
subjects randomized
active a
rec . ischemia leading to hasp
history of cabg surgery  n ( % )
western europe and other
qualifying mi type
potassium - sparing at last follow - up
congestive heart failure  n ( % )
score distribution : < $nmbr$
candesartan $nmbr$ / $nmbr$
planned treatment strategy
/ ’ - value $nmbr$ ’
parental history of myocardial infarction before $nmbr$ yr of age ( % )
hba $nmbr$ c distribution at baseline  n ( % )
change in haq - di ( mean ) t
normoalbuminuria at baseline ( $nmbr$ % of patients treated )
previous deep - vein thrombosis or pulmonary embolism
placebo mean ( n )
previous coronary revascularization — no . ( % )
medical history and risk factors — no . ( % )
rankin grade
previous heart failure
ptca or pci
inflammatory disease
exacerbations
statin ( open )
glyburide ( n = $nmbr$ )
history of cardiovascular disease — no . ( % ) ^ |
heart failure — no . ( % )
normoglycemic $nmbr$
fevi  % predicted  mean ( sd ) $nmbr$
cardiac failure  n ( % )
previous vascular disease
ethnic origin  n ( % )
abatacept monotherapy ( n = $nmbr$ )
calcium channel antagonists  n ( % )
high potencyc
ra symptom duration — year
previous myocardial infarction ( % )
post - bronchodilator fvc ( l ) a
moderate risk
< $nmbr$ . $nmbr$ mm hg diastolic blood pressure
$nmbr$ mg cohort
exercise times per week  ( minimum
other ( $nmbr$ . $nmbr$ % ) t
medical conditions  no . ( % )
smoking status at screening  n ( % )
low - dose rivaroxaban + aspirin ( n / n )
revascularization
hoehn and yahr stage ( range  $nmbr$ - $nmbr$ )
blood leukocyte count ( $nmbr$ cells per l )
low risk and fewer symptoms ( group a )
alt and / or ast > $nmbr$ times uln consecutive #
$nmbr$ yr km % ( n )
history of symptomatic
time of symptom onset to balloon inflation ( hrs )
statin potency stratum  n ( % )
no dysglycaemia or mets
weight $ $nmbr$ . $nmbr$ kg  < $nmbr$ . $nmbr$ kg  n
race or ethnic group
moderate impairment ( $nmbr$ to < $nmbr$ )
ascvd including tia
receiving concomitant corticosteroids
laba + ics ( free or fixed - dose combination )
fc - ldl - c  friedewald - calculated
egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ ( $nmbr$ . $nmbr$ % )
receptor blockers  n ( % ) baseline lipid and apolipoprotein levels
hyperkalemia ( > $nmbr$ . $nmbr$ meq / l )
region of enrollment  no . ( % )
mean score on haq - di §
medications at randomization
$nmbr$  $nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ )
history of cardiovascular disease
> $nmbr$ yr warfarin experience
intervention in complex lesions
peak creatine kinase - mb  u / l
secondary ( change in total updrs score from baseline to final visit in phase $nmbr$ )
leflunomide ( mean dose : $nmbr$ . $nmbr$ mg / day )
antithrombotic agents  n ( % )
leisure
angiotensin receptor blocker and / or ace
type of treatment  n ( % )
pancreatic cancer
mean iglar dose ± sd ( u / day )
int . p *
hawaiian / pacific
aspirin at any dose
baseline fpg
crp ( mg / l ) : < $nmbr$
large - artery atherosclerosis
antihyperglycemic medication usage
carotid
western european includinq australia  israel  and south africa
low density lipoprotein cholesterol  mg / dl * *
blood eosinophil count ( $nmbr$ cells per l )
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )
placebo n = $nmbr$ subjects
treatment with candesartan
hba $nmbr$ c $nmbr$ - < = $nmbr$ %
eze / simva $nmbr$ / $nmbr$ mg ( n = $nmbr$ )
pulmonary rales
loop at last follow - up
modified rankin scale score
qualifying event — no . ( % )
claudication ( fontaine class > $nmbr$ )
steroid use at baseline  n ( % )
metabolic syndrome ( > $nmbr$ of $nmbr$ characteristics )
killip class
respiratory medication ( % )
concomitant lipid - lowering therapy  n ( % )
duration of t $nmbr$ dm
egfr  ml min $nmbr$ $nmbr$ . $nmbr$ m $nmbr$
smoking status ( % )
bare - metal stent — no . ( % )
rate / $nmbr$ patient - years
> $nmbr$ servings / wk ( n = $nmbr$ )
key secondary end point : st
no . of risk factors ( % ) | |
prior antihypertensive medication  n ( % )
mean yearly decline
standard therapy
phosphorus  mmol $nmbr$ $nmbr$
lipid levels — mg / dl
smoking habit  n ( % )
open triple ( n = $nmbr$ )
no prior hf hospitalization ( n = $nmbr$  $nmbr$ )
glyburide
mean ( sd ) extent of exposure  days
triple therapy use at screening  n ( % )
europe $nmbr$ ( n = $nmbr$ )
ankle - brachial index < $nmbr$ . $nmbr$ — no . ( % )
number of subjects
fasting insulin
ace - i or arb use
pfo closure group ( n = $nmbr$ )
median ( q $nmbr$ : q $nmbr$ ) duration of insulin use  years
control group ( n = $nmbr$ )
normal troponin
ind / gly $nmbr$ / $nmbr$ pg o . d . n = $nmbr$
traditional chinese medicine for respiratory disease — no . ( % )
baseline copd exacerbation history  * n ( % )
european union
blood pressure - lowering treatment
ezetimibe
fish oil
cardiovascular inclusion criteriat
median duration of study - drug administration
psoriasis body surface area > $nmbr$ %
exenatide
cardiovascular risk factors — no . / total no . ( % )
( $nmbr$ % ci ) p value
time from symptom onset to randomization
percentage difference ( $nmbr$ % cl )
fpg ( mmol / l )  mean ( sd ) 、
apo a $nmbr$ ( g / l )
fibrinolysis ( n = $nmbr$ )
ticagrelor $nmbr$ mg vs . placebo hr ( $nmbr$ % ci )
combined n = $nmbr$
simplified disease activity index
ratio of ldl to hdl
st ( arc definite only )
duration of diabetes mellitus  y
sex  male / female  %
total study population ( n = $nmbr$  $nmbr$ )
sita / pio $nmbr$ / $nmbr$
blood eosinophils count
who / idf ifg
cardiovascular history 一 no . ( % )
ace inhibitor at last follow - up
prior cardiac surgery  n ( % )
ischemic aetiology  n ( % )
placebo $nmbr$ year km ( % )
vorapaxar n = $nmbr$
postmenopausal  never or past hormone therapy use
difference vs placebo  % [ $nmbr$ % cl ]  p
urinary albumin - to - creatinine ratio ^
percent change
standard care ( n = $nmbr$ )
cerebrovascular disorders  n ( % )
ace inhibitor — no . ( % )
location of treatment center
indacaterol $nmbr$ ug ( n = $nmbr$ )
history of peripheral arterial disease ( % )
creatinine  mean ( sd )  mg / dl
sf $nmbr$ - pcs
randomization groups $nmbr$ and $nmbr$
presence of honeycombing  $nmbr$ n ( % )
very severe n z $nmbr$
years since pah diagnosis
partial mayo score $ | |
rosuvastain + fenofibric acid $nmbr$ = $nmbr$
severity n ( % )
history of hypercholesterolemia
> $nmbr$ years education
angiographic complications  site - reported — no . / total no . ( % )
acute coronary syndrome $nmbr$
asastoppedat randomization  n
mean blood pressure  mmhg ( s . d . j
baseline lipids  mean ± sd ( mmol / l )
philippines
active cancer at randomization  n ( % )
current (  $nmbr$ cigs / day )
aspirin and ppi
screening % reversibility fev $nmbr$
prior pci or cabg surgery
lower - limb arterial — no . ( % )
baseline disease and quality - of - life scores
index event  %
endoscopy subscore
intended clopidogrel dose $nmbr$ mg
placebo + mtx
celecoxib ( n = $nmbr$ )
oral hypoglycemic agent
death  mi  idr  or st
unacceptable adverse events
tolal choleslerol - lo - hdl choleslerol ralio
median ( days )
ldl particle size ( week $nmbr$ )
gold $nmbr$ groups
parameter
vascular intervention
a $nmbr$ + ezio a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ )
amlodipine / vaisartan ( n = $nmbr$ )
ldl cholesterol — mg / dl | |
week $nmbr$ ( geometric mean  cv )
triglycerides ( week $nmbr$ ) a
cause of heart failure
copd or asthma
latin and north america
comorbid diseasesa diabetesb
cardiac rhythm
proactive intervention ( n = $nmbr$ a )
$nmbr$ = minor symptoms  no limitations
patients ' characteristics age ( years )  mean + sd
history of hypercholesterolemia  n ( % )
acc / aha lesion class b $nmbr$ or c  n ( % )
enact - $nmbr$ trial
fasting insulin — / tiu / ml §
biomarker low ( periostin < $nmbr$ ng / ml or blood eosinophils < $nmbr$ cells per pl )  na
age  mean years  [ sd ]
lipoprotein ( a ) ( mg / dl )
any pulmonary medication
non - study ppi use
> $nmbr$ : obese class iii
acute dvt study
high subgroup
mean ( sd ) body mass index  kg / m $nmbr$
diuretic drugs
gallbladder - related aes
rivastigmine ( n = $nmbr$ )
vitamin e
jvp > $nmbr$ cm
family history of venous thromboembolism ( % )
post - bronchodilator fev $nmbr$ ( % predicted * )
creatinine clearance by c - g ( ml / min )
associated with hiv infection
muscle spasms
copd severity ( gold stage )
rivaroxaban $nmbr$ mg
baseline cardiac biomarkers elevated
mental component score ( mcs )
combined end points
death  large mi
race  white  n ( % )
elevated tg
baseline scales  median ( range )
formal education  years
tiotropium $nmbr$ gg qd
thrombocytopenia
presence of mets
treatment at randomization — no . ( % )
other biologic agent
hdl < $nmbr$ / $nmbr$ mg / dl ( $nmbr$ . $nmbr$ / $nmbr$ . $nmbr$ mmol / l ) for men / women
baseline systolic bp
angina class iii or iv prior myocardial infarction
mucolytic agent
acenocoumaroi
multiple
emotional well - being
$nmbr$ ( fev $nmbr$ < $nmbr$ % pred )
rec . ischemia due worsening angina
current ( $nmbr$ + cigs / day )
prior surgery : no
carotid stenosis
smoking history  pack - years  mean ( sd )
ever smoked ( current / former )
estimated gfr  ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ ( sd ) a
isolated systolic hypertension  n ( % ) “
feno placebo ( lsm )
no . of prior tnfi
non - fatal myocardial infarction
involved intestinal area  n ( % )
normal fasting glucose level ( n = $nmbr$ )
saxa + dapa + met n = $nmbr$
joint damage outcomes ( mitt population )
discontinuations teaes
aldosterone inhibitor
adverse outcome
etoricoxib $nmbr$ mg n = $nmbr$ n ( % )
asia - pacific hr ( $nmbr$ % cl )
left bundle - branch block
any prior anti - tnf treatment failure
pioglitazone pts / n ( % )
central / eastern europe and russia hr ( $nmbr$ % cl )
copd - rosuvastatin ( n = $nmbr$ )
abatacept / open - label abatacept
nonblack race — no . ( % ) - j -
prior ischemic stroke
ff / vi $nmbr$ / $nmbr$ gg ( n = $nmbr$  $nmbr$ )
baseline nihss score ( % ) #
free fatty acids ( mmol / l )
laba or lama ’ versus ind / gly lsm difference ( $nmbr$ % cl )
change from baseline in hba $nmbr$ c ( % )
aspirin group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years )
angiogenin ( ng / ml )
weight  mean ± sd ( kg )
race / ethnicity  %
etanercept ( n = $nmbr$ )
serum creatinine — pmol / liter
prior carotid intervention
abx - facil . pci
antiplatelet — no . / total no . ( % )
other lipid - modifying drug use at study entry  n ( % )
without dm ( n = $nmbr$ i $nmbr$ * )
potassium
difference ( tiotropium - placebo ) ml ( $nmbr$ % ci )
any relevant infarct
baricitinib  $nmbr$ mg daily ( n = $nmbr$ )
ls mean % change from baseline _ se
established ascvd or > $nmbr$ cv risk factors
fasting plasma glucose  mg / dl  mean ( sd ) b
e $nmbr$ + a $nmbr$ -
filtration rate $nmbr$ - $nmbr$
placebo secukinumab $nmbr$ mg
sf - $nmbr$ physical component summaryjj
angiographic data
community hospital ( % )
death or absolute fvc decrease > $nmbr$ %
indacaterol $nmbr$ mg [ n z $nmbr$ ]
other statin
median ( iqr ) age  years
estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ : i : §
homa_ % b tx difference vs pbo  median change from baseline ( se ) $nmbr$
tim $nmbr$ nsk score
indication for pci
percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % )
$nmbr$ - aminosalicylates ’ i  i ‘
native latin
left atrial diameter  mm ( sd )
patient history of disease
copd severity : severe / very severe
mean platelet volume  fl
in ibdq total score at week $nmbr$  mean [ se ]
baseline ezetimibe usec
ics use at screening  n ( % )
mdi / hfa  n
moderate or severe exacerbations in the previous year ( range )
mixed chronic bronchitis and emphysema
triple - vessel disease  n ( % )
mean ( sd ) crp  mg / l *
epa / aa ratio
one or more requiring hospitalization in $nmbr$ mo before screening — no . ( % ) $nmbr$
health state index score  uk algorithm
time from onset of pain to randomization  median ( iqr )  h
homajr tx difference vs pbo  median change from baseline ( se ) $nmbr$ lipid parameters
ticagrelor  $nmbr$ mg ( n = $nmbr$ )
dpp - $nmbr$ inhibitor therapy
median cardiac troponin t ( iqr ) — pg / ml
> $nmbr$ ( ml ) additional angiography
sbp < $nmbr$ mmhg and dbp < $nmbr$ mmhg
insulin and oral hypoglycemic drugs
other antiplatelet
use of ics
mean hscrp  mg / l ( sd )
carotid revascularization
time from onset to randomization  h  mean ± sd
beta - adrenergic blocker
class l / ll heart failure
rerandomization to placebo ( n = $nmbr$ ) f
triglycerides > $nmbr$ mg / dl
history of cabg surgery
vomiting
thoracic cage fractures
baseline sgrq score
usa and canada
obesity ( body mass index > $nmbr$ kg / m $nmbr$ )
clopidogrel plus aspirin ( n = $nmbr$ )
intent of early invasive strategy  %
mean fev $nmbr$  l ( sd )
heavy calcification
cardiovascular medications  %
only peripheral artery disease
inhaled anticholinergic §
$nmbr$ - h plasma glucose during ogtt ( mmol / l )
uacra  mg / g  n ( % )
western europe and israel
sglt - $nmbr$ inhibitors ^
myocardial infarction — no . ( % )
united states
number of antidiabetes drugs at screening  n ( % )
any type  according to daily dose * *
glucocorticoids plus immunosuppressive agents
left anterior descending artery  n ( % )
albuterol reversibility  %
rivaroxaban + aspirin
anyantianginal agent
patients with diabetic nephropathy
hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo subtracted change ( se )
health - related quality of life
risk factors  %
concomitant therapy  no . ( % )
any cardiovascular disease history  n ( % )
cardiac history  %
subgroup by treatment interaction p - value
a $nmbr$ + ez $nmbr$ a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ )
dpi ( other than diskus )  n
previous copd treatment  n ( % ) *
body mass index ( kg / m $nmbr$ ) - mean ± sd
positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f
psoriasis duration  mean ± sd  years
fevi  l *
ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening
black race
lp ( a )  mean ( sd )
previous transient ischaemic attack / ischaemic stroke previous warfarin use
calculated ldl - c in $nmbr$ classes
rosiglitazone
without revascularsation
odds ratio
body mass index  kg / m $nmbr$  median ( q $nmbr$  q $nmbr$ )
exenatide n = $nmbr$
total score on the sgrq - c  i
elevated creatinine ( > $nmbr$ pmol / l )
valsartan / hctz
baseline : < $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ or < $nmbr$ . $nmbr$ meq / l
history of currently treated hypertension  n ( % )
tg  mmol / l [ mg / dl ]
terminal ileum
das $nmbr$ - esr lda
prior tnfi  n ( % )
liraglutide $nmbr$ . $nmbr$ mg / day ( n = $nmbr$ )
established ascvd
depressed and low perceived social support
limb ( sd )
emergent / urgent surgery
laboratory measurements
simva n = $nmbr$ n ( % )
czp $nmbr$ mg  % ( n / n )
fibrinogen ( pmol / l ) c
frailty status
basal insulin dose at run - in ( u / day )
worsening angina
use of parenteral antithrombotic
cvd or mi
screening bmi ( kg / m $nmbr$ )
atherosclerosis ^  n ( % )
none ( cdmard - naive or past use at baseline )
tender joint count ( $nmbr$ - $nmbr$ )
hba $nmbr$ c  %  n ( % ) b
ldl - c < $nmbr$ . $nmbr$ mmol / l
duration of last qualifying episode of atrial fibrillation > $nmbr$ days
saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$  $nmbr$ )
years [ range ]
potassium - sparing at enrollment
body mass index > $nmbr$ kg / m $nmbr$  n ( % )
modmy al randcnxzaton
additional investigations
peri - op amiodarone : no ( n = $nmbr$ )
ejection fraction  % nyha class  n ( % )
class i or iii aad use in $nmbr$ months before enrollment
intravenous anticoagulant during hospitalization
high density lipoprotein cholesterol  mg / dl ^
functional assessment of chronic illness
hormonal status
postmenopausal  current hormone
spironolactone ( n = $nmbr$ )
any disease
endothelin - receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors
bolus administered — no . ( % )
tofacitinib  $nmbr$ mg ( n = $nmbr$ )
medical history — no . / total no . ( % )
tobacco use ( % )
infliximab - naive ( n = $nmbr$ )
week $nmbr$ mean 士 sd
hr ( $nmbr$ % ci ) p value for interaction *
history of congestive heart failure
events  no .
event / total
serum cholesterol — mmol / liter
pooled empagliflozin ( n = $nmbr$ )
statin monotherapy
total comparators  patients with events / total patients
( % ) control ( $nmbr$ )
hypertension : no ( n = $nmbr$ )
angiotensin - converting enzyme inhibitor or angiotensin receptor blocker
bdmard - ir
estimated glomerular filtration rate
periprocedural medications — no . / total no . ( % )
proportion of predicted normal fev $nmbr$ value   §
mellitus
amiodarone
permanently stopped study drug because of adverse events
median ( q $nmbr$ : q $nmbr$ ) tg - rich lipoprotein cholesterol
apolipoproiein a $nmbr$ ( tng / $nmbr$ )
metformin dose  mg
placebo no . of events / total no . ( % )
hba $nmbr$ c $nmbr$ % - < $nmbr$ % ( n - $nmbr$ )
hypoglycaemic agents
apremilast $nmbr$ mg bid n = $nmbr$
duration  mean ( sd )  years
patient global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm )
intermittent claudication
myocardial ischaemia
arb at enrollment
rosuvastatin of patients ( rate )
recent cardioversion ( within $nmbr$ days before randomization ) —
denosumab ( n = $nmbr$ )
genotyping
remission  n ( % )
radius fracture
clopidogrel dose on / before pci
enoxaparin / vka
sf - $nmbr$ score
seropositivity
interval pain onset to admission
metrex modified intention - to - treat population with an eosinophilic phenotypey
number of previous anti - tnf treatments for psoriatic arthritis
serum creatinine  mean ( sd )  pmol / l
coronary heart disease ( % )
bmi ( kg / m $nmbr$ ) < $nmbr$
abdominal aortic — no . ( % )
mean weight  kg ( sd )
severe hyperkalemiac
history of bone disease ( predefined )  n ( % )
abrupt vessel closure
/ j - valuc ! l
> $nmbr$ days warfarin
non - hdl - c ( mmol / l  mean )
yes  non - insulin - treated
$nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$
baseline lp ( a ) in $nmbr$ classes
primary + gusto moderate or severe bleeding
dyspepsia
south asian
claudication
anticoagulant therapy
dactylitis  n ( % )
prior immunnosupressive failure but no anti - tnf failure
sf - $nmbr$ v $nmbr$ domain scores  mean [ sd ]
reversibility ( b $nmbr$ - agonist )  %  mean ( sd ) $nmbr$
icd therapy vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl )
fev  at baseline
low - density lipoprotein cholesterol  mg / dl
qualifying type of atherosclerosis — no . ( % )
white : black : other
placebo estimated mean
salmeterol - fluticasone group
impaired glucose tolerance or impaired fasting glucose — no . ( % )
duration of t $nmbr$ dm ( % )
therapy ( asa $nmbr$  $nmbr$ / placebo $nmbr$ )
antihyperglycemic oral agent therapy
gender  % of patients
planned thienopyridine at baseline
medical history
medium - or low - intensity statin
current / past
rosuvastatin n = $nmbr$
pulse rate ( bpm )
anti - cholinergics ( long - acting )
primary + gusto severe bleeding
mean age  years ( $nmbr$ % ci )
vertebrobasilar infarct
alathosterol ( % )
blood oxygenation  mean ± sd
rf positive  %
sf - $nmbr$ ( health transition score )
time since diagnosis of osteoarthritis — yr
no . of days to homa - ir testing — median ( iqr )
certolizumab group ( n = $nmbr$ )
$nmbr$ - $nmbr$ / week
p $nmbr$ y $nmbr$ inhibitor
previous cardiovascular disease !
acute and delayed reaction
atenolol strategy
nationality
bl updrs : high
history of paroxysmal atrial fibrillation  n ( % )
biomarker status
nicotine pack - years
congestive heart failure — no . ( % ) | |
fibrin - specific
≥ $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ years
duration of hypertension ( years )
therapy ( asa $nmbr$ / placebo $nmbr$ )
$nmbr$ prolonged antithrombotic pretreatment ( n = $nmbr$ )
isolated igt
pasi < $nmbr$ *
$nmbr$ locf )
uacr ( mgg - $nmbr$ )
vorapaxar placebo $nmbr$ - yr . km % rate
change from baseline  adjusted mean ( $nmbr$ % ci )  %
paclitaxel - eluting
distal anastomosis ( % )
< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % )
atrial fibrillation  n ( % )
uacr  mg / mmol ( interquartile range ) b
fasting glucose  mmol / l  mean ± sd
coronary artery bypass surgery
prior cardiovascular event — no . ( % )
concomitant atorvastatin dose  mg
n ( indacaterol $nmbr$ ug / indacaterol $nmbr$ ug / placebo )
etanercept
aortic stenosis  n ( % )
pretreatment / concomitant treatment
circumflex
diuretic drugs  n ( % )
baseline median ( iq range )
serum sodium — meq / liter
pacific islander
hbalc > = $nmbr$ % ( n - $nmbr$ )
hba $nmbr$ c ( % ) all countries
prior diabetes
number of events / patients
coronary heart disease
mean sgrq total score ( sd )
managed medically — no . / total no . ( % )
postoperative glucocorticoid use
losartan + placebo
geographical region ( % )
serum haemoglobin a $nmbr$ c concentration ( % )  mean ( sd )
creatinine ≥ $nmbr$ . $nmbr$ mg / dl
previous balloon angioplasty  n ( % )
thrombolytic treatment before randomization
apixaban
urgent cor revasc
diabetic treatments !
primary ep ( cvd / mi / ri )
cv death / mi / stroke
ticlopidine ( n = $nmbr$ )
alt  ast  or both > $nmbr$ x uln
qualifying nstemi  n ( % )
baseline nihss score  median ( range )
scr  gmol / l
baseline cardiovascular medication  c n ( % )
thienopyridine drug at start of open - label period
egfr ( mumin / $nmbr$ . $nmbr$ m $nmbr$ )
median ( sd )  mg / mmol
double - vessel disease  n ( % )
lipid profile
chronic obstructive pulmonary disease
treatment difference  ml
homa - ir  median ( q $nmbr$  q $nmbr$ )
$nmbr$ placebo n = $nmbr$
concomitant mtx use  n ( % )
atorvastatin ls means difference $nmbr$ mg ( $nmbr$ % ci ) a ( n = $nmbr$ )
dmard | |
calculated ldl cholesterol ( week $nmbr$ )
median ( q $nmbr$ : q $nmbr$ ) total daily insulin dose $nmbr$
hematologic
physician global assessment ( $nmbr$ - $nmbr$ mm vas )
ipf - related
history of major bleeding
fpg  mean ( sd )  mmol / l
ldl - c ( bq ) ( mg / dl ) - mean ± sd
body - mass index  !  waist - to - hip ratio
hba  % $nmbr$ c
current tobacco abuse  n ( % )
hormone therapy
total group ( n = $nmbr$ )
smoking pack year ( years ) fl
( $nmbr$ % ell ' ll  * non - hdl - c
terol  hdl - c  high - density lipoprotein cholesterol
age at first seizure  years  mean ( sd )
glomerular
median blood eosinophil count  cells per pla
cv death or first hhf
balloon angioplasty plus abciximab
lipoprotein ( a )  median ( ql  q $nmbr$ )  nmol / l
osteoporosis
acute rheumatic disorders
intensive control
treatment duration  days
warfarin ( n = $nmbr$ )
reported hypertension *
before bronchodilation
ccv history / condition at baseline
ivabradine ( n = $nmbr$ )
bmi ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )
physical function ( $nmbr$ - $nmbr$  short form - $nmbr$ subscale )
prior cerebrovascular disease
reason for enrollment in active a — no . ( % )
medical characteristics
medication use at baseline — no . ( % )
age < $nmbr$ years — no . ( % )
planned valve surgery  n ( % )
time from randomization to pci ( st - elevation mi )  min
haq - di score ( $nmbr$ - $nmbr$ )
mean ( sd ) das $nmbr$ - $nmbr$ ( esr ) *
randomised treatment
v alsartan / hctz  n ( % )
$nmbr$ year or more
crcb - ( ml / min )  mean ( s . e . )
three - vessel disease
st - segment depression > $nmbr$ . $nmbr$ mv on admission  %
planned treatment duration  n ( % )
z\tonastaiin
inadequate response / intolerance to prior therapy  %
change from baseline in das $nmbr$ - esr  mean $nmbr$ sd
cause of heart failure — no . ( % )
predominant type of heparin
western europe / australia / israel
preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria
glucose  mmol / l
aspirin + clopidogrel ( n = $nmbr$ ) $nmbr$ . $nmbr$
retinopathy — %
pulmonary embolism
mild or moderate copd
prior ml ( before index acs )
diabetes duration ( known )  % of patients
creatinine clearance ， : : $nmbr$ ml / min  %
baseline hb < $nmbr$ g $nmbr$ $nmbr$ n = $nmbr$
joint swelling
$nmbr$ mwd decrease > $nmbr$ m
profound thrombocytopenia ( < $nmbr$ x $nmbr$ / l )
body mass index  median  ( $nmbr$ th — $nmbr$ th percentiles )  kg / m $nmbr$
associated with connective tissue disease
postbronchodilator lung function at screening
non – small - cell lung cancer
prior anti - tnf therapy — no . ( % )
all rosuva
peripheral edema
insulin - na ' ive
gender  women n  % )
mean ( sd ) swollen joint count *
diuretic drugs ( excluding antialdosterone )
hfpef ( ef n $nmbr$ )  ( % )
extent of disease  n ( % )
tendonitis
previous hypertension
oral contraceptives
syncope — no . ( % )
anatomic complexity characteristics
conventional treatment
left circumflex
amiodarone vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl )
number of pack - years
baseline cardiac biomarkers
type $nmbr$ diabetes duration  mean ( sd )  years
oral study drug administered — no . / total no . ( % )
diltiazem or verapamil
major bleeding ( statin use vs non - use )
placebo secukinumab pooled
bilateral disease ( % ) ' j ' ' j '
pathological q waves
leukocytes  $nmbr$ / nl
lipid - lowering agents ( % )
history of second prior mi
study medication — no . ( % )
laboratory data  mean ( sd )
p value ( men versus women )
former n z $nmbr$
insulin : glucose ratio
t $nmbr$ dm duration ( years )
serum creatinine > $nmbr$ pmol / l . n ( % ) |
kellgren and lawrence radiographic reading grade $nmbr$ — no . ( % )
data missing or no drug given
gpiib / iiia receptor inhibitor
ethnic origin
supine after $nmbr$ minutes change from baseline
omega - $nmbr$ fatty acid ( n = $nmbr$ )
pulmonary rales  n ( % )
< $nmbr$ months  n ( % )
fibrinogen  g / l
right ventriculardysfunction atinclusion
nace ( primary endpoint )
micro - / macro - albuminuria  ckd and / or retinopathy
interaction : treatment by psoriasis p value $nmbr$
score > $nmbr$ %  % of patients
any aes  n ( % )
ace inhibitors or angiotensin ii
des ( % previous stenting )
comparison with placebo ( mean
mean ( s . d . ) hbalc  %
exercise
vascular territory # $nmbr$
native hawaiian or other pacific islander
control baseline ( n - $nmbr$ )
rando . in na * *
estimated glomerular filtration rate - ml / min  median ( iqr ) '
nyha class within past month — no . / total no . ( % )
aspirin group
non - hdl - c ( mg / dl ) - mean ± sd
fibrinolytic for qualifying event
$nmbr$ degree of ica stenosis 丰
calcium - channel blockers ( % )
duration of ra ( years )
min  max
estimated gfr  < $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$  n ( % ) a
ctn - l  ng / ml
chd + cerebral infarction
fenofibric acid + moderate - dose statin
highest tg tertile
days of study - drug administration ( % ) * * $nmbr$ day
emotional role
antithrombotic therapy
periprocedural medications — no . / total no .
kim $nmbr$ ( pg / ml )
mi or cad
d - dimer levelsatinclusion
any immunosuppressive agent
tender joint count  of $nmbr$
increased waist circumference
cross - damp time : < l : llhrs : min ( n = $nmbr$ )
aspirin only ( n = $nmbr$  $nmbr$ )
high risk with atherosclerotic vascular disease *
metrex overall modified intention - to - treat population ? :
basmi ( linear )  mean ( sd )
cor revasc
high ( > $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % )
adl subscale ( range  $nmbr$ - $nmbr$ ) *
baseline statin usec
unbound pcsk $nmbr$ ( nmol / l )
months from mi — median ( iqr )
enthesitis count
enalapril
history of alcohol use
initiation of dialysis  renal transplantation  or creatinine . $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mmol / l )
female race / ethnicity
bsa affected  mean ± sd  %
timing of clopidogrel loading dose
week $nmbr$ fpg  mean ( s . e . )
crohn ' s disease - related medication at baseline  n ( % )
post - menopausal ( a )
saxagliptin $nmbr$ mg ( n z $nmbr$ )
weight ( range ) ( kg )
monotherapy
small vessel
history of microvascular disease — no . ( % )
baseline sitosterol
hypertension and left ventricular hypertrophy
ls mean ( s . e . ) primary endpoint : % change from baseline to week $nmbr$
severe n z $nmbr$
arthritis
concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff
extensive
baseline corticosteroids *
lv hypertrophy  n ( % )
sex ( interaction : p = $nmbr$ . $nmbr$ )
native hawaiian / other
pain ( $nmbr$ - $nmbr$ mm vas )
randomized
$nmbr$ baseline mean
fc - ldl - c  mg / dl
patients with previous loss of response to and intolerance of infliximab *
other glp - $nmbr$ receptor agonist
baseline hematocrit  median ( iqr )
placebo event rate ( n = $nmbr$ )  %
history of amputation
low - dose rivaroxaban + aspirin group
documented asymptomatic cardiac ischemiac
seropositive ( rf + ve and / or acpa + ve ) subgroup
| ? ) - blocker  %
metabolizer phenotype ( % ) §
disease location / type : terminal ileum
selexipag ( n = $nmbr$ )
clinical presentation
patients not receiving corticosteroids at baseline
alteplase group ( n = $nmbr$ )
obesity  % *
cardiovascular history — no . / total no . ( % )
cardiac therapy  n ( % ) d
femoral access — no . / total no . ( % )
laboratory data
other drugs
apob : apoa - $nmbr$ ratio
length of stay ( randomization to discharge  h )
$nmbr$ - aminosalicylates | | | |
peripheral - artery disease ( % )
severity of the disease ( gold $nmbr$ )  n ( % )
apixaban  $nmbr$ . $nmbr$ mg
coronary bypass graft
vascular disease indicator no ( n = $nmbr$ )
laboratory values at randomization ( median and iqr )
acr  mg / mmol
tc / hdl - c
hba $nmbr$ c at baseline  %
indication for stent
history of intermittent claudication and abi < $nmbr$ - $nmbr$ or substantial peripheral arterial stenosis > $nmbr$ %
months since ra was first diagnosed  mean ( sd )
hemorrhagic stroke ( n = $nmbr$ )
mini - mental state examination
number of stents implanted
risk score category ( points )
microvascular complications  n ( % ) ’
erosion score  median ( min  max )
fev $nmbr$ / fvc ( post salbutamol )
type $nmbr$ diabetes
% predicted pre - bronchodilator fev $nmbr$  % *
patients receiving corticosteroids at baseline
odds ratio adj ( $nmbr$ % cl )
no statin vs statin alone vs any statin plus other llt
general and lumbar epidural
rf and acpa negative $nmbr$
hispanic
onsetofaf  no . ( % )
percentage with disease duration < $nmbr$ years
doubling of creatinine †
diameter stenosis  mean ( sd )  %
biologic naive
systemic corticosteroids  n ( % ) a
europe ( non - eu )
fasting blood glucose ( mg / dl )
fev $nmbr$ reversibilityz ( pre / post ipratropium )  %
mean eosinophil count  per ml
men  total ( n 二 $nmbr$ )
rhabdomyolysis  myopathy  or myalgia with ck elevation > $nmbr$ x uln
rf positive  n ( % )
without insulin or insulin - modifying therapy
hospitalized for heart failure during that time period
phospholipid omega - $nmbr$ levels : < $nmbr$ % ( n = $nmbr$ )
clinical and laboratory measurements
current medication — no . ( % )
infliximab $nmbr$ mg / kg
randomization - to -
low hdl cholesterol
history of chronic hf
race - non - white ( n = $nmbr$  $nmbr$ )
moderate teaes
sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$ )
time since diagnosis of type $nmbr$ diabetes
riva roxa ban n / n { % ) $nmbr$ ( $nmbr$ . $nmbr$ )
disease and quality - of - life scores
laba / ics use at screening  n ( % )
mean change in radiographic end points
screening % predicted fev $nmbr$
lntensityd
steroid use at baseline
angina class at baseline
emotional status
albuminuria ( g / g )
concomitant therapy
thrombophilia
mean — mg / dl level — no . ( % )
urine albumin - to - creatinine ratio - no . ( % ) § §
mean a ± sd ( mmhg )
hdl cholesterol ( week $nmbr$ ) a
low - dose rivaroxaban plus aspirin ( n = $nmbr$ )
clinical criteria $nmbr$
abatacept ( n = $nmbr$ * )
ind $nmbr$ gg q . d . n / n ( % )
lvef ( % )  mean ± sd
menopausal status and use of hrt ( % ) y
renin inhibitor ( e . g . aliskerin )
urine albumin - to - creatinine ratio
total n = $nmbr$ n ( % )
chronic heart failure
type $nmbr$ diabetes mellitus ’
mean score on das $nmbr$ - $nmbr$ ( crp ) ^
orthostatic hypotension
previous oral glucose - lowering agents  % of patients
aortic stenosis
no . of patients / total no . ( % )
any dose reduction
hazard ratio for event ( $nmbr$ % ci )
prior implantable cardiodefibrillator  n ( % )
crp ( mg / l )  median ( min  max )
gold $nmbr$ groups  n ( % )
enalapril + aliskiren dm = $nmbr$ non - dm = $nmbr$
ics  mg / day
psoriasis covering > $nmbr$ % bsa  n ( % ) §
antihypertensive drug  %
mean ( sd ) post - bronchodilator fev $nmbr$ reversibility  %
$nmbr$ - $nmbr$ ( severe )
stroke or pvd  ( % )
cabg > $nmbr$ month ago
history of percutaneous coronary intervention
current or previous atrial fibrillation
ace - inhibitor use
anemia — no . ( % ) | |
low - dose corticosteroid user
upper gastrointestinal
cad history and risk factors  n ( % )
das - $nmbr$ ( crp ) < $nmbr$ . $nmbr$  n ( % )
repaired chd
gusto - defined bleeding
peripheral vasodilators
mean ( sd ) number of albuterol per day  puff
liraglutide ( n = $nmbr$  $nmbr$ )
angiotensin - converting enzyme or angiotensin receptor blocker
perianal or anus
framingham $nmbr$ - year cv risk score
native coronary - artery lesions
current drinker
placebo ls means ( n )
( %  $nmbr$ % cl )
duration of disease  years
musculoskeletal
severe ( gold $nmbr$ )
moderate thrombocytopenia ( < $nmbr$ x $nmbr$ / l )
st change > $nmbr$ mm
received an oral aha within $nmbr$ weeks prior to screening
stiffness subscale
egfr < $nmbr$  n ( % )
rec . ischemia requiring revasc
type of concomitant statin
bmi ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ]
moderate ( $nmbr$ risk factor )
timi risk score $nmbr$ - $nmbr$
chronic obstructive pulmonary disease  n ( % )
glycopyrronium $nmbr$ mg ( n = $nmbr$ )
history of microvascular eye disease 本  n ( % )
oral aminosalicylates
bmi kg - m - $nmbr$
mean ± sd triglycerides  mg / dl
type of des
white  n ( % )
aspirin / antiplatelet
any peripheral arterial disease
ldl cholesterol mean ( mg / dl ± sd )
index event — no . ( % )
hospital factor # $nmbr$
baseline tobacco use
persistent anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i $nmbr$
previously taken tnfi  %
troponin t
exacerbations in the previous year
omega - $nmbr$ fatty acid
stroke risk score
daily insulin dose  mean ( sd )  iu
former or never
type $nmbr$ diabetes duration  years
ccv history / condition
microalbuminuria or proteinuria
absolute risk difference ( ci )  % *
elevated at wk $nmbr$ — no . ( % ) $nmbr$
proctosigmoiditis
mean age ( years ) race
cat total score
$nmbr$ no . of events
intervention group ( n = $nmbr$ )
( $nmbr$ % cl ) interaction
apoa - $nmbr$  g / l
yes  insulin - treated
epa treatment ( n = $nmbr$ )
responders of three - item end point at $nmbr$ weeks *
systemic glucocorticoid use at randomisation
duration of t $nmbr$ dm  y
ace inhibitors or angiotensin ii blockers
physician ' s global assessment of dis -
clopidogrel no . of patients % )
duration of crohn ' s disease ( yrs )
multivessel intervention  n ( % )
tertile $nmbr$
cabg surgery
crp concentration > $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mg / l )  n ( % )
fatal and nonfatal stroke
angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §
ace - i / arb  ( % )
gliclazide ( modified release ) 一 no . ( % ) ^
conventional treatment ( n = $nmbr$ )
currentother ( notpredefined ) medical conditions
history of coronary revascularization
concomitant conventional dmard use
dual antiplatelet
digitalis
active or previous cancer
therapy at discharge
north america hr ( $nmbr$ % cl )
intermediate ( $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % )
male sex — no . ( % ) race — no . ( % ) ) :
primary end point kaplan - meier rate  %
all ~ cause mort / hf hosp .
haemodynamics and lv function
duration of study - drug infusion
salmeterol $nmbr$ gg bid
p value for adjusted hr
vitamin k antagonist ( e . g . warfarin / coumarol )
a / v ( n = $nmbr$ )
unknown
ff / vi $nmbr$ / $nmbr$ pg od
ivabradine group
comparison with baseline ( mean
irofiban
laba / lama
< $nmbr$ years eze / simva
placebo ( dm - vs . dm + )
o total randomized
cabgorptca
total patients n = $nmbr$
left circumflex artery
lebrikizumab ( n = $nmbr$ )
disease duration  median ( range ) years
bl updrs : low
fev $nmbr$ % reversibility
lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se )
( $ $nmbr$ mg / dl [ $nmbr$ . $nmbr$ mmol / l ] )
very high risk
location of crohn ' s disease  %
baseline diabetes
number of vessels disease
patient history of disease n ( % )
tocilizumab ( n = $nmbr$ )
mean ( sd ) duration of smoking  pack years
difference ( a ) vs placebo ( $nmbr$ % cl )
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
demographic characteristics
ezetimibe use
subset of patients on metformin
$nmbr$ vessels or left main
congenital shunts
eze / simva gender
methotrexate dose at baseline
neoplasia  n ( % )
mesothelin ( ng / ml )
non - smoker ( n = $nmbr$  $nmbr$ )
amlodipine / valsartan $nmbr$ / $nmbr$ mg / v = $nmbr$
> $nmbr$ . $nmbr$ hdl cholesterol level
past or current angina pectoris
history of peripheral vascular disease
group — no . ( % )
number of treated vessels ( per patient )
ranolazine  n = i $nmbr$ i $nmbr$
prior failure of anti - tnf therapy — no . ( % )
concomitant medications for ulcerative colitis — no . ( % )
lipid - lowering therapy
dlqi  $nmbr$ - $nmbr$ *
patients treated for > $nmbr$ weeks ( % )
immunomodulatory agents
endothelin - receptor antagonists
nt - probnp  median ( iqr )  pg / ml
hosp . for hf
alcohol use ( > $nmbr$ drink / wk )
st - segment elevation mi
history of dyspepsia
ncep risk category at study entry  n ( % )
treated hypertension :
presence of dactylitis  n ( % )
placebo every $nmbr$ weeks ( n = $nmbr$ )
heart rate  mean ± sd ( b . p . m . )
post - bronchodilator fev $nmbr$  reversibility percentage of baseline value
intense physical activity
concomitant drugs
cholesterol absorption inhibitor ( ezetimibe )
cha $nmbr$ ds $nmbr$ - vasc score ( median  iqr )
serum potassium — mmol / liter
nadroparin vs control
type of event — no . ( % )
stroke or tia — no . ( % )
previous major bleeding
coexisting conditions
characteristics of pulmonary embolism at inclusion
time of symptom onset to randomization ( hrs )
recurrent heart failure
all completers ( n $nmbr$ $nmbr$ )
qualifying hba $nmbr$ c ( % )
medically important infectionsa
three arm
after $nmbr$ h
fev $nmbr$ % pred
copd assessment test ( cat ) score
aspirin use ( > $nmbr$ mg )
moderate ( gold $nmbr$ )
no ascvd + additional cv risk factors  n ( % )
arb / ace
hypertension serum lipid values
measured at clinic visit with usual device
average maximum cimt ( mm )
thrombophilia  no . ( % ) e
health assessment questionnaire - disability index
median ( q $nmbr$ : q $nmbr$ ) lp ( a )  mg / dl
any clinical ae
mean ( sd ) feno  ppb
cdai score §
unfractionated
physical and cognitive examination : ! :
syst . bp ( mmhg )
medications at discharge or day $nmbr$  if earlier ( % )
drug discontinuation not due to death
congestive heart failure ( < $nmbr$ wk )
aliskiren
physician global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm )
baseline dlco . mmol kpa - ’ -
role emotional
baseline ( geometric mean  cv )
pah classification
days without albuterol use  * %
simva ( % )
treatment with open - label perindopril
new diabetes — no . ( % )
adjusted change from baseline mean ( s . e . )
$ $nmbr$ and  $nmbr$ years
fpg ( range ) ( mmol / l )
arterial graft
any established coronary artery disease
time to treatment ( min ) t
serum potassium : < $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ )
hemoglobin concentration — g / liter
clopidogrel + aspirin ( n = $nmbr$ )
previous metformin use  %
current ( % )
ecg findings at baseline — no . ( % )
concomitant therapies n ( % )
baseline therapy
hba $nmbr$ c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ - $nmbr$ mmol / mol )
history of recurrent venous thromboembolism
magnetic resonance angiography
free fatty acids — mmol / liter
baseline post - bronchodilator % predicted fev  > $nmbr$ % and no concurrent tiotropium
id genotype
major coronary
cardiac rhythm disorders
previous ischemic stroke  n ( % )
apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se )
history of macroalbuminuriat  n ( % )
high ( > $nmbr$ risk factor )
psoriasis affecting > $nmbr$ % of body - surface
asthma duration ( sd )  years
glucose metabolism
glycated hemoglobin  median ( iqr )
blood pressure  mean ± sd mm hg
fpi  mean ( sd )  pu / mlt
secondary # $nmbr$
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$
primary pci no .
rectum and sigmoid colon only
radial access — no . / total no . ( % )
oral blood glucose - lowering
age $nmbr$ + yrs
> $nmbr$ . $nmbr$ pmol / liter hscrp level
other ischaemic heart disease ( non - infarction )
calcium supplements
a mini - mental state examination  insulin glargine vs standard care
country : argentina ( n = $nmbr$ )
estimated gfr — no . ( % ) $nmbr$
received > $nmbr$ prior anti - tnf therapies  n
$nmbr$ placebo ( n = $nmbr$ $nmbr$ )
standard care n ( % )
interval from clopidogrel loading  h
severity of copd *  n ( % )
acr deciles
change at week $nmbr$
europe  israel  or australia
low density lipoprotein cholesterol - mg / dltt
other dmard use
duration of hypercholesterolemia ( yr )
personal relationships
heart failure or lvef < $nmbr$ % associated with index acs event
previous venous thromboembolism — no . ( % )
prior biologic exposure
need for urgent coronary - artery bypass grafting
egfr ( ml / min / $nmbr$ - $nmbr$ mz )
egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$
previous stroke  n ( % )
alpha $nmbr$ blockers
moderate dysfunction
tnf - r $nmbr$ a ( ng / ml )
jejunum
neither ace - i nor arb use
history of vte * *
d - dimer level  mean ( sd )  ng / mld
gfr ( ml / min per $nmbr$ . $nmbr$ nr )
diastolic fmmhff ' )
diabetes duration  median ( iqr )  years
$nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ )
plaque score ( $nmbr$ - $nmbr$ )
prior disease
mean sd fpg  mg / dl
serum ctx ( ng / ml )
baseline triglycerides in $nmbr$ classes
ff / vi $nmbr$ mg / $nmbr$ mg ( n = $nmbr$ )
previous anti - tnf therapy  n [ % ]
dronedarone ( n = $nmbr$ )
standard ( $nmbr$ )
age  median ( interquartile range )  y
one or more copd exacerbations ( n / n [ % ] )
peripheral embolism
arterial blood pressure  mm hg
co - morbidities  a n ( % )
oral hypoglycemic drugs only
p value ( on vs off omt )
mucocutaneous
any new anti - hyperglycemic rx
metsyn with ldl > $nmbr$ . $nmbr$ mg / dl
severe or worse airflow limitation
periprocedural anticoagulant
lsms difference ( $nmbr$ % ci ) $nmbr$
age  y sex  no . ( % )
blood eosinophil
pah classification — no . ( % )
short - acting b $nmbr$ - agonists
fev $nmbr$ reversibility  pre - / post - albuterol  %
ischemia on cecg ( n = $nmbr$  $nmbr$ )
ularitide n / n ( % )
three of seven risk factors
moderately high risk without atherosclerotic vascular disease *
randomised to canakinumab $nmbr$ mg
ff $nmbr$ pgod
fev $nmbr$ post - bronchodilator  % predicted normal
migraine — no . ( % ) $
hypertension — no . / total no . ( % )
randomized to active yitamin e
low risk and more symptoms ( group b )
high risk
carotid artery diseaset
cholesterol — mmol / liter
fasting plasma glucose
daily activities
extended - duration enoxaparin ( n = $nmbr$ )
das $nmbr$ - $nmbr$ ( esr )
associated with corrected - congenital shunts
traditional nsaid use
baseline albumin : < $nmbr$
high - risk cvd  n ( % )
pro / pro homozygotes
sulfasalazine ( mean dose : $nmbr$ . $nmbr$ g / day )
> $nmbr$ years eze / simva baseline ldl - c
< $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ )
pe associated with dvt at diagnosis
baseline hba $nmbr$ c
renal function < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
blood eosinophil concentration  $nmbr$ cells per l
less severe $nmbr$
cardiovascular risk
prehospital ticagrelor ( n = $nmbr$ )
symptoms of atrial fibrillation in the $nmbr$ months before randomiza -
perindopril
tiotropium / olodaterol $nmbr$ / $nmbr$ mg ( n = $nmbr$ )
symptom onset to hospital admission
ldl - c ( measured ) *
rerapamil - sr strategy ( n = $nmbr$ )
erosion score  mean $nmbr$ sd
valve surgery  n ( % )
ticagrelor $nmbr$ mg $nmbr$ year km ( % )
north america ( plus australia and new zealand )
calcium antagonist — no . ( % )
penetrating disease  %
non - drug - eluting stent
number of exacerbations in the past $nmbr$ months
potassium supplement
age group
congestive heart failure ( chf ) ( in past $nmbr$ weeks )
platelet count  x $nmbr$ mm $nmbr$
other supraventricular tachycardia
egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ [ mdrdequation ] )
mean bmi  kg / m $nmbr$
* * * unstable angina
rate ratio
recurrent vte ( statin use vs non - use )
saxagliptin $nmbr$ mg ( n = $nmbr$  $nmbr$ )
irregular or ulcerated ica p ) laque : [ :
extreme tortuosity
angina status — no . ( % )
p value $nmbr$ . $nmbr$
nonaspirin antiplatelet
antihyperglycemictherapies  %
geographic distribution - no . ( % )
conventional synthetic dmard use at baseline
statins 一 no . ( % )
at six weeks
angiographic data and treatment :
clinical indication at the index procedure  n ( % )
mean bdi focal score ( sd )
cabg during index hospitalization
pci for index event
concomitant drug treatment
third primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ )
implanted pacemaker
concomitant asthma medications  n ( % )
hba $nmbr$ c $ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )
uacr not available
ret / abx - facil . pci
severity of copd  airflow limitation  n ( % )
claudication only
mean % predicted dlco * ( sd )
titre ( u / ml ) t
treatment before admission ( % )
overall quality of life
no baseline corticosteroids
high on - treatment platelet reactivity *
potassium ( meql )  mean + sd  available for $nmbr$ patients
all patients with opg n - $nmbr$
urinary albumin : creatinine ratio ( pg / mg )  median ( iqr )
cardiac rhythm disorder at baseline yes
islander
left circumflex coronary artery
risk category ( points )
nihss at randomization  $nmbr$ - $nmbr$
cilostazol
creatinine clearance category  ml / min  no . ( % ) b
tg > $nmbr$ mg / dl  n ( ° / o )
chf on losartan ( % )
comorbidities  %
prior lipid - lowering agent use
iwqol - lite total score ( arbitrary units ) #
absolute change
gusto moderate / severe
ls mean difference ( se ) vs placebo
stent implanted — no . ( % )
eze / simva ( „ = $nmbr$ }
low eosinophil subgroup (  $nmbr$ / ml ) ( n = $nmbr$ )
alaska native
| interactior $nmbr$ p
number ( s ) of features present
extent of disease — no . / total no . ( % ) § ^ |
eze / simva $nmbr$ / $nmbr$ mg n = $nmbr$
bivalirudin
two arm
metreo modified intention - to - treat population §
any blood pressure medications ( % )
p  net difference
statin users ( n = $nmbr$ )
simplified disease activity index score ( $nmbr$ - $nmbr$ )
calcium channel
level — no . ( % )
no regular consumption
$nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ )
time from randomization to pci ( non - st - elevation mi )  h
$nmbr$ e < $nmbr$ %  n ( % )
prior pacemaker  n ( % )
non - detectable / unknown  n ( % )
individuals without diabetes  n = $nmbr$  $nmbr$
post - fibrinolysis angioplasty ( n = $nmbr$ )
aerobic activity
pulse pressure
laboratory measures
deep - vein thrombosis ( % )
cardiovascu lar subg roup
greater than or equal to $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
statin  n ( % )
location of infarction
infliximab - experienced ( n = $nmbr$ )
time since first copd diagnosis ( years )
potassium — mmol / liter
rivaroxaban ( n = $nmbr$ )
investigator - determined myocardial infarction
time from first eval
diagnosis of heterozygous familial hypercholester
baseline crp ( mg / dl )
average of maximum far wall cimt ( mm )
hispanic ethnicity
other vasodilator
maintenance dose
thienopyridine type
perfusion defectsatinclusion
das $nmbr$ - esr remission
no . of panents . total no . $nmbr$ % )
disease activity outcomes ( itt population ) week $nmbr$
fluticasone furoate and vilanterol ( n = $nmbr$ )
any infarct
apolipoprotein a - i *
current smoking — no . / total no . ( % )
miami k antagonist received
rivastigmine
europa ( n = $nmbr$ l $nmbr$ )
lung function  mean
physician ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd )
$nmbr$ - $nmbr$ ( very severe )
high - risk clinical features
second primary composite outcome
baseline % predicted fev $nmbr$
treatment characteristics
digoxin at last follow - up
both impaired glucose tolerance and impaired fasting glucose tolerance — no .
ez / simva < % >
sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .
# of prior bdmards
acute reaction
ulcers / gangrene
fasting plasma glucose ( mmol / l )
other teaes
alcohol intake
change from baseline ( % )
ileum only
anti - tnf - ir patients
north america plus australia and new zealand
medial - distal - diag
bw at $nmbr$ weeks  kg +
haemoglobin ( mmol / l )
severity ofcopd ( gold $nmbr$ )  n ( % )
prior stroke — no . ( % )
adalimumab ( n = $nmbr$ )
aliskiren dm = $nmbr$ non - dm = $nmbr$
previous cabg ( before index acs ) *
number of patients ( % ) or mean 士 sd
severity of copd  n ( % ) ( gold $nmbr$ ) : moderate
western friroce
baseline lipids  mean ± sd ( mmol / $nmbr$ )
baseline calcium yes
cardiac mediations
large vessel
no . of treated vessels
sinus rhythm at baseline
ipah / hpah
ccs class §
antithrombotic and anticoagulant medications
ixeq $nmbr$ w  n = $nmbr$
warfarin group ( n = $nmbr$ )
white - cell count — x $nmbr$ _ $nmbr$ / liter
mean % predicted fvc ( sd )
only cerebrovascular disease
three or more agents
msfc timed $nmbr$ - foot walk test  median seconds
mean ( sd ) baseline scores
patients with > $nmbr$ % ■ $nmbr$ ml increase in fev $nmbr$ post - bronchodilator ( % )
meglitinide
prior tobacco use  n ( % )
graft occlusionsa
ascot - lla
cortical only
key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ $nmbr$ of the indicated char least - square means  except tc an note : all treatment by subgroup
prior disease - modifying drugs resulting in inadequate response — mean no . / patient
extent of disease
candesartan group ( n = $nmbr$ )
rivaroxaban alone ( n = $nmbr$ )
body mass index  mean ( sd ) [ range ] a
baseline antihyperglycemic medications  n ( % )
fasting lipid levels  mmol / l
proximal gastrointestinal tract
diabetes mellitus ( type $nmbr$ or $nmbr$ )
heart failure ( hf )  ( % )
platelet  $nmbr$ / l
hba $nmbr$ c < $nmbr$ % ( n - $nmbr$ )
spironolactone  n ( % )
b digit symbol substitution  insulin glargine vs standard care
proteinuria $nmbr$ ( g / day )
elevated blood pressure
ldl - c ( mg / dl ) < $nmbr$
laser or vitrectomy
total study population ( n = $nmbr$ )
presenting diagnosis
duration of type $nmbr$ diabetes ( years )
alt ( units / l )
severity of airflow limitation
patient ' s global assessment of disease
daily dose $nmbr$ - $nmbr$ mg n = $nmbr$
in - stent restenosis of des
baseline hba $nmbr$ c  mean ( s . e . )
predicted normal ( % )
killip class — no . ( % ) i
prior ml or abnormal angiogram
placebo + mtx ( n = $nmbr$ )
baseline corticosteroid use ( mg )
ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$  $nmbr$ )
patients who received positive results on test for antibodies to infliximabt
ptca < $nmbr$ h
verapamil - sr ( « = $nmbr$ $nmbr$ )
simvastatin ( $nmbr$ / $nmbr$ mg / d )
insulin 一 no . ( % )
duration of type $nmbr$ diabetes mellitus ( years )
central america and south america
hip circumference — cm
r $nmbr$ + ezio ( n = $nmbr$ )
male sex — no . of patients ( % )
stents per lesion  n
infliximab ( n = $nmbr$ )
dose of rosuvastatin
lvef < $nmbr$ %  n = $nmbr$ $nmbr$ ) “
n - terminal pro - brain natriuretic peptide  pg / ml
bmi — mean ( sd ) ( kg / m $nmbr$ )
vorapaxar event rate ( n = $nmbr$ )  %
death or $nmbr$ mwd decrease > $nmbr$ m
associated with transient or reversible risk factor
europe and australia
all countries
urinary protein : creatinine ratioa ( mg / mg )
serum cholesterol  median ( iqr )  mg / dl
intermediate risk ( ri = $nmbr$ )
cangrelor
baseline cdai score  mean ( s . d . )
major bleeding events *
baseline  mm hg
white / caucasian
body mass index  mean ± sd ( kg / m $nmbr$ )
recurrent ischemia
index event not confirmed
non - hdl cholesterol ( mg / dl )
comparison with placebo
current use of an ace inhibitor
mean total serum ige ( sd )  iu / ml
af or atrial flutter 卞
pain subscale
ejection fraction based on local reading
cardiac and echocardiography parameters
albuterol use ( sd )  puffs / day
white race — number ( % )
stable angina ( n - $nmbr$  $nmbr$ )
weight  kg  median ( $nmbr$ th  $nmbr$ th )
long - term aspirin
moderately impaired
left side only
past or never
gastroesophageal reflux disease
anticoagulant — no . ( % )
region  asia / paafic
arteriosclerosis
fasting plasma glucose $nmbr$ medan
age mean ( yrs ± sd )
chronic renal failure
peripheral artery
neither t $nmbr$ dm nor mets
time since first af diagnosis  yrs
anti - hypertensive therapy - no . ( % )
pacemaker
infarct ion w ithin previous $nmbr$ day s
cardiac death
interval between clinical evaluation and initiation oftreatment — no . ( % )
apolipoprotein b  mean ( sd )  g / l
no . of participants with events ( % )
mean a ± sd  mg / dl ( mmol / $nmbr$ )
homa - ir ( mu / l ^ mmol / l )
> $nmbr$ months ( n = $nmbr$  $nmbr$ )
elevated troponin ( > $nmbr$ . $nmbr$ mg / l )  %
mean weight ( sd )  kg
europe ( zone $nmbr$ )
cox bsl onlyc
number resulting in ed visit
left ventricular systolic or diastolic dysfunction
any other llts ( other than statin )
other blood - pressure drug
both ace inhibitor and arb
tg  median ( sdy rng / cjl
statin at last follow - up
p - value ( lnteraction )
mild dysfunction or normal
recurrent infections ( > $nmbr$ per year )
estimated glomerular filtration rate < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$
median ( q $nmbr$ : q $nmbr$ ) duration of diabetes  years
$nmbr$ l $nmbr$ mmhg
chronic non - steroidal antiinflammatory drugs
european subcategories
placebo + $nmbr$ mg / d of simvastatin ( n = $nmbr$ )
median c - reactive protein — mg / dl ^
use of other medications — no . ( % )
total - c : hdl - c
pre - bronchodilator fev $nmbr$ / fvc ( % )
reversibility ( % predicted fev $nmbr$ ) *
conversion to sinus rhythm in < $nmbr$ days
stent implanted
median weight  kg ( iqr )
saxagliptin ( % )
salmeterol - fluticasone group ( n = $nmbr$ )
abciximab
vein bypass graft stented
mean age ( sd )  years
prior treatment
bivalirudin used during pci
mean ( s . d . ) ldl particle number  nmol / l
pad symptoms ( % )
number of treated lesions
infliximab ( combined $nmbr$ mg / kg and $nmbr$ mg / kg )  n ( % )
high dose statin ( n = $nmbr$  $nmbr$ )
any recurrent stroke
distal one - third of radius
mean mayo score ( sd )
diagnosis at presentation
median disease duration — yr
events / control group
lowest tg tertile
other antihyperglycemic agents  not listed
index stroke > $nmbr$ days before randomization — no . ( % )
renal fmclicn : creatntoe clearance
prior mi ( n - $nmbr$  $nmbr$ )
losartan plus placebo ( n = $nmbr$ )
anti - ccp positive ( > $nmbr$ u / ml )  n ( % )
total occlusion  n ( % )
male sex — no . ( % ) risk factors
multiple tnfi and other bdmards §
stiffness ( min )
rosuvastatin $nmbr$ - $nmbr$ mg ( n = $nmbr$ )
randomization to angiography
thienopyridine n = $nmbr$
treatment difference
absolute reversibility in fev $nmbr$  ml *
time to treatment
duration of initial anticoagulation  mean ( sd )  mo
undetermined etiology
ace inhibitors through hospital discharge or day $nmbr$ — %
patient ' s global assessment ( vas )
triglycerides ( mg / dl )  mean + sd  available for $nmbr$ patients
qualifying type of atherosclerosis  n ( % )
patient ' s preference not to take vka  only reason
probable
at least two cardiovascular risk factors
surgical technique post - randomisation characteristic * *
age group  no . ( % )  y
disease location ( % ) *
previous oad ( % )
hdl cholesterol — mg / dl triglycerides — mg / dl
< $nmbr$ months in - $nmbr$ kill
antialdosterone agents
risk factors bmi ( kg / m $nmbr$ )  mean + sd
ex - smoker / current
at goal
history of heart failure — no . ( % )
diabetes duration subgroups
western europe ( including south africa )
randomization stratum
death  mi  idr  st or gusto severe bleeding
clopidogrel / total no . of patients % %
corticosteroid ( without imm )
creatinine ratio $nmbr$ - $nmbr$
overall pad
steroids ( other )
mean ± s . d . weight  kg
amlodipine ( n = $nmbr$ )
previous infliximab therapy — no . of patients ( % ) * *
anti - tnf - naive  n ( % )
previous acute hypersensitivity reaction to infliximab — no . of patients ( % )
non - elderly ( < $nmbr$ years )
pravastatin ( n = $nmbr$ >
week $nmbr$ ( mean  sd )
factor v leiden ( % )
tender joint count ( $nmbr$ - $nmbr$ possible joints )
male sex — no . / total no . ( % )
insulin glargine n ( x )
time since randomization
post - bronchodilator fev $nmbr$ ( % predicted normal ) a
vessel size  mean ( sd )  mm
hs - crp ( median  iqr )  mg / l
insulin - requiring
homa . ir  median ( ql  q $nmbr$ )  % / $nmbr$
baseline short - acting anticholinergics
multivitamin use ( current )
apob : apoal
cardiac stretch
hospitalization for heart failure within $nmbr$ mo
lv ejection fraction  mean ( sd ) [ range ]  %
pasi score  $nmbr$ - $nmbr$ *
patients with event / patients analyzed
mean ( sd ) periostin  ng / ml
any blood transfusion
low molecular weight heparin
yes ( stopped for trial )
previous chronic use of antiplatelet drugs
aspirin - erdp clopidogrel no . of patients / total no .
denosumab
patients randomized
days with asthma symptoms / week
statin with fibrate
delayed - start group ( n = $nmbr$ )
fev $nmbr$ % predicted ( post salbutamol )
intended durat - sm of antccagubficn
baseline dmard use  n ( % )
creatinine — mg / dl urinary albumin - to - creatinine ratio §
companion : wake - up stroke
placebo events / n ( % )
cdai score < $nmbr$
baseline ibdq total score  mean
positive for rheumatoid factor  anti - cyclic citrullinated peptide antibodies  or both — % ff
current alcohol use  n ( % )
cardiac medications at discharge  %
medical management only
shoulder pain
hbalc  mean ( s . d . )
$nmbr$ . $nmbr$ mg bid
pci during index hospitalization
history of cv disease
complex lesions ^
level $nmbr$ immobility ^
asia / pacific / other
calcium  mmol $nmbr$ $nmbr$
race  % caucasian
mtss cfb mean ± sd
study end concentration
potassium  mean ( sd )  meq / l
naive to antihyperglycemic agent therapy
swollen joint count  of $nmbr$
hemispheric tia n = $nmbr$
c - peptide tx difference vs pbo  median change from baseline ( se ) $nmbr$
severity of airflow limitation ( gold $nmbr$ )  n ( % )
other atherosclerotic event
retinopathy ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ )
mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$
fev $nmbr$ ( % predicted normal )
baseline total cholesterol
egfr category  n ( % )
rhabdomyolysis
any other antihyperglycaemic drugs
any risk factor for stent thrombosis
copd severity : mild / moderate
medications taken at time of randomization statins
neither n = $nmbr$  $nmbr$
exercise at least weekly ( a )
patients with previous intolerance of infliximab
mayo clinic score §
nob systolic blood pressure ( mm hg )
geographic region - other
months since first ra symptom  mean ( sd ) f
continuation ( n = $nmbr$ )
timi - defined bleeding
glycosylated hemoglobin  %
omeprazole
in - hospital ticagrelor ( n = $nmbr$ )
mean bmi ( $nmbr$ % ci )
physiological measures
atrial fibrillation pattern
corticosteroid + imm
thiazide at enrollment
nasopharyngitis
established atherosclerotic
overall effect
omega - $nmbr$ fa
ejection fraction : < $nmbr$ % ( n = $nmbr$ )
< $nmbr$ mm hg heart rate
lv ejection fraction ( % )
cangrelor clopidogrel no . of events / total no . ( % )
killip at baseline
time since asthma diagnosis ( years )
$nmbr$ placebo
carbamazepine
postmenopausal  current hormone therapy use
known duration of type $nmbr$ diabetes ( years )
beta - blocker at enrollment
number of exacerbations $nmbr$ months before randomisation
week $nmbr$ hba $nmbr$ c  mean ( s . e . )
tertile $nmbr$ ( n = $nmbr$ )
mean ( sd ) duration of copd  years
ci - aki risk score
risk factors for stroke  no . ( % )
esr ( mm / h )  median ( min  max )
units per week  mean ( sd )
c - reactive protein — mg / literj
non - u . s .
acuity - defined bleeding
vedolizumab
other / multiracial
time since qualifying event
> $nmbr$ vessels treated
statin use  n ( % )
previous coronary - artery bypass grafting
median ( min  max )
intensive control ( n = $nmbr$ ) no . of patients ( percent )
arterial hypertension  n ( % )
ranolazine ( n = $nmbr$ ) placebo ( n = $nmbr$ )
large shunt
history of hypertension  n ( % )
age y  median ( range )
companion : $nmbr$ - $nmbr$ hours
nt - pro bnp
lipid difference ( mg / dl )
other determined etiology
baseline pasi score
mean ( sd ) total asthma symptom scores
time since pah diagnosisc ( years )
alpha receptor antagonist
esrd on losartan ( % )
stroke at entry ( vs transient ischemic attack )
medical history and risk factors ( % )
placebo monthly ( n = $nmbr$ )
intravenous inotropes or vasopressors ( % )
overall a phase population
symptom onset to first medical contact : ambulance or emergency department
any glucocorticoid *
mean ( sd ) post - bronchodilator fev $nmbr$ percentage predicted
insulin ( mu / ml )
creatinine clearance < $nmbr$ ml / min
nihss at randomization
elevated serum potassium  > $nmbr$ . $nmbr$ mmol / l
concordant stress test abnormalities
eos serum k +  meq / l
duration of diabetes
arterial revascularization
endpoint rate
highest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl )
p interaction women vs men
malaysia
populations :
serum creatinine  弘 mol 儿 | |
index pci performed
retinopathy
history of nicotine use
insulin glargine n ( % ) / $nmbr$ py
no chd simva ( n = $nmbr$ ]
treated with insulin
previous ischemic stroke ortia
iglarlixi
previous cabg surgery
statin alone
study drug loading days ( actual ) : $nmbr$ ( n = $nmbr$ )
lumbar epidural
periprocedural medications
mean age  y  mean = sd
group dif . ( $nmbr$ )
prior cardiac resynchronization therapy  n ( % )
cardiac risk
albuterol use
no . of events / total
no . of participants per $nmbr$ patient - yr
estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . / total no . ( % ) §
established atherosclerotic disease
ukraine
negative for helicobacter pylori — no . / total no . ( % )
other medical history — no . / total no . ( % )
left atrial anteroposterior diameter — mm
any established peripheral arterial disease
serum k + level and drug treatment
chronic inflammatory disease
randomization to arrival in catheterization laboratory
rituximab
hemoglobin
high risk ( receiving treatment for ) :
c - reactive protein  median ( iqr )  mg / l
anti - tnf - naive patients
lipids  mean ( sd )  mg / dlt
high - dose statin use at screening *
second primary ( estimated change in total updrs score from baseline to wk $nmbr$ )
abciximab no . / total ( % )
no . of non - tnfi
current cvd / diabetes  n ( % )
cv mortality
duration of dementia symptoms  months
no pad baseline
pre ' rtous eptscde ( s } d dvt / pe
prior coronary artery bypass surgery
interaction p - value $nmbr$
ipah  hpah  hiv  drug or toxin induced
< $nmbr$ mg / dl simva ( n = $nmbr$ ]
location of disease  n ( % )
mtx ( mean dose : $nmbr$ . $nmbr$ mg / wk )
labs at the index acs event
black race ( n = $nmbr$ vs $nmbr$ )
treatment with any bp lowering drugs
placebo $nmbr$ / $nmbr$
diagnosed  y
peri - op statins : no ( n = $nmbr$ )
region  europe
copd disease severity
baseline dyslipidemia
difference in ls means ( $nmbr$ % ci ) $nmbr$
male gender  n ( % )
( $nmbr$ - $nmbr$ - cm vas )
screening absolute reversibility fev $nmbr$  ml
k - m %
type of surgery
hosp . worsening hf
rest of the world
placebo no . / total no .
azathioprine / $nmbr$ - mercaptopurine
duration of diabetes  mean ( sd )  y
cox - $nmbr$ selective nsaid
total ( n = $nmbr$  $nmbr$ ) - -
laboratory variables
baseline anti - hyperglycemic medications
ivabradine group ( n = $nmbr$ )
undergoing major vascular surgery
< $nmbr$ baseline killip class
statin intensity $nmbr$ * $nmbr$
multivitamin use
baseline body weight quartile
baseline fpg  mean ( s . e . )
primary pci n = $nmbr$
prior tnfi treatment
multiple ( > $nmbr$ ) chd risk factors that confer a $nmbr$ - year risk of chd > $nmbr$ %
pctindopnl - indapamide ( n = $nmbr$ )
history of impaired renal function
stroke of any etiology
fasting insulin ( pmol / l )
total body ( without head )
fatty acid composition
cerebral hemorrhage
pasi $nmbr$ response }
nonglycemic cardiovascular risk factors systolic blood pressure — mmhg
duration of diabetes ( months )
alpha - glucosidase inhibitors
anthropometry : mean ( sd )
white ethnicity
vascular history  %
time from qualifying myocardial infarction
$nmbr$ — $nmbr$ nlmw
postoperative glucocorticoid use post - randomisation characteristic * *
sinus rhythm
united states or canada
heparin  ‘ ondaparinux or brvalirudin use between rxjex event
community hospital  n ( % )
patient - reported outcome measures
> $nmbr$ . $nmbr$ mg / liter antiplatelet agents
ara functional class — no . ( % )
left ventricular ejection fraction
restenotic vessel
mean $nmbr$ - year cvd risk *
^ median > median
ace inhibitors / sartans
duration of hypertension  y
history of pci — no . / total no . ( % ) : t
current cigarette smoker or within past year
time to randomization from symptom onset
motor weakness
hospitalization for hf previous year  ( % )
st - segment depression < $nmbr$ . $nmbr$ mv  %
ab / ff $nmbr$ / $nmbr$ pg ( n = $nmbr$ )
severity of airflow obstruction
tender - joint count ( of $nmbr$ joints )
tenecteplase
median duration of symptoms ( range )  yr
history of pci / ptca
only dvt
glucose - lowering drug
age group ( years )
renal events
blood leucocyte concentration ( $nmbr$ cells per l )
baricitinib $nmbr$ mg
etd ( % ) [ $nmbr$ % ci ]
ranolazine ( n = $nmbr$ )
below - knee popliteal
uacr ( mg / g )
geographic location
albuminuria
angina  n ( % )
acr $nmbr$ response
dyslipidemia $nmbr$
past or current
interval from randomization to angiography
enthesitis
previous treatment
non - tnf inhibitors
any blood - pressure - lowering drug 一 no . ( % )
previous stroke — no . ( % )
proximal to the splenic flexure
high eosinophil subgroup ( > $nmbr$ / ml ) ( n = $nmbr$ )
patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n
slo days
cardiovascular mortality
m $nmbr$ subgroup
valsartan ( n = $nmbr$ )
japan n = $nmbr$
modified se - adl scale
corticosteroids only
p - value interaction
undetermined  other  or cardioembolism
percentage patients reaching target
hispanic  n ( % )
modified has - bled
insulin alone
statin only  n ( % )
body - mass index categories — no . ( % ) : c
monocytes  $nmbr$ / nl
criteria for subcortical vad ( by mri )  %
crp mean ( mg / dl ± sd )
angiographic features
> $nmbr$ years to < $nmbr$ years ( n = $nmbr$ )
pathologic q waves  n ( % )
duration of metformin therapy ( months )
baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks
lesion location
patients treated with statins ( n = $nmbr$ )
copd exacerbations during the previous year
biasp $nmbr$
insulin — iu
subject characteristics
primary composite outcome
category $nmbr$ and $nmbr$
race or ethnic background — no . ( % ) f
renal function subgroups
percent of patients
placebo / simvastatin
% of predicted normal value *
body - mass index ( kg / m $nmbr$ )  mean ( sd )
rolofylline dose
canagliflozin dose
pbo + statin $nmbr$
orthopaedic
geographic region — number ( % )
black race — no . / total no . ( % ) f
versus olodaterol $nmbr$ pg
antihypertensive agents  n ( % )
baseline cardiovascular medication
alpha - blocker
modified total sharp score * *
beta - blocker use at baseline
all - cause
class $nmbr$ or no symptoms
laboratory variables at baseline
pneumonia in past year
apixaban  $nmbr$ mg ( n = $nmbr$ )
chd men
calcium antagonist strategy ( cas ) ( events / n )
muscle twitching
other medication usage
qva $nmbr$ $nmbr$ / $nmbr$ | ig od n = $nmbr$
female sex — number ( % )
heart rate  beats / min  mean ± sd
mitral insufficiency  n ( % )
from baseline ( $nmbr$ % ci )
compression stockings
baseline triglycerides < $nmbr$ mg / dl
apo b / apo a - l
beta - carotene ( n = $nmbr$  $nmbr$ )
> $nmbr$ years baseline ldl - c
prevalence of each metabolic syndrome criterion
sex  men / women  %
high - dose statin use  n ( % ) e
fasting glucose ( mmol / l )
fistula at baseline  n ( % )
dizziness
coronary angiography — no . ( % )
presenting signs and symptoms
moderate copdb [ n z $nmbr$ ]
planned conservative therapy subgroup
sonti amenca
clopidogrel  $nmbr$ mg *
methotrexate
hs - crp ( mg / l  median )
previously taken dmards other than methotrexate  %
non - ischaemic ( n = $nmbr$ o $nmbr$ )
progestins
fasting serum glucose ( mg / dl )  median ( iqr )
normalized
time from hospital admission to pci  h  median ( q $nmbr$  q $nmbr$ )
known t ' rc - iitoji cccndilon
ii or iii
left ventricular ejection
left ventricular ejection fraction — no . / total no . ( % )
previous loss of response to and intolerance of infliximab  n ( % ) *
reported diabetes mellitus
other / missing
severe or moderate
coronary bypass  n ( % )
new zealand
cox - $nmbr$ selective nsaid use
heart failure cause
sbp ( mmhg ) < $nmbr$
past smoker  n ( % )
previous stroke — no . ( % ) concomitant treatment — no . ( % )
mean ( s . d . ) hdl cholesterol
amiodarone ( n = $nmbr$ )
previous disease — no . ( % ) f
esrd on placebo ( % )
acute respiratory insufficiency
> $nmbr$ % predicted arr ( n = $nmbr$ )
associated with drug or toxin exposure
ls mean change ± sea
reversible ( % )
left atrial dimension  cm
aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$
diuretics ( % )
ldl cholesterohhdl cholesterol ratio
renal insufficiency $nmbr$
> $nmbr$ : $nmbr$ hrs : min ( n = $nmbr$ )
sr ii b $nmbr$ - cjl $nmbr$
csdmards + mtx ( n = $nmbr$ )
uc duration  y  mean ( range )
ejection fraction category
high - probability ventilation / perfusion lung scanning
mmse $nmbr$ - $nmbr$
use oforal glucose - lowering agent — no . ( % )
baseline sgrq total score
min - max age
baseline gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )
ischemic stroke
medications at discharge
multiracial  n ( % )
q $nmbr$ : $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ )
heart rate
self - reported disease severity  $nmbr$ - $nmbr$ scale *
concomitant aedsa
immunosuppressant use  %
moderately high risk
triglycerides  median ( ql  q $nmbr$ )  mmol / l
$nmbr$ = some restrictions  no help needed
$nmbr$ or $nmbr$ high - risk categories
calcium antagonist strategy ( n = $nmbr$ $nmbr$ )
time to balloon / needle  min *
no - diuretics group ( n = $nmbr$ )
egfr . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ )
patients with any clinical
squamous cell carcinoma
( pg / mg )
phosphodiesterase type $nmbr$ inhibitors
history of stroke ( % )
age ^ $nmbr$ yrs  n ( % )
cangrelor ( n = $nmbr$ )
previous cabg ( % total )
baseline composite mayo clinic score
ticlopidine after completion of study drug
admission for hf in previous year  n ( % )
time since diagnosis — mo
left main coronary artery
other llt at randomization
other anti - hypertensives
a ngina > $nmbr$ day s previously *
% predicted
use of antihypertensive drugs
total cholesterol ( median  iqr )  mg / dl
hr ( $nmbr$ % ci ) p   value
loop or thiazide diuretic : ! :
monitoring group ( n = $nmbr$ )
ischemic coronary artery disease
blood eosinophil count > $nmbr$ / mm $nmbr$ at screening — no . ( % )
no known frtrontxtfufoc cond aon
mssbp / msdbp
devices for heart failure at screening visit
interleukin $nmbr$ ( pg / ml )
priorvascular disease  %
planned thienopyridine at enrollment
background csdmard category
relative risk ( $nmbr$ % ci ) ofprimary end point
history of gi bleeding or ulcer — no . / total no . ( % )
non - fibrin - specific
gly $nmbr$ . $nmbr$ mg b . i . d . n = $nmbr$
previous coronary angioplasty  n ( % )
mean ± sd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
octave induction $nmbr$ and $nmbr$
single vessel coronary artery disease $nmbr$
greater than or equal to $nmbr$ %
baseline nih stroke scale — no . ( % ) ^
history of stroke or tia — no . ( % )
chd + cerebrovascular disease men $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )
albumin ( mg / dl )
lp ( a ) ( pmol / l )
st - segment depression
statin — no . / total no . ( % )
> $nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo
ascvd as per protocol
oral antidiabetes combination therapy without insulina  n ( % )
interquartile range — yr
beta - blockers through hospital discharge or day $nmbr$ — %
korea  republic of
corticosteroid ( without imm )  n
index event subtype
residual perfusion defect > $nmbr$ % on lung scan  no . ( % )
antiplatelet agent or anticoagulant
atorvastatin monotherapy ( n = $nmbr$ * )
glycoprotein ilb / iiia inhibitor before pci ]
extensive disease other
catheter access site
number of individuals
congenital heart disease
ff $nmbr$ gg ( n = $nmbr$  $nmbr$ )
time from event to randomization — days
clinical
presence of mets ( % ) a
parental history of mii
fasting serum glucose  mg / dl
treatment at randomization
glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ ma
qrs duration > $nmbr$ ms  n ( % )
median time to first exacerbation ( months [ $nmbr$ % ci ] )
fasting c - peptide ( nmol / l ) c
tender joint count ( $nmbr$ joints )
all - cause hospitalization
duration of full - dose warfarin therapy before enrollment ( mo )
severe or very severe copd
$nmbr$ mg vs placebo
$nmbr$ mwd  m
proportion ( $nmbr$ % ci ) adjusted for baseline hba $nmbr$ c  %
waist ( cm )
qualifying diagnosis
mean disease duration  y ( sd )
daily activities / social functioning
saxa $nmbr$ . $nmbr$ mg
rosuva $nmbr$ mg n = $nmbr$
bmi group — no . ( % )
lv mass
hours from clopidogrel loading  mean ( sd )
non - ischaemic
omega $nmbr$ allocation
adjusted $nmbr$ risk reduction losartan vs placebo ( $nmbr$ % cl )
n - $nmbr$ pufa
combined ( n = $nmbr$ )
lamotrigine
maximal diameter stenosis
hispanic ethnic group  n ( % )
multivessel coronary artery disease — no . / total no . ( % )
history
patient ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd )
prior cardiovascular event  '
no . with event / total no . { % )
ras - aldosterone inhibitor ^
mean ( sd ) post - bronchodilator fev $nmbr$ / fvc  %
non - hispanic white
ethacrynic acid
aqlq ( s ) score
patients who received negative results on test for antibodies to infliximabt
non - hdl ( mg / dl ) < $nmbr$
all completers
mean difference = seb
> $nmbr$  n ( % ) gender  n ( % )
prior use of $ $nmbr$ systemic therapies
health assessment questionnaire ( $nmbr$ - $nmbr$ range )
low - molecular - weight heparin
non - hdl cholesterol ( mmol / l )
previous medication for respiratory disease — no . ( % )
characteristics of the index ml
history of heart failure
prior cardiovascular history
metabolic syndrome $nmbr$ *
consistency of effect
fondaparinux
other lipid - modifying drug 一 no . ( % )
initial timi flow
overall $nmbr$
absolute decrease > $nmbr$ %
recurrent hf hospitalization
intrathoracic or intraperitoneal surgery
former or never diabetes
geographic site  %
history of high cholesterol ( a ) $nmbr$
history of heart failure  n ( % )
sco . ’ ita ' rojs dvt . ' pe
general health vas  $nmbr$ - $nmbr$ mm
placebo / open - label abatacept
prior known stenosis > $nmbr$ %
ras antagonist  %
cancer medications
current other ( predefined ) medical conditions
center location
time from qualifying stroke to randomization
geographical region  n ( % )
priorbone disease
laba - inhaled glucocorticoid use at screening
main concomitant treatments  no . ( % )
use of rescue medication
p vs placebo
cardiac troponin t level > $nmbr$ . $nmbr$ pg / l
aspirin < $nmbr$ day
native coronary
arthralgia
other bdmards ( no tnfi taken ) t  n ( % )
hmgcoa rl
egfrmdrd  ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$
prior angioplasty
anti - ccp antibody ( u /
mean baseline ldl - c ( mmol / l )
composite events
foot fracture
non - caucasian simva ( „ = $nmbr$ }
tc  mean ( sd )  rrig / dl
high risk and fewer symptoms ( group c )
type $nmbr$ diabetes history  n ( % )
total cholesterol / hdl - c
hypertension absent
warfarin
moderate  n ( % ) a
urine acr ( mg / g )
baseline systolic blood pressure
hr $nmbr$ and $nmbr$ % cl
ventricular tachyarrhythmias
sulfonylurea based
medication use — no . ( % ) ^ |
bivalirudin ( n = $nmbr$ )
p - blockers  n ( % )
acarbose 一 no . ( % )
unfractionated heparin
all patients n = $nmbr$
sitagliptin no . / total no .
% anti - ccp + ( > $nmbr$ units )
septal anomaly — no . ( % )
intensified ( n 二 $nmbr$ )
long - acting b $nmbr$ - agonists
bodily pain
mmrc grade
alcohol consumption > once weekly
p - value for trend *
blood eosinophil count > $nmbr$ / mm $nmbr$ in $nmbr$ months before screening — no . ( % )
at entry
tiotropium group ( n = $nmbr$ )
$nmbr$ - $nmbr$ months ( n = $nmbr$ )
dapagliflozin $nmbr$ mg group ( n = $nmbr$ )
p value ( aged > $nmbr$ vs . < $nmbr$ years )
valvular disease
prior angina
japan and south korea
postoperative nsaid or glucocorticoid use post - randomisation characteristic * *
all randomized patients
pack - years  mean ( sd )
epa hr events ( % )
type of myocardial infarction — no . ( % )
pciperformed for qualifying event
nonsustained ventricular tachycardia — no . ( % ) - j -
ventricular tachycardia or fibrillation
percutaneous intervention
hazard ratio for cardiovascular death  stroke  or myocardial infarction ( $nmbr$ % ci )
hypercholesterolemia  n ( % )
diclofenac
$nmbr$ week to $nmbr$ month
gp llb / llla inhibitors
current  n ( % )
syndesmophyte present  n ( % )
angiographic findings | |
apixaban  $nmbr$ mg
bypass graft
bm $nmbr$ ( kg / m $nmbr$ )
$nmbr$ = no symptoms
prior brachytherapy
time since cessation of full - dose warfarin therapy
history of or current cardiac disorders  %
impaired glucose tolerance or impaired fasting glucose
severe  n ( % ) b
hospitalization for heart failure within previous $nmbr$ mo — no . ( % )
diuretics  n ( % )
mmse ( points )
apixaban ( n = $nmbr$ )
corticosteroid ( with or without immunosuppressants )
congestive heart failure
chf on placebo ( % )
overall hr ( $nmbr$ % cl )
hyperlipidemia — no . ( % )
p value for trend across tertiles
$nmbr$ - $nmbr$ drinks / wk
> $nmbr$ mg / dl — %
diagnosis of allergic rhinitis
refractory to such therapy — no . ( % )
lymphocytes  $nmbr$ / + il
adjusted * or ( $nmbr$ % ci ) p value
fev $nmbr$ % pred . ( post - albuterol )  %
known thrombophilia — no . ( % )
$nmbr$ - $nmbr$ ( mild )
simvastatin  n ( % )
age  mean ( sd ) [ range ]  y
copd exacerbation history  n ( % )
atio - pla
cardiac troponin t level  median ( iqr )  pg / l
estimated glomerular filtration rate  ml / min per $nmbr$ . $nmbr$ m $nmbr$
toast classification of qualifying stroke ( % )
duration of diabetes by tertiles
on drug treatment ( % )
triglyceride ( median  mg / dl ) - $nmbr$ [ $nmbr$ - $nmbr$ percentile |
pre - specified hr ( $nmbr$ % cl )
cardiac medications during indexhospitalization and / or discharge
neither corticosteroid nor immunosuppressant
albumin / creatinine ratio  n ( % )
score on modified rankin scale — median ( iqr )
placebo group
discontinuations due to ae
creatinine clearance  n ( % )
multi vessel ( or left main )
infarct location
elevated hscrp
laba + ics n = $nmbr$
renal function  severe
high - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl
mean ± sd fasting insulin  uu / ml
at least $nmbr$ / mo
atrial fibrillation — no . / total no . ( % )
ls - mean between - group difference ( $nmbr$ % ci )
all others  n ( % )
joint swelling  effusion  or both on clinical examination — no . ( % )
median age ( $nmbr$ %  $nmbr$ % )  y
history of cerebrovascular disease
laba or lama ’
metformin ( n = $nmbr$ )
prior cabg ( before index acs )
anti - tnf - experienced patients
digoxin / digitalis glycoside
body mass index ( range ) ( kg / m $nmbr$ )
patients with previous loss of response to infliximab
treatment group
haq - di  mean ( sd )
duration of copd ( years )  mean ( sd )
egfr < $nmbr$  ml / min / m $nmbr$
carotid infarct
negative ( < $nmbr$ . $nmbr$ )  n ( % )
endpoint week $nmbr$
homa - ir  mean ( sd ) ( mu / l $ mmol / l ) b
lipid and lipoprotein values ( mg / dl )
placebo no . of events / no .
for treatment of index event
mild ( > $nmbr$ to < $nmbr$ )
heterogeneity p value
number of stents ( per patient )
preoperative serum creatinine > $nmbr$ pmol / l
sacubitril / valsartan ( n = $nmbr$ )
mean ( s . d . ) apoc - ll $nmbr$  mg / dl
implanted cardioverter - defibrillator
swollen joint count ( n / $nmbr$ )
postmenopausal ( % )
coronary disease
prior lev treatment
rsg $nmbr$ mg / day
former or current smokers ( % )
topiramate
hydrochlorothiazide
toast classification of qualifying stroke  no . ( % )
class $nmbr$ antiarrhythmic agents
age  mean $nmbr$ sd years
concomitant methotrexate  n ( % )
corticosteroids . immunosuppressants . and antimalarials
bl mean  mg / dl ( mmol / $nmbr$ )
history of diabetes mellitus  n ( % )
median ( iqr ) admission data
not provided
current bone disease
triglyceride ( median : mg / dl ) a [ $nmbr$ - $nmbr$ percentile ]
stent plus abciximab
systolic blood pressure < $nmbr$ mm hg and diastolic blood pressure < $nmbr$ mm hg
vasoprotectives
associatedproximaldeep - veinthrombosisatdiagnosis  no . ( % )
discharge medication  n ( % )
other cardiac surgery  n ( % )
induction - trial group assignment — no . ( % )
bw  mean ( sd )  kg
first procedure
prior af ablation  n ( % )
fev $nmbr$ reversibilityz ( pre / post salbutamol )  %
second - generation stent
msasss  mean ( sd )
total cholesterohhdl cholesterol ratio
primary safety end point : severe / life - threatening
nt - probnp ( pg / ml ) ( q $nmbr$ - q $nmbr$ )
remodeling
smoking past
cigarette smoking status
use of concomitant lipid - lowering therapy - no . ( % )
prior arrhythmias  n ( % )
thienopyridine at enrollment
coronary risk factors — no . ( % )
cardiovascular risk factors
less than $nmbr$ year
anti - arthritic medications
some physical activity
first medical contact — no . ( % ) §
premature cad among family members
ppci in - $nmbr$
overall n = $nmbr$  $nmbr$
fev $nmbr$ % predicted  post - albuterol  %
medical therapy only
aspirin and thienopyridine therapy
heart rate  mean ( sd )  beats / min
tg  median ( interquartile range )
non - hispanic black
normal renal function
renal parameters
fasting blood glucose — mmol / liter
glycoprotein iib / iiiareceptorinhibitor
plaque ( n  % )
coronary angiography
age  mean ( min - max ) ( yrs )
evolocumab $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ )
patients not receiving immunosuppressive agents at baseline
no . ( % ) with event [ incidence rate per $nmbr$ patient - y ]
screening hba $nmbr$ c ( % )
modified rankin scale — no . ( % ) |
previous cancer  n ( % )
penetrating
more than $nmbr$ vessels stented
changes ( a ) in metabolic syndrome parameters hdl cholesterol
baseline acq - $nmbr$ score
dm medication  n ( % ) c
left main disease
> $nmbr$ lesions per vessel
xanthines $nmbr$
tg ( mmol / l  median )
verapamil sr strategy ( n = $nmbr$  $nmbr$ )
aspirin ( asa ) ( » = $nmbr$ $nmbr$ )
weight  mean $nmbr$ sd kg
hispanic black
atrial fibrillation or flutter — no . ( % )
on - treatment
killip class i — no . ( % )
killip class ( interaction : p = $nmbr$ . $nmbr$ )
adjusted hr ( enl vs lcz ) ( $nmbr$ % cl )
total basdai  mean ( sd )
placebo + statin ( n = $nmbr$  $nmbr$ )
thrombus aspiration
marital status  married
no . of days to randomization — median ( iqr )
exacerbations in previous year
pain ( $nmbr$ mm vas )
angiogenesis
non - fatal mi
who functional class — no . ( % ) : c
diabetic patients
type $nmbr$  n ( % )
abatacept $nmbr$ / — $nmbr$ mg / kg ( n = $nmbr$ )
black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ) ■ -
baseline treatments  n ( % ) a
imm ( without corticosteroid )
mean ( sd ) number of exacerbations *
s . e .
spiralcomputedtomographyangiography
p ( losartan versus placebo )
apo b / apo a - l ratio ( mean )
mean ( s . d . ) non - hdl cholesterol
secukinumab $nmbr$ mg
early - start group ( n = $nmbr$ )
p interaction ( rx arm * sex )
left ventricular hypertrophy  n ( % )
af pattern
severity of copd
post - bronchodilator fev   % predicted
copd or asthma  ( % )
body - mass index — no . ( % ) $
waist - to - hip ratio
$nmbr$ years or older
years since myocardial infarction
with alogliptin $nmbr$ mg ( n $nmbr$ $nmbr$ )
hoehn and yahr stage
elevated cardiac markers — no . ( % ) : t
scores for global and pain assessments §
documented coronary artery disease
large vessel atherosclerosis
hbalc < $nmbr$ % ( < $nmbr$ mmol / mol )  n ( % )
copd severity
geometric mean
assoc  with connective tissue disease
chronic kidney disease stage : egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
haq - di ( $nmbr$ - $nmbr$ )  mean ( sd )
egfr crcl < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
baseline weight  kg
bifurcation  n ( % )
pe ( with or without dvt )
difference $nmbr$
dilatative  n ( % )
arterial access
serum cholesterol ( mg / l ) *
cerebral thrombosis
rosuva $nmbr$ mg
dose of atorvastatin
mean ( sd ) weight  kg
congestive heart failure — %
no prior ms therapies
glucocorticoids only
background aha therapy at screening  n ( % )
established atherosclerotic cv disease §
angina symptoms ^
pain ( vas )
stroke subtype  n ( % )
with placebo
relative risk ( $nmbr$ % confidence interval )
r $nmbr$ mg + fa ( « = $nmbr$ )
previous pci or cabg
total pack - yrs
baseline trl - c by quintiles
mtx > $nmbr$ and £ $nmbr$ mg / week
ff / vi $nmbr$ / $nmbr$ | ig ( n = $nmbr$ )
( $nmbr$ % ell ' ll
corticosteroids and immunosuppressants only
number of vessels treated  index pci
mra ( spironolactone or eplerenone )
peripheral artery occlusive disease
baseline value
chronic cvd
established ( n = $nmbr$ )
known thrombophilia
normal > $nmbr$ - $nmbr$
estimated gfr renal function stage
tg  mmol / l ( mg / dl ) [ median ]
clinical characteristics
interval after index event
country  n ( % )
fractures ( site not specified )
number of previous dmards
non - hispanic
proportion of patients in corticosteroid - free clinical remission at week $nmbr$
pramlintide
height  inches
antithrombotic agents
ambulance  n ( % )
chd risk - no . ( % )
infusion administered — no . / total no . ( % )
non - hdl cholesterol ( week $nmbr$ )
inhaled glucocorticoid use at screening
type of vessel involved
oral blood glucose - lowering drug $nmbr$ ( $nmbr$ . $nmbr$ )
baseline pos frequency per $nmbr$ days  median ( min  max )
mean ( sd ) mtx dose  mg / week
laboratory ae  n ( % }
use of concomitant lipid - lowering treatment
age ( y )  median ( iqr )
heart failure  lvef < $nmbr$ %  or both
omalizumab ( lsm )
baseline cv medications  n ( % )
$nmbr$ or $nmbr$ high cardiovascular risk categories
pack - years smoked
exenatide lar
concomitant treatment
score on the minnesota living with heart failure scaled
eosinophil count ( cells per pl )
disease duration ( yr )  mean ± sd
baseline total pcsk $nmbr$ level by median
antiplatelet agents ( % )
peripheral vascular disease  n ( % )
duration of disease — yr : t
infarction $nmbr$ - $nmbr$ days
estimated difference ( $nmbr$ % ci )
non - st - elevation myocardial infarction
aspirin i clopidogrel ( n = $nmbr$  $nmbr$ )
pulmonary disease — no . ( % )
etn $nmbr$ mg + mtx n = $nmbr$
all stroke
previous respiratory disease other than copd — no . ( % )
history of stroke or transient ischemic attack
pelvic fractures
standard care allocation
ra duration ( months ) *
other drugs — no . ( % )
atherosclerotic disease *
angiography and revascularization
unfractionated heparin ( n = $nmbr$ )
demographic and clinical characteristics
mean lixi dose ± sd ( lg / day )
number ( % )
age subgroups
ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$ )
glycated hemoglobin  mean ( sd )  %
no . of events / no . of patients
carotid artery intervention *
hope patients with coronary - artery disease ( n = $nmbr$ )
linagliptin / metformin
ultrasound carotid arteries
pci or cabg surgery for index event
das $nmbr$ - $nmbr$ ( esr ) $nmbr$
cardiac therapy §
low - dose statin
oral anticoagulant  n ( % )
p - value for interaction $nmbr$ . $nmbr$
> $nmbr$ des type
placebo patients with events / total
average age ( year )
placebo + $nmbr$ mg / d of simvastatin
baseline hb $nmbr$ g i $nmbr$ n = $nmbr$
type of end point
copd medication at study entry
emphysema
mean ( sd ) esr  mm / h *
vilanterol  n = $nmbr$
latin america ( n = $nmbr$ )
third heart sound
tnfi naive
continued thienopyridine ( n = $nmbr$ )
total intravenous loop diuretic ( mg ) median
mild to moderate
median n - terminal probnp ( iqr ) — pg / ml
degree of stenosis  % of diameter
diagnostic angiography
left ventricular hypertrophy on echo
fasting serum glucose  median ( sd )  mg / dl
abatacept plus mtx ( n = $nmbr$ )
baseline measurements
non - compliance
duration of pre - randomization anticoagulant therapy
bmi at baseline ( kg / m $nmbr$ )
average maximum common and bifurcation cimt ( mm )
location
kheeatne index dvt
osteitis
$nmbr$ - $nmbr$ months fn = $nmbr$ . $nmbr$ )
glinide 一 no . ( % )
below - knee popliteal crural
pre - enrollment antihyperglycemic therapy
symptom duration
% patients with no progression
measured at clinic visit with automated device §
previous episode of heart failure
liraglutide ( n = $nmbr$ )
hba $nmbr$ c  % ( sd )
post - bronchodilator fev $nmbr$ — liters
renal insufficiency
lvef within $nmbr$ mo  %
ldl cholesterol  mmol / l  mean ± sd
history of hypertension for $nmbr$ mo or more
fish oil ( n = $nmbr$ )
digitalis glycoside
baseline mean
no previous dmard therapy
hba $nmbr$ c at $nmbr$ weeks *
glycated hemoglobin
elevated fasting glucose
no adk / e cancer
indacaterol + tiotropium ( n [ $nmbr$ )
ras % target dose
history of upper gastrointestinal event
ibdq score |
first primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ )
overweight ( $nmbr$ to < $nmbr$ kg / m $nmbr$ )
symptom onset - to -
median ( iqr ) cholesterol
week $nmbr$ mean ( se )
western europe  israel  australia  or south africa
imm + corticosteroid  n
t $nmbr$ dm duration  y
previous myocardial infarction  n ( % )
no . ( % ) of participants
previous tnf antagonist exposure  n ( % )
pharmacotherapy
ulcerative colitis
received $nmbr$ prior anti - tnf therapy  n
placebo n ( rate ) *
low - density lipoprotein
family history ^
fvc ( % predicted )
clinical ae  n ( % }
dietary epa - dha intake ( mg / day ) *
other llt use
ada $nmbr$ / $nmbr$ n [ $nmbr$
serious adverse events
change from baseline at week $nmbr$
medications at coronary angiography
$nmbr$ $nmbr$ years  n ( % )
no . of subjects
fpg  mean ( sd )  mg / dl [ mmol / l ]
acr $nmbr$ response  n / n ( % )
sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$  $nmbr$ )
geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mm $nmbr$
copd - placebo ( n = $nmbr$ )
pga subscore
mafcaiancy at randorrtzaton
$nmbr$ . $nmbr$ mg / dl triglycerides ^
antiplatelet within $nmbr$ mo before randomization
lesion characteristics
handihaler and diskus  n
baseline dyspnea index score
creatinine clearance — no . ( % )
any oral hypoglycemic drug 一 no . ( % )
sfc $nmbr$ / $nmbr$ pg b . i . d . n = $nmbr$
infarct related artery location
pen - label empagliflozin $nmbr$ mg ( baseline hba $nmbr$ c > $nmbr$ % )
other vasculars
patients who received indeterminate results on test for antibodies to infliximabt
history of diabetes requiring drugs
coronary intervention
elevated at wk $nmbr$ — no . ( % ) !
body mass index category  no . ( % ) l
liraglutide $nmbr$ . $nmbr$ mg mean ( n )
hab $nmbr$ c ( mean ± sem )  %
low risk ( $nmbr$ - $nmbr$ )
gfr as assessed by mdrd
history of ischemic stroke
$nmbr$ - minute walk distance — m
male / female  %
current inhaler +
phosphate ( mmol / l )
established cardiovascular disease
smoker ( current / former )
total cholesterol - to - hdl cholesterol ratio
oral anticoagulant drugs  n ( % )
definite
abciximab - facilitated pci ( n = $nmbr$ )
computed tomographic angiography
distribution — no . ( % )
intravenous heparin
$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ to < $nmbr$ mmol / mol )
$nmbr$ - month follow - up median ( iq range )
biventricular pacemaker
warfarin group
$nmbr$ aspirin ( n = $nmbr$ $nmbr$ )
short form $nmbr$ ( sf - $nmbr$ )
individual intended study duration — no . ( % )
male nyha class
metoprolol group ( n = $nmbr$ )
fenofibric acid
warfarin at enrollment
global ischemia
p value § ( < $nmbr$ vs . > = $nmbr$ years )
hf or lvef < $nmbr$ % associated with index event
subject completion status  n ( % )
egfr — ml / min / $nmbr$ . $nmbr$ m * *
coronary angioplasty or stenting
death from cardiovascular causes
$nmbr$ mg / dl ldl cholesterol | |
femur fracture
erythrocyte sedimentation rate  mm / hour
insulin sensitivity — % §
anti - tnf agent ( s )
medication after enrolment
number insulin glargine
asian ( $nmbr$ . $nmbr$ % )
lifestyle modifications
change from
% change  $nmbr$ % ci )
< $nmbr$ nwrrtn
moderate renal impairment
major diabetic eye disease  n ( % )
all participants
history of atrial fibrillation / flutter  ( % )
apixaban dose ( or matching placebo )
symptom onset
prosthetic
disease hare . no . ( % ) i
treatment by egfr stage
hormonal therapy — no . ( % )
angina pectoris  ( % )
type of stent at index procedure
blood pressure lowering medication use
gpi used during pci
lowzmedium intensity
antihypertensive therapy  n ( % )
any medication
mean — mm hg level — no . ( % )
chd simva $nmbr$ = $nmbr$ ]
diabetic history ( years ) x
urine albumin / creatinine ratio ( mg / g )
extensive colitis or pancolitis
moderate ckd at randomization
less than the median
qualifying cv event  n ( % )
peripheral artery occlusive disease ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ )
or placebo treatment
diabetes $nmbr$ ( % )
continued thienopyridine ( n $nmbr$ $nmbr$ )
saxagliptin $nmbr$ . $nmbr$ mg
patients with ra  as  or psa ( n = $nmbr$ )
chronic bronchitis ( % )
reduction in risk ( $nmbr$ % ci ) %
moderate disease activity : > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$  n ( % )
age $nmbr$ years or more
valsartan / hctz ( n = $nmbr$ )
ics users  n ( % )
since onset
diabetes at randomization
treated with pci — no . / total no . ( % )
device group ( n = $nmbr$ )
left main coronary artery  n ( % )
statin use at study entry  n ( % )
lipid disorder
history of atrial fibrillation  type 一 no . ( % )
total diuretic dose ( iv + oral ) on day $nmbr$  mg
enthesitis  n ( % )
immobazaton
digit symbol substitution
prior coronary revascularization ( pci or cabg )
hbalc  median ( ql  q $nmbr$ )  %
fasting cholesterol — mg / dl
idiopathic
mean ( sd ) [ range ]
inhaled corticosteroids
fasting insulin — pmol / liter
watchman ( n = $nmbr$ )
apixaban  $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
primary renal endpoint
hgb  g / dl
normal ( > $nmbr$ )
type of des at index procedure
$nmbr$ vitamin e ( n = $nmbr$ $nmbr$ )
persistent wrf ( n = $nmbr$ )
estonia
score on modified rankin scale ( ' % / '
atrial fibrillation or flutter ( ecg ) §
adcs - adl score *
mean sf $nmbr$ score ( $nmbr$ % ci )
qrs > $nmbr$ ms  n ( % )  available for $nmbr$ patients
baseline high - sensitivity crp
heart rates ( beats / minutes )
insulin glargine allocation
left side of colon
left ventricular hypertrophy
non - cortical
low - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl
unsuccessful procedure
previous angina  n ( % )
$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ( % )
nt - pro - bnp — pmol / liter - j -
sirukumab $nmbr$ mg q $nmbr$ w
baseline post - bronchodilator % predicted fev  > $nmbr$ % and concurrent tiotropium use
euroscore additive  median ( $nmbr$ th  $nmbr$ th % ) §
lev - naive
clinical disease activity index score ( $nmbr$ - $nmbr$ )
black / african - american ( $nmbr$ . $nmbr$ % )
chronic cox $nmbr$ inhibitors
no . of coronary vessels with > $nmbr$ % diameter stenosis
history of claudication
seated sbp at $nmbr$ weeks  mmhg +
ended > $nmbr$ days before trial entry
rope score * *
inter p - value
risk factor profile index event
use of ace inhibitor  arb  or both — no . ( % )
clopidogrel  $nmbr$ mg loading dose !
adverse eventy
discontinued
duration of osteoarthritis symptoms — yr
total cholesterol - mg / dl * *
peripheral revascularization ( n = $nmbr$ )
smoking in past yr
percentage of patients using ics or ics / laba on entry
mean change
neither ics nor laba
combination - facilitated pci ( n = $nmbr$ )
bifurcation
coronary heart disease death
< $nmbr$ mg / dl eze / simva ( n = $nmbr$ }
a / v ( n = $nmbr$ ) v ( n = $nmbr$ )
hypertrophic cardiomyopathy
median body mass index  kg / m $nmbr$ ( iqr )
$nmbr$ - year framingham chd risk ( % ) $nmbr$ mean / sd )
ecrcl  ml / min
time from longest event to randomisation
no prior hf hospitalization
conservative
serum creatinine ( pmol / l )  mean ( sd )
any cv history / risk factors  n ( % )
vte at day $nmbr$ +
age of completion of highest education  years ( sd )
pfo + asa
$nmbr$ mg / day - placebo
mtss cfb
mental component summary
low - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se )
dihydropyridine calcium - channel blocker
germany
high sensitivity c - reactive protein ( mg / l )
azathioprine
high risk ( ri ≥ $nmbr$ )
egfr ( ml / min per $nmbr$ - $nmbr$ m ' )
ez / simva $nmbr$ mg
patients receiving immunosuppressive agents at baseline
demographics age  years  mean ( sd )
previous aorta - femoral or lower extremity bypass surgery  pta of iliac  or infrainguinal artery
fracture
clopidogrel loading dose $nmbr$ mg
renal insufficiency — no . ( % )
caucasian eze / simva ( „ = $nmbr$ }
tg mg / dl  median ( sd )
locafon of index dvt
baseline nihss
clinical details
limited i -
intracranial disease of major artery 寸
mean bp ( mmhg )
no chd eze / simva $nmbr$ = $nmbr$ }
heart rate  b . p . m . mean ± sd
estimated glomerular filtration rate - no . ( % ) : :
moderate n z $nmbr$
central nervous system
drug - eluting stent implanted — no . ( % )
elevated bnp ( $nmbr$ pg / ml )  %
verapamil - sr strategy
baseline steroids
c - reactive protein  median ( q $nmbr$  q $nmbr$ )
albumin measurements ^ ^
dactylitis
no hypertension ( n = $nmbr$ )
history of other medical conditions  n ( % )
placebo allocation
cyclosporin
symptom onset to hospital arrival  hours
before amendment
baseline erosion
minimal important change threshold ( improvement ) a
digoxin
left ventricular ejection fraction  mean ( sd )  %
new york heart association congestive heart failure class
haemoglobin ( g / dl )  mean + sd  available for $nmbr$ patients
peripheral arterial revascularization
median daily dose - iu ™
hla - b $nmbr$ positive  n ( % )
renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
ldl particle numbers ( week $nmbr$ )
serum ldl cholesterol
all grafts
stroke thought due to atherothrombotic disease
first hhf
primary angioplasty ( n = $nmbr$ )
atenolol strategy ( n = $nmbr$ )
prothrombin mutation ( % )
cardiovascular risk factors and medical history
valsartan  n ( % )
qrs > $nmbr$ msec $nmbr$ - min walk test
immobilization at randomization  n ( % )
difference
participants n
left ventricular ejection fraction  median ( iqr )  %
associated with corrected
ckd ( egfr < $nmbr$ b )
lowering drugs
concomitant cardiovascular therapy ( taken > $nmbr$ days )
post - bronchodilator fev $nmbr$ / fvc ( % ) a
no . evenls
medical treatment
previous angina pectoris
indeterminate ! !
select lipids and lipoproteins
$nmbr$ - year framingham chd risk
> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ ) — number / n ( % )
egfr ( ckd - epi  cystatin c )  ml / min / $nmbr$ . $nmbr$ m $nmbr$
previous receipt of therapy against tnf - a — no . ( % )
prior to index event
race  % of patients
apo a - i  mg / dl
vessel treated  n
non - smokers receiving lipid - lowering drugs  p blockers
estrogen therapy
haq - di total score  mean ( sd )
high density lipoprotein cholesterol - mg / dl * *
systolic pulmonary arterial pressure  mean ( sd )  mm hg
> q $nmbr$ ( $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )
das - $nmbr$ ( crp )  mean ( sd )
blood transfusion
partial evolving to secondarily generalized ( ic )
hscrp > $nmbr$ to < $nmbr$ mg / l
ra symptom duration < $nmbr$ months — number ( % )
ldl - c < $nmbr$ mg / dl
ace / arb medication ( % )
positive family history of type $nmbr$ diabetes ( % )
urinary albumimcreatinine ratio
diabetes treatment
mucolytics
pooled analysis
infliximab
iduration of symptoms > $nmbr$ min
estrogens
$nmbr$ mg twice daily n = $nmbr$
major gastro - intestinal bleeding
anti - ccp antibody positive  n ( % )
egfrmdrd  ml / min / $nmbr$ . $nmbr$ m $nmbr$ bsa
weight > $nmbr$ kg  n ( % )
multiple diagnoses
cholecystitis chronic
baseline % bsa involvement
> $nmbr$ corticosteroids or immunosuppressants
history of atrial arrhythmia  n ( % )
chronic pulmonary disease
> $nmbr$  obesity class $nmbr$
congestive heart failure ( definite )
average dose ( mg / week )
urinary albumin : creatinine ratio *
previous pci ( % total )
highest killip classiciation pre - pci
edss stratification  no . ( % )
exenatide no . of events / total no . ( % )
method used to diagnose the incident pulmonary embolism  no . ( % )
blood glucose
rf or acpa positive
congestive heart failure — no . ( % )
mean ucsd - sobq score * ( sd )
morphine use for index event / pci
albumin - to - creatinine ratio
region  north america
medical therapy alone
continuation
$nmbr$ ( fevi $nmbr$ - < $nmbr$ % pred )
a $nmbr$ s - hydroxy -
qrs interval > $nmbr$ msec — no . ( % )
streptokinase
haq - di improvement > $nmbr$ . $nmbr$
baseline cv treatment  n ( % ) y
adalimumab croup  n / n ( % )
apob ( week $nmbr$ )
systemic arterial hypertension  n ( % )
reversibility to salbutamol  %
overall  male : female
$nmbr$ p value
evolocumab ( $nmbr$ mg )
bifurcation lesion
time from onset of symptoms to randomization — days
thiazide at last follow - up
% change median baseline crp > $nmbr$ mg / l
blood pressure systolic  mm hg
hf hospitalizations  median ( iqr )
history of carotid artery disease
history of diabetes mellitus
prior treatment history $nmbr$
patients with bw decrease of $ $nmbr$ % in patients with baseline bmi of $ $nmbr$ kg / m $nmbr$ +
interaction $nmbr$
no history of migraine
mild ( gold $nmbr$ )
iii : fev $nmbr$ > $nmbr$ % - < $nmbr$ % predicted
cat score category
baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$
statin only
drug therapy at admission 一 no . ( % ) aspirin
fatty acid profile
residual deep - vein thrombosis  no . ( % )
unstable angina  n ( % )
completed trial
duration of symptoms  h
% predicted ” fev  at baseline  % *
aspirin dose at randomization
normoglycemia ^
race / ethnicity
oral antidiabetic drugs
ef $nmbr$ - $nmbr$ % hfmref ( n = $nmbr$  $nmbr$ % )
cerebral embolism
fev $nmbr$ / fvc prebronchodilatort
previous use of antiplatelet drugs
laba non - users
thiazolidinedione based
chronic respiratory failure
coronary artery disease history
current prescribed medications
current weekly alcohol use ( % )
calcium ( mmol / l )
region ( pooled )
bdmard - naive
general andthoracic epidural
first co - primary outcome
cvd  mi  stroke  or recurrent ischemia - urgent revascularization  or hospitalization for unstable angina
age at enrolment  years
not available
use of antiplatelet agents ^
aspirin or thienopyridines ( % )
baseline trig > $nmbr$ millycerides g / dl
baseline anti - hypertensive usea
intent - to - treat population  n ( % )
dyslipidaemia and hypertension  n ( % )
saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
estimated response rate and odds ratio
first loading dose
ex - smokers $nmbr$
atrial fibrillation ldl cholesterol level
duration of
weight ab  %
race or ethnic group — no . / total no . ( % ) f
loop at enrollment
current cigarette use  n ( % )
central europe
atopic ( based on phadiatop test )
baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks
kccq ( $nmbr$ months )
mean eq - $nmbr$ d response ( $nmbr$ % ci )
tp vs no tp
mitral insufficiency
r $nmbr$ mg + fa
total study population
subacute ( $nmbr$ - $nmbr$ days )
assoc  with corrected congenital shunts
spinal fractures
multivessel disease  n ( % )
normoalbuminuria or microalbuminuria
low ( no risk factor )
hospitalisation for chf within $nmbr$ years of randomisation
rec . ischemia due to ecg changes
event / patients ( $nmbr$ / pt - y )
calcium - channel antagonists
angiotensin receptor
dbp  mean ( sd )  mm hg glycaemic parameters
priorother ( predefined ) medical conditions
t $nmbr$ lesion volume  mm $nmbr$
african - american / african heritage ( n = $nmbr$ )
new anti - anginal therapy
smoking : current smoker
total cataract
no . of patients ( % )
ami $nmbr$ mg n = $nmbr$
baseline lvef
change from baseline stage $nmbr$ ckd
indacaterol group ( n = $nmbr$ )
iv : fev $nmbr$ < $nmbr$ % predicted
education $nmbr$ - $nmbr$ years
waist circumference
hispanic — no . ( % )
> $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
rituximab  n = $nmbr$
stroke  n ( % )
family history of premature
change in bp  mm hg
nonfatal ischemic stroke
pci delay due to low risk
prior percutaneous coronary intervention
oral anticoagulant agent
alcohol intake ( a )
hba $nmbr$ c subgroups
history of atherosclerotic vascular disease — no . ( % ) §
renal function : creatinine clearance
mercaptopurine
transient monocular blindness
nyha functional class  n ( % )
entire cohort gender
inhaled §
patient global assessment of pain ( vas $nmbr$ - $nmbr$ mm )
rituximab ( $nmbr$ x $nmbr$ mg ) + mtx ( n = $nmbr$ )
peripheral artery revascularization without amputation
other cause  n ( % )
immunosuppressants and antimalarials only
* * positive stress test
aspirin use at baseline
randomisation scheme
ala carriers
arterial hypertension — no . ( % )
bmi ( median  iqr )  kg / m $nmbr$
alternative disability
non - hdl cholesterol / apob ( ratio )
other risk factors
hf hospitalization or cardiovascular death
no revascularization for index acs event
p - value for variance
apo b  mean ( sd )  mg / dl
at ldl - c ( bq ) goal * at baseline - no . ( % )
missing data initial diagnosis — no .
aspirin at enrollment
prespecified analysis
k ( rate )
r | r ' ' ' ( $nmbr$ % ci )
glyburide dose duringthe study ( mg )
ptca / cabg
score  %
seizure types reported during baseline  b n ( % )
biologic therapeutic failure
simva ( „ = $nmbr$ }
partial mayo score  mean ( sd )
selected clinical characteristics — no . / total no . ( % )
. $nmbr$ . $nmbr$ ml / s / m $nmbr$ ( $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % )
prior use of conventional dmards only ( biologic - nai ' ve )  n ( % )
family history  n ( % )
patients with diabetes mellitus
thiazolidinedione ( includes pioglitazone )
corticosteroids and antimalarials only
total pack - years mean ( sd )
medications at study entry — no . / total no . ( % )
gold iii - iv
reason for enrollment in active a
asia / australia / new zealand
octave induction $nmbr$
tachyarrhythmias  n ( % )
europe n z $nmbr$
atrial fibrillation alone )
supraventricular tachyarrhythmias ( incl . atrial
previous cerebrovascular event
stroke — no . ( % )
bronchodilator response  ml
$nmbr$ ( fevi ^ $nmbr$ % pred )
mental component
apo a - l ( g / l )
veflonzumao
pfo with large shunt and atrial septal aneurysm
classification of index venous thromboembolism — no . ( % )
fev $nmbr$ at baseline
incidence rate per $nmbr$ person - years
time of randomization ( interaction : p = $nmbr$ . $nmbr$ )
chronic renal failure  n ( % )
both deep - vein thrombosis and pulmonary embolism
myocardial infarction without st - segment elevation — no . ( % )
pooled eze / simva
other sglt - $nmbr$ inhibitor
clavicle fracture
ecg abnormality ( resting )  %
musculoskeletal stiffness
psoriatic arthritis  %
medication prior to admission  ( % )
death / st
bdi focal score
time to randomisation [ hours ] ( interaction : p = $nmbr$ . $nmbr$ )
laboratory examination
placebo patients with events
organ system involvement  no . ( % )
enalapril lcz $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ )
high - dose statin
peripheral
ldl cholesicrol ( minol / l )
hispanic / latino ethnicity  n ( % )
$nmbr$ - $nmbr$ drinks
aborted cardiac arrest
baseline crp < $nmbr$ mg / l
relative risk reduction ( $nmbr$ % cl ) percent
unprotected left main stented
catheterization performed for qualifying event
fraction ( % )
$nmbr$ % ci for difference
index event to randomization  median ( iqr )  h
inclusion criteria — no . ( % )
normal hscrp
^ $nmbr$ - cell function — % §
previous tnf - antagonist use  n ( % )
depressed only
acute infection without septic shock
mtss units
previous statin use
mean ( s . d . ) calculated ldl cholesterol
$nmbr$ % confidence interval
type of concomitant statin by daily dose
statin with ezetimibe
history of ml or ischemic stroke
within $nmbr$ h
placebo n = $nmbr$ n ( % )
nyha class not reported
neither uh or lmw heparin
fpg tx difference vs pbo  median change from baseline ( se ) $nmbr$
iglarlixi ( fixed - ratio combination )
previous congestive heart failure
periostin ( ng / ml )
belimumab $nmbr$ mg sc ( n $nmbr$ )
glycatedhemoglobin category  %
canvas - r
waist circumference  cm mean ( sd )
tg > $nmbr$ . hdl < $nmbr$ ( mg / dl ) ( / ? = $nmbr$ )
africa  asia  or the middle east
history of gestational diabetes mellitus — no . ( % of women )
non - black race ( n = $nmbr$ vs $nmbr$ )
community hospital
not - japan n = $nmbr$  $nmbr$
stage > $nmbr$ chronic kidney disease ( % )
$nmbr$ - hr plasma glucose — mg / dl
not at goal
concomitant aminosalicylates  n [ % ] concomitant corticosteroids  n [ % ] mayo score  mean [ sd ]
baseline fecal caicrctectin
hospitalization for unstable angina
patients having exacerbation
regular alcohol consumption per week  no . ( % )
improving anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$
qualifying peripheral arterial disease
previous bypass surgery  n ( % )
anthropometric characteristics
baseline fev $nmbr$  l *
$nmbr$ - lead ecg heart rate  beats / min
aspirin + dipyridamole ( n = $nmbr$ )
patients entering pt period n = $nmbr$
surgical technique
psoriatic arthropathy
with alogliptin $nmbr$ mg
revascularisation but no antiplatelets  lipid - lowering agents  or p blockers
pfo with large shunt without atrial septal aneurysm
clinical and patient - reported characteristics at baseline and randomization
or ( unadjusted )
unknown or missing
reported high cholesterol ' !
syndecan - $nmbr$ ( ng / ml )
long - acting
use of antiarrhythmic agent
egfr using cg / mdrd formulae  % of patients
baseline body mass index
swollen - joint count ( of $nmbr$ joints )
region  n ( % )
> $nmbr$ - $nmbr$ mg / week
hypertension $nmbr$ ( % )
psa - modified total shs
minor ischaemic stroke
annualized rate ind / gly sfc
sulfasalazine
mean change at week $nmbr$
acpa positive ( > $nmbr$ iu / ml )  n ( % )
history of stroke $nmbr$
long - term warfarin ( n - $nmbr$ )
crp ( mg / l )  median ± sd
obese ( > $nmbr$ kg / m $nmbr$ )
facit - fatigue . mean $nmbr$ sd ( range $nmbr$ - $nmbr$ )
infarct location ( interactsn $ : p = $nmbr$ . $nmbr$ )
not hospitalized for heart failure in the year prior to study enrollment
calcification  n ( % )
all ischemic stroke
rosuvastatin  n ( % )
hormone replacement therapy use
older than $nmbr$ years
rolofylline
apo a - $nmbr$  mean ( sd )  mg / dl
long - term antiplatelet therapy
prior bypass graft surgery
bone erosion ( judged by physician )  n ( % )
triglyceride ( mm
cigarettesmoking  %
pentraxin - $nmbr$ ( ng / ml )
tnfi exposed
history of atrial fibrillation  n ( % )
asa or antiplatelet agent
ischemic stroke ( vs . tia )
men : women ( % )
patients not treated with statins ( n = $nmbr$ )
severe renal impairment
om $nmbr$ mg / aml $nmbr$ mg / hctz $nmbr$ mg
history of atrial fibrillation
corticosteroid use at baseline
sedentary
no . of patients ( indacaterol / placebo )
insulin plus oral
> $nmbr$ . $nmbr$  n ( % )
ics use  %
age category ( years )  n ( % )
atherosclerotic disease ( % )
copd duration  y
thrombolytic therapy
acpa positive  n ( % )
baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks
acei vs . non - acei
risk factors for atherosclerosis
bifurcation lesion with side branch $ $nmbr$ . $nmbr$ mm stented
fevi  % predicted *
heart rate at rest in the supine position ( beats / min )
feno $nmbr$ mg / eze $nmbr$ mg ( n = $nmbr$ )
mean ( s . d . ) total pcsk $nmbr$  ng / ml
baseline cdai score  mean ( sd )
severity of copd  combined assessment  n ( % )
ambulance ( % )
estimated means and difference
concomitant medication ( % )
qualifying atherosclerosis
ada impaired fasting glucose
death  q wave mi or ischemia - driven revasc
stented vessels
diabetes duration  n ( % )
tender - joint count  of $nmbr$ joints examined
verapamil sr
thiazolidinedione 一 no . ( % )
difference  % median
edema  ( % )
medications on admission  %
rf positive ( > $nmbr$ iu / ml )  n ( % )
worsening heart failure
previous limb or foot amputation
alcohol consumption ( % )
uacr  mgg $nmbr$ ( gm )
om $nmbr$ / aml $nmbr$ /
hypertension history
swollen - joint count  of $nmbr$ joints examined
racial group  n ( % )
$nmbr$ to < $nmbr$ ml per $nmbr$ - $nmbr$ m $nmbr$
risk factors
deep vein thrombosis only
within last $nmbr$ d
egfr at baseline  $nmbr$ ml / min ( % ) b
low - density lipoprotein cholesterol  mean ( sd )  mmol / l
intermediate
duration of hypertension ( months )
wap $nmbr$ c ( ng / ml )
left circumflex artery  n ( % )
fpg  median ( ql  q $nmbr$ )  mmol / l
ischaemic cause
total cholesterol > $nmbr$ mg / dl
intention - to - treat
enoxaparin / vka n / n ( % ) $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )
in - stent restenosis
high risk without atherosclerotic vascular disease +
priorother ( not predefined ) medical conditions
reteplase / abciximab - facilitated pci ( n = $nmbr$ )
established atherosclerotic disease  n ( % )
concomitant drugs  %
after amendment ( % )
antianginal medications
eular good response
ls means difference ( $nmbr$ % ci ) $nmbr$
prior stroke ( before index event )
interval from onset of symptoms
low risk ( ri = $nmbr$ - $nmbr$ )
patients with prior copd - related
duration of ra  mean ( min - max ) ( yrs )
myocardial infarction / cabg / pci < $nmbr$ years
dilatative
ncep atp iii risk factors
change from baseline  adjusted mean ( $nmbr$ % ci )
antiarrhythmic therapy
mean ( sd ) tender joint count *
• ? sd ml / min
renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  according to mdrd )  n ( % )
serum creatinine
first - recorded event  no . ( and % ) of patients
fevi  l  mean ( sd ) $nmbr$
male / female
unknown ( none of the above )
baseline creatinine clearance
drug - eluting stent — no . ( % )
mean disease duration  years
spacer use during the study
non - end - stage renal dysfunction
duration of epilepsy  years  mean ( sd )
blood pressure control
medications through day $nmbr$
nyha class ii ( n = $nmbr$ l $nmbr$ )
nadroparin
past smoking
$nmbr$ - min walk distance ( m )
biologics user
other medical history — no . ( % )
blood pressure ( % )
sfc $nmbr$ mg / $nmbr$ mg
cardioversion in previous $nmbr$ wk
$nmbr$ - $nmbr$ ( low risk )
hypercholesterolemia ( > $nmbr$ mg / dl )
use of medication at baseline — no . ( % )
revascularization during index hospitalization  %
gender  %
brv dosage  mg / d
not rando . in na *
age  median ( iqr )  years
oral antidiabetic drugs / insulin ( % / % )
risk factors specified as inclusion criteria — no . ( % ) f
asian or pacific islander
reversibility : > $nmbr$ - < $nmbr$ %
average daily dose ( % of target ) *
target - vessel revascularization
severity of copd — no . ( % ) f
lvef  %  median ( iqr )
fev $nmbr$ / fvc  post - albuterol  %
esrd saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
time since diagnosis of pah — yrf
right coronary artery  n ( % )
younger patients ( aged $nmbr$ years )
fvc ( l ) proportion taking pulmonary medications ( % ) b
vein graft stented
qualifying stroke
difference vs . pbof mean ( s . e . ) t
oral hypoglycaemics only
baseline history of vascular disease ( % )
prednisone - equivalent dose — mg
aspirin alone group no of events / total n ( % )
known thrombophilic condition — no . ( % )
blood eosinophil proportion ( % )
( a ) demographics
cox bsl + yr $nmbr$ hbd
direct thrombin inhibitors
body - mass index - kg / m $nmbr$  median ( iqr )
acute coronary syndrome
waist circumference  cm ( sd )
moderate impairment ( egfr $nmbr$ - $nmbr$ )
use of supplemental oxygen  n ( % )
unadjusted or ( $nmbr$ % ci ) p value
rarely / never
st - elevation myocardial infarction
woscops
age ( yrs )  mean *
non - ischaemic cardiomyopathy
history of myocardial infarction  n ( % )
cardiac catheterization
estimated glomerular filtration rate  n ( % )
no aspirin or ppi
inadequate response
drinking  n ( % )
non - ics +
endovascular
sbp ( mmhg )  mean ± sd
hormone - refractory prostate carcinoma
drug - eluting stent implanted ( at least one )
pah origin / cause
experience
chinese subgroup
history of cardiovascular events
disease duration : < baseline mean
physician ' s global assessment . mean $nmbr$ sd
glycated hemoglobin < median
% stenosis  as assessed by core laboratory
upper respiratory tract infection
antibiotics * *
normoalbuminuria — no . / total no . ( % )
aggressive ( $nmbr$ )
patients with specific disease characteristics
work and school
activity ( $nmbr$ - $nmbr$ vas )
age ( yrs ) $nmbr$ - $nmbr$
afcaps /
clinical presentation of vte at initial diagnosis — no . ( % )
aspirin < $nmbr$ hours
glucosamine ( n = $nmbr$ )
neither ace inhibitor nor arb
previous coronary intervention
time since diagnosis of diabetes — no . ( % )
egfr ( ckd - epi  cystatinc )  ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )
dyslipidaemia and hypertensiont
presence of erosions  n ( % )
sitting pulse  bpma
post - cabg
cigarette smoking  mean pack - years ( sd )
> $nmbr$ - $nmbr$ ( moderate risk )
triglycerides tx difference vs pbo  ls mean % change from baseline ( se )
$nmbr$ - $nmbr$ / $nmbr$ - $nmbr$ mm hg
body mass indexa < median
dmard user
admission for hf in previous year
duplex ultrasonography
all of the colon
$nmbr$ - $nmbr$ - $nmbr$  obesity class $nmbr$
coronary artery disease — no . / total no . ( % )
body mass index  mean + sd ( kg / m )
> $nmbr$ previous venous thromboembolisms ( % )
remission at maintenance - trial entry — no . ( % )
improved
treatment stratum ^ :
red blood cell counting  $nmbr$ / l
$nmbr$ - wk kaplan - meier rate  %
continuous variables  mean ( sd )
intensified $nmbr$ months ( n - $nmbr$ )
elevated troponin
smoking history : current smoker
jbs - $nmbr$ primary prevention only $nmbr$
( se ] tf hdl - c
baseline hs - crp tertiles ( mg / i ]
not reported
diabetes and currently on an oral hypoglycaemic agent orinsulin
standard care n ( % ) / $nmbr$ py
apremilast
anterior myocardial infarction — no . ( % )
oxcarbazepine
mildly impaired
incidence [ n / n ( rate per $nmbr$ person - years ) ]
blood pressure at target level ( % ) §
egfrmdrd ， ml - min - $nmbr$ - $nmbr$ . $nmbr$ m_ $nmbr$
benign prostatic hyperplasia
> $nmbr$ erosion  n ( % )
body - mass index > $nmbr$
alcohol consumption  n ( % )
rhabdomyolysis or myopathy
treatment arm
concomitant therapies at hospital discharge
hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % ( > $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se )
specific risk of bleeding ^
number resulting in emergency department visit
elevated troponin ( > $nmbr$ . $nmbr$ pg / l )
hi ) ah ( % )
number of exacerbations
cpk > $nmbr$ times uln
glucosamine + chondroitin sulfate ( n = $nmbr$ )
serum trap - $nmbr$ b ( u / liter )
sex ( male ) ethnic origin
no corticosteroids or immunosuppressants
lvef within $nmbr$ months  %
ls mean change from baseline $nmbr$
uric acid ( mg / dl ) creatinine clearance ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
weight — kg ( median )
non - black
myocardial infarction
duration of assigned regimen before surgery
asian / black / white / hispanic / other ( % ) clinical parameters
> $nmbr$ mg / dl eze / simva $nmbr$ = $nmbr$ }
risk factors for pad
baseline hemoglobin  median ( iqr  g / dl )
insulin  iu / ml  median ( q $nmbr$  q $nmbr$ )
prior percutaneous coronary intervention — no . ( % )
other bdmard §
icd therapy ( n =
apo a - l ( mg / dl ) - mean ± sd
with alogliptin $nmbr$ . $nmbr$ mg ( n $nmbr$ $nmbr$ )
symptomatic pad of lower extremities *
pfor heterogeneity
severe impairment ( egfr < $nmbr$ )
previous use of amiodarone
levetiracetam
peri - op beta - blockers : no ( n = $nmbr$ )
patient global assessment ( $nmbr$ - $nmbr$ mm vas )
background treatment  n ( % )
high titre ( > $nmbr$ times of uln )  n ( % )
no corticosteroid  no imm
greater than or equal to $nmbr$ mm hg
antiarrhythmic agent
white not of hispanic origin
cause of dvt or pe — no . ( % )
sulfonylurea — no . ( % )
mean preoperative abpi of the index
met criterion at finalt
orthopnea  ( % )
total mortality
pace  no . ( $nmbr$ )
non - caucasian simva
high periostin subgroup ( > $nmbr$ ng / ml ) ( n = $nmbr$ )
overall population
all randomized women
respiratory - related ^
treated vessel - native coronary
< $nmbr$ . $nmbr$ mmol / liter estimated gfr
prior ms treatment with ifn - beta or
no hemoconcentration hemoconcentration
clopidogrel  $nmbr$ - mg loading dose
body weight ( kg )  mean ( s . d . )
das $nmbr$ ( c - reactive protein )
blood pressure  pbo y patients with diabe teristics ( ncep atp i
patients with normoalbuminuria at baseline
stenting plus medical therapy ( n = $nmbr$ )
mean - sd change in pre - bronchodilator fev $nmbr$  l
change from baseline in % predicted fev $nmbr$
patients with uncomplicated events ( p = o - $nmbr$ 十 )
post - bronchodilator percent of predicted fev $nmbr$  % ( sd )
comparison with baseline
previous ml ( interaction : p = $nmbr$ . $nmbr$ )
cardiac glycosides
previously taken any other dmards  n ( % )
crp ( normal range : $nmbr$ - $nmbr$ . $nmbr$ )  mg / dl  mean ( sd )
modified rankin score
a a ( $nmbr$ ( % )
mean involved bsa  % ( $nmbr$ % ci )
other defined
without ( n = $nmbr$ $nmbr$ )
treatment with drugeluting stent
$nmbr$ - $nmbr$ ( moderate )
angiography
sbp / dbp $ $nmbr$ / $ $nmbr$ mmhg
non - extensive
electrocardiographic findings — no . ( % )
beta receptor antagonist
baseline triglycerides by quintiles
median albumin - to - creatinine ratio ( interquartile range )
< $nmbr$ regardless of historical count
stent type
$nmbr$ vessel pci
body mass index subgroups
pioglitazone
b - agonists ( long - acting ) a
tg ( mg / dl )  median ± sd
risk factors for recurrent vte — no . ( % ) f
caucasian eze / simva
$nmbr$ - < $nmbr$ mvmin
pioglitazone ( n = $nmbr$  $nmbr$ )
time from onset to medication  h  mean ± sd
baseline insulin daily dose / kg
mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area
telmisartan group ( n = $nmbr$ )
total cholesterol ( mmo $nmbr$ / $nmbr$ )
african - latin american
more than $nmbr$ lesions per vessel
fpg  mg / dl ( mmol / l )
> = $nmbr$ % and < $nmbr$ % ( > = $nmbr$ and < $nmbr$ mmol / mol )
no . of events / total no . ( % )
ind $nmbr$ mg q . d . n = $nmbr$
smoking history : ex - smoker
troponin level
duration of copd — days ^
other antiplatelet agents  n ( % )
thienopyridine at randomization
bmi ( kg / m $nmbr$ ) cardiovascular history
controlled $nmbr$ — no . ( % )
sulfonylurea derivatives
score $nmbr$ - $nmbr$
radial access site
use of parenteral antithrombotic agents — no . ( % )
immunosuppressant ( with or without corticosteroid )
ml with st - segment elevation
remission in overall population
v / hctz
pulse ( beats / min ) cholesterol ( mmol / l )
number of participants
beta - carotene
hemispheric stroke n = $nmbr$
pci for index mi ( % )
absolute fvc decrease > $nmbr$ %
hemoglobin ( gl ' )
low ( $nmbr$ - $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % )
> $nmbr$ % and < $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ )
duration from hospital admission to pci  h ( median  iqr )
prednisone
enalapril dm = $nmbr$ non - dm = $nmbr$
entire cohort
intravenous loop diuretics !
peripheral revascularization
no ischemia ( n = $nmbr$  $nmbr$ )
fp / sal $nmbr$ / $nmbr$ pg ( n = $nmbr$ )
antithrombotic use
p lace of randomization ( interaction : p = $nmbr$ . $nmbr$ )
km event rate ( % )
revascularisation + antiplatelets + lipid - lowering agents + p blockers
beta $nmbr$ selective
iii and iv ejection fraction
antiarrhythmic drug
median time since diagnosis * ( range )  yr
bmi  kg / m $nmbr$ uac  no . ( % )
high - density lipoprotein cholesterol  mean ( sd )  mmol / l
serum potassium ( mmol / l )
gissi prevention $nmbr$ / $nmbr$ - $nmbr$ / $nmbr$
nyha class $nmbr$ or higher
concomitant medication — no . ( % )
history of major cardiovascular disease  n ( % )
versus tiotropium $nmbr$ pg
nyha functional class at screening
time from most recent qualifying
use of loop diuretics  n ( % )
glycemia  mg / dl
duration of asthma  years
bisphosphonates
cardiovascular disease history
no pci or cabg — no . ( % )
any statin ( with / without llt )
associated with drug / toxin
non - diabetic patients
baseline hba $nmbr$ c in $nmbr$ classes
coronary artery disease — no . ( % ) : ! :
patients with egfr $nmbr$ > $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n
baseline corticosteroidst ( mean dose : $nmbr$ . $nmbr$ mg / day )  n ( % )
vka  only reason
reported in ecrf
evidence or thombus  n ( % )
prior aortocoronary bypass surgery 一 no . ( % )
regional anaesthesia
events / n
anti - coagulants - no . ( % )
other antihypertensive
thrombus - containing lesion
sgrq total score ( week
americas ( n = $nmbr$ )
placebo - adjusted mean difference in % hba $nmbr$ c ( $nmbr$ % ci  [ p value ] )
serum total cholesterol ( mmol / l )  mean ( sd )
creatinine level
heart rate  mean ( sd ) [ range ]  beats / min
cv death / mi / stroke / ucr
irbesartan
time from acs to randomization
time intervals  h
history of stroke or tia
medications at timing of randomization  n ( % )
cv death or hf hospitalization n
cvd events
$nmbr$ - point mace
low - dose aspirin use
moderate / severe exacerbations  itt population  n ( % )
lp ( a ) §
hba $nmbr$ c levels
weekly
> $nmbr$ ( high risk )
percentage of time in therapeutic inr range  mean ( sd )
> $nmbr$ prior myocardial infarction — no . ( % )
threatened abrupt vessel closure
prior therapy  %
duration of pci ( min )  median n ( iqr )
age > $nmbr$ y  n ( % )
van der heijde mtss  mean ( sd )
form / bud
no . of patients ind / gly sfc
missing hb at yr $nmbr$
within $nmbr$ h after
left ventricular ejection fraction < $nmbr$ %
mestizos
ankle - brachial index < $nmbr$ . $nmbr$
p - value ( anova )
patients with > $nmbr$ exacerbations resulting in emergency department visit
difference in change
established atherosclerotic cardiovascular disease
other vascular disease
black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ )
qualifying mi : stemi
coenzyme q $nmbr$
history of a transient ischaemic attack
known tiromtcch * c ccndifeon
total patients
periprocedural medications  n ( % ) clopidogrel  $nmbr$ mg *
swollen joint count ( $nmbr$ - $nmbr$ possible joints )
prior amputation
weight  kg  median ( range )
arterial area ( mm $nmbr$ )
statin + fibrate or
presence of enthesitis  n ( % )
nyha class ( when patient was last in stable condition before admission )  %
history of second prior mi  n ( % )
ischaemic ( n = $nmbr$ l $nmbr$ )
sbp > $nmbr$ mmhg and / or dbp > $nmbr$ mmhg
caucasian  n ( % )
use of cardiac medication *
pioglitazone ( n = $nmbr$ )
hdl cholesterol < $nmbr$ ( men ) or < $nmbr$ mg / dl ( women )
cardiac valvular disease
randomized to receive vitamin e
indication for index procedure
total c ( mmol / l  mean )
left ventricular ejection fraction — %
non - reversible ( % )
peripheral neuropathy
acuity major
standard therapyy ( n = $nmbr$ )
acq $nmbr$ score
baseline cardiovascular disease
myalgia
time since as diagnosis  mean ( sd ) years
albumin / creatinine ratio - mg / mmol  median ( iqr )
change in das $nmbr$ - esr ( mean ) i physical function outcomes week $nmbr$
venous insufficiency
pdqol scale
baseline $nmbr$ - asa
current medication  n ( % )
baseline pulmonary medication
median ( range )
mean ( sd ) aqlq
humerus fracture
high - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se )
clopidogrel pretreatment duration
lower than normal range — % ^
months ( log - transformed )
saba reversibility
previous stroke or tia
high disease activity : > $nmbr$ . $nmbr$  n ( % )
alcohol use ( % )
americas  excluding us
acitretin
stratification variables
factor v leiden or prothrombin mutation
simplified disease activity index score
diabetic kidney disease
prior coronary artery disease yes
intravenous nitrates
toast classification
£ $nmbr$ . $nmbr$ % * *
yes previous revascularization
no . / $nmbr$ person - yr
p - blocker intake at randomisation ( n = $nmbr$ o )
> l : $nmbr$ hrs : min ( n = $nmbr$ )
oral glucocorticoid use at baseline — no . ( % ) : t
adjusted mean change
age at completion of highest level of
age group 一 ％
combined macro + micro
race / ethnicity chinese
history of more than $nmbr$ prior mi ( % )
physical activity §
systolic blood pressure  mm hg < $nmbr$
diagnoses / risk factors  n ( % )
medication effects
insulin glargine
mean age  years ( sd )
diuretic thiazide
paclitaxel
total back pain  mean ( sd )
previous intolerance of infliximab  n ( % ) *
uae ( p  g / min )
any statin versus no statin at randomization
adalimumab group ( n = $nmbr$ ) t
hgb  g / dl < $nmbr$ men  < $nmbr$ women
fracture during follow - up
biguanides
> $nmbr$ . $nmbr$ kg / m $nmbr$ hypertension :
values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .
aminosalicylates
prediabetes — no . ( % ) $nmbr$
history of pci with stenting
brain volume  cm $nmbr$
swollen joint count ( $nmbr$ - $nmbr$ )
no . of strokes ( % )
demographic and medical variables
australia / nz
no . of events / patients
chd history  n ( % )
jsn score ( $nmbr$ - $nmbr$ )
ascvdor > $nmbr$ cv risk factors
previous transient ischemic attack
number of stent = l or $nmbr$ or $nmbr$
ischemic stroke with hemnrrhnaic cnnversinn
chronic stable angina
fenofibric acid + low - dose statin
daily iglar dose at week $nmbr$ ( u )
anticholinergic
contrast volume
rituximab ( $nmbr$ x $nmbr$ mg ) + mtx
> $nmbr$ mg / dl simva $nmbr$ = $nmbr$ ]
glucagon - like peptide - $nmbr$ agonist
acr $nmbr$ response at week $nmbr$  n ( % )
alcohol intake ( + ) ( % )
# of prior tnfi among non - tnfi naive
remission
triglycerides ( median  iqr )  mg / dl
total antihypertensive use
a $nmbr$ c distribution ( % )
middle third
symptom score ( sd )
atorvastatin factorial study
former / non - drinker
electrocardiographic findings at randomization
lumbar spine bmd t - score
multiple ( $nmbr$ + ) chd risk
hyperlipidemia  n ( % )
place of randomization
beta - blocker % target dose
left circumflex  n ( % )
ranolazine vs . placebo km failure rate
biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl )  na
at or above the median
indacaterol - glycopyrronium group ( n = $nmbr$ )
infarct on brain imaging 丰
baseline laboratory values  median ( iqr ) d
timi major or minor bleeding
olodaterol $nmbr$ mg ( n = $nmbr$ )
race / ethnicity white
tnfi ( no other bdmard taken ) t  n ( % )
patients treated
distribution time
previous treatment failure — no . ( % ) § * *
median body weight — kg
raas inhibitor use
previous cardiovascular event at randomization
aspirin alone ( n = $nmbr$ )
wml load at baseline mri
clopidogrel plus aspirin
alanine aminotransferase or aspartate aminotransferase > $nmbr$ x upper limit of normal ( n = $nmbr$ )
non - endstage renal dysfunction *
active inflammatory bowel disease
current alcohol use — no . / total no . ( % )
complex partial ( ib )
saxagliptin ( n = $nmbr$  $nmbr$ )
low subgroup
high - dose statin pretreatment ( n = $nmbr$ )
common study baseline
lm bifurcation treated
renal impairment  n ( % )
> $nmbr$ failure
coronary revascularization procedure
intensified baseline ( n - $nmbr$ )
time from onset of qualifying stroke to randomization
statin non - users ( n = $nmbr$ )
barc $nmbr$ - $nmbr$
laba use  % patients
enoxaparin ( n = $nmbr$ )
who / idf impaired fasting glucose
dip involvement  ! n ( % )
copd severity ( gold $nmbr$ )
erosion score ( $nmbr$ - $nmbr$ )
st - segment depression > $nmbr$ . $nmbr$ mv
fasting tgs §
total cataract extraction
$nmbr$ mg / day early - start
$nmbr$ - $nmbr$ with cv risk but not disease ( n = $nmbr$ )
oral treprostinil ( n = $nmbr$ )
acute ( < $nmbr$ hr )
total ldl - c *
obese patients  ! n ( % )
baseline aspirin dose < $nmbr$ mg
immunologic
high - dose aspirin
a - glucosidase inhibitor
history of stroke  n ( % )
crusade bleeding score
% with haq - di decrease > $nmbr$ . $nmbr$
= $nmbr$ ’ )
simple partial ( ia )
monitoring ( n = $nmbr$ )
crp median ( se )  rng / l
no . of previous venous thromboembolic events
d / mi / idr / st
smoking ( % ) laboratory parameters
female sex  n ( % ) race  n ( % )
hypertension  treated
no . in the $nmbr$ mo before screening
severity of copd  n ( % ) *
reduced ef
disease duration  years : median ( range )
absent ( < $nmbr$ mg / dl )
sgrq total score * *
black race  n ( % )
indication for index pci
forearm fracture
clinical copd phenotype ^
symptoms and feelings
extent of index event
gold stage — no . ( % ) * *
drugs used in diabetes
baseline short - acting anticholinergics  n ( % )
stent plus medical therapy
significant worsening in kccq clinical score ( > $nmbr$ ) at $nmbr$ months $nmbr$
diet + pravastatin
doubling of serum creatinine
before index acs event
global ischemia ( % ) * *
il - $nmbr$  ng / l
> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l $ mmol / l
glycoprotein llb / llla inhibitors
statin intolerance $nmbr$  n ( % )
ccsc at $nmbr$ month before enrollment
fevi auc $nmbr$ - $nmbr$ l
total  adjusted weight of $nmbr$ . $nmbr$ for gastrointestinal bleeding
indacaterol n = $nmbr$
cv risk factors  % of patients
egfr  median ( sd )  ml / min
% rf +
moderate or severe copd exacerbations
beta - blocker use at randomization
hscrp > $nmbr$ mg / l
exacerbation rate in the previous year ( range )
bdp / ff / g ( n = $nmbr$ )
high density lipoprotein ( mg / dl )
dose ( n )
hormone replacement therapy
europe ( eu )
events / statin group
site of disease — no . ( % )
proximal - mainleft
pharmaco - invasive n = $nmbr$
$nmbr$ % c . i .
metformin : no / yes  %
laba or lamab n = $nmbr$
physical role
colorectal cancer
estimated odds ratio
secukinumab intravenous $nmbr$ mg ( n = $nmbr$ )
clopidogrel dose
ex - smoker / smoker  %
moderate ( > $nmbr$ to < $nmbr$ )
stroke of undetermined cause
screening visit
medications before admission
antiplatelet therapy dual
fenofibric acid $nmbr$ = $nmbr$
asia / pacific ( % )
number of patients with fractures
before amendment ( % )
( haq - di  $nmbr$ - $nmbr$ )
race or ethnic group — no . f
loss of response : ! : : ! :
post - bronchodilator fev $nmbr$ — % of predicted value
medical history duration of heart failure ( years ) primary cause of heart failure
major cardiovascular
bmi > $nmbr$ ( % )
high risk ( $nmbr$ - $nmbr$ )
seronegative ( rf - ve and acpa - ve ) subgroup
functional outcome ( mrs $nmbr$ - $nmbr$ )
previous balloon angioplasty
mean number of exacerbations in previous $nmbr$ months ( sd )
duration from clopidogrel / placebo to pci  min ( median  iqr )
( ci ) b
hispanic ethnic group — no . / total no . ( % ) ‘ j ‘
age  y . o .
serum triglycerides  mg / dle
post - acute ischemic stroke
death / mi / idr / st / gusto - defined moderate or severe bleeding
use of rescue albuterol  puffs / day *
intent of conservative strategy  %
> < $nmbr$ . $nmbr$  < $nmbr$ . $nmbr$  r < mmse = mini - mental
estimated gfr
stenosis > $nmbr$ %
$nmbr$ - year rates in placebo groups
previously on acei + arb
peripheral artery disease details
egfr ( median  iqr )  ml / min / $nmbr$  $nmbr$ m $nmbr$
dipeptidyl peptidase - $nmbr$ inhibitor
body mass index $nmbr$
traditional nsaid
menopausal status and use of ht
standard care
non - european trial
patient ' s assessment of pain ( $nmbr$ - $nmbr$ vas )
tdi total score ( week $nmbr$
p  treatment - by - region interaction
insulin only
catscorecategory  n ( % )
anacetrapib ( n = $nmbr$  $nmbr$ )
control $nmbr$ months ( n - $nmbr$ )
no immomtedion
delayed reaction
disease site — no . of patients ( % ) |
$nmbr$ . $nmbr$ - < $nmbr$
sgrq total score ( units ) : ! :
qualifying myocardial infarction
psoriasis
no glucocorticoids or immunosuppressants
mean ± s . d . hba $nmbr$ c
time from last dose of p $nmbr$ y $nmbr$ inhibitor  days
s $nmbr$ gallop  n ( % )
any condition
sitagliptin n = $nmbr$
mean weight  kg  mean = sd
abciximab ( n = $nmbr$ )
antiplatelet — no . ( % )
ischemic heart disease indicator no ( n = $nmbr$ l )
ifg / prediabetes ^
no . of target vessels
adjusted mean ± se ( $nmbr$ % ci )
albuminuria < $nmbr$ gram / gram cr
nyha lll - iv
chronic kidney disease  n ( % )
patients with fistulas at baseline
standard control
cvd  mi  stroke  or recurrent ischemia - urgent revascularization
white race  %
> $nmbr$ / tmol / liter — no . ( % )
renin inhibitors
not localized
ischemic stroke without hemorrhagic conversior
constitutional
smoking status  n ( % ) former
crp ( mg / dl ) * *
ularitide ( n = $nmbr$ )
vorapaxar placebo $nmbr$ - yr . km %
cv death  ml  ischemic stroke  hosp . for hf  cor . revasc .  ua
prior anti - tnf therapy
reinfarction
sgrq total score
first primary composite outcome
score on modified mini - mental state examination — median ( iqr )
hormone replacement
composite endpoint of doubling of serum creatinine  esrd
exercise ( % )
history of ischemic heart disease — no . ( % )
statin therapy
stratified analyses
seated sbp at $nmbr$ weeks  mmhg + * *
former / current smoker  n ( % )
( sd )  mg / dl
primary trial end point
fasting blood glucose
number ( % ) reporting migraine on $nmbr$ - month questionnaire
concomitant corticosteroid use
elevated bun ( > $nmbr$ . $nmbr$ meq / l )
slowest third
clinical features of hf
tertile $nmbr$ index pci performed
risk factor ( predefined ) for falling at screening  n ( % )
left ventricular dysfunction
serum cholesterol  mg / dld
acs treatment
< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ nt - pro - bnp
prednisone use  %
actual treatment strategy
other antiplatelet agent 一 no . ( % )
% change from baseline ls means ( se )
use of blood pressure lowering medication *
multivessel disease 一 no . ( % )
patients using concurrent tiotropium
time since copd diagnosis ( yrs )
use of medications for pah — no . ( % )
ace - i or arb use at baseline
medical history of diabetic retinopathy §
a $nmbr$ + ez n = $nmbr$ a $nmbr$ n = $nmbr$
anti - tnf - naive patients $nmbr$
total patients  n
heterogeneity test
infarction  date not reported
rates per $nmbr$ patient - years
% difference  $nmbr$ % ci )
tofacitinib $nmbr$ mg bid
smoking index — pack - yr §
body weight ( kg )  n ( % )
spironolactone
non - frail
$nmbr$ vitamin e
low potencyc
osteopontin ( ng / ml )
pvaluefor any mi versus no mi
prerandomization statin therapy
multivessel cad  n ( % )
glomerular filtration rate §
$nmbr$ mg sirukumab every $nmbr$ weeks ( n = $nmbr$ )
baseline lvef  %
hypertension ( % ) : t
previous loss of response to infliximab  n ( % ) *
number of treated vessels
extracranial carotid stenosis  n ( % )
coronary artery disease  n ( % )
telmisartan
physician
black and other
diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .
smokers ( at baseline )
baseline use of hormone therapy ( % )
high hdl - c ( for men ≥ $nmbr$   mg / dl / for women ≥ $nmbr$   mg / dl )
myocardial infarction or angina
exposed ( n = $nmbr$ )
primary composite end point
fasting insulin ( giu / ml )
met criterion at final ( n [ % ] )
mean ( sd ) bmi ( kg / m $nmbr$ )
mean body weight ( sd )  kg
lean ( < $nmbr$ kg / m $nmbr$ )
previous treatment with a laba and / or lama  n ( % ) c
new des ( n = $nmbr$ )
homa - ir index — median ( iqr )
timi risk score ( interaction : p = $nmbr$ . $nmbr$ )
prior use of systemic
all randomized
obesity ( % ) §
diabetes therapy
balloon angioplasty
ibdq domain scores  mean [ sd ]
rosiglitazone ( n = $nmbr$ )
smoking ( ever )
patella fracture
screening
medical history and risk factors
ineffective therapy
risk group
hdl - c ( mg / dl ) - mean ± sd
very severe ( gold $nmbr$ )
glycated hemoglobin  n ( % )
antihypertensive therapy — no . ( % )
non - ischaemic cause
low periostin subgroup (  $nmbr$ ng / ml ) ( n = $nmbr$ )
infarct location — no . / total no . ( % )
enrollment by region  no . ( % )
fixed triple ( n = $nmbr$ )
multivessel stenting
estimated creatinine clearance < $nmbr$ rmb ' mint
event rate
fev $nmbr$  litres ( pre salbutamol )  mean ( sd )
gpifeellla inhibitor use before angography
gender  female  n ( % )
latin america or south africa
patients with complicated events ( p = $nmbr$ - $nmbr$ 十 )
triglycerides $ $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l )
patients with > $nmbr$ exacerbations resulting in ed visit
use of statins
time between cessation of full - dose warfarin therapy and enrollment ( mo )
egfr $nmbr$ - $nmbr$
egfr > = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % )
peri - op ace - inhibitors / arbs : no ( n = $nmbr$ )
cangrelor ( n = $nmbr$ ) n / n ( % )
baseline fev $nmbr$ % predicted
age ( range ) ( years )
mean — yr age group — no . ( % )
history of atrial fibrillation or flutter treatment at randomisation
previous stenting ( % previous pci )
bivalirudin only
medical history ( % )
clopidogrel given before procedure
ezetimibe + simvastatin ( n = $nmbr$  $nmbr$ * )
aliskiren / valsartan ( n = $nmbr$ )
urinary protein - to - creatinine ratio | |
cerebrovascular accident
male sex — no . ( % ) weight — no . ( % )
weight — no . ( % )
$nmbr$ non - mtx
fasting triglycerides — mg / dl
concomitant csdmards other than methotrexate  n ( % )
( b ) concomitant respiratory medications [ n ( % ) ]
copd population ( n = $nmbr$ )
ibdq score  mean ( sd )
lifestyle
disease location  %
haq - di  number ( % )
cardiac pacemaker — no . ( % )
patient ' s preference not to take
tofacitinib  $nmbr$ mg twice daily
diet + pravastatin group
glycated hemoglobin level
asthma population ( n = $nmbr$ )
albumin creatinine ratio
apolipoproiein b ( mij / $nmbr$ )
aliskiren ( dm - vs . dm + )
regadenoson
change in erosion score ( mean )
fecal calprotectin — pg / g * *
infarction before age $nmbr$ ( a )
patients  no . / total no . ( % )
prior biologic use
time since diagnosis of type $nmbr$ diabetes - no . ( % )
metabolic syndrome visit $nmbr$ low - density lipoprotein cholesterol strata
nonbiologic disease - modifying drug other than methotrexate : :
moderate risk ( $nmbr$ - $nmbr$ )
csf a ( $nmbr$ ( pm )
combination - facilitated pci ( % )
time since psa diagnosis ( years )  mean ( sd )
deep - vein thrombosis
> $nmbr$ to < $nmbr$ - $nmbr$ mg / week
aspirin alone ( n / n )
prior treatment — %
homa - ir ( % ) b
duration of diabetes  median ( iqr )
interquartile range height — cm
mild thrombocytopenia ( < $nmbr$ x $nmbr$ / l )
reversibility ( anticholinergic )  %  mean ( sd ) $
number of exacerbation in the previous $nmbr$ months  n ( % )
established cvd ( age > $nmbr$ )
crci > $nmbr$ - < $nmbr$
who functional class ii / iii
( n $nmbr$ $nmbr$ )
cigarette smoking in the past year
candesartan
previous pci / cabg  n ( % )
coronary angiography during the index hospitalization
baseline free pcsk $nmbr$ level by median
( se ] tf total - c
continued thienopyridine %
before pci
glomerular filtration rate  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
elevated troponin t ( > $nmbr$ . $nmbr$ / xg / l )
rivaroxaban
prior history ml or stroke
atorvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ )
alcohol  % with > $nmbr$ drink / d
western europe and lebanon
body mass index  kg / m $nmbr$ ( sd )
current smoker ( > $nmbr$ cigarettes / day ) — no . ( % )
atorvastatin $nmbr$ mg ( n = $nmbr$ )
unstable angina > $nmbr$ mo ago
amlodipine / valsartan $nmbr$ / $nmbr$ vs $nmbr$ / $nmbr$ mg
mean ( s . d . ) apob  mg / dl
tobacco use — no . ( % )
previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis
dapagliflozin $nmbr$ mg / day ( n = $nmbr$ )
edema  peripheral
peripheral vascular disease
angina ( past $nmbr$ weeks )
drug - eluting stent implanted
rhabdomyolysis ( n = $nmbr$ )
hospitalizations  n
baseline heart failure severity amongthose with priorheartfailure  %
patients with end point
us resident
less than $nmbr$ mm hg
p value for mra vs no mra
insulin - treated diabetes
$nmbr$ rrmnl )
metastatic disease
no stroke n = $nmbr$ $nmbr$
physical component score ( pcs )
bmi > $nmbr$ — no . ( % ) f
oral contraceptive pills — no . / total no . ( % )
renal function  moderate
$nmbr$ - yr risk of coronary heart disease ( % ) ^ |
llt other than statin at randomization
other antihypertensive agents
ace inhibitor at enrollment
b - agonists ( short - acting ) a
egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % )
hemoglobin a $nmbr$ c  mean ( sd )  % b
duration of ulcerative colitis
positive for rheumatoid factor — no . ( % ) : t
euroscore logistic  median ( $nmbr$ th  $nmbr$ th % ) £
simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg ( n = $nmbr$ /
age — mean ( sd ) ( years )
cerebrovascular or peripheral arterial disease  n ( % )
low feno subgroup (  $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ )
blood - pressure medications at randomization — no . / total no . ( % )
index event  n ( % )
other or missing data
number of copd exacerbations in the previous year  n ( % )
rivaroxaban plus aspirin ( n = $nmbr$ )
diuretics * *
one vessel
intended duration of anticoagulation
non - stenotic vessels  n ( % )
gusto severe
> $nmbr$ . $nmbr$ bpm current smoker
patients with any clinical event
previous diabetes
mmrc dyspnea scale  n ( % )
brv $nmbr$ mg / day ( n = $nmbr$ )
urinary tract infection
baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$
hospitalization for heart failure
any history of congestive heart failure
time from study drug administration to coronary revascularization  median ( iqr )  h
heart failure ( class i — iii )
c - reactive protein — mg / liter * *
liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$  $nmbr$
placebo $nmbr$ yr km %
prebronchodilator fev $nmbr$ ( % predicted normal ) t
rest of world
mean age ( sd )  y
low - molecular weight heparin or intravenous unfractionated heparin
$nmbr$ early intervention ( n = $nmbr$ )
no statin ( + / - llt )
treatment satisfaction
pathologic q waves — no . ( % )
total periventricular wml score  mean ( sd )
laboratory values at admission ( median and iqr )
corticosteroid use  $nmbr$ n ( % )
use of inhaled glucocorticoids at screening — no . ( % )
comorbidity score  mean ( sd ) t
non - smokers ( at baseline )
tender joint count ( n / $nmbr$ )
total intravenous loop diuretics  mg
atorvastatin $nmbr$ mg + ezetimibe $nmbr$ mg ( n = $nmbr$ )
angiotensin ll - receptor antagonist — no . ( % )
mean serum glucose  mg / dl  mean = sd
gold stage ( % ) f
non - hdl - c / hdl - c
multivessel ( two vessel  three vessel  or left main )
body weight index ( kg / m $nmbr$ )
triglycerides  mmolt $nmbr$ ( gm * )
procalcitonin ( ng / ml )
fasting blood glucose > $nmbr$ mg / dl
category $nmbr$
type of event
quality of life
diagnosis ( y )  mean ( sd )
persistent or permanent immobilization
modified rankin scale at screening  $nmbr$ - $nmbr$
placebo $nmbr$ . $nmbr$ pt yrs
diet controlled or no
body weight
cvd  mi  or stroke
no . of patients / no . of events
intravenous study drug administered — no . ( % )
number of females n ( % )
> $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %
treatment with statins
prior heart failure  n ( % )
systemic symptoms
persistent or paroxysmal
metabolic syndrome w / o t $nmbr$ dm
stroke — no . / total no . ( % )
nice primary prevention onlyb
cv death  mi  ischemic stroke  hospitalization for hf  coronary revascularization  ua
change from pre - to
any lipid - lowering agent
abatacept
indacaterol - glycopyrronium group
warfarin naive
prior or new diabetes
tender and swollen joints — mean no . : :
systolic blood pressure > $nmbr$ mm hg or diastolic blood pressure > $nmbr$ mm hg
rolofylline ( n = $nmbr$  $nmbr$ )
total stent length ( mm )  mean ± sd
swollen joint count ( $nmbr$ joints )
mean $nmbr$ sd
previously taken methotrexate  %
gusto moderate
procedure * *
hormone replacement ! !
other cardiovascular risk factors
severe copdc [ n z $nmbr$ ]
cardiac biomarker status !
$nmbr$ - mercaptopurine
patient presentation
baseline serum k +  meq / l
other sulfonylurea 一 no . ( % )
hctz * ( n = $nmbr$ )
cardiometabolic syndrome  ^ n ( % )
carotid artery — no . ( % )
cardiac valve surgery : no ( n = $nmbr$ )
other cause
beyond popliteal pedal
> $nmbr$ cv risk factors 咐 or established atherosclerotic cv disease
oral anticoagulant drugs
fracture history ( predefined )  n ( % )
any coronary revascularization
ex - / current smoker
vorapaxar $nmbr$ - y
fluindione  no . ( % )
current n z $nmbr$
concomitant oral corticosteroids  n ( % ) * *
anaesthesia / analgesia
local eosinophil count ( cells per pl ) t
age ( years )  mean ( s . d . )
ethnic group ( % )
physician ' s global assessment ( vas )
antihypertensive drugs
median age — yr §
cad and / or crvd ( % )
chronic obstructive lung disease
exercise category ( % )
prior congestive heart failure yes
secondary prevention subgroup
aspirin $nmbr$ mg ( n = $nmbr$ )
night - time awakenings / week
non - hdl - c  mean ( sd )  rng / dl
laa closure ( n - $nmbr$ )
p - value * ' '
known prothrombotic genotype
> $nmbr$ concomitant medication
function subscale
high risk and more symptoms ( group d )
white ( $nmbr$ . $nmbr$ % )
osteoarthritis
age ( y )  median ( $nmbr$ th to $nmbr$ th percentiles )
history of microalbuminuria — no . ( % )
tender joint count ( $nmbr$ joints )  mean ( sd )
$nmbr$ mg / day delayed - start
documented symptomatic chdb
c - reactive protein
ejection fraction  percent ( sd )
previous pneumonia
das $nmbr$ - esr remission  %
budesonide — no . ( % )
linagliptin  patients with events / total patients
middle tg tertile
density lipoprotein  csf =
hscrp  median ( min  max )  mg / l
concomitant medication after randomisation
non - black ( n = $nmbr$ )
dmard or corticosteroid
non - epa number of <
hbalc tx difference vs pbo  median change from baseline ( se ) $nmbr$
trough fevi l
eq - $nmbr$ d ( visual analog score )
antihypertensive medication  open - label  no . ( % )
mer ’ s disease assessment
baseline ldl - c strata  n ( ° / o )
with alogliptin $nmbr$ . $nmbr$ mg
anacetrapib ( n = $nmbr$ )
secondary dvt . ' fe
with laba  n ( % ) pretreatment
basal insulin analogue dose * ( coefficient
theophyllines
angina class iii or iv — no . ( % )
n ( $nmbr$ yr km event rate  % )
age — year ( median )
tnt and ideal ( pooled )
cabg or ptca / pci
ex - smoker ( n z $nmbr$ )
event rate ( % ) of primary endpoints
insulin - dependent diabetes
malignancy at randomization
short - acting
serum potassium  meq / l
rest of world n z $nmbr$
never smoked  n ( % )
seizure worry
placebo group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years )
rest - of - world ( n = $nmbr$ )
no use ofdiabetes drugs — no . ( % )
no estimate
baseline ( n )
pci > $nmbr$ month ago
swollen joint count ( $nmbr$ joints )  mean ( sd )
> $nmbr$ years $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )
time in therapeutic range before inclusion
initial diagnosis — no . ( % )
angiotension converting enzyme - inhibitor
xanthines
management distribution medical treatment
pharmaco - invasive ( n = $nmbr$ )
estrogen - containing hormones
uac $nmbr$ - $nmbr$ mg / g
$nmbr$ % < hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ )
mean ( s . d . ) measured ldl cholesterol
history of hypertension — no . ( % )
prior cv history  n ( % )
time to end - of - study ivus  median ( iqr )  days
steroids ( inhaled ) a
> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )
previous angioplasty  n ( % )
time since diagnosis of diabetes
uric acid tertile $nmbr$ ( $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mg / dl )
major hypoglycemia
prosper
dyspnea at rest ( nyha iv )  ( % )
czech republic
gusto moderate or severe bleeding
baseline cdai
% change from baseline  mean ( s . e . )
enalapril + aliskiren ( n = $nmbr$ )
non - calcium antagonist strategy ( n = $nmbr$ $nmbr$ )
ankle fracture
number standard care
digitalis  n ( % )
warfarin at last follow - up
pci data
end of follow - up
handihaler only  n
certolizumab pegol ( n = $nmbr$ )
mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ level — no . ( % )
egfr via mdrd ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
core laboratory percent stenosis
native american / alaskan
mean cdai score ( sd )
insulin glargine vs standard care least - squares mean ( $nmbr$ % cl )
difference in ls mean $nmbr$ ( $nmbr$ % cl )
prior diagnosis - no . ( % )
moderate - dose statin
tnf - alpha ( pg / ml )
antithrombotic drug use at time of event
jbs - $nmbr$ secondary prevention only $nmbr$
full cohort
c - peptide
immobilization
death  mi  idr  st  or gusto moderate / severe bleeding
thienopyridine ( n = $nmbr$ )
$nmbr$ - year framingham chd risk  %
etoricoxib
previous coronary artery disease  n ( % )
elevated cardiac markers
ifx + aza ( n = $nmbr$ )
open - label clopidogrel after completion of study drug
baseline low - density lipoprotein cholesterol ( mg / dl )
symptom onset to randomization
stricturing
insulin tx difference vs pbo  median change from baseline ( se ) $nmbr$
duration of rheumatoid arthritis ( years )
beta - blocker — no . / total no . ( % )
second loading dose
trochanter
low perceived social support only
white / other
treatment groups [ n / nb ( % ) ]
cardiovascular medication usage
non - calcium antagonist strategy ( ncas ) ( events / n )
simvastatin ( $nmbr$ / $nmbr$ mg / d ) ( n = $nmbr$ )
baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$
n / n $nmbr$ / $nmbr$
not - japan
previous cardiovascular events
trigl yeerides * ( m mol / l )
total cholesterol : hdl - c ratio
proadm ( ng / ml )
interact !
older des ( n = $nmbr$ )
second co - primary outcome
pe ± dvt
previous warfarin use  no . ( % )
nice secondary prevention onlyb
ankle / brachial index
non - caucasian eze / simva
use of compression stockings  no . ( % )
prior angiography showing stenosis > $nmbr$ %  n = $nmbr$ °
previous use of antiarrhythmic drugs
location  n ( % )
associated with ctd
clopidogrel ( n = $nmbr$ ) n / n ( % )
physical exam oedema
triglyceride ( mmol / l ) * blood pressure
valproate
ls - mean change from baseline ( $nmbr$ % ci )
median age ( iqr  years )
cardiac medications during index hospital stay and / or discharge
cardiac medications during index hospitalization  %
no ipst ( n = $nmbr$  $nmbr$ )
non high dose statin ( n = $nmbr$  $nmbr$ )
gall bladder adverse event ( n = $nmbr$ )
elevated crp ( > ulnt )  n ( % )
liraglutide
type of drug - eluting stent  n ( % )
ratio of fev $nmbr$ to fvc
infarct localization  n ( % )
racial category *
inhaled j $nmbr$ - agonist §
nonwhite race — no . ( % ) ejection fraction
theophylline use at screening
history of omalizumab treatment
symptom onset to arrival in catheterization laboratory
omega - $nmbr$ fatty acid vs placebo least - squares mean ( $nmbr$ % cl )
tnfi and other bdmardst  n ( % )
atenolol strategy ( n = $nmbr$  $nmbr$ )
left atrial diameter : < $nmbr$ mm ( n = $nmbr$ )
ethnic group
baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks
rf ( iu / ml )
coronary heart disease risk equivalents  n ( % ) c
medical history of hypertension
mepolizumab group
microalbuminuria or macroalbuminuria
baseline ldl - c > $nmbr$ mg / dl
combination therapy * *
uac > $nmbr$ mg / g
health assessment questionnaire score
age at onset  y
antidiabetes drug usage [ % ( n ) ]
ibdq total score  mean [ sd ]
fenofibric
era and pde $nmbr$ inhibitors
allogliptin
current smoker ( n = $nmbr$  $nmbr$ )
weight ( kg )  mean ( s . d . )
previous stroke or tia ( % )
average of maximum common carotid cimt ( mm )
new or suspected thrombus
lacosamide
natalizumab ( n = $nmbr$ ) f
family history of coronary disease
multivessel cad ( % )
long - acting bronchodilator use at screening
fev $nmbr$ / fvc ratio  % ( sd )
mild impairment ( egfr $nmbr$ - $nmbr$ )
all randomly assigned
diet and exercise
diabetesduration  mean ( sd )  y
median feno  ppba
non - detectable / unknown
primary enrollment diagnoses  n ( % )
low hdl - c ( for men < $nmbr$   mg / dl / for women < $nmbr$   mg / dl )
mean body mass index ( sd )  kg / m $nmbr$
ace inhibitor or angiotensin ii receptor
diet diet + pravastatin
unspecified
atherosclerotic cardiovascular disease
dilated cardiomyopathy
participation in phase a
region of enrollment
white race  n ( % )
after amendment
laba + ics versus indzgly lsm difference ( $nmbr$ % cl )
number of patients > $nmbr$ years ( % )
hypoglycemia
gold stage [ n ( % ) ]
not treated
motor subscale ( range  $nmbr$ - $nmbr$ )
feno + eze
total group
asthma control test score at baseline
lipid values  mmol / l
esr  $nmbr$ - $nmbr$ mm / hour
europe and canada
total mayo score $ | |
egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )
as - needed inhalations / day
warfarin  no . ( % )
habitual fish intake : < $nmbr$ servings / wk ( n = $nmbr$ )
number resulting in hospital admission
infarction > $nmbr$ days previously
pasi score ( $nmbr$ - $nmbr$ ) t  mean ( sd )
index mi ( n - $nmbr$  $nmbr$ )
> $nmbr$ % coronary stenosis
mean ( s . d . ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
triglycerides  mmol / l  mean ± sd
losartan + lisinopril
male  n / n ( % )
isolated deep - vein thrombosis
esrd or death
tiotropium $nmbr$ . $nmbr$ mg
other major risk factors
csf lathosterol ( | jlg / cll )
diagnosis at presentation — no . ( % )
number of concomitant csdmards  n ( % )
radiographic characteristics at baseline and randomization
probability  of event %
d - dimer ( ng / ml )
insulin  median ( ql  q $nmbr$ )  pmol / l
cerebrovascular
methotrexate use at randomisation
method of identification ofstenosis ( % )
treatment of the index ml
saba puffs per day at baseline
joint space narrowing score
evolocumab $nmbr$ mg monthly ( n = $nmbr$ )
intent - to - treatb
ace - i or angiotensin receptor blocker
body mass index > $nmbr$ — no . ( % ) f
mean change  % ( se )
prebronchodilator fev $nmbr$ / fvc
less than $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
previous tia or stroke
non - ischaemic aetiology
stroke n = $nmbr$
crp concentration > $nmbr$ mg / l  n ( % ) \
european quality of life - $nmbr$ dimensions - $nmbr$ level ( eq - $nmbr$ d )
major clinical response
mean ham - d score ( $nmbr$ % ci )
bowel function
laa ostium
bnp o $nmbr$ pg / ml or nt pro - bnp o $nmbr$ pg / ml  n ( % )
laa length
patient ' s preference not to take vka  only reason * *
risk factors and immobility level  n ( % )
pasi score > $nmbr$ *
cardiac history
drug - eluting stent  n ( % )
copd — no . ( % ) medication use
interquartile range
acute stroke of other determined cause
severe exacerbations  itt population  n ( % )
europe $nmbr$
male gender ( % )
no . of vessels
n - $nmbr$ fatty acids - placebo lsm ( $nmbr$ % cl )
rheumatoid arthritis
> $nmbr$ % focal seizure frequency responders
medication within $nmbr$ days before enrolment
sex ( male ) - no . ( % )
worsened
digoxin at enrollment
prostate cancer
pre - bronchodilator fvc ( l )
creatinine clearance
no . of treated lesions
cholecystectomy ( n = $nmbr$ )
# of prior non - tnfi bdmards *
immunosuppressive agents only
enalapril ( n = $nmbr$ )
deep - vein thrombosis or pulmonary embolism — no . ( % )
age - years  median ( iqr )
total no . of patients
n - $nmbr$ fatty acids ( n = $nmbr$ )
baseline cv treatment
selena - sledai ( range u - $nmbr$ u $nmbr$ ) t
bnp > $nmbr$ pg / ml  n = $nmbr$
ms & ng
global assessment of disease status score
all patients ( n = $nmbr$ )
isolated impaired glucose tolerance — no .
angiographic extent of disease
type of concomitant statin by daily dose - no . ( % )
postoperative nsaid or glucocorticoid use
airflow reversibility — no . ( % ) |
devices
age at enrollment ( years )
mean ( sd ) disease duration  years
race - white ( n = $nmbr$  $nmbr$ )
fluticasone furoate  n = $nmbr$
baseline hba $nmbr$ c  n ( % )
aldosterone antagonists ( e . g . spironolactone )
pci duration in min ( median  iqr )
age > $nmbr$ years  n ( % )
active cancer — no . ( % )
insulina  n ( % )
skull  and facial bone fractures
$nmbr$ - aminosalicylates {
hemorrhagic stroke
immy ( without corticosteroid )  n
renal function  normal - mild
log rank p - value
prior myocardial infarction  n ( % )
high - density lipoprotein
antibodies to infliximab  n ( % ) * *
safety : non - cabg - related bleeding
diabetes mellitus — no . ( % )
mmrc grade  n ( % )
inspiratory capacity ( l )
hf  lvd  or both
percent of predicted fev $nmbr$
ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % )
diuretics group ( n = $nmbr$ )
prior aortocoronary bypass surgery
neutrophils  $nmbr$ / nl
antiplatelet or anti - inflammatory drugs
presentation of index event
statin at enrollment
ethnicitya hispanic or latino
waist circumference s $nmbr$ ( men ) or > $nmbr$ cm ( women )
baseline mssbp / msdbp  mm hg
hispanic american
hba ] c ( mmol / mol )
men / women
pbo ( n $nmbr$ $nmbr$ )
creatinine clearance < $nmbr$ ml / min ( % )
total comparators ( n = $nmbr$ )
heart rate ( b . p . m . )
smoking history  n ( % )
disease duration  mean yr ( sd )
high feno subgroup ( > $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ )
hba $nmbr$ c in patients with baseline hba $nmbr$ c < $nmbr$ % ( < $nmbr$ mmol / l )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se )
overall event rate
prior biologic therapeutic failures  n ( % )
losartan plus lisinopril ( n = $nmbr$ )
us site of enrollment
killip class lll - iv
coronary artery osteochondrosis
time from onset of pain to randomization  median ( $nmbr$ th — $nmbr$ th percentiles )  n
subset of patients not on metformin
no persistent wrf ( n = $nmbr$  $nmbr$ )
clopidogrel plus aspirin % / yr
percutaneous coronary revascularization
plus metformin
calcium - channel inhibitor
uacra  mg / g  gmean = gcv
cure trial
ratio ( $nmbr$ % ci ) *
baseline pre - bronchodilator fev $nmbr$  l
physical component summary
placebo croup  n / n ( % )
smoking status at screening
copd medication taken for at least $nmbr$ months before st
st - segment - elevation myocardial infarction — no . ( % )
ada $nmbr$ / $nmbr$ ( n [ $nmbr$ )
previous segmental resection — no . ( % )
older patients ( aged > $nmbr$ years )
pre - operative cardiac medications *
other forms of
mean ( s . d . ) hbalc  mmol / mol
number of ( % ) patients > $nmbr$ years
ck - mb  ng / ml
prior cardiovascular disease
current / past smoker
on - pump time : < l : $nmbr$ hrs : min ( n = $nmbr$ )
diuretic — no . ( % ) surgery
< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )
types of fibrinolytic agent
u » c » ( mg / g )
anticoagulant group ( n = $nmbr$ )
< $nmbr$ yr of education — no . ( % )
non - colorectal cancer
all bleeding
hbalc ( % )  mean ( sd ) ^
simvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ )
losmapimod ( n = $nmbr$ )
number of e
region  europe union
hydochlorothiazide ( n = $nmbr$ )
continued treatment study
death / q - wave mi / idr
p value for trend
time since diagnosis of heart failure
mean ( s . d . ) ldl particle size  nm
single vessel pci
pfo with mild - to - moderate shunt and atrial septal aneurysm
obesity ( bmi > $nmbr$ kg / m $nmbr$ )  %
colon only
lp ( a ) ( week $nmbr$ )
n - $nmbr$ pufa events / patients ( % )
arthritis type *
aml / val  $nmbr$ / $nmbr$ mg rr = $nmbr$ *
in emergency department before ambulance transfer
gold d
saaca
ecg
之 $nmbr$
total ( n = $nmbr$ )
race  %
race — no . ( % ) |
% $nmbr$ - $nmbr$
severe
pbo  n = $nmbr$
bnp
male sex  ( % )
females  %
< $nmbr$ mm
s $nmbr$ %
age ' ^ $nmbr$ yrs
atv $nmbr$ mg ( n = $nmbr$ )
female  no . ( % )
> $nmbr$ mo
male sex — %
lvh
stent
acr $nmbr$
diet
cg / ld
age ( years ) *
nonsmoker
ics use
no ( % )
lips
≤ $nmbr$
ocs
tg < = $nmbr$ . $nmbr$
vka
rate * ( n )
statin ( n - $nmbr$ )
« s $nmbr$ - $nmbr$
$nmbr$ to < $nmbr$ mmhg
males ( % )
三 $nmbr$ to < $nmbr$
cough
> median
smoking *
etd ( $nmbr$ % ci )
% ( se )
pm  n ( % )
placebo  n ( % )
n ( % )
> $nmbr$ beds
number
male  no ( % )
> $nmbr$ years ( n = $nmbr$ )
femaleb
< $nmbr$ hr
> $nmbr$ to < $nmbr$ mm hg
deaths
uvb
asian ( n — $nmbr$ )
bms
p - int
l ’ - value ’
abnormal
placebo
crt
sex :
icd
cabg
≤ median
$nmbr$ - $nmbr$ ft
lad
$nmbr$ yrs
hs - crp
no prior llt
range
phi ( n = $nmbr$ )
> $nmbr$ h
women ( n = $nmbr$ )
> $nmbr$ - < $nmbr$ years
men ( % )
> $nmbr$ ug / g
cdai
age $nmbr$
age > = $nmbr$ years
hbalc < median
arr ( $nmbr$ % ci )
msdbp
ato $nmbr$ mg ( n = $nmbr$ )
redon
daily
placebo n / n ( % )
statin ( n = $nmbr$ )
white
blockers
idr
p - valuec
$nmbr$ ( > $nmbr$ % )
≥ $nmbr$ . $nmbr$ years
men  %
a $nmbr$ n = $nmbr$
p valued
study
> $nmbr$ % $nmbr$
no pci
igm
ex - smoker
etn  no
rales  n ( % )
pooled
total
female sex ( % )
acs
$nmbr$ . $nmbr$ min
motor
apo bt
age  years
asian  n ( % )
age < $nmbr$ yr
hr $nmbr$ % cl
sal $nmbr$ mg
frail
> l $nmbr$ years
iv ( n z $nmbr$ )
( $nmbr$ % cl )
* p value
arb
oad
fema le
$nmbr$ e $nmbr$ years
black ( n = $nmbr$ )
missing
single
events ( % )
> $nmbr$ kg
s
< $nmbr$ ng / ml
rr ( $nmbr$ % ci )
result
age > $nmbr$ years  %
patients n
placebo [ n = $nmbr$ |
$nmbr$ % cl
$nmbr$ $nmbr$
> $nmbr$ %
hbak < median
yes
> $nmbr$ yr sex
< $nmbr$
> = $nmbr$ years
$nmbr$ mg / g
ascvd  n ( % )
lgm ( n = $nmbr$ )
mace
neither
> = $nmbr$ kg
( se ) t *
esrd
placebo n [ $nmbr$
death
mtx
loop
japanese
chda
> $nmbr$ lb
age ( years ) +
l ( % )
chads $nmbr$
( n = $nmbr$ )
new om
$nmbr$ % $nmbr$
former  n ( % )
b lack
median
$nmbr$ — < $nmbr$ years
hdl - cd
low
> $nmbr$ ( n — $nmbr$ )
rr *
iii / iv
pla
hr
bmi < $nmbr$
$nmbr$ . $nmbr$ yrs
plac
women  n ( % )
other  n ( % )
lmwh
mexico
lcz $nmbr$ ( n = $nmbr$ )
$nmbr$ % cit
black ( n — $nmbr$ )
< $nmbr$ yr
< $nmbr$ » < $nmbr$ y
hba „ ( % )
htn
p for i
af
# $nmbr$ year
beta - blocker use
naive ( n = $nmbr$ )
change $nmbr$
< l $nmbr$ years
treated
t $nmbr$ d
mtx n = $nmbr$
white ( n — $nmbr$ )
pasi *
aged ^ $nmbr$ years
> $nmbr$ - < $nmbr$ mmhg
copd ( n = $nmbr$ )
$nmbr$ +
< $nmbr$ kg
< $nmbr$ ( n — $nmbr$ )
bmi > $nmbr$
lsm ( $nmbr$ % ci )
dd
x / n
age yrs
diet alone
sfc ( n [ $nmbr$ )
> $nmbr$ / > $nmbr$ mm hg
former
< $nmbr$ ft
■ $nmbr$ years
$nmbr$ - $nmbr$ years
p value *
beta blocker
< $nmbr$ years ( n = $nmbr$ )
beta - blocker  %
race ( % ) $
fibrate
primary pci
egfr
colon
n
arb  n ( % )
aphasia
heparin
white  %
low ’
f emale
igm ( n = $nmbr$ )
> $nmbr$ $nmbr$
< $nmbr$ mg
ics : yes
< $nmbr$ ml
placebo ( n = $nmbr$
unprovoked
strategy
asia ( n = $nmbr$ )
region  %
cse ] +
age > $nmbr$ y * *
i % $nmbr$
mca
taci ( n = $nmbr$ )
hdl - c
medium
placebo ( n = $nmbr$ )
women men
both
rca  n ( % )
events
patients  n
italy
$nmbr$
> $nmbr$ - $nmbr$ years
s $nmbr$
chf
^ - blockers
$nmbr$ ( n = $nmbr$ )
ale
p valuea
age ( yrs )
≤ $nmbr$ %
$nmbr$ mg
placebo n = $nmbr$
anemia
eze
mean *
atv $nmbr$ mg
ef $nmbr$ - $nmbr$ %
open — no . ( % )
oriental
\ $nmbr$ %
anakinra
of patients
arb  %
sex  men ( % )
sedbp
£ $nmbr$ kg
japan
> $nmbr$ hrs
female ( % )
hbak > median
aspirin  n ( % )
other — no . ( % )
male ( n z $nmbr$ )
dm absent
vora
* $nmbr$ to < $nmbr$ y
male
never smoking
female sex — no . ( % )
( gm )
st +
≥ $nmbr$ to < $nmbr$ %
aqe i $nmbr$
n / pyr
apobe
age : > $nmbr$ years
crci > $nmbr$
$nmbr$ mg bid
psa ( n = $nmbr$ )
ldl *
pin /
overall
( se ] tf
oa
grade $nmbr$
off omt
gold a
no ascvd
mean bmi
female sex
serum
othersc
eze $nmbr$ mg
crt - p
itherchdt
dm present
non - smoker
> = $nmbr$ - < $nmbr$ mmhg
$nmbr$ or $nmbr$ days
group d
age  $nmbr$ years
placebo pts / n ( % )
= s $nmbr$
$nmbr$ - $nmbr$ min
ii ( n = $nmbr$ )
rectum
age  yrs *
total *
< $nmbr$ . $nmbr$ %
cana $nmbr$ mg ( n = $nmbr$ )
mae
$nmbr$ % - $nmbr$ %
^ $nmbr$ - $nmbr$
on omt
race — no . ( % )
age : < $nmbr$ years
hdl - cy
≥ $nmbr$ %
africa
cardiac
feno $nmbr$ mg ( n = $nmbr$ )
lvef < $nmbr$ %
pa
hr ( $nmbr$ % ci )
nsaid
pe
white ( n = $nmbr$ )
placebo n ( % )
egfr > $nmbr$
other *
> $nmbr$ . $nmbr$ yrs
past
< $nmbr$ mm hg
> $nmbr$ % to < $nmbr$ %
known chd
sex  n ( % )
nnt
all ( n = $nmbr$ f )
tia
$nmbr$ / $nmbr$ mg
mmse < $nmbr$
> $nmbr$ - $nmbr$ kg
< $nmbr$ . $nmbr$ bpm
placebo ( n z $nmbr$ )
locf )
< $nmbr$ days
erosion
smokers  %
weight
iiiv
( i - blocker
das $nmbr$
all ( n = $nmbr$ )
placebo  n = $nmbr$
no htn
sex  no . ( % )
race ( % )
vitality
us
pain
age — y £
< $nmbr$ week
hbalc  %
open
> $nmbr$ y
avm ( n = $nmbr$ )
mild
ami $nmbr$ mg
$nmbr$ mg / day
ever - smoker
no . ( % )
lateral
placebo  n / n ( % )
region — no . ( % )
age ^ $nmbr$
pvd
> $nmbr$ mm hg
romania
$nmbr$ < - $nmbr$
< $nmbr$ mg / dl
patients
n / n ( % )
> = median
> $nmbr$ ( n = $nmbr$ )
$nmbr$ — $nmbr$ years
> $nmbr$ % and < $nmbr$ %
cancer
macce
£ $nmbr$ to < $nmbr$ years
or $nmbr$ % ci
> i
any use
never
p - blocker
age > $nmbr$
period i
$nmbr$ to < $nmbr$ hr
swollen
rrr ( $nmbr$ % cl )
≤ $nmbr$ . $nmbr$ %
hscrp
$nmbr$ % ci
second ( n = $nmbr$ )
chd death
pbo ( n = $nmbr$ )
mean — kg
ab $nmbr$ pg ( n = $nmbr$ )
p +
yes *
age
ageadj
aqc < $nmbr$
rr ^ ( $nmbr$ % ci )
$nmbr$ mmhg
$nmbr$ - $nmbr$ mo
> $nmbr$ mg / dl
age - years
statin usage
age $nmbr$ y
race — no . ( % ) 卞
> $nmbr$ / day
des
< median
$nmbr$ - < $nmbr$ yrs
taiwan
$nmbr$ - $nmbr$ yrs
some
≥ $nmbr$ years
> $nmbr$ to < $nmbr$ years
female  no ( % )
cabg — no . ( % )
women - no . ( % )
paci
a $nmbr$ c
age :
vldl
lvef ( % )
$nmbr$ - $nmbr$ hr
mi
ls mean
n *
ldl
risk *
present
age > $nmbr$ y  %
sex
bid
pci
statin use
month $nmbr$
primary
placebo ( n = $nmbr$ o )
< $nmbr$ years
niacini
dm
$nmbr$ to < $nmbr$ yr
edge
spoke
bmi < = $nmbr$
epa ( n = $nmbr$ )
mean ( sd )
cdmard
sd
$nmbr$ mo to $nmbr$ yr
pfor
$nmbr$ - < $nmbr$ %
alert
lvef
$ $nmbr$
apo - b
cohort
ali
ace
woman
apob
$nmbr$ to < $nmbr$ mm hg
£ median
ckd
or ( $nmbr$ % cl )
af alone
region
nsclc
other ( n  % )
monthly
beta - blockers
race  n ( % )
australasia
fp $nmbr$ mg
mean ( se )
iii - iv
$nmbr$ or $nmbr$
or [ $nmbr$ % ci ]
asian
itt
id ( n = $nmbr$ )
state
a $nmbr$
hub
> $nmbr$ hr
lsm ( $nmbr$ % cl )
pci  n ( % )
no . ( % ) *
≥ $nmbr$ to < $nmbr$ years
wssng
f
fp ( n [ $nmbr$ )
» $nmbr$ yr
mean — yr
prior dm
pre - h
acid
hctz
r $nmbr$
korean
placebo %
. $nmbr$
age < median
nste - acs
age £ $nmbr$
w
p - value *
stent ( n = $nmbr$ )
value *
sso - $nmbr$
id
iorii ( n z $nmbr$ )
belgium
hbalca median
use
male sex ( % )
> $nmbr$ yrs sex :
female ( n z $nmbr$ )
pci ( % )
or ( $nmbr$ % ci )
( e - blocker
nsteacs
other '
bmi ^
smoking
race n ( % )
risk
homa
africa *
sex ( % )
jvp  ( % )
r $nmbr$ ( n = $nmbr$ )
py = $nmbr$ )
a - blocker
p blocker
hba  c ( % )
r $nmbr$ mg
female sex  n ( % )
> $nmbr$
> $nmbr$ to < $nmbr$
rales  ( % )
tion — no . ( % )
p trend
ada  no
macce ( % )
nonwhite
pt
apo b *
% ( $nmbr$ % ci )
^ - blocker
no betablocker use
age  ( years )
> $nmbr$ type
female
us ( n = $nmbr$ )
tzd
$nmbr$ - < $nmbr$
peace ( n = $nmbr$ )
< $nmbr$ lb
< $nmbr$ mg / g
non - mtx
age  year
py *
feno
mental
smokers
> $nmbr$ ft
women  %
mssbp
uac =
acei
usa
class > $nmbr$
europe ii
/ ’ - value
sabaa
prior mi
no statin
cv death
age > = $nmbr$
$nmbr$ §
alone
r
ultra
paci ( n = $nmbr$ )
age < $nmbr$
stage $nmbr$
laba alone
eze $nmbr$ mg ( n = $nmbr$ )
no prior ml
$nmbr$ ( < $nmbr$ % )
statin
n $nmbr$ yrs
male ( n = $nmbr$ )
psa
$nmbr$ / $nmbr$
region - no . ( % )
placebo ( n = $nmbr$ l )
otherz
$nmbr$ years
$nmbr$ yr
asp
aqe < $nmbr$
n = $nmbr$
fh ii
overallb
nitrate
age > $nmbr$ y
black
new dm
< $nmbr$ mon ( n = $nmbr$ )
lower
age  mean
dvt
m
black  n ( % )
obesity
women
il - $nmbr$
< $nmbr$ y ( n = $nmbr$ )
placebo r %
mg / dl
ml c
tg +
sotalol
cdai < $nmbr$ t
$nmbr$ ( $nmbr$ % )
mmse > $nmbr$
tg §
v ( n = $nmbr$ )
= $nmbr$
p
race  no . ( % )
fa $nmbr$ mg
none
no smoking
usa ( n = $nmbr$ )
rate *
gender
male ( n - $nmbr$ )
austria
$ $nmbr$ years
fh $nmbr$
no ?
dd ( n = $nmbr$ )
lu / kg
no ststm
st -
p - valuea
yes ( n = $nmbr$ )
abi < $nmbr$ . $nmbr$
iv
sama
latvia
mra
asian *
bm i < $nmbr$
age > $nmbr$ yrs
chf ( % )
ef  %
vi $nmbr$ mg ( n = $nmbr$ )
< $nmbr$ % ( n = $nmbr$ )
hbaic ( % )
tjc
cvd
> $nmbr$ ml
$nmbr$ to < $nmbr$
obese
gold  n ( % )
age $ $nmbr$ yrs
placebo ( % )
rr ( $nmbr$ % cl )
« $nmbr$ - $nmbr$
whitea
age > : $nmbr$
stroke
median ( iqr )
sjc
< $nmbr$ h
pbo
$nmbr$ - $nmbr$ yr
< $nmbr$ %
chads $nmbr$ ^
p blockers
£ $nmbr$ years
> $nmbr$ / week
$nmbr$ - < $nmbr$ y
non - c
group a
< $nmbr$ - $nmbr$
ldu - c
$ $nmbr$ ( n = $nmbr$ )
≥ $nmbr$ mg / dl
> $nmbr$ % ( n = $nmbr$ )
rca
age  n ( % )
nyha ii
$nmbr$ . $nmbr$
£ $nmbr$ yo ( n = $nmbr$ )
ni
noneh
» $nmbr$ y
saba §
cabg  n ( % )
nitrates
sita $nmbr$
a $nmbr$ + ez $nmbr$
male sex  %
laaca
> $nmbr$ mmhg
age > $nmbr$ yr
bmi
stemi ( % )
cabg ( % )
european
pvalue
lll - iv
bmi > = $nmbr$
o $nmbr$
fp ( n = $nmbr$ )
crt - d
severity
normal
age > $nmbr$ yrs  %
patients ( n )
hr  $nmbr$ % cl
sdai < $nmbr$ t
no *
age years
row
beta blockers
lvmi ( $nmbr$
care
egfr -
prior om
n %
early ( n = $nmbr$ )
$nmbr$ to < $nmbr$ cells
mm hg
any death
> $nmbr$ < $nmbr$
cl $nmbr$ %
poci ( n = $nmbr$ )
pbo n ( % )
$ $nmbr$ years ( n = $nmbr$ )
all patients
laba '
< $nmbr$ ( n = $nmbr$ )
smoking  %
male  %
level $nmbr$
placebo  n = i $nmbr$
< $nmbr$ mmhg
no psa
$nmbr$ e $nmbr$
placebo [ n z $nmbr$ ]
ls mean ( se )
prior stemi
betablocker use
aml $nmbr$ /
acr
\ $nmbr$
homa > median
p - blocker yes
> = $nmbr$ mmhg
no dm ( n = $nmbr$ )
otherx
age — yrf
fragile
no beta - blocker use
n o
asa > $nmbr$ mg
mra  ( % )
india
gold $nmbr$
csf
$nmbr$ mo
sites
aspirin ( n = $nmbr$ )
< $nmbr$ days ( n = $nmbr$ )
first ( n = $nmbr$ )
age > $nmbr$  y
sesbp
( se ] t *
value
ics usage
> $nmbr$ to < $nmbr$ yr
< $nmbr$ beds
ptca
≥ $nmbr$ bpm ( n = $nmbr$ )
no beta - blocker
age < $nmbr$ y
fa $nmbr$ mg ( « = $nmbr$ )
p value 十
spinal
arr
acm
age > $nmbr$ yrs *
orc ( $nmbr$ % cl )
saba
in - h
males
female  n ( % )
brachial
age ( yr )
italy ( n = $nmbr$ )
$nmbr$ - $nmbr$
hiv
ale < $nmbr$
chd *  n ( % )
iglar
arbs
age in years
l / ll
> $nmbr$ yrs
tg ’
age < $nmbr$ yrs
ff $nmbr$ pg ( n = $nmbr$ )
pad
arr ( $nmbr$ % cl )
americas
st
hctz *
> $nmbr$ . $nmbr$ mm hg
placebo ( n - $nmbr$ )
gold ii
lama
chd
median  iqr
cv death n
ldl  - c
p - value
edge ii
$nmbr$ kg
both ( % )
ml
cad
all
age > $nmbr$ years
sa
racea
male sex  n ( % )
others
reqion
m / f
cat > $nmbr$
atv n ( % )
< $nmbr$ y
> $nmbr$ days
ebria
other
no pa
poland
prior pci
b - blocker
( n = $nmbr$
abi # $nmbr$ . $nmbr$
oradj ( $nmbr$ % cl )
labaa
hr $nmbr$ % ci
minor
ufh
dm ( n = $nmbr$ )
never smoked
copd
v total ( n = $nmbr$ )
egfr < $nmbr$
other !
hba < median
event ( % )
general
≤ $nmbr$ ug / g
rr ( $nmbr$ % ci ) *
yes ( % )
post - mi
laba
$nmbr$ years ( n = $nmbr$ )
sdai
> $nmbr$ mg
p value
stemi
< $nmbr$ ( n z $nmbr$ )
age > $nmbr$  %
area
male sex — no . ( % )
teaes
sex — no . ( % )
age  y
male ( % )
cvd death
chinese
nstemi
qmi
$nmbr$ - $nmbr$ h
apo b
> $nmbr$ mm ( n = $nmbr$ )
female sex  %
all n = $nmbr$
abi
any statin
tg > $nmbr$ . $nmbr$
$nmbr$ y
race — no . ( % ) : c
e
angina
ns
age  yr
oretal
no smo king
women  n ( % ) *
p value c
mets
pbo ( n = $nmbr$ ) vs
race — no . ( % ) f
lipid
females
$nmbr$ mg ( n = $nmbr$ )
ada  yes
placebo [ n = $nmbr$ ]
< $nmbr$ mo
$ $nmbr$ %
> = $nmbr$ . $nmbr$
< $nmbr$ min
no .
hbaic — %
n .
russia
race *
< $nmbr$ hrs
hps
patients ( ft )
prior stent
$nmbr$ — < $nmbr$
all ( n = $nmbr$ * )
asa < $nmbr$ mg
< $nmbr$ year
stage $nmbr$ b
iv nitrates
pio $nmbr$
beta - blocker !
femoral
australia
placeboa
pint
hdl
$nmbr$ / week
> $nmbr$ y ( n = $nmbr$ )
phi ( n - $nmbr$ )
iii & iv
aqe ^ $nmbr$
region ( % )
$nmbr$ to < $nmbr$ kg
age # $nmbr$ yrs
placebo ( n $nmbr$ )
anemia ( % )
pbo ( n $nmbr$ )
ckdc  n ( % )
provoked
race
mtx ( n = $nmbr$ )
> $nmbr$ years
upper
mean a ± sdt
no prior mi
mean ± sd
female ( n — $nmbr$ )
tics — no . ( % )
apo a - i
ascvd
glipizide
years
stage $nmbr$ a
asian ( n = $nmbr$ )
ics alone
i / ii
%
lesions
total c
> $nmbr$ mon ( n = $nmbr$ )
nstemi ( % )
ppci ( n = $nmbr$ )
women  no . ( % )
no ipst
( n = ms )
uti
obesityj
asia
p [ int ]
rarely
tc
qd
age  yrs
age ( year )
age  years *
> $nmbr$ mm
europe
≥ $nmbr$
$nmbr$ min
statins
canvas
niacin
study $nmbr$
graft  n ( % )
c
ipst ( n = $nmbr$ )
f * >
high  %
ml )
male sex 一 no . ( % )
£ $nmbr$ %
no po
y es
ff - blocker
no prior stemi
< $nmbr$ . $nmbr$ years
african
fibrates
canada
venous
$nmbr$ - < $nmbr$ ( % )
total n = $nmbr$
mate
i
met ( n = $nmbr$ )
nausea
other chd
lda  %
ics : no
aspirin
age ( years )
rrr
$nmbr$ - $nmbr$ days
hr ( $nmbr$ % cl )
etn  yes
> $nmbr$ and < $nmbr$ %
male sex — no . ( % ) f
n $nmbr$
ipst
age > = $nmbr$ yrs
m being
oral
race  zz ( % )
> $nmbr$ - < $nmbr$
tgt
sfc ( n = $nmbr$ )
prior llt
> = $nmbr$ y
non - white
ldl - c
( $nmbr$ % ci ] h
gold b
men  n ( % )
hbalc ( % )
never smoker
men
≥ $nmbr$ mg / g
≥ $nmbr$ ng / ml
no psa ( n = $nmbr$ )
$nmbr$ - i
low  %
haq
beta - blocker
urti
renal
lama +
( sem )
primary *
no mi
statini
n_
metsyn
< $nmbr$ / < $nmbr$ mm hg
no use
> $nmbr$ . $nmbr$ %
tvr
laa
om $nmbr$ /
arm
r $nmbr$ mg ( « = $nmbr$ )
female  %
cancer §
hbalc > median
men ( n = $nmbr$ )
crcl < $nmbr$
chd  n ( % )
age — yr
gold c
mean = sd
avr
epa
l $nmbr$
treatment
< $nmbr$ yo ( n = $nmbr$ )
wegu
hba $nmbr$ c
( se ] +
cards
$nmbr$ mg / dl
hdl *
year $nmbr$
p - blockers
< $nmbr$ yrs
( se ] t
no prior pci
$nmbr$ . $nmbr$ %
diet ( n 二 $nmbr$ )
pnorpci
hr ( $nmbr$ % cl ) *
iu
^ median
> $nmbr$ min
$nmbr$ to < $nmbr$ mo
> = $nmbr$ yea ' s
median — yr
$nmbr$ to < $nmbr$ years
no des
> $nmbr$ mg / g
> $nmbr$ . $nmbr$
hrqol
p values
no acs
other $nmbr$
> $nmbr$ to $nmbr$ years
cat < $nmbr$
age > $nmbr$ yr 十
smoker
oads  n ( % )
paod
$nmbr$ or more
site
> = $nmbr$ years ( n = $nmbr$ )
ifg
cancer * *
race — no . ( % ) ' (
aged < $nmbr$ years
( ri = $nmbr$ )
x / n *
s £ $nmbr$
aml
age ( years ) :
htn hx
lvef > $nmbr$ %
non - dm
group b
total hip
obesity t
b
no
total  n = $nmbr$
race - no . ( % )
< $nmbr$ . $nmbr$
r $nmbr$ mg ( n = $nmbr$ )
ics # #
off pump
china
abi > $nmbr$ . $nmbr$
male  n ( % )
female ( n = $nmbr$ )
age  ya
adl
ii - iv
any
ff $nmbr$ | ig ( n = $nmbr$ )
crp
nste - mi
n =
korea
ckd  n ( % ) t
icd  n ( % )
poba  n ( % )
no aspirin
yes  n ( % )
placebo $nmbr$
no chd
sfc
asthma
[ $nmbr$ % cl ]
$nmbr$ to < $nmbr$ ( % )
lvef  %
> = $nmbr$
y $nmbr$
age < $nmbr$ years
n / n
race $nmbr$
placebo ( n [ $nmbr$ )
vdhmtss
poci
> $nmbr$ . $nmbr$ min
placebo ( n = $nmbr$ * )
aicd  ( % )
hscrp §
major
prior
ccb
male - no . ( % )
b - blockers
placebo ( lsm )
median — vr
ileum
no ( n = $nmbr$ )
> $nmbr$ - $nmbr$
no statin use
absent
age $ $nmbr$ years § *
ics
laci
< $nmbr$ bpm ( n = $nmbr$ )
% pred
prior ml
> $nmbr$ yr
on $nmbr$
tg
on pump
t $nmbr$ dm
others  n ( % )
mean
high
hazard
p valuey
cana $nmbr$ mg
age ( y )
( $nmbr$ % ci )
age ( yij
ssi - $nmbr$
« = $nmbr$
ucr
tender
p *
iii ( n z $nmbr$ )
cyclo
hbalc < medan
non - hdl
sodium
£ $nmbr$
simva
laci ( n = $nmbr$ )
puva
icsa
ua
hr ( $nmbr$ % ci ) “
asa
ng
patient
rr
race ( % ) ) '
> $nmbr$ to $nmbr$
ii
otherb
ldl - cz
( a blocker
event
iii
^ $nmbr$
ef < $nmbr$ %
israel
glinide
brazil
pasi ^ i
indian
europe i
male sex
ifx ( n = $nmbr$ )
week $nmbr$
right
tg *
sama $nmbr$
high *
hope ( n = $nmbr$ )
active ( n = $nmbr$ )
> $nmbr$  < $nmbr$
group c
ex - smokers
male sex  no . ( % )
with ( n = $nmbr$ )
poor
radial
n $nmbr$ / n $nmbr$
ef > $nmbr$ %
stalin
> = $nmbr$ yr
race  n ( % ) b
ra
sal $nmbr$ pg ( n = $nmbr$ )
pci — no . ( % )
hrt
mtss
$nmbr$ e < $nmbr$ %
yes '
ratio
sal ( n = $nmbr$ )
nyhaii
women — no . ( % )
smoking status  no . ( % )
smoking status  n ( % )
smoking status — no . ( % )
systolic bp  mm hg
systolic bp ( mm hg )
diastolic ( mmhg )
systolic — mm hg
diastolic ( mm hg )
systolic bp ( mmhg )
systolic ( mm hg )
diastolic bp  mm hg
systolic ( mmhg )
diastolic bp ( mmhg )
diastolic — mm hg
diastolic bp ( mm hg )
das $nmbr$ ( esr )
das $nmbr$ - crp §
das $nmbr$ - hscrp
das $nmbr$ ( crp )
das $nmbr$ - crp
das $nmbr$ - esr
unadjusted
unadjusted hr
unadjusted irr
adjusted
unadjusted hr .
ejection fraction
lv ejection fraction
apolipoprotein a $nmbr$ ( g / l )
apolipoprotein a $nmbr$ ( mg / dl )
fpg  mmol / l
fpg ( mmol / l )
tg ( mmol / l ) c
na ( mmol / l )
k ( mmol / l )
ldl ( mmol / l )
bun  mmol / l
tc ( mmol / l )
tg ( mmol / l )
ffa ( mmol / l )
fpg  mmol / lt
mdg ( mmol / l )
ppg  mmol / l
hdl ( mmol / l )
mssbp  mm hg
dbp ( mmhg )
sbp ( mm hg )
sbp  mmhg
dbp  mm hg
sbp ( mmhg )
dbp  mmhg
msdbp  mm hg
msdbp  mm hga
mssbp  mm hga
sbp  mm hg
dbp ( mm hg )
map ( mmhg )
cvd subjects
all subjects
mrf subjects
c - reactive protein ( mg / l )
c - reactive protein ( mg / dl )
c - reactive protein  mg / l
c - reactive protein  * mg / l
c - reactive protein ( mg / dl_ )
body - mass index ( kg / m $nmbr$ ) t
body mass index - kg / m $nmbr$ t
body mass index ( kg / m $nmbr$ )
body mass index  kg / m $nmbr$
body mass index ( kg / nr )
body - mass index ( kg / m $nmbr$ )
bodymass index ( kg / m $nmbr$ )
body mass index ( kg / m $nmbr$ ) * '
body mass index  * kg / m $nmbr$
comorbidities  n ( % ) a
comorbidites  n ( % )
controls ( n = $nmbr$ )
control ( n z $nmbr$ )
control ( nz $nmbr$ )
control ( n = $nmbr$ )
control ( n - $nmbr$ )
african - american
african american
african americans
african america
history of hypertension ( n = $nmbr$ )
no history of hypertension ( n = $nmbr$ )
egfr ( ml / min )
egfr  ml / min
- ics / + laba n z $nmbr$
+ ics / + laba nz $nmbr$
baseline mean ( se )
baseline ( mean  sd )
baseline  mean ( sd )
no current smoking
current smoker  %
current smokers
current smokers ( % )
current smoker ( % )
current smoker
current non - smoker
current smoking
current smokers  %
current smokers *
current smoking *
current nonsmoker
current smoker yes
current nonsmokers
prior ptca or pci
prior ptca / pci
interactior p - value
interaction p - value
interaction p value 中
interaction p value §
interaction p value
duration of copd ( yr )
duration of copd  y
duration of copd — yr
duration of copd  yr
duration of copd  years
duration of pd  y
duration of copd
duration of copd ( years )
multivariate p - value
univariate p - value
group b ( n = $nmbr$ )
group c ( n = $nmbr$ )
group a ( n = $nmbr$ )
rage ( ng / ml )
ltbr ( ng / ml )
pigr ( ng / ml )
vegfr ( ng / ml )
imt ( $nmbr$ )
imt ( mm )
haq - di *
haq - di
haq - di * *
non - fatal stroke
nonfatal stroke
antiplatelet or anticoagulant
antiplatelets or anticoagulants
hypercholesterolemia — no . ( % ) *
hypercholesterolemia — no . ( % )
hypercholesterolemia 一 no . ( % )
pre - menopausal without hormone replacement
post - menopausal with hormone replacement
pre - menopausal with hormone replacement
post - menopausal without hormone replacement
bumetanide
budesonide
$nmbr$ - hour madbp  mm hg
$nmbr$ - hour masbp  mm hg
no prior heart failure
prior heart failure
prior cancer
no prior cancer
$nmbr$ to < $nmbr$ ( n = $nmbr$ )
$ $nmbr$ to  $nmbr$ ( n = $nmbr$ )
$nmbr$ to < $nmbr$ ( n z $nmbr$ )
ace - i or arb
no ace - i / arb
ace - lorarb
ace - i / arb
acei or arb
ace - l / arbs
aceis / arbs
acei / arb
triglycerides
triglyceride a
triglycerides *
triglycerides * *
triglyceride
fluvastatin ( n = $nmbr$ )
simvastatin ( n = $nmbr$ )
rosuvastatin ( n = $nmbr$ )
diabetic yes
diabetes
antidiabetic
diabetes $nmbr$
nondiabetic
prediabetes  %
diabetic no
non - diabetic
diabetes ( % )
diuretics
diuretic use
diabetic $nmbr$
diabetesf
diabetes  %
prediabeticb
diureticff
n o diabetes
diabetes *
dabetes
non - diabetes
non - diabetics
diabetics
diuretic
no diabetes
diurciic
diabetic
diabeticb
stage $nmbr$ a : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$
stage $nmbr$ b : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$
pm pef ( sd )  l / min
am pef ( sd )  l / min
fev $nmbr$ : fvc ratio
fev $nmbr$ / fvc ratio *
egfr  * ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) §
dyslipidaemiat
dyslipidaemia
dyslipidaemia 本
dyslipidemia
$nmbr$ st < $nmbr$ . $nmbr$
$nmbr$ / $nmbr$ ( $nmbr$ )
$nmbr$ ( $nmbr$  $nmbr$ )
$nmbr$ ( $nmbr$ . $nmbr$ % )
$nmbr$ ( $nmbr$ e < $nmbr$ % )
> $nmbr$ - $nmbr$ - $nmbr$
$nmbr$ rd > $nmbr$ . $nmbr$
$nmbr$ - $nmbr$ . $nmbr$
$nmbr$ ( $nmbr$ . $nmbr$ )
$nmbr$ . $nmbr$ % ( $nmbr$ )
$nmbr$ - < $nmbr$ . $nmbr$
oral hypoglycemic
oral hypoglycemics
north america ( % )
south america ( % )
sitagliptin $nmbr$ mg n = $nmbr$
disease activity ]
disease activity
ease activity ]
class i
class ia
class iii
class ii
class ib
class ic
class iv
nt - probnp  pg / mlt
nt - probnp ( pg / ml ) h
nt - probnp ( pg / ml )
nt - probnp — pg / ml * *
nt - probnp  pg / ml
drug - eluting stent
drug eluting stent
race : non - white
race  nonwhite
race - non - white
race nonwhitet
race  % nonwhite
race  non - white
smoking status *
smokinq status
smoking status
nyha iii or iv
nyhaiiioriv
csf cholesterol
hdl - cholesterol
vldl cholesterol
ldl cholesterolt
ldl - cholesterol (
hdl cholesterol §
ldl cholesterol
tolal choleslerol
total cholesterol *
hdl cholesterol *
total cholesterol  %
total cholesterol
hdl choleslerol
ldl choleslerol
aldl cholesterol
hdl cholesterol
ldl - cholesterol
medical therapy
medical therapies
topical therapy
hba $nmbr$ c ( n )
> $nmbr$  no . ( % )
> $nmbr$ h  n ( % )
> $nmbr$ days ( % )
< $nmbr$ h  n ( % )
< $nmbr$ %  n ( % )
> $nmbr$ ( % )
a $nmbr$ c ( % )
> $nmbr$ y  no . ( % )
hba $nmbr$ c  %
hba $nmbr$ c  % §
> $nmbr$ %  n ( % )
hba $nmbr$ c ( % )
> $nmbr$ yr — no . ( % )
< $nmbr$ vr — no . ( % )
$ $nmbr$ %  n ( % )
> $nmbr$  n ( % )
< $nmbr$ { % )
< $nmbr$ y  n ( % )
^ $nmbr$ y  n ( % )
aab $nmbr$ ( % )
< $nmbr$ yr — no . ( % )
< $nmbr$ ( % )
> = $nmbr$ * ( % )
> $nmbr$ yr ( % )
> = $nmbr$ ( % )
> $nmbr$ y  n ( % )
< $nmbr$ days ( % )
> $nmbr$ y . n ( % )
< $nmbr$  n ( % )
£ median ( $nmbr$ )
> median ( $nmbr$ % )
> median ( $nmbr$ kg )
> median ( $nmbr$ mm )
> median ( $nmbr$ )
< median ( $nmbr$ kg )
women < $nmbr$ years
women > $nmbr$ years
diclofenac ( n = $nmbr$  $nmbr$ )
diclofenac ( n = $nmbr$ $nmbr$ )
previous mi — no . ( % )
previous vte — no . ( % )
previous chf — no . ( % )
bl h / y : bilateral
bl h / y : unilateral
diabetes status
diabetic status
mean ( sd ) age in years
mean ( sd ) age  yr
mean ( sd ) age  years
mean ( sd ) age ( years )
no symptoms
symptoms
age at randomization
age at randomisation
vadas score *
mmse score *
mean acrn
rope score
cat score
sss score
gds score *
mmse score
edss score
chads score
mean score
mhis score
cat scoreff
kccq score
aqlq score
accp score
baseline sbp ( mm hg )
baseline dbp ( mm hg )
itt population
mitt population
tiotropium + placebo ( n [ $nmbr$ )
tiotropium + placeb ( n [ $nmbr$ )
myocardial infarction  n ( % )
myocardial infarction  ( % )
sinusitis
synovitis
no history of tia / stroke
history of tia or stroke
history of tia / stroke
heart rate ( beats per min )
heart rate  beats / min
heart rate  beats per min
heart rate — beats / min
heart rate ( beats / min )
heart rate ( beats per minute )
pga  $nmbr$ - $nmbr$
tjc  $nmbr$ - $nmbr$
sjc  $nmbr$ - $nmbr$
ptga  $nmbr$ - $nmbr$
region latin american
region  latin america
calcium - channel blockers
calcium channel blockers
calcium - channel blocker
calcium channel blocker
calcium - channel blockerf
baseline median [ mg / l ]
baseline median  mg / dl
baseline mean  mg / dl
baseline mean ( mg / dl ]
baseline median  mg / l
baseline mean mtss
baseline mean 士 sd
glucocorticoids
glucocorticoid
glucocorticoids *
esr ( mm / h )
esr  mm / hour
esr — mm / hr
esr ( mm / hour ) git config - - global user . name  your name
ns cardiac cisease
cardiac disease
no cardiac disease
education < $nmbr$ years
education > $nmbr$ years
triglyceride ( mmol / l )
triglyceride ( mmol / l ) t
triglyceride  mmol / l
triglycerides ( mmol / l ) :
triglycerides ( mmol / l )
triglycerides  mg / l
triglycerides  mmol / l §
triglycerides * ( mg / dl )
triglycerides  mg / dl
triglyceride ( mg / dl ) d
triglycerides — mg / dl
triglycerides ( mg / dl )
triglycerides  mg / dl ^
triglycerides  mmol / l
triglyceride ( mg / dl )
triglycerides  mmol / lf
patients without diabetesb
patients with diabetesb
no prior heart failure ( n = $nmbr$  $nmbr$ )
prior heart failure ( n = $nmbr$  $nmbr$ )
prior lev use
prior asa use
postmenopausal
premenopausal
hs - crp ( mg / l )
apob  mg / dl
fpg  mg / dl
bnp ( pg / ml )
fpg ( mg / dl )
hs - crp  mg / l
bun  mg / dl
crp — mg / l
crp ( ng / ml )
hscrp  mg / l
apob  g / l
bun ( mg / dl )
tgs ( mg / dl )
hdl ( mg / dl )
ppg  mg / dl
bnp  pg / ml
apo b ( g / l )
crp ( mg / dl )
apoal  mg / dl
mpo ( ng / ml )
hscrp ( mg / l )
hscrp  mg / dl
hscrp ( mg / l ) c
apo b  mg / dl
hscrp ( nmol / l )
troy ( ng / ml )
apob ( mg / dl )
bnp ( pg / ml ) h
crp  mg / l
bnp  pg / mlt
triglycerides $nmbr$  d third
triglycerides $nmbr$ st third
triglycerides $nmbr$ nd third
no multivessel disease
multivessel disease
fastng plasma glucose < median
fascng plasma glucose a medan
fasting plasma glucose < median
caucasian  %
caucasian ( % )
caucasiana ( % )
concomitant cardiovascular therapies — no . ( % )
concomitant cardiovascular therapy — no . ( % )
dissatisfied with / stopped $ $nmbr$ prior systemic therapies because of side effects
dissatisfied with / stopped $ $nmbr$ prior systemic therapy because of side effects
linagliptin ( n z $nmbr$ )
vildagliptin ( n = $nmbr$ )
linagliptin ( n = $nmbr$ )
sitagliptin ( n = $nmbr$ )
smoking — current
smoking  % current
current smoking — no . ( % )
current smoking  n ( % )
current smoker 一 no . ( % )
current smokers  n ( % )
current smoker — no . ( % )
current smoker  n ( % )
current smoker  no ( % )
without t $nmbr$ dm n = $nmbr$
with t $nmbr$ dm n = $nmbr$
val / hctz ( n = $nmbr$ )
v / hctz ( n = $nmbr$ )
aml / hctz ( n = $nmbr$ )
ind / gly
indzgly
gdf - $nmbr$ ( ng / ml )
mmp - $nmbr$ ( ng / ml )
st - $nmbr$ ( ng / ml )
mmp - $nmbr$ ( ng / ml ) *
il - $nmbr$ ( pg / ml )
diabetes  n ( % )
diabetes — no . ( % )
diabetes  no . ( % )
diabetes  * n ( % )
prediabetes  n ( % )
unstable angina — no . ( % )
stable angina — no . ( % )
a $nmbr$ c < $nmbr$ . $nmbr$ % ( median )
a $nmbr$ = $nmbr$ . $nmbr$ % ( median )
hazard ratio ( $nmbr$ % cl )
hazard ratio ( $nmbr$ % ci ) *
hazard ratio ( $nmbr$ % ci )
hazard ratio * ( $nmbr$ % ci )
hazard ratiof ( $nmbr$ % ci )
lipid - lowering agent §
lipid - lowering agents
lipid - lowering agent
zotarolimus
zotarolimust
pci orcabg
prior cabg
no prior cabg
pnorcabg
diastolic blood pressure  mm hg  median ( range )
systolic blood pressure  mm hg  median ( range )
very severe
more severe ^
less severe
more severe
cholesterol ( mg / dl )
cholesterol — mg / dl
treatment difference ( $nmbr$ % cl )
treatment difference ( $nmbr$ % ci )
insulin
insulina
> median ( $nmbr$ ) — number / n ( % )
< median ( $nmbr$ ) — number / n ( % )
baseline mssbp ( mmhg )  mean ± sd
baseline msdbp ( mmhg )  mean ± sd
age range ( years )
age range  years
inflammation
inflammatory
hispanic or latino
hispanic / latino
< $nmbr$ cells / pl
> $nmbr$ cells / pl
american indian
american indian /
with an sfua
without an sfua
men  > $nmbr$ cm
men  < $nmbr$ cm
women  < $nmbr$ cm
women  > $nmbr$ cm
sulphonylureas
sulphonylurea
on sulfonylurea
sulfonylureaa
sulfonylurea
pbo + mtx
czp + mtx
caucasians
caucasian
noncaucasian
non - caucasian
ldl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients
hdl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients
previous or current use of im or cs : no
previous or current use of im and cs : no
$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
$nmbr$ to o $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
≥ $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
without psoriasis ( zi = $nmbr$ )
with psoriasis ( n = $nmbr$ )
with psoriasis ( zi = $nmbr$ )
placebo events / patients ( % )
placebo  events / patients ( % )
ldl - cholesterol ( mg / dl )
ldl cholesterol  mg / dl
hdl cholesterol ( mg / dl )
ldl cholesterol — mg / dl
i idl cholesterol ( mg / dl )
hdl cholesterol — mg / dl
hdl cholesterol  mg / dl
ldl cholesterol ( mg / dl )
hdl - cholesterol ( mg / dl )
baseline ldl - c
baseline ldl - c :
who fc ii symptoms at baseline
who fc iii symptoms at baseline
$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$
> $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$
$nmbr$ - $nmbr$ - $nmbr$ - $nmbr$
$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ %
> $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$
$nmbr$ . $nmbr$ + $nmbr$ . $nmbr$
$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ )
$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ %
$nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ )
$nmbr$  $nmbr$ - < $nmbr$ . $nmbr$
$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )
$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$
> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )
> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ %
$nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ %
no mra at baseline
mra at baseline
ss at baseline
mmrc at baseline
pad at baseline
nihss at baseline
aspirin dose
aspirin alone
aspirin use
arrhythmia
arrhythmia !
arrhythmias
hypertensive
hypertensiont
hypertension  n ( % )
hypertension 本
hypotension
hypertension  * n ( % )
hyper - tension
hypertension
hypertension  %
hypertension ( % )
hypertension  ( % )
no hypertension
hyperlension
hypertension *
hypertensive  n ( % )
hypertension §
hypertension !
unstable angina *
unstable angina age
unstable angina §
unstable anginad
unstableangina
stable angina
unstable anginat
unstable angina
arb monotherapy
era monotherapy
cardioembolism
cardioembolic
age category >
bmi category
age category
aspirin or other antiplatelet agents
aspirin or other antiplatelet agent
mean ( sd ) pga vas *
mean ( sd ) ptga vas *
mean ( sd ) pain vas *
previous ml ( before index acs )
previous pci ( before index acs )
fibula fracture
tibia fracture
weight in kg  mean ( sd )
weight  kg  mean ( sd )
weight  kg : mean ( sd )
weight ( kg )  mean ( sd )
weight ( kg )  mean ± sd
serum creatinine  umol / lf
serum creatinine  gmol / l |
serum creatinine ( gmol / )
serum creatinine ( mmol / l )
serum creatinine  ^ mol / l
> $nmbr$ years eze / simva ( „ = $nmbr$ }
< $nmbr$ years eze / simva ( n = $nmbr$ }
im use : no
cs use : no
stent diameter < $nmbr$ mm
stent diameter $ $nmbr$ mm
overall ( n = $nmbr$  $nmbr$ )
overall ( n = $nmbr$ vs $nmbr$ )
leukotriene receptor antagonists
leukotriene - receptor antagonist
high - sensitivity c - reactive protein  mg / ltt
high - sensitivityc - reactive protein  mg / l
etn + mtx ( n = $nmbr$ )
hcq + mtx ( n = $nmbr$ )
ssz + mtx ( n = $nmbr$ )
lef + mtx ( n = $nmbr$ )
> $nmbr$ drinks
$nmbr$ drinks
glucose ( mg / dl )
glucose — mg / dl
thienopyridine
+ thienopyridine
no thienopyridine
- thienopyridine
acholesterol ( % )
cholesterol ( % )
< $nmbr$ . $nmbr$ mg / dl
> $nmbr$ . $nmbr$ mg / mmol
> $nmbr$ . $nmbr$ - g / l
$nmbr$ - $nmbr$ mg / g
$nmbr$ $nmbr$ mg / dl
≥ $nmbr$ to < $nmbr$ mg / g
> $nmbr$ . $nmbr$ mg / l
> $nmbr$ . $nmbr$ mmol / l
≥ $nmbr$ to < $nmbr$ mg / dl
< $nmbr$ . $nmbr$ mmol / l
< $nmbr$ . $nmbr$ mg / mmol
> $nmbr$ & < $nmbr$ mg / dl
> $nmbr$ and < $nmbr$ mg / dl
> $nmbr$ to $nmbr$ mg / g
> $nmbr$ but < $nmbr$ mg / dl
< $nmbr$ . $nmbr$ ng / ml
> $nmbr$ + $nmbr$ mmol / l
$nmbr$ - $nmbr$ mg / dl
. $nmbr$ . $nmbr$ mg / mmol
< $nmbr$ - $nmbr$ mmol / l
$nmbr$ . $nmbr$ mg / mmol
$nmbr$ to $nmbr$ mg / g
$nmbr$ to < $nmbr$ mg / dl
> $nmbr$ . $nmbr$ mg / dl
> $nmbr$  < $nmbr$ mg / dl
< $nmbr$ . $nmbr$ l - g / l
> $nmbr$ . $nmbr$ ng / ml
> $nmbr$ ' $nmbr$ mmol / l
> $nmbr$ - $nmbr$ mmol / l
< $nmbr$ . $nmbr$ mg / l
cerebral vascular disease
cerebrovascular disease
linagliptin
vildagliptin
sitagliptin
saxagliptin
mean ( s . e . )
mean ( s . e . ) t
mean ( s . d . )
mean bmi  kg / m $nmbr$ ( sd )
mean bmi ( kg / m $nmbr$ ) ( sd )
tiotropium ( nz $nmbr$ )
tiotropium ( n z $nmbr$ )
tiotropium ( n = $nmbr$ )
gastroduodenum
gastroduodenal
primary endpoint
primary end point
dyslipidemia — no . ( % )
dyslipidemia — no . ( % ) |
tjc ( $nmbr$ - $nmbr$ )  mean ( sd )
sjc ( $nmbr$ - $nmbr$ )  mean ( sd )
non cv mortality
non - cv mortality
patients with prevalent kidney disease at baseline
patients without prevalent kidney disease at baseline
mean ( s . d . ) age  years
mean ± s . d . age  years
$nmbr$ mg / day early - start - delayed - start
$nmbr$ mg / day early - start - delayed start
£ $nmbr$ kg / m $nmbr$
a $nmbr$ kg / m $nmbr$
< $nmbr$ kg / m $nmbr$
> $nmbr$ kg / m $nmbr$
s $nmbr$ kg / m $nmbr$
≥ $nmbr$ kg / m $nmbr$
hypokalemia ‡   ( potassium < $nmbr$ . $nmbr$ mmol / l )
hyperkalemia ‡   ( potassium ≥ $nmbr$ . $nmbr$ mmol / l )
heparin only
aspirin only
mitral regurgitation  n ( % )
mitral regurgitation  ( % )
< $nmbr$ years n z $nmbr$
> $nmbr$ years n z $nmbr$
age < $nmbr$ y ( n = $nmbr$ )
age ' $nmbr$ y ( n $nmbr$ )
age > $nmbr$ y ( n = $nmbr$ )
ace inhibitor  %
ace inhibitor
ace inhibitors
tnf inhibitors
tnf inhibitor
ace inhibitor yes
body - mass index : ! :
body - mass index  !
change from baseline to eos  uu / ml
change from baseline to eos  mg / dl
right coronary artery
r ight coronar y artery
duration of t $nmbr$ dm > $nmbr$ years
duration of t $nmbr$ dm < $nmbr$ years
time to randomization
time of randomization
p value ( cangrelor versus clopidogrel in men )
p value ( cangrelor versus clopidogrel in women )
weight ( kg )
weight  kg *
height — cm
w eight ( k g )
weight  lbs
weight  kg
height  cm
weight 一 kg
height ( cm )
weight — kg
weight - kg
height  cm *
ldl - c  mmol / l ( mg / dl )
hdl - c  mmol / l ( mg / dl )
body - mass index ) -
body mass index  %
body - mass indexj
body - mass indexf
body - mass index )
body - mass index *
body - mass index §
body mass index *
body - mass index $
body mass indexc
body mass index +
body mass index
body mass index :
body - mass index
family history of premature chd
family history of premature chdj
abatacept $nmbr$ mg / kg ( n = $nmbr$ )
abatacept ~ $nmbr$ mg / kg ( n = $nmbr$ )
prior tnf antagonist failure - no
prior tnf antagonist failure - yes
previous cabg
previous mi
previous ptca
previous pci
previous hf
previous tia
previous ml
previous chf
previous cad
previous ami
previously
previous
w event ( rate )
n event ( rate )
type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ )
no type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ )
family history of vte
family history of cad
with p blockers
without p blockers
triglycerides < $nmbr$ - $nmbr$ mmol / l
triglycerides > $nmbr$ - $nmbr$ mmol / l
non - hdl - c  mg / dl
non - hdl - c ( mg / dl )
lipid - lowering medications ^
lipid - lowering medications
lipid - lowering medication
history of cad
no history of af
history of pci
history of copd
history pci
history of mi
history of vte
history of chf
history of chd
history of cabg
no history of chf
history of pad
history of ml
history of hf
history of af
lesion length $ $nmbr$ mm
lesion length > $nmbr$ mm
male gender
female gender
ratio of hrs ( $nmbr$ % cl )  p for sex interaction
ratio of hrs ( $nmbr$ % ci )  p for sex interaction
statins / ezetimibe
statin or ezetimibe
> median ( $nmbr$ . $nmbr$ ) — number / n ( % )
< median ( $nmbr$ . $nmbr$ ) — number / n ( % )
renal impairment
renal impairmentt
antiplatelet drugs
antiplatelet drug
cha $nmbr$ ds $nmbr$ - vasc $ $nmbr$
cha $nmbr$ ds $nmbr$ - vasc # $nmbr$
cha $nmbr$ ds $nmbr$ - vasc > $nmbr$
reversibility to
reversibility ( % ) t
reversibility *
reversibility
reversibility  %
reversibility ( % )
reversibility %
present ( £ $nmbr$ mg / dl )
present ( > $nmbr$ mg / dl )
hba $nmbr$ c < = $nmbr$ %
hba $nmbr$ c < $nmbr$ %
hba $nmbr$ c > $nmbr$ %
hba $nmbr$ c > = $nmbr$ %
metformin 一 no . ( % )
metformin — no . ( % )
women / men [ % ]
women / men  %
$nmbr$ . $nmbr$ to # $nmbr$ . $nmbr$ mg / mmol
$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ mg / mmol
baseline tav - > = median ( n = $nmbr$  $nmbr$ )
baseline pav - > = median ( n = $nmbr$  $nmbr$ )
baseline tav - < median ( n = $nmbr$  $nmbr$ )
baseline pav - < median ( n = $nmbr$  $nmbr$ )
ifg / igt
ifg and igt
< $nmbr$ % ( < $nmbr$ mmol / mol )
> $nmbr$ % ( > $nmbr$ mmol / mol )
> = $nmbr$ % ( $nmbr$ mmol / mol )
< $nmbr$ % ( $nmbr$ mmol / mol )
no mi ( n - $nmbr$  $nmbr$ )
pad ( n - $nmbr$  $nmbr$ )
no mvd ( n - $nmbr$  $nmbr$ )
acs ( n - $nmbr$  $nmbr$ )
mvd ( n - $nmbr$  $nmbr$ )
any mi ( n - $nmbr$  $nmbr$ )
no pad ( n - $nmbr$  $nmbr$ )
total cholesterol > $nmbr$ - $nmbr$ mmol / lt
total cholesterol < $nmbr$ $nmbr$ mmol / lt
total cholesterol < $nmbr$ - $nmbr$ mmol / lt
total cholesterol > $nmbr$ ' $nmbr$ mmol / lt
body mass index  mean ( sd )
body mass index  mean ( sd ) t
body massindex  mean ( sd ) a
body - mass index  mean ( sd )
body mass index  mean ( sd ) d
change from baseline *
change from baseline
% change from baseline
rectal bleeding subscore {
rectal bleeding subscore
ldl - c ( mmol / l )
ldl - c  mmol / l
hdl - c  mmol / l
hdl - c ( mmol / l )
ldl - c * ( mmol / l )
insulin - dependent
insulin dependentc
antihypertensive therapy
anti - hypertensive therapy
ace inhibitors or angiotensin - receptor blockers ^
ace inhibitor or angiotensin receptor blocker
ace inhibitor or angiotensin ii receptor blocker
ace inhibitors or angiotensin receptor blockers
diabetes duration  years
diabetes duration ( years )
age ( years ) mean ± sd
age  y  mean ( sd )
cdai  mean ( sd )
age  years ( sd )
age  years  mean + sd
age  yr mean ( sd )
age  mean ( sd )
bmi  mean ( sd )
age ( years ) mean ( sd )
age ( years ) ( mean  sd )
tc  mean ( sd )
bmi  mean ( sd ) b
ibdq  mean ± sd
age ( years )  mean ± sd
age  y  mean ± sd
age  years  mean ( sd )
bmi  mean ± sd
age  yr  mean ( sd )
sdai  mean ( sd )
age  mean ± sd
age ( yrs )  mean ± sd
age ( years )  mean ( sd )
age  years  mean ± sd
age  mean yr ( sd )
basfi  mean ( sd )
age in years  mean ( sd )
age ( years ) - mean ± sd
age  yrs  mean ( sd )
one of the above
two of the above
all of the above
none of the above
any of the above
asian or oriental
asian / oriental
no . of stents
no . of events
no . of patients
serum creatinine — mg / dl §
serum creatinine ( mg / dl )
serum creatinine — mg / dl
serum creatinine  mg / dlb
serum creatinine  mg / dl
no diabetes ( n - $nmbr$  $nmbr$ )
diabetes ( n - $nmbr$  $nmbr$ )
final median  mg / l
final mean  mg / dl
nonwhite race !
nonwhite race
white race
non - white race
non - white raceb
> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a
current cigarette smoker
current cigarette smoking
at home systolic pressure > $nmbr$ mm hg
at home diastolic pressure < $nmbr$ mm hg
at home diastolic pressure > $nmbr$ mm hg
at home systolic pressure < $nmbr$ mm hg
hx stroke / tia
stroke or tia
stroke ortiab
stroke / tia
no stroke / tia
clinical history — no . ( % )
clinical history  no . ( % )
clinical history  n ( % )
combination therapy ( n = $nmbr$ )
combination therapy  n = $nmbr$
a $nmbr$ c at baseline < $nmbr$ . $nmbr$ %
a $nmbr$ c at baseline ≥ $nmbr$ . $nmbr$ %
native american
latin american
latin america
liraglutide $nmbr$ . $nmbr$ mg
medical history  no . ( % )
medical history — no . ( % )
medical history  n ( % )
diabetes mellitus :
diabetes mellitus
no diabetes mellitus
diabetes mellitus  n ( % )
diabetes mellitus !
diabetes mellitus  § n ( % )
diabetes mellitus  %
diabetes mellitus ( % )
diabetes mellitus  ( % )
since diagnosis
index diagnosis
> $nmbr$ months  mean ( sd )
< $nmbr$ months  mean ( sd )
placebo ( n = $nmbr$ $nmbr$ )
placebo ( n = $nmbr$  $nmbr$ )
placebo ( n - $nmbr$ . $nmbr$ )
placebo ( n $nmbr$ $nmbr$ )
second mi
no second mi
controlled
coronary
country
controlld
uncontrolled
control
diabetes status  n ( % )
diabetes status  no . ( % )
ezetimibe $nmbr$ mg ( n = $nmbr$ * )
ezetimibe $nmbr$ mg ( n = $nmbr$ )
chads $nmbr$ score
chads $nmbr$ score *
chads $nmbr$ scoreb
age  mean = sd  years
age  mean ± sd ( year )
age  mean ± sd years
age  mean ( sd ) years
age  mean ( sd )  years
age  mean ( sd )  y
age  mean ( sd )  yrs
age  mean ± sd  years
aiirocumab ( n = $nmbr$ )
alirocumab ( n = $nmbr$ )
< $nmbr$ enroll
> $nmbr$ enroll
das $nmbr$ - crp  ls mean change from baseline ( se ) ¥
das $nmbr$ - crp  ls mean change from baseline ( se ) §
anacetrapib $nmbr$ mg ( n = $nmbr$ )
anacetrapib $nmbr$ mg ( n - $nmbr$ )
current
currently
total stent length - mm
total stent length  mm
body mass index > $nmbr$ kg / m $nmbr$ *
body mass index < $nmbr$ kg / m $nmbr$
p inleraclion
p $nmbr$ interaction
p for interaction
pfor interaction
p interaction
pinteraction
p  interaction !
p for interaction *
interaction p
age - interaction
interaction - p
p - interaction
p . interaction
p : interaction
p - interactio n
angiotensin receptor blockers
angiotensin receptor blocker yes
angiotensin ii receptor blocker
angiotensin - receptor blocker
angiotensin receptor blocker
angiotensin ll - receptor blocker
creatinine — mg / dl
creatinine  mg / dl_
creatinine ( mg / dl )
creatinine  mg / dl
baseline post - bronchodilator % predicted fev  > $nmbr$ % and no prior ics use
baseline post - bronchodilator % predicted fev  > $nmbr$ % and prior ics use
fev $nmbr$ ( % predicted )
fev $nmbr$  % predicted
fev $nmbr$  % predicteda
fev $nmbr$ % predicted
fev $nmbr$  l *
fev $nmbr$  l
fev $nmbr$  la
fev $nmbr$ ( l )
mean sitting sbp ( mmhg )
mean sitting dbp ( mmhg )
potassium ( mmol / l )
potassium ( meq / l )
potassium  mmol / l
£ $nmbr$ ( men ) / £ $nmbr$ ( women )
< $nmbr$ ( men ) / < $nmbr$ ( women )
creat clearance < $nmbr$ ml / min
creat clearance > $nmbr$ ml / min
pre - bronchodilator
prebronchodilator
post - bronchodilator
postbronchodilator
heritable
variable
apolipoprotein b ( mg / dl )
apolipoprotein b ( g / l )
tiotropiumc
tiotropium
no prior statin use
prior statin use
nyha iv  n ( % )
nyha ii  n ( % )
nyha iii  n ( % )
metabolic syndrome
metabolic syndrome *
tiotropium $nmbr$ mg
tiotropium $nmbr$ m g
pitavastatin $nmbr$ mg
pravastatin $nmbr$ mg
rosuvastatin $nmbr$ mg
simvastatin $nmbr$ mg
atorvastatin $nmbr$ mg
fluvastatin $nmbr$ mg
lovastatin $nmbr$ mg
stage $nmbr$ b : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
stage $nmbr$ a : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
stage $nmbr$ : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
readmission ( n = $nmbr$ )
no readmission ( n = $nmbr$ )
nyha class iii
nyha class iv
nyha class
nyha class ii
nyha class > ii
nyha class i
no prior cv event
prior lgi event
prior ugi event
no prior ugi event
prior cv event
major cv event
no prior lgi event
prior peripheralarterialdisease
prior peripheral arterial disease
pre - bronchodilator fev $nmbr$ ( l )
post - bronchodilator fev $nmbr$  l
post - bronchodilator fev $nmbr$  l *
postbronchodilator fev $nmbr$  l
prebronchodilator fev $nmbr$ ( l ) t
post - bronchodilator fev $nmbr$ ( l ) a
post - bronchodilator fev $nmbr$ ( l ) *
prebronchodilator fev $nmbr$ ( l )
prebronchodilator fev $nmbr$  l
post - bronchodilator fev $nmbr$ ( l )
pre - bronchodilator fev $nmbr$  l *
amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ )
amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ i )
noncardiovascular
cardiovascular
etoricoxib ( n = $nmbr$  $nmbr$ )
etoricoxib ( n = $nmbr$ $nmbr$ )
no previous cv event
previous cv event
asa use at baseline  n ( % )
ics use at baseline  n ( % )
ics users at baseline  n ( % )
icsusers atbaseline  n ( % )
mean fvc ± sd
mean dlco ± sd
saphenous vein graft
saphenous - vein graft
hypercholesterolemia
hypercholesterolemia *
hypercholesterolemiat
hypercholesterolaemia
one tnfi and
one tnfi *
with stent ^ l
with stent
without stent
postmenopausal and current hrt
postmenopausal and current ht
postmenopausal  current hrt
end point
endpoint
end points
endpointc
telmisartan ( n = $nmbr$ )
irbesartan ( n = $nmbr$ )
olmesartan ( n = $nmbr$ )
duration of rheumatoid arthritis  year
duration of rheumatoid arthritis — yr
dyslipidaemia  n ( % )
dyslipidemia  n ( % )
heart failure $nmbr$ mo before admission
heart failure $nmbr$ month before admission
no anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$
new anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i - $nmbr$
no previous myocardial infarction
previous myocardial infarction
peripheral artery disease
peripheral arterial disease
peripheral - artery disease
peripheral artery disease *
peripheral artery diseasef
history of pvd  n ( % )
history of chd  n ( % )
history of mi  n ( % )
history of chf  n ( % )
history of tia  n ( % )
history of pci  n ( % )
history of cabg  n ( % )
white race — no . / total no . ( % ) $
white race — no . / total no . ( % ) f
aspirin $nmbr$
aspirin $nmbr$ mg
total cholesterol  mmol / l
total cholesterol ( mmol / l )
total cholesterol  mmol / l 本
total cholesterol ( mmol / l ) :
no myocardial infarction at presentation ( n = $nmbr$ )
myocardial infarction at presentation ( n = $nmbr$ )
< $nmbr$ mmol / l
> $nmbr$ mmol / l
black / african american
black or african - american
black / african - american
black or african american
black or african america
black / african american *
saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
saxagliptin $nmbr$ . $nmbr$ mg ( n z $nmbr$ )
bmi ( kg / m $nmbr$ )  mean ± sd
bmi ( kg / m $nmbr$ ) mean ± sd
bmi ( kg / m $nmbr$ )  mean ( sd )
bmi  kg / m $nmbr$  mean + sd
bmi  kg / m $nmbr$  mean ( sd )
bmi  kg / m $nmbr$  mean ± sd
bmi in kg / m $nmbr$  mean ( sd )
bmi ( kg / m $nmbr$ ) mean ( sd )
> $nmbr$ years  n ( % )
< $nmbr$ years  n ( % )
hazard ratio or difference $nmbr$ * ( $nmbr$ % cl ) p - value
hazard ratio or difference $nmbr$ ( $nmbr$ % cl ) p - value
history of hypertension ( a ) c
history of hypertension ( % )
women ( n = $nmbr$ )  n / n ( % )
men ( n = $nmbr$ )  n / n ( % )
aldosterone antagonists
aldosterone antagonist
diastolic blood pressure  mm hg  mean ± sd
diastolic blood pressure ( mm hg )  mean ( sd )
systolic blood pressure  mm hg  mean ± sd
systolic blood pressure ( mm hg )  mean ( sd )
systolic blood pressure  mm hg  mean ( sd )
diastolic blood pressure  mm hg  mean ( sd )
length of stent > median
length of stent < median
£ median ( $nmbr$ . $nmbr$ )
< median ( $nmbr$ . $nmbr$ )
> median ( $nmbr$ . $nmbr$ )
with previous surgery
without previous surgery
corticosteroids
corticosteroid use
no corticosteroid
corticosteroidsa
corticosteroid
full population
full po pulatio n
no epa group n = $nmbr$
epa group n = $nmbr$
coronary artery disease — %
coronary artery disease ( % )
olodaterol $nmbr$ m g
olodaterol $nmbr$ mg
baseline : > $nmbr$ . $nmbr$ meq / l eos : < $nmbr$ . $nmbr$ meq / l
baseline : > $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ meq / l
digoxin  ( % )
digoxin  n ( % )
vitamin k antagonists
vitamin k antagonist
off omt ( n = $nmbr$ )
on omt ( n = $nmbr$ )
ticlopidine
ticlopidin
type $nmbr$ diabetes  n ( % )
type $nmbr$ diabetes  n ( % ) d
laba use at screening  n ( % )
lama use at screening  n ( % )
das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ *
das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ t
modified acc / aha lesion class b $nmbr$ / c
modified acc - aha lesion class b $nmbr$ or c
modified acc / aha lesion class b $nmbr$ or cj
modified acc or aha lesion class b $nmbr$ or c
mtss ( $nmbr$ - $nmbr$ )
vas ( $nmbr$ - $nmbr$ )
oad only
diet only
past only
cabg only
dvt only
ptca only
ics only
< $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$
> $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$
gold stage
gold stage  %
gold stage ii
gold stage iv
gold stage iii
gold stage #
austrafca and new zealand
australia / new zealand
australia and new zealand
simvastatin
pravastatin
subjects $ $nmbr$ years of age  n ( % )
subjects  $nmbr$ years of age  n ( % )
previous mi  n ( % )
previous ami  n ( % )
previous cabg  n ( % )
previous pci  n ( % )
$nmbr$ - $nmbr$ vr — no . ( % )
$nmbr$ - $nmbr$ yr — no . ( % )
$nmbr$ = $nmbr$ yr — no . ( % )
ldl cholesterol  mmol / l 丰
hdl cholesterol  mmol / 冲
hdl cholesterol ( mmol / l )
ldl - cholesterol ( mmol / )
hdl cholesterol ( mmol / l ) :
hdl cholesterol  mmol / l
kdl cholesterol ( mmol / )
ldl - cholesterol ( mmol / l )
hdl cholesterol  ( mmol / l )
ldl cholesterol ( mmol / l ) :
hdl cholesterol  mmol / l *
ldl cholesterol ( mmol / l )
ldl cholesterol  mmol / l
ldl cholesterol  mmol / l *
hdl - cholesterol ( mmol / l )
no renal dysfunction
renal dysfunction
renal function
prebronchodilator fev $nmbr$  % predicted
postbronchodilator fev $nmbr$  % predicted
post - bronchodilator fev $nmbr$  % predicted
< q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )
> q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )
p value $nmbr$
p value * $nmbr$
eze / simva - $nmbr$ yr km rale ( % )
pbo / simva - $nmbr$ yr km rale ( % )
age  median ( iqr )
bmi  median ( iqr )
inter .
intense
< $nmbr$ . $nmbr$ kg / m $nmbr$
$nmbr$ - $nmbr$ kg / m $nmbr$
> $nmbr$ . $nmbr$ kg / m $nmbr$
thiazide
thiazides
antiplatelet agents
antiplatelet agent
hemoglobin  g / dl
haemoglobin ( g / dl )
haemoglobin ( g / l )
hemoglobin ( g / dl )
hemoglobin ( gm / dl )
hemoglobin  mg / dl
hemoglobin  g / l
haemoglobin  mg / dl
hemoglobin — g / dl
hemoglobin  g / dlf
usual care ( n = $nmbr$ la )
usual care ( n = $nmbr$ a )
usual care ( n = $nmbr$ )
ace - inhibitors  n ( % )
ace inhibitor  n ( % )
total ho population ( n = $nmbr$ )
total population ( n = $nmbr$ )
mean age  years
mean age ( years )
mean age  yrs
mean age ( yrs )
mean age — yr
waist - to - hip  female
waist - to - hip  male
at index acs event
index acs event
chronic bronchitis !
chronic bronchitis
post - bronchodilation fev $nmbr$
pre - bronchodilation fev $nmbr$
pre - bronchodilator fev $nmbr$
lama use at screening
laba use at screening
exetimibe / simvastatin
ezetimibe / simvastatin
cv death  ml  ischemic stroke
cv death  mi  ischemic stroke
cv death  mi  or ischemic stroke
proton pump inhibitors
proton - pump inhibitors
proton - pump inhibitor
proton pump inhibitor use
duration of t $nmbr$ dm ( years )
duration of t $nmbr$ dm  years
duration of t $nmbr$ d ( years )
anti platelet therapy
anti - platelet therapy
no antiplatelet therapy
antiplatelet therapy
antiplatelet therapy §
diastolic blood pressurea  mmhg
systolic blood pressure — mm hg
diastolic blood pressure ( mm hg )
systolic blood pressure  mm hg
systolic blood pressure ( mmhg )
diastolic blood pressure ( mm hg ) :
systolic blood pressurea  mm hg
diastolic blood pressure  mm hg
systolic blood pressure ( mm hg )
diastolic blood pressure  mmhg
diastolic blood pressure - mmhg
diastolic blood pressure ( mmhg )
systolic blood pressure - mmhg
systolic blood pressure  mmhg
diastolic blood pressure — mm hg
mineralocorticoid receptor antagonist
mineralocorticoid receptor antagonists
diet group ( n = $nmbr$ )
stent group ( n = $nmbr$ )
haq - di scoreff
haq - di scored
haq - di score
sirolimus
everolimus
ambulance
in ambulance
p value for heterogeneity
pvalue for heterogeneity
race  while
racea white
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / l
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l
macroalbuminuria  n ( % )
microalbuminuria  n ( % )
womac score
total score
lacunar
vascular
dbp  mm hg  mean ± sdc
sbp  mm hg  mean ± sdc
sbp  mm hg  mean + sdc
mean dlqi score ( $nmbr$ % ci )
mean pasi score ( $nmbr$ % ci )
tc  mmol / l ( mg / dl )
fpg  mmol / l ( mg / dl )
body weight  mean ± sd  kg
body weight  mean = sd  kg
race / ethnicity n ( % )
race / ethnicity  n ( % )
race / ethnicity  no . ( % )
race or ethnicity  n ( % )
arial flutter or fibrillation
atrial flutter / fibrillation
current smoker ( n z $nmbr$ )
current smoker ( n = $nmbr$ )
waist circumference  mean ( sd )  cm
waist circumference  mean ( sd )  in
empagliflozin
dapagliflozint
canagliflozin
coronary - artery bypass grafting
coronary artery bypass grafting
coronary artery bypass graft
sex : male
sex  male
sex  % female
sexa male
sex : female
sex  female
sex ( female )
dbp  mean ( sd )  mm hg
sbp  mean ( sd )  mmhg
dbp  mean ( sd )  mmhg
sbp  mean ( sd )  mm hg
sbp  mean = sd  mmhg
contrast volume ( ml )
contrast volume  ml
crp — mg / liter ^
hscrp — mg / liter
omega - $nmbr$ fa intake $nmbr$ nd third
omega - $nmbr$ fa intake $nmbr$ st third
omega - $nmbr$ fa intake $nmbr$  d third
mean ( sd ) pre - bronchodilator
mean ( sd ) post - bronchodilator
former smoking
former smoker
egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr > $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr > $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
egfr < $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$
egfr < $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ *
egfr £ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ §
primary outcomes
primary outcome !
primary outcome
$nmbr$ vessel
$nmbr$ vessels
non - st - segment elevation mi
non - st - segment elevation acs
rate ratio ( $nmbr$ % ci )
rate ratio ( $nmbr$ % cl )
extensive colitisy
extensive colitis
lipid - lowering therapy — no . ( % )
lipid - lowering therapy - no . ( % )
patients with at least one concomitant disease *
patients with at least one concomitant disease | |
hyperlipidemia ( % ) §
hyperlipidemia  %
hyperlipidaemia ( % )
hyperlipidemia ( % )
diagnosed diabetes ( n = $nmbr$ )
undiagnosed diabetes ( n = $nmbr$ )
salmeterol ( n [ $nmbr$ )
physician ' s judgment that vka inappropriate ]
physician ' s judgment that vka inappropriate
female simva
male simva
western europe ( n = $nmbr$ )
eastern europe ( n = $nmbr$ )
elevated creatine kinase - mb ( > $nmbr$ u / l )
elevated creatine kinase mb ( > $nmbr$ u / l )
current tobacco use
no current tobacco use
bare metal
bare - metal
corticosteroid or azathioprine / $nmbr$ - mercaptopurine
corticosteroid - azathioprine / $nmbr$ - mercaptopurine
dapagliflozin $nmbr$ mg
empagliflozin $nmbr$ mg
ertugliflozin $nmbr$ mg
ics / lama
ics / laba
ics + laba
duration of disease — yr
duration of disease — mo
eze + statin
pbo + statin
ze + statin
coronary endpoint
coronary end point
patients with baseline crp concentration £ $nmbr$ mg / l
patients with baseline crp concentration < $nmbr$ mg / l
none 一 no . ( % )
score  no . ( % )
score 一 no . ( % )
female simva ( „ = $nmbr$ }
male simva ( „ = $nmbr$ }
aspirin — no . ( % )
aspirin 一 no . ( % )
adas — cog score
adas - cog score *
troponin $nmbr$ at baseline *
troponin $nmbr$ at baseline
lower limb fracture
upper limb fractures
upper limb fracture
lower limb fractures
inflix  yes
inflix  no
east europe
e . europe
western europe
w . europe
eastern europe
w est europe
eastern european
general health
mental health
canakinumab dose ( per mo )
canakinumab dose ( per month )
age ( years ) : < $nmbr$
age ( years ) : > $nmbr$
chd status §
chd status
rheumatoid factor positive
rheumatoid factor - positive
priorheartfailure  %
prior heart failure yes
prior heart failure  %
gender  male
gender male
metabolic syndrome * n = $nmbr$
metabolic syndrome ( n = $nmbr$ )
nonmetabolic syndrome ( n = $nmbr$ )
bmi ( kg / m $nmbr$ )
bmi  kg / m $nmbr$
bmi  kg / m $nmbr$  n
bmi ( kg / m $nmbr$ ) *
baseline bmi < $nmbr$ kg / m $nmbr$
baseline bmi > $nmbr$ kg / m $nmbr$
duration of assigned regimen before surgery post - randomisation characteristic *
duration of assigned regimen before surgery post - randomisation characteristic * *
asa use at baseline
no asa use at baseline
ics use at baseline
female eze / simva ( „ = $nmbr$ }
male eze / simva ( „ = $nmbr$ }
body mass index  kg / m $nmbr$  mean + sd
body mass index  kg / m $nmbr$  mean ( sd )
body mass index  kg / m $nmbr$  mean ± sd
abdominal obesity *
abdominal obesity
cohort $nmbr$ ( n = $nmbr$ )
cohort $nmbr$ ( n = $nmbr$ ) f
age  median ( $nmbr$ th - $nmbr$ th percentiles )  y
age  median ( $nmbr$ th — $nmbr$ th percentiles )  y
baseline hba $nmbr$ c  %
baseline hba $nmbr$ c ( % )
no aminosalicylates  n
aminosalicylates * *
aminosalicylates  n
vildagliptin $nmbr$ mg qd
vildagliptin $nmbr$ mg bid
< $nmbr$ kg / m $nmbr$ ( n — $nmbr$ )
> $nmbr$ kg / m $nmbr$ ( n — $nmbr$ )
baseline ldl - c > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc
baseline ldl - c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc
methotrexate use
methotrexate user
bare metal stent
bare - metal stent
other ( n = $nmbr$ )
other ( n — $nmbr$ )
amputationsa
amputation
p — value for interaction
p - value for interaction *
p value for interactiont
p value for interaction
p - value for interaction
p value for interaction ^
p value fo interactio
waisthip ratio
waist - hip ratio
tnglycendes < median
tngtycerides a median
tngtycendes a median
tngtycerides < median
furosemide
torsemide
drinker ( % ) a
drinker ( % )
uncertain
uncerlain
mean diastolic blood pressure  mm hg
mean systolic blood pressure  mm hg
maximum cimt < median
maximum cimt a med an
at clinic diastolic pressure > $nmbr$ mm hg
at clinic systolic pressure > $nmbr$ mm hg
at clinic systolic pressure < $nmbr$ mm hg
at clinic diastolic pressure < $nmbr$ mm hg
thiazolidinediones
thiazolidinedioneb
thiazolidinedione no
thiazolidinedione
thiazolidinedione yes
crcl < $nmbr$ ml / min
crcl > $nmbr$ ml / min
ecrcl < $nmbr$ ml / min
stroke or transient ischemic attack
stroke / transient ischemic attack
hdl cholesterol  mmol / l  women  mean ± sd
hdl cholesterol  mmol / l  men  mean ± sd
disease duration > $nmbr$ years ( n = $nmbr$ )
disease duration b $nmbr$ years ( n = $nmbr$ )
bmi ( kg / rrr )
bmi ( kg / m )
anterior ( n  % )
inferior ( n  % )
blood pressure — mm hg
blood pressure  mm hg
blood pressure — mmhg
blood pressure  mm
blood pressure ( mm hg )
blood pressure ( mmhg )
blood pressure  mmhg
non - st - elevation mi
non - st — elevation mi
non - st - elevation ml
$nmbr$ - $nmbr$ . $nmbr$ : overweight
$nmbr$ - $nmbr$ - $nmbr$  overweight
intention - to - treat with st - segment - elevation myocardial infarction
intention - to - treat without st - segment - elevation myocardial infarction
no history of cancer
history of cancer
antidiabetic agent
antidiabetic agents
age > = $nmbr$ years old
age < $nmbr$ years old
ics use at baseline : no
ics use at baseline : yes
crp $ $nmbr$ mg / l  n
crp < $nmbr$ mg / l  n
stent thrombosis *
stent thrombosis
high - dosage ics plus laba with baseline blood eosinophils > $nmbr$ cells per pl ( n = $nmbr$ )
high - dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl ( n = $nmbr$ )
high - dosage ics plus laba with baseline blood eosinophils < $nmbr$ cells per pl ( n = $nmbr$ )
not hispanic or latino ( n = $nmbr$ )
not hispanic or latino ( n — $nmbr$ )
< $nmbr$ mg / dl simva
> $nmbr$ mg / dl simva
cardiovasculardeath
cardiovascular death !
cardiovascular death
mean body - mass index  kg / m $nmbr$
mean body mass index  kg / m $nmbr$
mean body mass index ( kg / m $nmbr$ ) *
mean body mass index ( kg / m $nmbr$ )
a $nmbr$ + e $nmbr$ ( n = $nmbr$ )
a $nmbr$ / $nmbr$ ( n = $nmbr$ )
$nmbr$ - $nmbr$ ( n = $nmbr$ )
mean sd $nmbr$ - h asbp  mm hg
mean ± sd $nmbr$ - h adbp  mm hg
egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr $nmbr$ – $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
$nmbr$ - $nmbr$ / month
$nmbr$ - $nmbr$ months
with corticosteroid treatment < $nmbr$
with corticosteroid treatment > $nmbr$
postmenopausal  no hrt
postmenopausal and no ht
poslmenopausal  no ht
postmenopausal and no hrt
poslmenopausal  ht
depression
depression ^
no depression
concomitant medications
concomitant medication
$nmbr$ blocker
( $nmbr$ - blockers
$nmbr$ blockers
( $nmbr$ blocker
/ $nmbr$ - blockers
$nmbr$ - blockers
no prior stroke / tia
prior stroke / tia
prior stroke or tia
cv entry criteria
entry criteria
fev $nmbr$ / fvc  % a
fev $nmbr$ / fvc  % *
placebo  % > ( n / n )
placebo  % ( n / n )
mayo < $nmbr$  n
mayo $ $nmbr$  n
weight in kg  median ( iqr )
weight - kg  median ( iqr )
weight ( kg )  median ( iqr )
prior myocardial infarction — no . ( % )
prior myocardial infarction 一 no . ( % )
baseline ics use : no
baseline ics use : yes
tg  median ( min  max )
mtss  median ( min  max )
jsn  median ( min  max )
all - cause mortality or hf hospitalization
all - cause mortality or hf hospitalization ^
fbs < $nmbr$ mg / dl
fbs > = $nmbr$ mg / dl
amlodipine / valsartan $nmbr$ / $nmbr$ mg
amlodipine / wlsartan i $nmbr$ / $nmbr$ mg
all - cause mortality
all cause mortality
renal insufficiency / failure
renal insufficiency or failure
anticoagulants
anti - coagulants
anticoagulant
oral corticosteroids
oral corticosteroid
prior lower gi clinical event
prior upper gi clinical event
complex anatomy ( n - $nmbr$  $nmbr$ )
noncomplex anatomy ( n - $nmbr$  $nmbr$ )
all cana
all cancer
ace inhibitors / arb
ace inhibitor or arb
ace inhibitors and arb
ace inhibitors or arb
ace inhibitors or arbs
ace inhibitors / arbs
physician ' s global assessment
physician ' s global assessment !
previous or current im use : no
previous or current cs use : no
nyha class  n ( % ) i
nyha class  n ( % )
nyha class  n ( % ) ii
nyha class  ( % )
baseline heart rate ( beat / min )
baseline heart rate ( beats / min )
concomitant medications  %
concomitant medication | |
metabolic syndrome  ! n ( % )
metabolic syndrome  n ( % )
body weight ( kg )
body weight  %
body weight  kg
body weight — kg
bodyweight ( kg )
body weighta  kg
fev_ ( l ) :
fvc  l
fvc ( l )
fvc ( l ) *
no fracture history
fracture history
$nmbr$ to < $nmbr$ ml / min
> $nmbr$ to < $nmbr$ ml / min
$nmbr$ - < $nmbr$ ml / min
$nmbr$ - $nmbr$ ml / min
met criterion at blt ( n [ % ] )
met criterion at bl ( n [ % ] )
( % ) ( $nmbr$ . $nmbr$ )
( % ) ( $nmbr$ - $nmbr$ )
post - bronchodilator fev $nmbr$ reversibility  % a
postbronchodilator fev $nmbr$ reversibility  %
post - bronchodilator fev $nmbr$ reversibility  %
cigarette smoking
cigarette smoker
daily dose $nmbr$ mg n = $nmbr$
daily dose > $nmbr$ mg n = $nmbr$
female ( n = $nmbr$  $nmbr$ )
male ( n = $nmbr$  $nmbr$ )
hemoglobin ( g r $nmbr$ )
hemoglobin ( g $nmbr$ ! )
with lipid - lowering agents
without lipid - lowering agents
macroalbuminuria
macroalbuminuriaf
microalbuminuria
macro - albuminuria
micro - albuminuria
egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ )
egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ) t
macroalbuminuria — no . / total no . ( % )
microalbuminuria — no . / total no . ( % )
chd simva
no chd simva
> $nmbr$ . $nmbr$ mu / l $ mmol / l
< $nmbr$ . $nmbr$ mu / l $ mmol / l
stage $nmbr$ a : > = $nmbr$ and < $nmbr$
stage $nmbr$ b : > = $nmbr$ and < $nmbr$
canakinumab  hscrp > $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ )
canakinumab  hscrp < $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ )
post - bronchodilator screening fev $nmbr$ ml
pre - bronchodilator screening fev $nmbr$ ml
duration of hypercholesterolaemia  mean ± sd ( year )
duration of hypercholesterolemia  mean ± sd ( years )
< $nmbr$ with no historical count > $nmbr$
< $nmbr$ with historical count > $nmbr$
baseline hbalc > $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$
baseline hbalc < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$
difference from placebo ( $nmbr$ % ci )
difference from placebo * ( $nmbr$ % ci )
central eosinophil count ( cells per pl )
central eosinophil count ( cells per pl ) t
other anti - platelet agents
other antiplatelet agents
other forms of atherosclerosis ^
other forms of atherosclerosis ’
race or ethnic group  no . ( % )
race or ethnic group — no . ( % ) f
prior smoker
prior stroke
no prior stroke
gender  n ( % )
gender  no . ( % )
coronary heart disease  n ( % ) b
coronary heart disease  n ( % ) t
mean ± s . d . fpg
mean ( s . d . ) fpg
troponin i ( pg / ml )
troponin t ( pg / ml )
> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
ischemia - driven revascularization
ischemia driven revascularization
timi minor
timi major
history of major microvascular disease  n ( % )
history of major macrovascular disease  n ( % )
pre - bronchodilation fvc
post - bronchodilation fvc
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ )
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )
history of macrovascular disease ( % )
history of microvascular disease ( % )
patient characteristics
patients ' characteristics
treatment with anti - platelet drugs
treatment with antiplatelet drugs
concomitant medications  * n ( % )
concomitant medication  n ( % )
concomitant medications  n ( % )
fpg  mean ( sd )  mg / dl
fpg  mean ( sd )  mg / dlt
one - vessel disease
two - vessel disease
ethnicity
ind / glyb n = $nmbr$
ind / gly n = $nmbr$
non - hispanic / latino
not hispanic or latino
not hispanic / latino
north american
north america
south africa
south american
sou ti africa
south america
northamerica
bloodpressure  mean ( sd )  m m hg
blood pressure  mean ( sd )  mm hg
tiotropium / olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg
tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg
tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg
diastolic bp  mmhg ( sd )
systolic bp  mmhg ( sd )
postamendment
preamendment
fasting glucose — mg / dl
fasting glucose ( mg / dl )
mean systolic bp  mmhg  mean = sd
mean diastolic bp  mmhg  mean = sd
number of prior aeds  n ( % ) b
number of prior aeds  n ( % )
mean ( sd ) sdai *
mean ( sd ) cdai *
age > $nmbr$ years $nmbr$
age < $nmbr$ years $nmbr$
baseline systolic blood pressure ( mm hg )
baseline diastolic blood pressure ( mm hg )
adp antagonist
tnf antagonist
comorbidities
co - morbidities
vildagliptin $nmbr$ mg bid n = $nmbr$
vildagliptin $nmbr$ mg qd n = $nmbr$
migraine with aura
migraine without aura
previous cancer
previous cancerc
lipid - lowering drugs
lipid - lowerinq druq
lipid - lowering drug
des type
acs type
fev $nmbr$ ( post - albuterol )  l
fev $nmbr$  pre - albuterol  l
fev $nmbr$ ( pre - albuterol )  l
fev $nmbr$  post - albuterol  l
p blockers ( % )
p - blocker ( % )
severe or very severe
severe / very severea
difference ( $nmbr$ % cl )
difference ( $nmbr$ % ci ) *
$nmbr$ months
$nmbr$ mentis
$nmbr$ mortis
> $nmbr$ months
< $nmbr$ months
$nmbr$ montlts
seated sbp  mean ( sd )  mmhg
seated dbp  mean ( sd )  mmhg
alcohol abuse
alcohol use
> $nmbr$ microg / l
< $nmbr$ microg / l
tobacco abuse
tobacco use
hospital stay ( days )
hospital stay  days
fev $nmbr$ — % of predicted value
fev $nmbr$ ( % of predicted value )
maternal history  n ( % )
paternal history  n ( % )
plp - c  mean ( sd )  mg / dl
ldl - c  mean ( sd )  mg / dl
hdl - c  mean ( sd )  mg / dl
$nmbr$ drinks / wk
> $nmbr$ drinks / week
$nmbr$ + drinks / wk
> $nmbr$ drinks / wk
prior hypertension yes
prior hypertensiona yes
drug - related ae *
drug - related teaes *
subgroup p valuef
subgroup p value 本
white ethnic origin
while ethnic origin
> $nmbr$ yr since menopause
< $nmbr$ yr since menopause
ls mean difference ( $nmbr$ % ci )
( mean difference  $nmbr$ % ci )
( mean % difference  $nmbr$ % ci )
reversibility : < $nmbr$ %
reversibility : > $nmbr$ %
male eze / simva
all ez / simva
female eze / simva
glycated hemoglobin - % ’
glycated hemoglobin  %
glycated hemoglobin ( % )
glycated hemoglobin — %
glycated haemoglobin ( % )
a $nmbr$ c ( mmol / mol )
hba $nmbr$ c  mmol / mol
hba $nmbr$ c ( mmol / mol )
arterial hypertension *
arterial hypertension
intervention
interruption
waist circumference ( cm )
waist circumference — cm
waist circumference  ( cm )
waist circumference  cm
dbp ( mm hg )  median ( iqr )
sbp ( mm hg )  median ( iqr )
total cholesterol  mg / dl
total cholesterol — mg / dl
total cholesterol ( mg / dl )
toial cholcsierol ( mg / dl )
total cholesterol  mg / dl ^
no change
% change
> $nmbr$ ml / min
£ $nmbr$ ml / min
< $nmbr$ ml / min
smoking history ( pack - years )
smoking history  pack - years
smoking history ( pack - yr )
dm + ( aliskiren vs . placebo )
dm - ( aliskiren vs . placebo )
without beta blocker
with beta blocker
timi risk score !
timi risk score
timi risk score  %
angiotensin - converting enzyme inhibitor
angiotensin - converting - enzyme inhibitor
total asthma symptom score
total asthma symptom score :
diastolic bp  mmhg  mean ± sd
systolic bp  mmhg  mean ± sd
uric acid fertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl )
uric acid tertile $nmbr$ ( < $nmbr$ . $nmbr$ mg / dl )
uric acid tertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl )
> $nmbr$ . $nmbr$ mmol / liter
> $nmbr$ . $nmbr$ mg / liter
< $nmbr$ . $nmbr$ mg / liter
< $nmbr$ . $nmbr$ mmol / liter
< $nmbr$ . $nmbr$ pmol / liter
age ( years ) - < median ( n = $nmbr$  $nmbr$ )
age ( years ) - > = median ( n = $nmbr$  $nmbr$ )
macrovascular disease  n ( % )
microvascular disease  n ( % )
vorapaxar ( n = $nmbr$ . $nmbr$ )
vorapaxar ( n = $nmbr$ $nmbr$ )
vorapaxar ( n = $nmbr$  $nmbr$ )
risk difference
lsm difference
aspirin ( n = $nmbr$  $nmbr$ )
aspirin ( n = $nmbr$ $nmbr$ )
rosuvastatin
rosuvastatin +
metformin use
no metformin use
copd severity  n ( % ) a
copd severity  n ( % )
copd severity  n ( % ) *
prior revascularization
pci revascularization
ldl - c : hdl - c
ldl - c / hdl - c
ldl - c / hdl - cx
oral agents
two agents
ras agents
mean ( sd ) fev $nmbr$ ( l ) pre - bronchodilator
mean ( sd ) fev $nmbr$ ( l ) post - bronchodilator
< $nmbr$ years simva ( n = $nmbr$ }
> $nmbr$ years simva ( „ = $nmbr$ }
bmi > $nmbr$ kg / m $nmbr$
bmi < $nmbr$ kg / m $nmbr$
bmi  x $nmbr$ kg / m $nmbr$
bmi > = $nmbr$ kg / m $nmbr$
bmi  median ( sd )  kg / m $nmbr$
bmi  mean ( sd )  kg / m $nmbr$
physical function
physical functioning
ldl - c ( mg / dl )
hdl - c ( mg / dl )
hdl - c  mg / dl
ldl - c  mg / dl
regular aspirin use
no regular aspirin use
> $nmbr$ beats / min
< $nmbr$ beats / min
antiplatelets
antiplatelet
characteristics
characteristic
hypokalemia
hvookalemia
hyperkalemiab
hungary
surgery
baseline uacr < $nmbr$ mg / g
baseline uacr > $nmbr$ mg / g
insulin plus $nmbr$ oral agent
insulin plus > $nmbr$ oral agent
long - acting nitrates
long acting nitratef
long - acting nitrate
ischaemic aetiology
ischemic aetiology
systolic blood pressure  mean ( sd )  mm hga
systolic blood pressure  mean ( sd )  mm hg
hscrp < $nmbr$ . $nmbr$ mg / l
hscrp > $nmbr$ . $nmbr$ mg / l
hscrp > $nmbr$ . $nmbr$ mga .
hs - crp > $nmbr$ . $nmbr$ mg / l
hs - crp < $nmbr$ . $nmbr$ mg / l
hs - crp < $nmbr$ . $nmbr$ g / l
creatinine clearance  ml / min
creatine clearance  ml / min
creatinine clearance ( ml / min )
total cholesterol $nmbr$ < $nmbr$ mg / dl
total cholesterol $nmbr$ > $nmbr$ mg / dl
rosuvastatin  n ( rate )
rosuvastatin n ( rate ) *
rosuvastatin n ( rate )
tiotropium / olodaterol $nmbr$ / $nmbr$ mg
tiotropium + olodaterol $nmbr$ / $nmbr$ mg
tiotropium + olodaterol $nmbr$ / $nmbr$ pg
diastolic blood pressure
systolic blood pressure
cardiac failure *
cardiac failure §
cardiac failure
major cardiovascular event
major cardiovascular event *
major cardiovascular events
no concomitant immunosuppressive and / or prior anti - tnf use
concomitant immunosuppressive and / or prior anti - tnf use
triglycerides - mg / dl * *
triglycerides ( mg / dl ) * *
$nmbr$ - $nmbr$ months  n ( % )
$nmbr$ - < $nmbr$ months  n ( % )
received $nmbr$ prior biologic therapies  n
received $nmbr$ prior biologic therapy  n
immunosuppressants onlyff
immunosuppressants only
mtx > $nmbr$ mg / week
mtx £ $nmbr$ mg / week
active smoking
active smoker
cardiovascular risk factors  no . ( % )
cardiovascular risk factors  n ( % )
demographic
demographics
demography
no stroke ( n = $nmbr$ )
any stroke ( n = $nmbr$ )
left main
back pain
neck pain
rest pain
< $nmbr$ mg / dl eze / simva
> $nmbr$ mg / dl eze / simva
no st depression or elevation
st depression or elevation
medication use at baseline  n ( % )
medications at baseline  n ( % )
history of atrial fibrillation or fl utter
history of atrial fibrillation / flutter
statin without other llt
statin with other llt
< q $nmbr$ ( $nmbr$ ) — number / n ( % )
> q $nmbr$ ( $nmbr$ ) — number / n ( % )
time from qualifying mi  %
time from qualifying mi  yrs
prior history of ml or ischemic stroke
prior history of mi or ischaemic stroke
hazard ratio ( $nmbr$ % confi dence interval )
hazard ratio ( $nmbr$ % confidence interval )
hazard ratio ( $nmbr$ % confidence interval ) *
with antiplatelets
without antiplatelets
range  ( min  max )
range : min  max
range ( min  max )
aml $nmbr$ mg / hctz $nmbr$ mg
om $nmbr$ mg / hctz $nmbr$ mg
insulin therapy
noninsulin therapy
mean ± sd  n
mean ± sd ( yr )
mean ± sd ( n )
stage $nmbr$ : > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
stage $nmbr$ : < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
median ( q $nmbr$  q $nmbr$ )
median ( q $nmbr$ : q $nmbr$ )
bmi category ( % )
age category ( % )
supplementary oxygen
supplemental oxygen
fvc ( liters )
fvc — liters
> $nmbr$ years of age
< $nmbr$ years of age
$ $nmbr$ exacerbations
$nmbr$ exacerbation
> $nmbr$ exacerbations
$nmbr$ exacerbations
history of mi ( n = $nmbr$  $nmbr$ )
no history of mi ( n = $nmbr$  $nmbr$ )
vka therapy
dual therapy
egfr  mean ( sd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr  mean = sd  ml / min / $nmbr$ . $nmbr$ m $nmbr$
nt - probnp ， pmol / h
nt - probnp  pmol / l ^
nt - probnp  pmol / l
antihypertensive
antihypertensives
gender  n ( % ) male
gender  n [ % ] male
ldl - c ( mmol / l  mean )
hdl - c ( mmol / l  mean )
all patients ( « = $nmbr$ $nmbr$ )
all patients ( n = $nmbr$  $nmbr$ )
eastern europe ( % )
western europe ( % )
om $nmbr$ mg / aml $nmbr$ mg
ischaemic heart disease
ischemic heart disease
hba $nmbr$ c  mean ( sd )  %
hba $nmbr$ c  mean = sd  %
hba $nmbr$ c  median ( sd )  %
asia pacific
asia - pacific
asia / pacific
previous coronary revascularization
previous coronary revascularisation
corticosteroid use at baseline - no
corticosteroid use at baseline - yes
fev $nmbr$ reversibility  % *
fev $nmbr$ reversibility  % b
serum triglycerides — mmol / liter
serum triglycerides — pmol / liter
angina pectoris
angina pectoris 本
angina pectoris *
angina pectorisf
alc > = $nmbr$ . $nmbr$ %
alc < $nmbr$ . $nmbr$ %
major bleeding
minor bleeding
a from baselineb
a from baseline
bmi : < $nmbr$ . $nmbr$ kg / m $nmbr$
bmi : > $nmbr$ . $nmbr$ kg / m $nmbr$
mayo score  mean ( sd )
mayo score ( mean ± sd )
total ( n = $nmbr$ $nmbr$ )
total  n = $nmbr$ $nmbr$
total ( n = $nmbr$  $nmbr$ )
> median ( $nmbr$ . $nmbr$ years ) — number / n ( % )
< median ( $nmbr$ . $nmbr$ years ) — number / n ( % )
difference vs placebo * *
difference vs placebo '
difference vs . placebo
difference vs placebo
avm % △ ( se )
met % △ ( se )
chronic kidney diseased
chronic kidney disease
estimated difference %
estimated difference
u . s . site
u . s . sites
history of diabetes ( n = $nmbr$ )
no history of diabetes ( n = $nmbr$ )
< $nmbr$ months  median ( min  max )
> $nmbr$ months  median ( min  max )
posterior circulation
anterior circulation
insulin yes
insulin use
insulin based
non - black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ )
non - black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ )
family history of diabetes ( % ) *
family history of diabetes ( - )
family history of diabetes ( + )
duration of diabetes  years
duration ofdiabetes — yr
duration of diabetes ( years )
duration of diabetes — yr
duration of diabetes  yrs
duration of diabetes ( y )
duration of diabetes ( years ) t
duration diabetes ( years )
at index event
index event
moderate ckd
moderate ’
moderatey
no moderate ckd
moderate
weight < $nmbr$ . $nmbr$ kg  n
weight $ $nmbr$ . $nmbr$ kg  n
history of microvascular disease
history of macrovascular disease
disease duration  years
disease duration ( years )
disease duration ( yr )
glycated hemoglobin  nonstandardized level — %
glycated hemoglobin  standardized level — %
baseline characteristics
baseline characteristic
patients without chronic
patients with chronic
baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ c
baseline egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
ldl - c  mean ( sd )
tchdl - c  mean ( sd )
hdl - c  mean ( sd )
symptomatic pad
symptomatic padt
statin during admission
no statin during admission
rosuvastatin events / patients ( % )
rosuvastatin  events / patients ( % )
average weekly mtx dose ( mg / week )
average weekly mtx dose ( mg / week ) t
all teaes *
all teaes
mild teaes
sbp  mean ± sd ( mmhg )
dbp  mean ± sd ( mmhg )
death ( all - cause )
death ( all cause )
q $nmbr$ : > $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ )
q $nmbr$ : < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ )
> = $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ )
< $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ )
without psoriasis ( zi = $nmbr$  $nmbr$ )
without psoriasis ( n = $nmbr$  $nmbr$ )
heart rate > $nmbr$ bpm
heart rate < $nmbr$ bpm
inferior
non - anterior
nonanterior
not anterior
anterior
hyperlipidaemia
hyperlipidemia
hyperlipidemia ^
left - sided colitisz
left sided colitis
left - sided colitis
nadroparin ( n = $nmbr$ )
no nadroparin ( n = $nmbr$ )
social functioning
social function
eze / simva
ez / simva
aniagonisi
antagonist
all - cause death n
all - cause death
family history of cancera
family history of cancerf
indacaterol $nmbr$ mg
indacaterol $nmbr$ pg
p  regional difference
p  regional difference *
liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$
liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$
liraglutide $nmbr$ - $nmbr$ mg ( n = $nmbr$ )
liraglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
fev $nmbr$ pre - bronchodilator
fev $nmbr$ post - bronchodilator
ace inhibitors / arbs  n ( % )
ace - inhibitors / arbs  n ( % )
increase creatinine  < $nmbr$ . $nmbr$ mg / dl
increase creatinine  > $nmbr$ . $nmbr$ mg / dl
> $nmbr$ . $nmbr$ ( % )
< $nmbr$ . $nmbr$ ( % )
baseline lipid and lipoprotein values
baseline lipid / lipoprotem values
baseline lipid / lipoprotein values
previous stroke *
previous stroke
hypertension — no . ( % )
hypertension — no . ( % ) |
overall ( n = u $nmbr$ )
overall ( n = $nmbr$ )
history of diabetes :
history of diabetes
beta - blockers  n ( % )
beta - blockers  ( % )
history of hypertension *
history of hypertension
ischemic heart disease  ( % )
ischemic heart disease  n ( % )
ischaemic heart disease  n ( % )
patients receiving enl  no . ( % )
patients receiving lcz  no . ( % )
urinary albumin : creatinine ratioa ( mg / g )
urinary albumin : creatinine ratio ( mg / g )
indian ( american ) or alaska native
indian ( american ) or alaskan native
saxagliptin $nmbr$ mg
mssbp < $nmbr$ mmhg
mssbp > $nmbr$ mmhg
infarct localisation
infarct localization
placebo group ( n = $nmbr$ )
placebo group ( n = $nmbr$ ) f
sjc ( $nmbr$ joints )
sjc ( / $nmbr$ joints )
tjc ( / $nmbr$ joints )
tjc ( $nmbr$ joints )
oral anticoagulants
oral anticoagulant
ischemia
ischaemic
disease characteristics
disease characteristics *
nyha functional class
ara functional class
teaes ( > $nmbr$ % in any treatment group ) *
teaes ( > $nmbr$ % in any treatment group )
history myocardial infarction
history of myocardial infarction
acq - $nmbr$ score *
npi - $nmbr$ score *
acq - $nmbr$ scoret
$nmbr$ - h ppg ( mmol / l )
$nmbr$ - h ppg ( mmol / l ) *
$nmbr$ - h pg ( mmol / l )
fvc post - bronchodilator
fvc pre - bronchodilator
baseline su dose < $nmbr$ / $nmbr$ maximal
baseline su dose > $nmbr$ / $nmbr$ maximal
mean sd ldl - c  mg / dl
mean sd hdl - c  mg / dl
laa closure
pfo closure
cdai < $nmbr$ . $nmbr$ *
sdai < $nmbr$ . $nmbr$ *
nyha class — no . ( % ) $
nyha class — no . ( % )
drug - eluting
drug eluting
homa - p
homa - ir
no . of patients with psa
no . of patients with ra
no . of patients with as
ng ( n = $nmbr$  $nmbr$ )
no ( n = $nmbr$  $nmbr$ )
$nmbr$ ( n = $nmbr$  $nmbr$ )
sf - $nmbr$ v $nmbr$ mcs  mean [ sd ]
sf - $nmbr$ v $nmbr$ pcs  mean [ sd ]
regular ppi use
no regular ppi use
hospitalization for acs
hospitalization for
hospitalization for hf
pbo + mtx to mtx
czp + mtx to mtx
tg  mg / dl  mean ± sd
tc  mg / dl  mean ± sd
tc  mg / dl  mean + sd
aiirocumab
alirocumab
hispanic or latino ethnic groupf
hispanic or latino ethnic group !
hispanic or latino ethnic groupb
hispanic or latino ethnic group *
prior aspirin
no prior aspirin
medication  n ( % )
medications  n ( % )
medication — no . ( % )
medications . no . ( % )
medications  no . ( % )
eze + statin n = $nmbr$
pbo + statin n = $nmbr$
incidence *
incidence  %
incidencea
asia  pacific and other
asia pacific or other
asia pacific and other
apo b : apo a - i ratio
apob : apoal ratio
apob : apoa - l ratio
saxa + met n = $nmbr$
dapa + met n = $nmbr$
patients with uncomplicated events
patients with complicated events
sf - $nmbr$ mcs  mean ± sd
sf - $nmbr$ pcs  mean ± sd
systolic blood pressure subgroups
diastolic blood pressure subgroups
losartan  n / n ( % )
valsartan  n / n ( % )
persistent
persistent af
ukpds $nmbr$ - year risk score < $nmbr$ %
ukpds $nmbr$ - year risk score > $nmbr$ %
sirolimus - eluting
everolimus - eluting
immunosuppressants
immunosuppressant ^ ^
hdl - c  mg / dl  mean ± sd
ldl - c  mg / dl  mean + sd
ldl - c  mg / dl  mean ± sd
hdl - c  mg / dl  mean + sd
medication use
medication
education *
medications *
medications
sgrq total score * ( units )
sgrq total score  units
sgrq total score ( units )
weight  median ( sd )  kg
weight  mean ( sd ) kg
weight  median ( iqr )  kg
weight  mean ( sd )  kg
diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .
diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .
total no .
total body
ind / gly ( n = $nmbr$ )
ind + pbo ( n = $nmbr$ )
ind + gly ( n = $nmbr$ )
score of $ $nmbr$  no . ( % )
score of # $nmbr$  no . ( % )
body - mass index ( kg / m ' )
body - mass index ( kg / m - ) !
body - mass index ( kg / m - )
time to treatment initiation ( min
time to treatment initiation ( min )
patients with microalbuminuria at baseline
patients with macroalbuminuria at baseline
atrial fibrillation !
atrial fibrillation  %
atrial fibrillation
atrial fibrillation ( % )
prior tnf antagonist treatment - no
prior tnf antagonist treatment - yes
pt baseline ( week $nmbr$ )
db baseline ( week $nmbr$ )
odds ratio ( $nmbr$ % ci )
odds ratio ( $nmbr$ % cl )
ethnicity  n ( % )
ethnicity  no . ( % )
ethnicity - no . ( % )
pacemaker  n ( % )
pacemaker  ( % )
physical examination
physical examinations
ileum and colon
ileum or colon
killip class > ii ( % )
killip class  n ( % )
qrs < $nmbr$ msec
qrs > $nmbr$ ms *
hba $nmbr$ c  %  mean ( sd ) b
hba $nmbr$ c  %  mean ( sd )
hba $nmbr$ c  %  mean ± sd
< $nmbr$ % blood eosinophils at baseline
> $nmbr$ % blood eosinophils at baseline
czp $nmbr$ mg ( n $nmbr$ )
age ( median  iqr )  y
age  median ( iqr )  y
atrial fibrillation / flutter
atrial fibrillation or flutter
metformin
no metformin
q wave
q wave mi
q - wave mi
hand fracture
hip fracture
canagliflozin ( n = $nmbr$ )
empagliflozin ( n = $nmbr$ )
smoking history
post - bronchodilator fev $nmbr$ / fvc  %
postbronchodilator fev $nmbr$ / fvc  %
smoker ( % )
smoker ( % ) a
ast  u / l
alt  u / l
non - hdl - c  mmol / l
non - hdl - c ( mmol / l )
menopause and ht
menopause and hrt
minimum - maximum
minimum : maximum
patients < $nmbr$ %
patients > $nmbr$ %
women ( n = $nmbr$ vs $nmbr$ )
men ( n = $nmbr$ vs $nmbr$ )
men ( n = $nmbr$ $nmbr$ )
diastolic — mean ( sd ) ( mm hg )
systolic — mean ( sd ) ( mm hg )
active cancer
no active cancer
ac tve cancer
physical activity  kcal / wk
physical activity  kcal / wk *
loop or thiazide diuretic
loop or thiazide diuretic #
alcohol use  drinks / wk
alcohol use  drinks / wk *
total population
total population n
interruption ( n = $nmbr$ )
intervention ( n = $nmbr$ )
non - st - segment elevation myocardial infarction
non — st - segment — elevation myocardial infarction
% risk reduction ( $nmbr$ % ci )
risk reduction ( $nmbr$ % cl )
use of beta - blocker
use of beta - blockers
hf hospitalization
hf hospitalization n
hospitalization
r elative risk ( $nmbr$ % ci )
relative risk ( $nmbr$ % ci )
relative risk ( $nmbr$ % cl )
> $nmbr$ . $nmbr$ ( n — $nmbr$ )
< $nmbr$ . $nmbr$ ( n — $nmbr$ )
mi > $nmbr$ months *
mi < $nmbr$ months *
> $nmbr$ months — number / n ( % )
< $nmbr$ months — number / n ( % )
all n = $nmbr$  $nmbr$
all n = $nmbr$ $nmbr$
any clinical or lesion rf for st
no clinical or lesion rfs for st
neuropathy
nephropathy
hba $nmbr$ c > $nmbr$ % ( n $nmbr$ $nmbr$ )
hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ )
am △ 士 s . e .
ama 士 s . e .
im or cs use : no
im and cs use : no
hdl $nmbr$ - c
ldl $nmbr$ - c
at randomization
randomization
to randomization
> $nmbr$ years simva
< $nmbr$ years simva
simvastatin $nmbr$ mg ( n = $nmbr$ ) *
simvastatin $nmbr$ mg ( n = $nmbr$ )
hispanic or latino ( n — $nmbr$ )
hispanic or latino ( n = $nmbr$ )
copd exacerbation : yes
copd exacerbation : no
hdl cholesterol > $nmbr$ - $nmbr$ mmol / l
ldl cholesterol < $nmbr$ - $nmbr$ mmol / l
ldl cholesterol > $nmbr$ - $nmbr$ mmol / l
hdl cholesterol < $nmbr$ - $nmbr$ mmol / l
sex  female  n ( % )
sex ( male )  n ( % )
sex  male  n ( % )
sex  male  no . ( % )
adjusted p - value for interaction
unadjusted p - value for interaction
no chd eze / simva
chd eze / simva
aspirin use ( p = $nmbr$ - $nmbr$ t )
aspirin use ( p = $nmbr$ - $nmbr$ 十 )
dapagliflozin $nmbr$ mg ( n = $nmbr$ )
ertugliflozin $nmbr$ mg ( n = $nmbr$ )
empagliflozin $nmbr$ mg ( n = $nmbr$ )
prior coronary artery bypass grafting
prior coronary artery bypass graft
cholesterol ( mmol / l )
cholesterol  mmol / l
fev $nmbr$  litres ( pre ipratropium )  mean ( sd )
fev $nmbr$  litres ( post ipratropium )  mean ( sd )
insulin ( pmol / l )
insulin  pmol / l
proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - < median ( n = $nmbr$  $nmbr$ )
proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - > = median ( n = $nmbr$  $nmbr$ )
( mmol / l ]
mmol / mol
mmol / l
wc ( cm )
rr ( cl )
patient ' s global assessment
patient ' s global assessment !
patient ' s global assessment of
no epa group no . of events ( % )
epa group no . of events ( % )
nitrates  ( % )
nitrates  n ( % )
cox hr ( $nmbr$ % ci )
cmh rr ( $nmbr$ % ci )
coronary revascularization
coronary revascularisation
n - $nmbr$ pufa ( n = $nmbr$ )
n - $nmbr$ - pufa ( n = $nmbr$ )
antihypertensive agents
antihypertensive agents *
mean ( sd )  y
mean ( sd ) bmi
non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = $nmbr$  $nmbr$ )
non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = $nmbr$  $nmbr$ )
aldosterone blocker
aldosterone blockers
adjusted hr ( $nmbr$ % ci )
adjusted hr ( $nmbr$ % cl )
cohort $nmbr$ ( uacr < $nmbr$ . $nmbr$ mg / g )
cohort $nmbr$ ( uacr > $nmbr$ . $nmbr$ mg / g )
no extensive colitis  n
extensive colitis  n
prior migraine
prior migraine *
primary endpoint death / mi / idr / st
primary end point : death / mi / idr / st
difference from placebo
difference from placeboa
difference from placebo ¥
standing after $nmbr$ minute change from baseline
standing after $nmbr$ minutes change from baseline
american indian or alaskan native
american indian / alaska native
american indian or alaska native
multiracial
multi - racial
aqlq ( s ) + $nmbr$ scored
aqlq ( s ) + $nmbr$ scorets
antiarrhythmic
anti arrhythmic
ct findings
ecg findings
lipoprotein ( a ) ( nmol / l )
lipoprotein ( a ) ( mmol / l )
baseline . mean _ sd  mg / dl
baseline . mean _ sd . mg / mg
baseline . mean _ sd . mg / dl
≤ $nmbr$ u / kg / day
> $nmbr$ u / kg / day
valsartan
bosentan
losartan
history of stroke
history of stroke *
patients without syndesmophytes at baseline
patients with syndesmophytes at baseline
lipid - lowering
lipid lowering
stratum ii
stratum i
aapo $nmbr$ at rest  mm hg
pao $nmbr$ at rest  mm hg
mean ( s . d . ) systolic blood pressure  mm hg
mean ( s . d . ) diastolic blood pressure  mm hg
> $nmbr$ to < $nmbr$ h  n ( % )
$nmbr$ to < $nmbr$ h  n ( % )
coronary artery disease ^
coronaiy artery disease
coronary artery disease
> o - $nmbr$ - i - i
> o - $nmbr$ - ii
egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd )
egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ± sd
baseline fev $nmbr$
baseline fev $nmbr$ #
$nmbr$ ( n $nmbr$ $nmbr$ )
$nmbr$ mg ( n $nmbr$ $nmbr$ )
respiratory rate  breaths / min
respiratory rate ( breaths / min )
karnofsky score < $nmbr$
karnofsky score 竺 $nmbr$
ldl - csmedian
ldl - c > median
non - hdl - c *
non - hdl - c
duration of pci — min
duration of pci  min
mean ( s . d . ) bmi  kg / m $nmbr$
mean ± s . d . bmi  kg / m $nmbr$
baselinec
( baseline )
baselineb
baseline
< $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )
≥ $nmbr$ . $nmbr$ % ( ≥ $nmbr$ mmol / mol )
inferior ( % )
anterior { % )
age group  no . ( % )
age group  n ( % )
qualifying mi < $nmbr$ yrs prior
qualifying mi $ $nmbr$ yrs prior
hawaiian / pacific islander
hawaiian pacific islander
bl mean ( mmhg )
bl mean ( cm )
no or unknown
no / unknown
loop diuretic
loop diuretics
non diuretics
esam ( ng / ml )
ngal ( ng / ml )
fev $nmbr$ / fvc
fev $nmbr$ / fvc %
history of diabetes ( a )
history of diabetes ( % )
age : < $nmbr$ years ( n = $nmbr$ )
age < $nmbr$ years ( n = $nmbr$ )
age  years  mean ( range )
age  years : median ( range )
metabolic syndrome ( % ) b
metabolic syndrome ( % )
peripheral artery disease — no . ( % )
peripheral - artery disease — no . ( % )
aiorvasiaiin
atorvastatin
epa ( mol % )
aa  mol %
epa  mol %
cardiovasculardeath / myocardial infarction / stroke
cardiovascular death / myocardial infarction / stroke
m o nito ring treatment
monitoring treatment
baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$  q $nmbr$ )
baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$ - q $nmbr$ )
thiazide diuretics
thiazide diuretic
diabetes present $nmbr$ ( $nmbr$ . $nmbr$ )
diabetes absent $nmbr$ ( $nmbr$ . $nmbr$ )
baseline medication
baseline cv medications
baseline medications
calcium aniagonisi
calcium antagonist
calcium antagonists
at qualifying event
qualifying event
$nmbr$ - $nmbr$ . $nmbr$ : obese class ii
$nmbr$ - $nmbr$ . $nmbr$ : obese class i
white race — no . ( % ) f
white race — no . ( % ) : t
white race — no . ( % ) :
ileocolon
lleocolon
tiotropium $nmbr$ mg ( n = $nmbr$
tiotropium $nmbr$ mg ( n = $nmbr$ )
multi - vessel coronary artery disease
multivessel coronary artery disease
mean ± sd msdbp  mm hg
mean sd mssbp  mm hg
mean age  y ( sd )
mean age ( y ) ( sd )
age in $nmbr$ classes
egfr in $nmbr$ classes
heart rate  bpm
heart rate — bpm
heart rate ( bpm )
biguanide ( metformin )
biguanides ( metformin )
naive : no
naive : yes
no steroids ( n = $nmbr$ vs $nmbr$ )
steroids ( n = $nmbr$ vs $nmbr$ )
secondary ' outcomes
secondary outcomes
clopidogrel
clopiodogrel
antiplatelet - onl group ( n = $nmbr$ )
antiplatelet - only group ( n = $nmbr$ )
myopathyt
myopathy
baseline hdl - c in $nmbr$ classes
baseline trl - c in $nmbr$ classes
with diabetes
without diabetes
treated vessel
treated vessel !
estimated glomerular filtration rate - ml / min / $nmbr$ . $nmbr$ m $nmbr$ tt
estimated glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
inferior or posterior
inferior / posterior
weight > $nmbr$ kg
weight < $nmbr$ kg
systolic ( mean  sd )
diastolic ( mean  sd )
tertile $nmbr$ ( > $nmbr$ . $nmbr$ pg / ml ) n - $nmbr$
tertile $nmbr$ ( < $nmbr$ . $nmbr$ ng / ml ) n - $nmbr$
patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline
patients with egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline
baseline hba $nmbr$ c > $nmbr$ . $nmbr$ %
baseline hba $nmbr$ c < $nmbr$ . $nmbr$ %
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % f
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % t
number of stents
number of patients
tjc ( $nmbr$ joints )  mean ( sd )
sjc ( $nmbr$ joints )  mean ( sd )
body mass index  median ( iqr ) b
body mass index  median ( iqr )
all other
all others
secondary *
secondary pci
no . of prior aeds  n ( % )
no . of prior aeds  c n ( % )
( mean change  $nmbr$ % ci )
( mean % change  $nmbr$ % ci )
hazard ratiof
hazard ratio
prior myocardial infarction yes
prior myocardial infarction  %
dpp - $nmbr$ inhibitor
dpp - $nmbr$ inhibitors
ldl - c / hdl - c ratio
ldl - c : hdl - c ratio
modified has - bled $ $nmbr$
modified has - bled < $nmbr$
subgroup
subgroups
old stroke *
new stroke *
low risk
lower risk
high - intensity statin
high - intensity statin *
no high - intensity statin
smoker  ! n ( % )
smokers  n ( % )
ics use yes / no  %
ics use  yes / no %
ics use  yes / no  %
present smokerc
present smoker
p - value ( int )
p value ( int )
alteplase
reteplase
western europe / australia
western europe and australia
geographical region
geographic region
tiotropium $nmbr$ mg respimat ® ( n z $nmbr$ )
tiotropium $nmbr$ mg respimat ® ( n = $nmbr$ )
body - mass index > $nmbr$  n ( % )
body mass index > $nmbr$  n ( % )
pbo + mtx n = $nmbr$
czp + mtx n = $nmbr$
ef < $nmbr$ % hfref ( n = $nmbr$  $nmbr$ % )
ef > $nmbr$ % hfpef ( n = $nmbr$  $nmbr$ % )
macroalbuminuria at baseline ( $nmbr$ % of patients treated )
microalbuminuria at baseline ( $nmbr$ % of patients treated )
any coronary artery disease
only coronary artery disease
estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
estimated gfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
female patients  n ( % )
male patients  n ( % )
history  pack - years
history ( pack - years )
duration of diabetes > $nmbr$ years
duration of diabetes < $nmbr$ years
structural heart disease §
structural heart disease
no family history of chd ( n = $nmbr$  $nmbr$ )
family history of chd ( n = $nmbr$  $nmbr$ )
subcortical wml load diameter  mm  mean ( sd )
subcortical wml load diameter  mm   mean ( sd )
etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . . ( . % . . ) . . . . . . . . . . .
etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .
glycoprotein iib / iiia inhibitor
glycoprotein iib / iiia inhibitors
with acei / arb
without acei / arb
corticosteroid or immunosuppressant
corticosteroids and immunosuppressants
corticosteroid and immunosuppressant
egfr < $nmbr$ ml / min
egfr > $nmbr$ ml / min
st - segment — elevation myocardial infarction
st - segment elevation myocardial infarction
patients with psoriasis ( n = $nmbr$ )
patients without psoriasis ( n = $nmbr$ )
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ mz
egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ mz
age > $nmbr$ years ( median )
age < $nmbr$ years ( median )
no . pts
no . men
$nmbr$ mg qw $nmbr$ . $nmbr$ pt yrs
$nmbr$ mg biw $nmbr$ . $nmbr$ pt yrs
fasting plasma glucose ( mg / dl )
fasting plasma glucose — mg / dl
antidiabetic medications
antidiabetic medication
ldl - c ( median  iqr )  mg / dl
hdl - c ( median  iqr )  mg / dl
nonischemic cardiomyopathy
ischaemic cardiomyopathy
ischemic cardiomyopathy
no ilb / iiia inhibitors
ilb / iiia inhibitors
nontatal ml
nonfatal ml
no of events women men *
no of events womenmen *
demographic features
demographic feature
non - epa ( n = $nmbr$ )
non - us ( n = $nmbr$ )
heart failure *
heart failure
heart failurea
acetylsalicylic acid
acetyl - salicylic acid
difference ( % )
difference ( se )
exercise > once weekly
exercise > once weekly ?
$nmbr$ - $nmbr$ days ( % )
$nmbr$ - $nmbr$ yr ( % )
number stent > $nmbr$
number ste  t > $nmbr$
most common concomitant aeds  d n ( % )
most common concomitant aeds  n ( % )
> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to $nmbr$ mmol / mol )
> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )
baricitinib $nmbr$ mg ( n = $nmbr$ )
baricitinib $nmbr$ mg qd ( n = $nmbr$ )
alcohol consumption
alcohol consumption !
sri response  %
acr response  %
endpoint / baseline
endpoint / baselinec
ranozaline
ranolazine
left anterior descending coronary artery
l eft anterior descending coronary artery
renal subgroup
female subgroup
ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ )
ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ )
transient ischemic attack
transient ischaemic attack
$nmbr$ mg ew n = $nmbr$
$nmbr$ mg eow n = $nmbr$
phgada ( mm )
ptgada ( mm )
patient ' s assessment of pain !
patient ' s assessment of pain
lama ( only monotherapy )
laba ( only monotherapy )
insulin glargine ( n = $nmbr$ )
insulin glargine ( n = $nmbr$ ll )
secukinumab  $nmbr$ mg ( n = $nmbr$ )
secukinumab $nmbr$ mg ( n = $nmbr$ )
paroxysmal
paroxysmal af
history of major microvascular disease — no . ( % )
history of major macrovascular disease — no . ( % )
non - hdl cholesterol
non - hdl choleslerol
insulin treated
insulin - treated
msdbp  mmhg ( sd )
mssbp  mmhg ( sd )
no prior statin ( n = $nmbr$  $nmbr$ )
prior statin ( n = $nmbr$  $nmbr$ )
fev $nmbr$ ( liters )
fev $nmbr$ — liters
systolic
diastolic
czp + mtx ^ mtx
pbo + mtx ^ mtx
history of paroxysmal af
no history of paroxysmal af
stage $nmbr$ : > = $nmbr$
stage $nmbr$ : < $nmbr$
ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg ( n = $nmbr$ )
ato $nmbr$ mg and sim $nmbr$ - $nmbr$ mg ( n = $nmbr$ )
- - week $nmbr$ - -
- < — ■ bb — - ►
- hdl cholesterol
- ldl cholesterol
- median fasting serum glucose ( mg / dl ) ( iqr )
- median pulse pressure ( mm hg ) ( iqr )
- median tg ( iqr )
- median urine acr ( mg / g ) ( iqr )
- recurrent vte during overall study period
- triglycerides
- [ the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -
- ° - $nmbr$  wom -
- $nmbr$ - $nmbr$ ( - $nmbr$ - $nmbr$ too $nmbr$ )
- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to - $nmbr$ - $nmbr$ )
- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ )
- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) a - $nmbr$ . $nmbr$ %  * p = $nmbr$ . $nmbr$
- $nmbr$ placebo
- $nmbr$ < flex fn f - score
- $nmbr$ . $nmbr$ < ls t - score
- $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$  - c ) . $nmbr$ r
- $nmbr$ . $nmbr$ < flex fn f - score < - $nmbr$
- $nmbr$ . $nmbr$ < ls t - score < — $nmbr$ . $nmbr$
- $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) * ll
- $nmbr$ . $nmbr$ ± lno ^
- $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ § ti
- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) * p = $nmbr$ . $nmbr$
- $nmbr$ . $nmbr$ to - $nmbr$ cm
- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )
- b - i -
- b - i —
- bi -
- f $nmbr$ . $nmbr$ ( - i - $nmbr$ . $nmbr$ )
- major bleed
- o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )
- o . os
- o $nmbr$ o ( - $nmbr$ - loto - $nmbr$ - $nmbr$ )
- oil
— no . ( % )
— $nmbr$ . $nmbr$ < fn t - score
— $nmbr$ . $nmbr$ < fn t - score < — $nmbr$ . $nmbr$
— b - h —
! amlodipine
# pts
# $nmbr$ kg
$ race was determined by the investigator during the patient ' s interview .
% - point difference ( $nmbr$ % ci ) c
% \mean ± sd
% asthma control days {  #
% bronchial reversibility ( sd )
% change ( mean ± se )
% change ( meanlse )
% change ( meantse )
% change ( median  q $nmbr$  q $nmbr$ )
% change from baseline to week $nmbr$
% fhg
% hba $nmbr$ c ( mmol / mol )
% improvement in dactylitis score at week $nmbr$  n
% improvement in enthesitis score at week $nmbr$  n
% of patients $nmbr$ . $nmbr$ $nmbr$ . $nmbr$
% of predicted
% patients
% phg
% predicted fev
% predicted fev ^
% predicted fev $nmbr$
% predicted post - bronchodilator fev  ( sd ) ml
% predicted post - bronchodilator fev $nmbr$  mean ( sd )  l
% predicted pre - bd
% predicted prebronchodilator fev $nmbr$  mean ( sd )  l
% predicted value ( sd )
% reduction
% reversibility
% reversibility in fev ^ at
% risk reduction ( $nmbr$ % cl )
% stenosis ( core lab )
% stenosis ( investigator )
% to goal
% / year
% / yr
& median
( $ $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
( % of group )
( % of target ) ∗
( % )  $nmbr$ mean ( sd )
(  $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
( : > blockers
( _ > $nmbr$ . $nmbr$ mmol / l ) hdl - c women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ) men : < $nmbr$ mg / dl
( < $nmbr$ . $nmbr$ mmol / l )
( < $nmbr$ mg / l )
( < $nmbr$ ml / minute ) *
( ≥ $nmbr$ mg / l )
( $nmbr$ patients )
( $nmbr$ subjects )
( $nmbr$ - blocker
( $nmbr$ - sitosterol ( p . mol / l )
( $nmbr$ - $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
( $nmbr$ . $nmbr$ % )  values were not collected for $nmbr$ patients ( $nmbr$ . $nmbr$ % ) who were enrolled
( $nmbr$ % ci ) a
( $nmbr$ % ci ) b
( $nmbr$ % ci ) c
( a ) aza treatment ( ref )
( a ) bmi subgroups
( b ) age subgroups
( b ) aza treatment ( ref )
( c ) ' ' kza treatment ( ref )
( cells per pl ) t
( cm )
( composite endpoint )
( d ) aza treatment ( ref )
( e ) aza treatment ( ref )
( fxs )
( id
( incl . uncertain )
( including hypertension )
( interquartile range ) ( mm )
( iqr )
( iqr ) — days
( l ) t
( mean + . sd )
( mean ± sd )
( median  h )
( mg / dl ± sd )
( mg / dl )
( min ) *
( minimum - maximum ) focal seizure fre - quency / $nmbr$ days at baseline
( mmol / l )
( mu / l $ mmol / l ) b
( n = $nmbr$ ) ( n = $nmbr$ )
( n = $nmbr$ )  ' ( n = $nmbr$ )
( n = $nmbr$ l $nmbr$ )
( n = l $nmbr$ )
( ne  ne )
( ngml ' ' ) total mean ipss score
( nyha grade iii or iv )
( ofl )
( phase $nmbr$ dose - finding trial )
( points )
( range )
( ref )
( scale diabetes )
( scale obesity and prediabetes )
( sd )
( sd ) l / min acq - $nmbr$ score  mean ( sd )
( se )
( subgroup )
( tiotropium n = $nmbr$  placebo n
( tiotropium n = $nmbr$  placebo n =
( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ )
( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ $nmbr$
( total ses - cd score at
( week )
( women only )
( years )
( yes / no )
* data are expr
* eligibility risk factors  n ( % ) *
* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter ( $nmbr$ . $nmbr$ mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute . ‡ to convert weight to kilograms  divide by $nmbr$ . $nmbr$ . § to convert values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ¶ data for follow - up medication were available for $nmbr$ patients ( amiodarone  $nmbr$  placebo  $nmbr$  and icd  $nmbr$ ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < $nmbr$ . $nmbr$ for the comparison among the groups
* non - black *
* nonfatal ml
* patient characterization data are reproduced from morrow et al . ( $nmbr$ ) .
* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by
* plus - minus values are means ± sd . there were no significant differences ( at
* plus – minus values are means ± sd . percentages may not total $nmbr$ because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ace denotes angiotensin - converting enzyme  cabg coronary - artery bypass grafting  nt - probnp n - terminal pro - b – type natriuretic peptide  nyha new york heart association  and pci percutaneous coro - nary intervention . † race was reported by the investigators . ‡ one patient in nyha class i was mistakenly included in the placebo group . § this category includes any angina - like symptoms at any time in the past  with no confirmation of diagnosis of coro - nary heart disease required . ¶ possible scores range from $nmbr$ to $nmbr$  with lower scores indicating a better quality of life . ∥ anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women . * * nt - probnp levels are influenced by a variety of factors  including age  sex  body - mass index  and renal function . no clinically useful normal range has been established . † † some patients were taking both loop and thiazide diuretics .
* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .
* atherosclerotic coronary heart disease  ischaemic stroke or peripheral arterial disease . † n / n = number of people in phase $nmbr$ studies only . ‡ high ‐ intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg  rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily .
* ci denotes confidence interval .
* data are expressed as median ± sd  except
* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert triglycerides to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpg to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpi to picomoles per liter  multiply by $nmbr$ . $nmbr$ .
* data reported as n ( % ) or median ( quartiles $nmbr$  $nmbr$ ) .
* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^ consecutive defined as two or more measurements at least one week apart or one measurement < $nmbr$ days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal
* interquartile range
* other - europe ( n = $nmbr$ )  australia ( n = $nmbr$ ) and india ( n = $nmbr$ ) - the data from these regions were collapsed due to the small numbers
* p < $nmbr$ . $nmbr$ for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein
* p < $nmbr$ . $nmbr$ for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease
* p for heterogeneity of treatment effect between tertiles > $nmbr$ . $nmbr$ .
* per $nmbr$ participant years . composite of first occurrence death ( all cause )  nonfatal ml  or nonfatal stroke . cardiovascular death excluding those classified as “ unable to determine . ”
* rate is number of events per $nmbr$ patient - years of follow - up . fthe p value for number of patients from log - rank  for total number of hospitalizations from permutation test . ^ by treatment comparing the
* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .
* risk reduction  $nmbr$ percent confidence interval ( ci )  and p value are derived from cox models . for risk reductions  negative numbers indicate an increase in risk . † diabetes and hypertension were defined by clinical history . ‡ a family history was defined as having one or more first - degree relatives with either myocardial infarction or sudden death before the age of $nmbr$ . § hdl cholesterol levels are shown according to the median value ( $nmbr$ . $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¶ triglyceride levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¿ ldl cholesterol levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) and according to the values that divide the subjects into three equal groups ( < $nmbr$  $nmbr$ to $nmbr$  and > $nmbr$ mg per deciliter [ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$  and > $nmbr$ . $nmbr$ mmol per liter ] ) .
* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$  to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » $nmbr$ . $nmbr$ ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .
* the $nmbr$ substrata with baseline ( bl ) ldl cholesterol $nmbr$ to $nmbr$ mg / dl and $nmbr$ to $nmbr$ mg / dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg / dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg / dl . † bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg / dl for men and $nmbr$ or $nmbr$ mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe $nmbr$ mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides
$nmbr$ - blocker
$nmbr$ step
. $nmbr$ kg
. $nmbr$ kg mtx use
. $nmbr$ step or incident vitrectomy or photocoagulation
/ \ge category
/ ’ interaction
/ $nmbr$ - blocker
/ pl $nmbr$ $nmbr$
: mi  previous pci and chronic obstructive pulmonary disease .
? f ? n
[ } ifrerence vs . placebo  % ( $nmbr$ % cl )
[ $nmbr$ . $nmbr$ mmol / l ] )
[ $nmbr$ % ci ] *
[ cm ( female ) / cm ( male ) ]
[ cm { female ) / cm { male ) ]
[ kg / m ^ ]
[ min  max ]
[ no / yes ] ( % )
[ sd ]
[ zi = $nmbr$ ] $nmbr$ ( $nmbr$ . $nmbr$ )
\bl - sc n / n
^ ≥ $nmbr$ % incidence in any treatment group in the overall safety population .
^ $nmbr$ days
^ $nmbr$ months
^ $nmbr$ mm hg
^ $nmbr$ mg / g  n ( % )
^ $nmbr$ hrs
^ $nmbr$ ml / min
^ numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^ hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . § hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . | | diabetes was defined by self - report .
| : s blocker
| ? > - blocker ( n  % )
“ off ”
“ on ” with troublesome dyskinesia
“ on ” without troublesome dyskinesia
“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age  reciprocal of serum creatinine  sbp  up excretion  treatment assignment and terms for studies $nmbr$  $nmbr$ $nmbr$ and $nmbr$ ( see footnotes of table $nmbr$ ) . other baseline variables considered for analysis ( p < $nmbr$ . $nmbr$ in univariate analysis ) included dp mean arterial pressure  type of antihypertensive regimen in the control group  planned duration of follow - up  whether or not the investigators were blinded  whether or not dietary advice was given and the year of publication .
£ $nmbr$ min
£ $nmbr$ . $nmbr$ yrs
£ $nmbr$ . $nmbr$ min
£ $nmbr$ . $nmbr$ mmol / l
£ $nmbr$ mg / dl
£ $nmbr$ % bsa psoriasis  no . ( % )
£ $nmbr$ yr
£ $nmbr$ m b ' m in
£ $nmbr$ ml / minute
£ l $nmbr$ kg
+ ics / + laba n z $nmbr$
< - $nmbr$ . $nmbr$ - vfx
< - $nmbr$ . $nmbr$ + vfx
< - $nmbr$ . $nmbr$ cm
< $nmbr$ . $nmbr$ tng > cll
< $nmbr$ cells / ul $nmbr$ $nmbr$
< $nmbr$ mg / dl eze / simva ( n = $nmbr$ )
< $nmbr$ mg / dl simva ( n = $nmbr$ )
< $nmbr$ st quartile
< $nmbr$ mgday p . eq .
< $nmbr$ month n = $nmbr$
< $nmbr$ l / min
< $nmbr$ . $nmbr$ yrs
< $nmbr$ years ( % )
< $nmbr$ years eze / simva ( n = $nmbr$ )
< $nmbr$ years simva ( n = $nmbr$ )
< $nmbr$ . $nmbr$ min
< median $nmbr$ . $nmbr$
< = $nmbr$ yr
< = € $nmbr$ kg
< = $nmbr$ year  n ( % )
< = $nmbr$ kg
< $nmbr$ . $nmbr$ ld
< $nmbr$ mg / l ( n = $nmbr$ )
< $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ )
< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ) n ( % )
< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ )
< $nmbr$ mg / dl *
< $nmbr$ . $nmbr$ mm hg
< $nmbr$ mm hg — no . ( % )
< $nmbr$ / $nmbr$ mm hg +
< $nmbr$ / $nmbr$ mmhg  ldl - c < $nmbr$ mg / dl
< $nmbr$ / $nmbr$ mm hg
< $nmbr$ ml / s
< $nmbr$ cells / mm ^
< $nmbr$ and no moderate or severe deformity ( n = $nmbr$ )
< $nmbr$ mg / liter
< $nmbr$ mg / d peq
< $nmbr$ mg / day
< $nmbr$  kg / m $nmbr$
< $nmbr$ — no . { % )
< $nmbr$ kg / m $nmbr$ ( n = $nmbr$ )
< $nmbr$ ppb
< $nmbr$ xuln
< $nmbr$ — no . ( % )
< $nmbr$ no . ( % )
< $nmbr$ crcl
< $nmbr$ kg  mj ( reference )
< $nmbr$ kg / m ^
< $nmbr$ kg / ma $nmbr$
< $nmbr$ ky / nr
< $nmbr$ mg dl ( reference )
< $nmbr$ mg / g  n ( % )
< $nmbr$ ml / min / $nmbr$ . $nmbr$ ni -
< $nmbr$ ml / minute
< $nmbr$ % predicted
< $nmbr$ mlmin ) $nmbr$
< $nmbr$ meters
< $nmbr$ mo  n ( % )
< $nmbr$ . $nmbr$ mu / l - mmol / l
< $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l )
< $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$
< $nmbr$ crcl  n ( % )
< $nmbr$ ml / min — %
< $nmbr$ ml / min ( n = $nmbr$ )
< $nmbr$ mg / l
< $nmbr$ weeks
< $nmbr$ kg ' i '
< $nmbr$ mi / min
< $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m  $nmbr$
< $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )
< $nmbr$ ml / min / $nmbr$  $nmbr$ m ^
< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . { % )
< $nmbr$ mlymin
< $nmbr$ yr — no . { % )
< $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % )
< $nmbr$ y ears
< $nmbr$ yr ( n = $nmbr$ )
< $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ )
< $nmbr$ yea ' s
< $nmbr$ kg  n ( % )
< $nmbr$ . $nmbr$ kg
< $nmbr$ . $nmbr$ % ( < $nmbr$ mmol / mol )
< $nmbr$ ml / minute )
< $nmbr$ cm
< mean
< median ( $nmbr$ year - old )
< median ( $nmbr$ days )
< median { $nmbr$ days )
< median prednisone dose  n ( % )
★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .
卞 at discharge .
赛 $nmbr$ years
= calcium channel blocker  bmi = body
= cerebrospinal fluid .
= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having
= international prostate symptom score
= placebo  eze : tes ( fc j > $nmbr$ rr $nmbr$ definition ) .
= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are
≤   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % )
≥   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % )
≥ $nmbr$ ae
≥ $nmbr$ sae
≥ $nmbr$ teae
≤ $nmbr$   year
≥ $nmbr$  kg / m $nmbr$
≤ $nmbr$ years
≤ $nmbr$ mg / l
≥ $nmbr$ . $nmbr$ % and < $nmbr$ . $nmbr$ %
≥ $nmbr$ yearsa
≥ $nmbr$ a ( n = $nmbr$ )
≥ $nmbr$ ml / min
≥ $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %
= sia
> - $nmbr$ . $nmbr$ - vfx
> - $nmbr$ . $nmbr$ + vfx
> - $nmbr$ . $nmbr$ and < - $nmbr$ . $nmbr$
> - $nmbr$ cm
> $nmbr$ med at baseline cardiac disorder *
> $nmbr$ years vs .   ≤   $nmbr$ years
> $nmbr$ mg / dl eze / simva ( „ = $nmbr$ )
> $nmbr$ mg / dl simva ( „ = $nmbr$ )
> $nmbr$ st and < $nmbr$ nd quartile
> $nmbr$ to   ≤   $nmbr$ years vs .   ≤   $nmbr$ years
> $nmbr$ nd and < $nmbr$ rd quartile
> $nmbr$ . $nmbr$   vs . $nmbr$ . $nmbr$ to   ≤   $nmbr$ . $nmbr$
> $nmbr$ kg / m $nmbr$ smokers
> $nmbr$ cells / ul
> $nmbr$ rd quartile
> $nmbr$ and   ≤   $nmbr$   vs .   ≤   $nmbr$
> $nmbr$ to   ≤   $nmbr$   vs .   ≤   $nmbr$
> $nmbr$ and < $nmbr$ years
> $nmbr$ to s $nmbr$ yrs
> $nmbr$ month n = $nmbr$
> $nmbr$ and   ≤   $nmbr$   vs   ≤   $nmbr$
> $nmbr$ years ( % )
> $nmbr$ years eze / simva ( n = $nmbr$ )
> $nmbr$ years old
> $nmbr$ years simva ( n = $nmbr$ )
> $nmbr$ years bmi
> $nmbr$ ml min ) $nmbr$
> $nmbr$   vs .   ≤   $nmbr$
> is years
> median $nmbr$ . $nmbr$
>   $nmbr$ – <   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ % )    n   ( % )
> = $nmbr$ kg / m $nmbr$
> = $nmbr$ l / min
> = $nmbr$ l_ / min
> = $nmbr$ ml / mln
> = $nmbr$ . $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % )
> = $nmbr$ day s initial heparin treatment duration
> = $nmbr$ days
> = $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % )
> = $nmbr$ mmhq
> = $nmbr$ ng / l ( n = $nmbr$ ) n ( % )
> = $nmbr$ ng / l ( n = $nmbr$ )
> = $nmbr$ kg / ma $nmbr$
> = $nmbr$ mg / g
> = $nmbr$ meters
> = $nmbr$ years and < $nmbr$ years
> = $nmbr$ ^ initial heparin treatment duration
> = $nmbr$ . $nmbr$ % ( > = $nmbr$ mmol / mol )
> = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
> = medan ( $nmbr$ year - old )
> = median ( $nmbr$ days )
> = medion ( $nmbr$ days )
> $nmbr$ aes
> $nmbr$ aes leading to discontinuation
> $nmbr$ antihypertensive medication  no . ( % )
> $nmbr$ drug - related
> $nmbr$ drug - related aes *
> $nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ )
> $nmbr$ glucose - lowering medication . no . ( % )
> $nmbr$ oral antidiabetic medication
> $nmbr$ serious aes
> $nmbr$ to < = $nmbr$ years  n ( % )
> $nmbr$ to $nmbr$   years
> $nmbr$ year
> $nmbr$ yr  n ( % )
> $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ )
> $nmbr$ / $nmbr$ lung fields
> $nmbr$ da of capillary nonperfusion in the eyec
> $nmbr$ years to < $nmbr$ years
> $nmbr$   years
> $nmbr$ ng / l
> $nmbr$ b ( $nmbr$ b to $nmbr$ a )
> $nmbr$ cm
> $nmbr$ months  n ( % )
> $nmbr$ . $nmbr$ mm
> $nmbr$ ^ mol / liter — no . ( % )
〉 $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )
> $nmbr$ mm hg — no . ( % )
> $nmbr$ ml / s
> $nmbr$ at screening
> $nmbr$ per pl at screening
> $nmbr$ to < $nmbr$ cells / mm ^
> $nmbr$ to < $nmbr$ cells / mm ’
> $nmbr$ and < $nmbr$
> $nmbr$ and / or > $nmbr$ moderate or severe deformity  or both ( n = $nmbr$ )
> $nmbr$ antihypertensive medications
> $nmbr$ chd risk factors
> $nmbr$ cv risk factors ^ or established atherosclerotic cv disease
> $nmbr$ mg / liter
> $nmbr$ oads
> $nmbr$ symptom days per week
〉 $nmbr$ years
> $nmbr$ ( $nmbr$ ) drinks / day if male ( female )
> $nmbr$ ( n = $nmbr$ l $nmbr$ )
> $nmbr$ mg / d peq
> $nmbr$ mg / day
> $nmbr$ - ^ $nmbr$ kg / m ’
> $nmbr$ - s $nmbr$ kg / m ’
> $nmbr$ - < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ )
> $nmbr$ - < s $nmbr$ kg / m ’
> $nmbr$ to < $nmbr$ ppb
> $nmbr$ . $nmbr$ pmol / liter
> $nmbr$ to < $nmbr$ uln
> $nmbr$ diseased vessels
> $nmbr$ drinks / dav
> $nmbr$ mg / l ( n = $nmbr$ )
> $nmbr$ . $nmbr$   vs .   >   $nmbr$ . $nmbr$ and   ≤   $nmbr$ . $nmbr$
> $nmbr$ — no . { % )
> $nmbr$ ( moderate or high bleeding risk )  no . / total ( % )
> $nmbr$ days to $nmbr$ year ( n = $nmbr$ )
> $nmbr$ kg nr
> $nmbr$ kg / m ^
> $nmbr$ kg / m ^ ( obesity )
> $nmbr$ kg / m ’
> $nmbr$ kg / m $nmbr$ ( n = $nmbr$ )
> $nmbr$ ky / nr
> $nmbr$ to < $nmbr$ ml / min / l $nmbr$ nr
> $nmbr$ to < $nmbr$ mg dl
> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
> $nmbr$ to < $nmbr$ iu / l
> $nmbr$ % predicted to < $nmbr$ % predicted
> $nmbr$ cells / mm ^
> $nmbr$ in previous
> $nmbr$ per pl in $nmbr$ months before screening
> $nmbr$ kg / nr
> $nmbr$ y pathogenesis  n ( % )
> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l - mmol / l
> $nmbr$ - $nmbr$ yr
> $nmbr$ ppb
> $nmbr$ % predicted
> $nmbr$ % responder rate  n ( % )
> $nmbr$ % stenosis of major artery  n ( % )
> $nmbr$ uln
> $nmbr$ yearstos is years
> $nmbr$ mg / l
> $nmbr$ weeks
> $nmbr$ crcl
> $nmbr$ kg body weight at randomization
> $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ) + +
> $nmbr$ mi / min
> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % )
> $nmbr$ ml / niin / l $nmbr$ ni -
> $nmbr$ mlymin
> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
> $nmbr$ to < $nmbr$ iiil / iiim / $nmbr$ . $nmbr$ m $nmbr$
> $nmbr$ years of age  n ( % )
> $nmbr$ yr ( n = $nmbr$ )
> $nmbr$ yr from the united states
> $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ )
> $nmbr$ to < $nmbr$ mg / dl
> $nmbr$ . $nmbr$ mg / day  %
> $nmbr$ yr — no . { % )
> $nmbr$ iu / l
> $nmbr$ ( n  % ) weight  kg
> $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % )
> $nmbr$ years or < $nmbr$ crcl  n ( % )
> $nmbr$ yr — %
> $nmbr$ . $nmbr$ bpm
> $nmbr$ bpm ( n = $nmbr$ )
> $nmbr$ %  n ( % of patients )
> $nmbr$ . $nmbr$ mu / l - mmol / l
> $nmbr$ ( n  % ) chads $nmbr$ score
> $nmbr$ kg — no . ( % )
> $nmbr$ ml / min ( n = $nmbr$ )
> $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg
> $nmbr$ mg / dl baseline high - sensitivity crp
> $nmbr$ bpm ( n = $nmbr$ l $nmbr$ )
> $nmbr$ mg dl
> $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$
> $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^
> $nmbr$ ml / min / $nmbr$ . $nmbr$
> $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
> $nmbr$ . $nmbr$ kg
> $nmbr$ - $nmbr$ cm
> ii
> lto £ $nmbr$ symptom days per week
> lto < $nmbr$ ( n = $nmbr$ )
> mean
> ulnand < $nmbr$ ng / l
> year $nmbr$
± sd .
± standard deviation . triglyceride
« $nmbr$ kg
» $nmbr$ years
§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv
† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least $nmbr$ . $nmbr$ % of the patients in the any secukinumab group during the $nmbr$ ‐ week placebo ‐ controlled period and events with an eair of at least $nmbr$ . $nmbr$ cases per $nmbr$ patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version $nmbr$ . $nmbr$ )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .
• $nmbr$ : death from any cause  major coronary event  or nonfatal stroke
• any mi
• any stroke
• death from any cause
• death from coronary heart disease
• death from cv causes  major coronary event  or nonfatal stroke
• hemorrhagic stroke
• hospitalization for unstable angina
• ii : death from coronary heart disease  nonfatal mi  coronary revascularization > $nmbr$ days
• iii : death from cv causes  nonfatal mi  hospitalization for ua  all revascularization > $nmbr$ days  nonfatal stroke
• ischemic stroke
• ml with st - segment elevation
• ml without st - segment elevation
• unstable angina
• urgent coronaiy revascularization > $nmbr$ days
• j . the body - mass index is the weight in kilograms divided by the square of the
$nmbr$ - $nmbr$ hours
$nmbr$ - $nmbr$ ( o $nmbr$ - o - $nmbr$ )
$nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )
$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ )
$nmbr$ - $nmbr$ mm
$nmbr$ - $nmbr$ ( o - $nmbr$ o - o - $nmbr$ )
$nmbr$ - $nmbr$ ( o - $nmbr$ - i - $nmbr$ )
$nmbr$ - $nmbr$ ( o - $nmbr$ - i - o $nmbr$ )
$nmbr$ - $nmbr$ fo - $nmbr$ $nmbr$ - $nmbr$ ^
$nmbr$ - $nmbr$ ( o - $nmbr$ s - o - $nmbr$ )
$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ o )
$nmbr$ - $nmbr$ ( o - $nmbr$ i - o - $nmbr$ )
$nmbr$ - $nmbr$ ( o - $nmbr$ - $nmbr$ - oo )
$nmbr$ - $nmbr$ fo - $nmbr$ - o - q ^ i
$nmbr$ - $nmbr$ { o - $nmbr$ - $nmbr$ - o $nmbr$ )
$nmbr$ - $nmbr$ ( o $nmbr$ o - i - i $nmbr$ )
$nmbr$ - $nmbr$ ( s $nmbr$ - $nmbr$ ) t
$nmbr$ - $nmbr$ ( o - $nmbr$ s - i - $nmbr$ )
$nmbr$ — $nmbr$ days
$nmbr$ ( or $nmbr$  if female only )
$nmbr$ $nmbr$ fo $nmbr$ - $nmbr$ $nmbr$ )
$nmbr$ $nmbr$ ( o - $nmbr$ - i - o $nmbr$ )
$nmbr$ or $nmbr$ — no . / total no . ( % )
$nmbr$ or $nmbr$  n ( % )
$nmbr$ or $nmbr$  no . / total no . ( % )
$nmbr$ to $nmbr$ symptom days per week
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . i $nmbr$ i )
$nmbr$ . $nmbr$ mg
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$
$nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$
$nmbr$ . $nmbr$ $nmbr$ % ci : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ p = $nmbr$ . $nmbr$
$nmbr$ . $nmbr$ mg ( n = $nmbr$ )
$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - l . l )
$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$
$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ } pty = $nmbr$
$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ )
$nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$
$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . os )
$nmbr$ . $nmbr$ to . $nmbr$ . i . iot
$nmbr$ . i $nmbr$ ( $nmbr$ . $nmbr$ i - $nmbr$ . $nmbr$ )
$nmbr$ ( o - o $nmbr$ - o - $nmbr$ )
$nmbr$ ( oo $nmbr$ - o . $nmbr$ )
$nmbr$ ( o - $nmbr$ - o - $nmbr$ )
$nmbr$ ix
$nmbr$ tob $nmbr$ months
$nmbr$ tob $nmbr$ months  n ( % )
$nmbr$ tol ( n = $nmbr$ )
$nmbr$ - $nmbr$ drinks / dav
$nmbr$ - $nmbr$ / week ( n = $nmbr$ )
$nmbr$ - $nmbr$ / day
$nmbr$ — — bh — i
$nmbr$ — e - h
$nmbr$ — em
$nmbr$ ( $ $nmbr$ ml / min )
$nmbr$ ( $nmbr$ si
$nmbr$ ( except for female alone )
$nmbr$ ( ref )
$nmbr$ abciximab ( n = $nmbr$ )
$nmbr$ amlodipine - chlorthalidone
$nmbr$ antihypertensive medication
$nmbr$ baricitinib $nmbr$ mg ■ baricitinib $nmbr$ mg
$nmbr$ chlorthalidone
$nmbr$ chlorthalidone ( n = $nmbr$ )
$nmbr$ chlorthalidone amlodipine
$nmbr$ cl )
$nmbr$ day l
$nmbr$ event  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )
$nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ )
$nmbr$ is ( $nmbr$ . $nmbr$ )
$nmbr$ lisinopril
$nmbr$ lisinopril - chlorthalidone
$nmbr$ low ( n = $nmbr$ )
$nmbr$ med at baseline
$nmbr$ mg ( $nmbr$  $nmbr$ . $nmbr$ % )
$nmbr$ mg a
$nmbr$ month l
$nmbr$ n qi
$nmbr$ n / n
$nmbr$ oad
$nmbr$ oam
$nmbr$ oral antidiabetic medication
$nmbr$ parameter
$nmbr$ prior tnf antagonist failure  n ( % ) b
$nmbr$ standard ( n = $nmbr$ )
$nmbr$ t i
$nmbr$ to $nmbr$ years
$nmbr$ to $nmbr$ mg / l ( n = $nmbr$ )
$nmbr$ year mean change from baseline
$nmbr$ . $nmbr$ ( reference )
$nmbr$ . $nmbr$ ( referent )
$nmbr$ . $nmbr$ ( ref . )
$nmbr$ . $nmbr$ f $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ h
$nmbr$ . $nmbr$ ( fi . $nmbr$ )
$nmbr$ . $nmbr$ % vs . $nmbr$ . $nmbr$ %
$nmbr$ . $nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ )
$nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ )
$nmbr$ - year risk for chd
$nmbr$ - year risk of chd  % #
$nmbr$ - year risk of chd  % # < $nmbr$ . $nmbr$
$nmbr$ - yr rate / $nmbr$ participants
$nmbr$ μ g ( n = $nmbr$ )
$nmbr$ mg empagliflozin
$nmbr$ mg / d ( n = $nmbr$ )
$nmbr$ mg / kg
$nmbr$ ml / min
$nmbr$ years or more
$nmbr$ % ( - ito $nmbr$ )
$nmbr$ % ( oto $nmbr$ )
$nmbr$ % participants
$nmbr$ . $nmbr$ per $nmbr$ py
$nmbr$ - $nmbr$ mg / dl *
$nmbr$ mg + mtx
$nmbr$ mg / $nmbr$ mgb
$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ )
$nmbr$ / $nmbr$ mga ( n = $nmbr$ )
$nmbr$ ( mono )
$nmbr$ % ( ito $nmbr$ )
$nmbr$ mg dabigatran
$nmbr$ mg dabigatran ( n = $nmbr$ )
$nmbr$ ( $nmbr$ % cl $nmbr$ to $nmbr$ )
$nmbr$ < sbp < $nmbr$ mmhg n = $nmbr$
$nmbr$ b ( $nmbr$ b to > $nmbr$ a )
$nmbr$ carotid artery sites
$nmbr$ mo  mean ( sd ) x
$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n - $nmbr$ / $nmbr$ )
$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ) §
$nmbr$ to $nmbr$ mm hg
$nmbr$ to < $nmbr$ mm hg — no . { % )
$nmbr$ events
$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmhg
$nmbr$ o - i $nmbr$ mm hg
$nmbr$ . $nmbr$ per $nmbr$ pyr
$nmbr$ [ $nmbr$ - $nmbr$ js
$nmbr$ f $nmbr$ q % )
$nmbr$ . $nmbr$ ( $nmbr$ % ci : $nmbr$ . $nmbr$  $nmbr$ . $nmbr$  n = $nmbr$ )
$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mm hg
$nmbr$ - year predicted risk ( % ) of
$nmbr$ min / time )
$nmbr$ to < $nmbr$ cel
$nmbr$   mg
$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ )
$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per pyr $nmbr$ pyr
$nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per $nmbr$ pyr pyr
$nmbr$ ( $nmbr$ . $nmbr$ ) ( continued )
$nmbr$ ( only $nmbr$ distal )
$nmbr$ o / $nmbr$ o $nmbr$ ( $nmbr$ - $nmbr$ % )
$nmbr$ f $nmbr$ l % $nmbr$
$nmbr$ ( $nmbr$ s . s )
$nmbr$ < $nmbr$ s ) n $nmbr$ ( $nmbr$ . $nmbr$ )
$nmbr$ - < $nmbr$ years
$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ pyr
$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) ]
$nmbr$ b ( $nmbr$ b to $nmbr$ a )
$nmbr$ st tertile ( < = $nmbr$ mg / dl [ < = $nmbr$ . $nmbr$ mmol / l ] ) b
$nmbr$ st : $nmbr$ - $nmbr$ . $nmbr$ pmol / l
$nmbr$ - gi
$nmbr$ - h pmg ( mmol / l )
$nmbr$ - h pmg  mmol / l ( mean ± sd )
$nmbr$ - h postprandial c - peptide ( ng / ml )
$nmbr$ - h postprandial insulin ( miu / ml )
$nmbr$ - h postprandial proinsulin ( pmol / l )
$nmbr$ - hour postload glucose
$nmbr$ - hour ppg  mmol / l
$nmbr$ - y kaplan - meier rate ( $nmbr$ % ci )
$nmbr$ — no . / total no . ( % )
$nmbr$ ( $nmbr$ to < $nmbr$ ml / min )
$nmbr$ $nmbr$ to < $nmbr$ kg / m $nmbr$
$nmbr$ hr after glucose challenge
$nmbr$ oads
$nmbr$ or $nmbr$ d / mo
$nmbr$ or $nmbr$ d / wk
$nmbr$ or $nmbr$ step
$nmbr$ prior tnf antagonist failures  n ( % ) b
$nmbr$ yr . km rate
$nmbr$  no . / total no . ( % )
$nmbr$ . $nmbr$ ( ne  ne )
$nmbr$ . $nmbr$ range $nmbr$ - $nmbr$
$nmbr$ . $nmbr$  range $nmbr$ - $nmbr$
$nmbr$ . $nmbr$ % vi . $nmbr$ . $nmbr$ %
$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ]
$nmbr$ i - $nmbr$ - $nmbr$ ai
$nmbr$ mg  rosuvastatin $nmbr$ mg .
$nmbr$ . $nmbr$ ( ll . $nmbr$ )
$nmbr$ / $nmbr$ mg ( n = $nmbr$ )
$nmbr$ mgrdl
$nmbr$ - $nmbr$ mmol / l
$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ . $nmbr$ per $nmbr$ pyr $nmbr$ pyr
$nmbr$ mm hg
$nmbr$ kg / m $nmbr$
$nmbr$ . $nmbr$ % vi  $nmbr$ . $nmbr$ %
$nmbr$ mg / g  n ( % )
$nmbr$ - < $nmbr$ kg / m $nmbr$
$nmbr$ ( oh ) vitamin d ( ng / ml )
$nmbr$ μ g bid ( n = $nmbr$ )
$nmbr$ to < $nmbr$ — no . { % )
$nmbr$ < bmi < $nmbr$
$nmbr$ ( io - $nmbr$ % )
$nmbr$ th — $nmbr$ th percentiles
$nmbr$ c . t
$nmbr$ a . g
$nmbr$ hr prandial glucose ' * ’
$nmbr$ i $nmbr$ ( $nmbr$ i . $nmbr$ )
$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ l )
$nmbr$ nd tertile ( > $nmbr$ to < = $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ to < = $nmbr$ . $nmbr$ mmol / l ] ) c
$nmbr$ nd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l
$nmbr$ s . $nmbr$ ± s . $nmbr$
$nmbr$ - < $nmbr$ mo  n ( % )
$nmbr$ - $nmbr$ — no . / total no . ( % )
$nmbr$ - $nmbr$  no . / totalno . ( % )
$nmbr$ - polnt mace
$nmbr$ - yr km mortality rate
$nmbr$ - yr %
$nmbr$ – $nmbr$ months
$nmbr$ ( moderate disease )
$nmbr$ blocker before admission
$nmbr$ coenzyme q $nmbr$ subgroups for time to first hospitalization ( number of patients variable ) .
$nmbr$ mo - $nmbr$ y
$nmbr$ . $nmbr$ ( lo - $nmbr$ . $nmbr$ )
$nmbr$ − $nmbr$ mg / g
$nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
$nmbr$ - $nmbr$ ml min ) $nmbr$
$nmbr$ - $nmbr$ ml / rain
$nmbr$ - $nmbr$ crcl
$nmbr$ – ≤ $nmbr$ ml / min
$nmbr$ days composite of death / new mi / urgent revascularization and definite st
$nmbr$ days definite st
$nmbr$ days new mi
$nmbr$ days new mi or definite acute st
$nmbr$ days stroke ( ischemic )
$nmbr$ days until end of study ( landmark analysis )
$nmbr$ days urgent revascularization
$nmbr$ kg / m $nmbr$ or more
$nmbr$ mg qd ( n = $nmbr$ )
$nmbr$ to < $nmbr$ mumin
$nmbr$ to < $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^
$nmbr$ to < $nmbr$ ml / minute
$nmbr$ to less than $nmbr$
$nmbr$ wk
$nmbr$ mg ld
$nmbr$ mg q $nmbr$ w
$nmbr$ q $nmbr$ w ( n = $nmbr$ )
$nmbr$ events [ $nmbr$ . $nmbr$ ]
$nmbr$ . l ( $nmbr$ . l )
$nmbr$ s f $nmbr$ )
$nmbr$ ms score †
$nmbr$ rd tertile ( > $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) d
$nmbr$ rd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l
$nmbr$ - $nmbr$ ( < $nmbr$ ml / min )
$nmbr$ - $nmbr$ — no . ( % )
$nmbr$ - point mace ( $nmbr$ - point mace plus hospitalization for unstable angina )
$nmbr$ ‐ point reduction in selena – sledai score  %
$nmbr$ - year cumulative incidence  % ( ci )
$nmbr$ ( severe disease )
$nmbr$ tcz + mtx
$nmbr$ tcz + mtx mtx
$nmbr$ week
$nmbr$ yrs l
$nmbr$ . $nmbr$ ± $nmbr$ . lf
$nmbr$ - $nmbr$  cv disease ( n = $nmbr$  $nmbr$ )
$nmbr$ / week ( n = $nmbr$ )
$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ]
$nmbr$ / day
$nmbr$ min twice / week
$nmbr$ . $nmbr$ ± ii . $nmbr$
$nmbr$ - $nmbr$ ( men )
$nmbr$ to < $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$
$nmbr$ . i ± ii . $nmbr$
$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ]
$nmbr$ ( $nmbr$ cl )
$nmbr$ . $nmbr$ ( io . i )
$nmbr$ s = scandinavian simvastatin survival study . $nmbr$ woscops = west of scotland coronary prevention study . $nmbr$ care = cholesterol and recurrent events . $nmbr$ post - cabg = post - coronary artery bypass graft . $nmbr$ afcaps / texcaps = air force / texas coronary atherosclerosis prevention study . $nmbr$ lipid = long - term intervention with pravastatin in ischaemic disease . $nmbr$ gissi prevention = gruppo italiano per lo studio della sopravvivenza nell ’ infarto miocardico . $nmbr$ lips = lescol intervention prevention study . $nmbr$ hps = heart protection study . $nmbr$ prosper = prospective study of pravastatin in the elderly at risk . $nmbr$ allhat - llt = antihypertensive and lipid - lowering treatment to prevent heart attack trial . $nmbr$ ascot - lla = anglo - scandinavian cardiac outcomes trial - lipid lowering arm . $nmbr$ alert = assessment of lescol in renal transplantation . $nmbr$ cards = collaborative atorvastatin diabetes study . $nmbr$ s = simvastatin . l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  $nmbr$ s  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step $nmbr$ diet and care intensi ﬁ ed to step $nmbr$ diet if ldl cholesterol $nmbr$ · $nmbr$ mmol / l ( $nmbr$ mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease
$nmbr$ th : $nmbr$ . $nmbr$ - $nmbr$ pmol / l
$nmbr$ - $nmbr$ / week ( n = $nmbr$ ) $nmbr$ - $nmbr$ / week ( n = $nmbr$ )
$nmbr$ - asa compounds  n ( % )
$nmbr$ . $nmbr$ ( $nmbr$ . o - $nmbr$ . o )
$nmbr$ . $nmbr$ ± l . l
$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mm
$nmbr$ . $nmbr$ or more
$nmbr$ - $nmbr$ ml min  $nmbr$
$nmbr$ - $nmbr$ kg
$nmbr$ – < $nmbr$ ml / min
$nmbr$ - < $nmbr$ kg
$nmbr$ to < $nmbr$ m um in
$nmbr$ to < $nmbr$ ml / min ( n = $nmbr$ $nmbr$ )
$nmbr$ to $nmbr$ y  n ( % )
$nmbr$ % decrease in womac pain score
$nmbr$ . $nmbr$ ± b . b
$nmbr$ mg / $nmbr$ mgc
$nmbr$ kg / m ’
$nmbr$ - $nmbr$ ( women )
$nmbr$ . $nmbr$ ( i $nmbr$ . s )
$nmbr$ %  n ( % of patients )
$nmbr$ . $nmbr$ ( $nmbr$ l . l )
$nmbr$ ( $nmbr$ . $nmbr$ ) / $nmbr$ z ( $nmbr$ ze )
$nmbr$ tq - fi ' i
$nmbr$ fe black *
$nmbr$ ii ( $nmbr$ . $nmbr$ )
$nmbr$ l ( l $nmbr$ )
$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ )
$nmbr$ - mercaptopurine / azathioprine
$nmbr$ - min walk distance m
$nmbr$ - min walk distance  ft
$nmbr$ - up and / or aza at baseline
$nmbr$ - y incidence rate ( se ) per $nmbr$ participants
$nmbr$ - y rate per $nmbr$ persons ( se )  n
$nmbr$ - year km %
$nmbr$ days
$nmbr$ mg / kgf ( n = $nmbr$ )
$nmbr$ mq / kq *
$nmbr$ . $nmbr$ ( g . l )
$nmbr$ - $nmbr$  risk  not disease ( n = $nmbr$  $nmbr$ )
$nmbr$ to < $nmbr$ yr — no . { % )
$nmbr$ to < $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$
$nmbr$ to < $nmbr$ ml / min / $nmbr$ - $nmbr$
$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
$nmbr$ to $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )
$nmbr$ . $nmbr$ ( lo . i )
$nmbr$ ( $nmbr$ i . i )
$nmbr$ to < $nmbr$ yr — no . ( % )
$nmbr$ to $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % )
$nmbr$ to $nmbr$ yr
$nmbr$ years  n ( % )
$nmbr$ yrs or more
$nmbr$ +  no . ( % )
$nmbr$ moto < $nmbr$ yr  n ( % )
$nmbr$ mw distance  m
$nmbr$ mwt ( m )
$nmbr$ events  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )
$nmbr$ . $nmbr$ % or more
$nmbr$ to < $nmbr$ bpm ( n = $nmbr$ )
$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ) ( continued )
$nmbr$ - $nmbr$ y  n ( % )
$nmbr$ ( $nmbr$ j ) z $nmbr$ ( $nmbr$ . e
$nmbr$ . $nmbr$ ± o . lt
$nmbr$ ± ll
$nmbr$ . $nmbr$ ± l . ot
$nmbr$ nil
$nmbr$ . l ( $nmbr$ l . $nmbr$ )
$nmbr$ tcz
$nmbr$ - $nmbr$ . $nmbr$ mm
$nmbr$ . ' ^ / $nmbr$ t $nmbr$ c } u
$nmbr$ - day cce
$nmbr$ - day mortality
$nmbr$ mg / $nmbr$ wk ( n = $nmbr$ )
$nmbr$ or greater
$nmbr$ % ci $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$
$nmbr$ % ci $nmbr$
$nmbr$ % clf
$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ) a
a
a - blockers
α - glucosidase inhibitor
a - glucosidase inhibitors
a - glucosidase inhibitors ' $nmbr$
a $nmbr$ years
a cardiovascular death or hospitalization for heart failure
a compared w
a compared wi
a decrease of > $nmbr$ points in the cdai score
a excludes two randomized patients with unknown diabetes status at baseline .
a median
a new vertebral fractures ( mfas )
a prebronchodilator fevl ( % predicted )
a reslizumab $nmbr$ . $nmbr$ mg / kg n / n
a severe hypoglycemia
a stroke
a vs . c
a ) those receiving no inhaled pre - treatment maintenance medication
a  no vhd ( n = $nmbr$ $nmbr$ )
a . acr $nmbr$
a . beuralizuinab $nmbr$ ing q $nmbr$ w
a . overall and subgroups bv statin potency - -
a . primary composite outcome
a / aml ( n = $nmbr$ )
a / c
a / ga
a : worldwide black and non - black patients
a $nmbr$ vs placebo
a $nmbr$ c [ n ( % ) ]
a $nmbr$ c < median
a $nmbr$ c < $nmbr$ . $nmbr$ %
a $nmbr$ c > = median
a $nmbr$ c  %
a $nmbr$ c  % ( mmol / mol )
a $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %
a $nmbr$ c > $nmbr$ . $nmbr$ %
a $nmbr$ c > s . $nmbr$ - s . $nmbr$ %
a $nmbr$ . $nmbr$ ± $nmbr$ a . $nmbr$
aa
aa / g
abaloparatide - sc  n ( % )
abatacept $nmbr$ / $nmbr$ ( n = $nmbr$ )
abatacept ‡
abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hba $nmbr$ c  hemoglobin a $nmbr$ c  hmg - coa  $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a . asome subjects took more than $nmbr$ oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .
abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( $nmbr$ - $nmbr$ )  intermediate ( $nmbr$ - $nmbr$ )  and high ( $nmbr$ - $nmbr$ ) risk . $nmbr$
abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg  less severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .
abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal $nmbr$ due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^ history of or currently have elevated serum creatinine level but less than $nmbr$ mg / dl_ ( < $nmbr$ pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = $nmbr$ for calcium antagonist strategy and n = $nmbr$ for non - calcium antagonist strategy ) .
abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^ defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . $nmbr$ for major cardiovascular event . no other interactions are significant . ^ calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl_ ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . ^ diabetes defined by self - report . # calculated using the framingham risk score among $nmbr$ $nmbr$ women who provided a blood sample at baseline .
abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .
abbreviations : egfr = estimated glomerular filtration rate  imt = intimal medial thickness  lv = left ventricular . * two - sample comparison t - tests were calculated based on log - transformed variables . * * geometric mean with $nmbr$ % confidence interval in parenthesis .
abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .
abciximab - facilitated pci
abciximab vs . primary
abl - sc mean
abl - sc n / n
about $nmbr$ mg / l or more
about $nmbr$ mg / l
absence
absolute ( l )
absolute decline in fvc > $nmbr$ % predicted
absolute decline in fvc > $nmbr$ % predicted or death  n ( % )
absolute difference estimate vs placebo ( $nmbr$ % ci )
absolute risk difference ( $nmbr$ % cl )
absolute risk reduction ( $nmbr$ % ci )  % / y
absolute risk reduction ( $nmbr$ % cl ) *
absolute risk reductions
absolute time spent “ on ” with troublesome dyskinesia  h / day
absolute time spent “ on ” without troublesome dyskinesia  h / day
absolute time spent “ on ”  h / day
absolutedifferenceestimate vs placebo ( $nmbr$ % ci )
access site
accord acr < $nmbr$ - $nmbr$
accord acr > $nmbr$ - $nmbr$
accord primary  n ( % )
acd
ace - i ( n  % )
ace ‐ i or arb
ace - i or arb  % ( n )
ace - inhibitor or arb ( % )
ace - inhibitors
ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary
ace inhibitor / arb
ace inhibitor and / or arb
ace inhibitor or arb use
ace inhibitor treatment
ace inhibitor use ( % )
ace inhibitor  arb  or both
ace inhibitor / arb therapy
ace inhibitor / arb  %
ace inhibitors or angiotensin - receptor blockers
ace or arb
ace / arb
ace / arb use
ace / arb users
ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .
acei and / or arb
acei  n ( % )
acei / arb therapy  n ( % )
aceis
aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .
aceis  n ( % )
acetaminophen
aclidinium $nmbr$ pg
aclidinium $nmbr$ pg vs placebo
aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) a
aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) b
aclidinium $nmbr$   μ g ( n   =   $nmbr$ )
aclidinium $nmbr$   μ g bid ( n   =   $nmbr$ )
aclidinium / formoterol $nmbr$ / $nmbr$ pg twice daily
acpa positive
acpa positive  no . ( % )
acq - $nmbr$ score
acq - $nmbr$ score ' ! '
acq - $nmbr$ score  mean ( sd ) e
acq - $nmbr$ score 本
acq - $nmbr$ total score ∗
acq score  mean
acq $nmbr$ score  mean ( sd )
acr ( mg / g )  mean ( sd )
acr > $nmbr$ mg / g
acr functional class  n ( % )
acr response by baseline mtx use  no . / total no . ( % ) acr $nmbr$
acr response by baseline weight
acr response  % acr $nmbr$
acr $nmbr$ week $nmbr$ responders  ( n = $nmbr$ )
acs ( n = $nmbr$  $nmbr$ )
acs event
acs management  no . ( % )
acs presentation
act - $nmbr$
act total score ≥   $nmbr$
act total score   ≥   $nmbr$ and / or improvement from baseline   ≥   $nmbr$
act . $nmbr$
action tested is between the continuous variable and treatment .
active
active - control study
active canakinumab ( n   =   $nmbr$  $nmbr$ )
active cancer at any timeb
active cancer at baseline
active cancer at randomisation
active cancer at randomization
active comparatorb
active pso wi $nmbr$ bsa > $nmbr$ %  n ( . % y
active smokers
active treatment
active vs placebo
active   versus   placebo
activities of daily living updrs subscore ( baseline )  mean ( sd )
activity
activity ( range $nmbr$ - $nmbr$ )  mean ± sd
activity limitation
actual ( l )
actual or estimated weight  kg
acuity - bleeding major / minor
acuity major or
acuity minor
acute increase in serum creatinine
acute medication intake ( days / month )
acute reperfusion
acute stent thrombosis ( definite or probable )
adalimumab
adamantane derivatives
add - on to met
add - on to met + su $nmbr$
add - on to met + su
add - on to met $nmbr$
additional angiography
additional antihypertensive subgroup
additional endpoints
additional heparin
additional radiographic findings at week $nmbr$
additional subgroup analyses
adhere
adherence > $nmbr$ %
adherence to study regimen — no . ( % )
adherence to study regimen — no . ( % ) ff
adiusted hazard ratio *
adj . hr ( $nmbr$ % cl ) a
adjudicated mace $nmbr$
adjusted $nmbr$ or ( $nmbr$ % cl )
adjusted change from baseline
adjusted exacerbation rate ( per patient peryear )
adjusted exacerbation rate { per patient peryear )
adjusted for all baseline variables and interaction between acei and baseline upb
adjusted for all baseline variables  interaction between acei and baseline up  and declines in sbp and up
adjusted for all baseline variables $nmbr$
adjusted hazard ratio ( $nmbr$ % ci ) †
adjusted hazard ratio ( $nmbr$ % cl ) *
adjusted hazard ratio ≠ ( $nmbr$ % ci )
adjusted hazard ratio *
adjusted hazard ratio § ( $nmbr$ % ci )
adjusted hazard ratio ‡ ( $nmbr$ % ci )
adjusted hr ( $nmbr$ % ci ) * compared with no diabetes at bl or at year $nmbr$
adjusted hr ( $nmbr$ % ci ) * comparing idm with bl
adjusted hr losartan vs atenolol *
adjusted hr * ( $nmbr$ % ci )
adjusted hr * ( $nmbr$ % cl ) pvalue
adjusted hr  $nmbr$ % ci
adjusted mean ( se )
adjusted mean ( se ) fevi auco_ $nmbr$  ml
adjusted mean ( se ) trough fevi  ml
adjusted mean _ se change from baseline
adjusted mean ± se change from baseline
adjusted mean change ( kg )
adjusted mean change from baseline
adjusted mean change from baseline ( se )
adjusted mean difference ( $nmbr$ % ci )
adjusted modelc hr  $nmbr$ % ci  p value
adjusted or ( $nmbr$ % ci ) b
adjusted or ( $nmbr$ % ci ) c
adjusted or ( $nmbr$ % cl )
adjusted rate of fev $nmbr$   decline ( se )  ml / yr
adjusted rate of hospitalized pneumonia events ( per patient - year )  mean ( $nmbr$ % ci )
adjusted rate of pneumonia events ( per patient - year )  mean ( $nmbr$ % ci )
adjusted *   hr
adjusted ∗   mean ( se ) ( ml )
adjusted ∗   mean of difference ( se ) ( ml )
adjusted ⁎ hazard ratio ( $nmbr$ % ci )
adjustedahr
adjustedaor
adjustedb  c beta ( se )
administration of study - drug bolus — no . / total no . ( % )
administration of study drug ( % )
admission grace score
adolescents ( aged $nmbr$ - $nmbr$ y )  no . ( % )
adults ( aged   ≥ $nmbr$ y )  no . ( % )
advanced  n ( % )
adverse event
adverse events ( any grade )
adverse events leading to premature treatment discontinuation
ae ' ( per cm / s )
ae / a ratio ( per $nmbr$ . $nmbr$ unit )
ae / e ' ratio ( per $nmbr$ unit )
aed inducer status
aerobic exercise
aes in ≥ $nmbr$ japanese patients in a study arm  n ( % ) §
aes leading to
aes leading to discontinuation of study drugb
aes leading to dose reduction of study drugb
aes related to
aes *
aetiology of pah
af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme  hf heart failure  and lvd left ventricular dysfunction .
af duration  n ( % )
af first diagnosis > $nmbr$ years  n ( % )
af on baseline ecg  n ( % )
af or atrial flutter !
af type
af type — no . ( % )
affected body - surface area > $nmbr$ % — no . { % )
africa ! near east
africa or near east
african american n = $nmbr$
african american  n ( % )
african american / black
african descent
after bronchodilator use
ag
ag + gg
aga group
age - mean ( sd ) years
age — y  meantsd
age — yr age group — no . ( % )
age — yr race — no . ( % ) f
age & $nmbr$
age ( median [ iqr ] )  y
age ( median  years )
age ( p = o - $nmbr$ )
age ( per $nmbr$ years )
age ( sd )  y
age ( y ) [ mean - sd ]
age ( y ) ∗
age ( y )  mean ( range )
age ( y )  mean ( sd )
age ( y )  median ( min  max )
age ( y )  median ( min  max }
age ( year )  mean ± sd
age ( years ( s . d . ) )
age ( years ) ( mean ± sd )
age ( years )  mean _ sd
age ( years )  mean ± s . d .
age ( years )  mean   ±   sd
age ( years )  median ( range )
age ( years ) : mean ± sd
age ( years ) a
age ( years  sd )
age ( yr ) *
age ( yr )  mean ( sd )
age ( yr )  mean ( sd ) bmd t - score  mean ( sd )
age [ year ]  mean ± sda
age [ years ]
age [ years ]  median ( range )
age £ $nmbr$ years ( itt ) ( n = $nmbr$ )
age < $nmbr$ gd lesion > $nmbr$ n = $nmbr$
age < $nmbr$ gd lesion = $nmbr$ n = $nmbr$
age < $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$
age < $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$
age < $nmbr$ vears n = $nmbr$
age < $nmbr$ years ( itt ) ( n = $nmbr$ )
age < $nmbr$ years ( n = $nmbr$  $nmbr$ )
age < $nmbr$ years  n ( % )
age < $nmbr$ yr or > $nmbr$ yr
age < $nmbr$ : qvai $nmbr$ - sfc
age < $nmbr$ years ( n =
age ≥ $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$
age ≥ $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$
age ≥ $nmbr$ years
age ≥ $nmbr$ years  n ( % )
age ≥ $nmbr$ yearsa
age >
age > - median
age > $nmbr$ gd lesion > $nmbr$ n = $nmbr$
age > $nmbr$ gd lesion = $nmbr$ n = $nmbr$
age > $nmbr$ yr ( % )
age > $nmbr$ yr and elevated biomarkers
age > $nmbr$ yr and st - segment changes
age > $nmbr$ yr  elevated biomarkers  and st - segment changes
age > $nmbr$ ( years ) t
age > $nmbr$ vears n = $nmbr$
age > $nmbr$ y ( % )
age > $nmbr$ y *
age > $nmbr$ yr — no . ( % )
age > $nmbr$ yr  no . ( % )
age > $nmbr$ : qvai $nmbr$ - sfc
age > $nmbr$ y  n / n ( % )
age > $nmbr$ years ( itt ) ( n = $nmbr$ )
age > $nmbr$ years ( n = $nmbr$ )
age > $nmbr$ yrs  n ( % )
age ± sd ( yrs )
age $nmbr$ $nmbr$ y
age $nmbr$ years
age $nmbr$ years ( n = $nmbr$ )
age $nmbr$ * $nmbr$ yr
age $nmbr$ - $nmbr$ yr  elevated biomarkers  and previous vascular
age $nmbr$ - $nmbr$ y ( n = $nmbr$ )
age $nmbr$ - $nmbr$
age $nmbr$ - $nmbr$ years ( itt ) ( n = $nmbr$ )
age $nmbr$ - $nmbr$ years ( n = $nmbr$ )
age $nmbr$ +
age $nmbr$ + y
age $nmbr$ + years
age a $nmbr$
age at asthma diagnosis years
age at baseline ( years )
age at baseline in years  mean ( sd )
age at diagnosis < $nmbr$ years
age at diagnosis of ln  years
age at diagnosis of sle  years
age at diagnosis s $nmbr$ years
age at disease onset  n ( % ) *
age at disease onset  years *
age at enrollment ( years )  mean ( sd )
age at entry ( years )
age at lipid randomization ( y )
age at menopause ( yr )
age at time of first seizure
age b $nmbr$ y ( n = $nmbr$ )
age categories
age categories ( y )  n ( % )
age categories  n ( % )
age category  n ( % )
age category  n ( % ) < $nmbr$ years
age category  n ( % ) :
age cohort  no . ( % )
age distribution
age distribution  n ( % )
age distribution  years  n ( % )
age groiro : < $nmbr$ years
age group — no . ( % )
age group ( ≥ $nmbr$ years ) — no . ( % )
age group ( ≥ $nmbr$ ) — no . ( % )
age group ( y )
age group $nmbr$
age groups
age groups  n ( % )
age in years  mean
age in years  median ( iqr )
age is > $nmbr$ vrs  positive biomarkers  and no si . gni . fi . canr ecg changes
age is > $nmbr$ vrs  significant ecg changes  and no positive bi . omark . ers
age is > $nmbr$ vrs  significant ecg changes  and positive biomarkers
age mean age  years sex
age of asthma onset  years
age of onset
age of onset < $nmbr$ years ( n = $nmbr$ )
age of onset $nmbr$ years ( n = $nmbr$ )
age range
age range  y
age s * $nmbr$ yr
age s $nmbr$ years ( n = $nmbr$  $nmbr$ )
age s $nmbr$
age subgroup  y
age when diabetes first diagnosed ( years )  mean ( sd )
age years geographic region
age yr  range
age *
age  mean ( range ) years
age  mean ( s . e . )
age  mean ( sd ) ( years )
age  mean ( sd ) years  n ( % )
age  mean ( sd )  y ethnicity  no . ( % )
age  mean ( sd )  yearsa
age  mean ( sd )  yr
age  mean ± sd  y
age  mean years ( sd )
age  mean years ( sd ) ’ gender  n ( % )
age  mean yr
age  mean  years ( ± sd )
age  mean  yrs ( sd )
age  median ( $nmbr$ th  $nmbr$ th )  y
age  median ( range ) ( years )
age  median years
age  x
age  y ( $nmbr$ th  $nmbr$ th percentiles )
age  y ( mean ± s . d . )
age  y ( mean ± sd )
age  y ( sd )
age  y < $nmbr$
age  y gender  n ( % )
age  y mean ( sd )
age  y  median ( q $nmbr$ – q $nmbr$ )
age  year ( median )
age  years ( mean _ + sd ) sex  n ( % ) :
age  years ( mean = sd )
age  years ( mean ± sd )
age  years ( mean $nmbr$ sd )
age  years mean ( s . d . )
age  years mean ( sd )
age  years mean ± sd
age  years ^
age  years “
age  years $nmbr$ '
age  yf $nmbr$ - $nmbr$
age  yr  n ( % )
age  yrs ( mean ± sd )
age  yrs  median ( iqr )
age  yt
age  years geographical distribution of patients
age . y
age . years
age . . . . . . . . y ( n = $nmbr$ )
age / gd lesion
age\\yr
age   ≥ $nmbr$   y  n ( % )
agea
aged ≥ $nmbr$ years
aged $nmbr$ y or older  n ( % )
aged a $nmbr$ years
aget  y
agi
aha status at screeningb  n ( % )
ai $nmbr$
aii participants ( n = $nmbr$ )
aii patients ( n = $nmbr$ )
ain  no . ( % ) * *
ain  no . ( % ) “ *
air ( n = $nmbr$ )
air + ig ( n = $nmbr$ )
airway compromise
airway reversibility  %
airway reversibility  mean  %
alanine aminotransferase increased
alanine aminotransferase  u / l
alav ( per ml )
albiglutide ( n = $nmbr$ )
albiglutide events / patients ( %
albumin - to - creatinine ratio ' i  /
albumin - to - creatinine ratio ( acr )
albumin  g / dl
albuminuria ( acr > $nmbr$ m . g / g ) at baseline to normoalbuminuria
albuminuria and previous maerovaseular disease plus established renal disease ( egfr $nmbr$ - $nmbr$ ml / min / l $nmbr$ in - with an uacr > $nmbr$ mg / g or egfr $nmbr$ - < $nmbr$ ml / inin / l $nmbr$ in - with any uacr mg / g )
albuminuria and previous maerovaseular disease without established renal disease
albuminuria progression
albuminuria_p_interaction
alc ( % )
alc ( mmol / mol )
alc < $nmbr$ . $nmbr$ % at baseline  n ( % )
alc > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %
alc at week $nmbr$ ( % )
alc at weeko ( % )
alc group ( % )
alcohol
alcohol < = $nmbr$ / wk
alcohol > $nmbr$ / wk
alcohol > $nmbr$ drinks per week
alcohol consumption ( % ) < $nmbr$ drink / dav
alcohol consumption ( yes ) ( n )
alcohol consumption at baseline
alcohol consumption *
alcohol consumption  no . ( % )
alcohol drinker
alcohol drinker  n ( % )
alcohol intake never / rarely
alcohol use ( %  > $nmbr$ / day )
alcohol use  n ( % )
alcohol useb
alcohol usef  n ( % )
alcohol users  n ( % )
alcohol ^
aldosterone receptor antagonists
aldosterone use
alendronate
alendronate ( n = $nmbr$ )
algorithm $nmbr$
alirocumab $nmbr$ mg q $nmbr$ w
alirocumab $nmbr$ / $nmbr$ mg
alirocumab n = $nmbr$
alive ( n = $nmbr$ )
all - baricitinib ra ( n = $nmbr$ ) *
all - causa mortality
all - cause death / stroke / see
all - cause mortalitv
all - cause mortality ( n = $nmbr$ )
all - cause mortality ( no . of events )
all - cause mortality ( per $nmbr$ person - years )
all - cause mortality at $nmbr$ year
all ( n = $nmbr$  $nmbr$ )
all ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
all bleed
all canakinumab
all cause mortality or hosp . for worsening hf hs - crp < $nmbr$ . $nmbr$ mg / l
all death
all diabetesd
all doses
all doses ( n = $nmbr$ )
all dulaglutide $nmbr$ . $nmbr$ mg + insulin lispro / insulin glargine ( n = $nmbr$ )
all itt sutajects
all major cardiovascular events
all men
all mis
all mis *
all mn - na ï ve patients
all non - mn
all noncompleters
all others eteed for $nmbr$ mg edoxaban dose at
all participants ( n = $nmbr$ )
all participants history of cabg
all participants * ( n = $nmbr$ / $nmbr$ )
all participants  mm hg : sbp  mean ( sd )
all participants ^ ^ ( n = $nmbr$ / $nmbr$ )
all participantsa
all participantst ( n = $nmbr$ / $nmbr$ )
all patients ( n $nmbr$ $nmbr$ )
all patients ( n   =   $nmbr$ ) b
all patients ( p < $nmbr$ . $nmbr$ )
all patients ( p = $nmbr$ . $nmbr$ )
all patients n = $nmbr$ $nmbr$
all patients on maximally tolerated statin ± other llt
all patients  n =
all patientsb
all randomized all - cause mortality
all randomized all - cause mortality or hospitalization for worsening hf ^
all randomized coronary end point
all recurrent strokes
all responders  ( n = $nmbr$ )
all strokes
all strokes *
all strokes  n ( % )
all subjects - n
all treatments
all trials
all with diabetes ( n = $nmbr$ )
all without diabetes ( n = $nmbr$ )
all women
alleles
allergic disease by historyb  n ( % )
allergic rhinitis
allergic rhinitis — no . ( % )
allergic rhinitis duration  mean ± sd  y *
allopurinol
allopurinol $nmbr$ / $nmbr$ mg daily n = $nmbr$
allopurinol $nmbr$ / $nmbr$ mg n = $nmbr$
allopurinol $nmbr$ mg ( n = $nmbr$ ) +
allopurinolt
alogliptin
alogliptin ( n = $nmbr$ )
alogliptin $nmbr$ . $nmbr$ mg + pioglitazone ( n = $nmbr$ )
alogliptin $nmbr$ mg + pioglitazone ( n = $nmbr$ )
alogliptin  n ( % )
alpha - blocker / other vasodilator
alpha - blockers
alpha blockers
alpha glucosidase inhibitors
alpha reductase inhibitors
alprostadil ( n = $nmbr$ )
alprostadil n / n
alprostadil n / n %
alt > $nmbr$ x uln on two consecutive visits
alt increased
alt or ast > $nmbr$ x uln $nmbr$
alvedv ( per ml )
alvef ( per $nmbr$ % )
alvesv ( per ml )
alvmi ( per g / m $nmbr$ )
am_ % delta
am_delta
amann whitney u test / wilcoxon sum rank test .
ambition
ambulatory sbp  difference vs placebo ( $nmbr$ % cl )
ambulatory sbp  n
amended dabigatran protocol
america
american
american ‐ indian / alaska native
american hispanic ( n   = $nmbr$ )
american indian or
american indian or alaska native  :
american indian or alaskan
american indian  alaskan native  or aboriginal canadian
american indian / alaskan native
american indian / alaskan native  n ( % )
american indian / native alaskan
americas * *
aminosalicylate
amiodarone ( n  % )
amiodarone ote at baseline
amiodarone use at baseline
amiodarone use at baseline yes $nmbr$  $nmbr$
amiodarone vs . placebo
aml ( n = $nmbr$ )
aml $nmbr$ mg + hctz $nmbr$ mg
aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ )
aml vs . chl
aml vs . lis
amlodipine
amlodipine $nmbr$ to $nmbr$ mg ( n = $nmbr$ )
amlodipine and valsartan
amlodipine vs chlorthalidone normal
amlodipine vs chlorthalidone obese
amlodipine vs chlorthalidone overweight
amlodipine / chlorthalidone
amlodipine / lisinopril $nmbr$
amlodipine / lisinopril / chlorthalidone comparison
amlodipine / valsartan $nmbr$ to $nmbr$ / $nmbr$ mg ( n = $nmbr$ )
ampd $nmbr$
amputation — no . ( % )
amputation due to diabetes — no . ( % )
amputations  n ( % )
anacetrapib $nmbr$ mg
analgesic medication  n ( % )
analysis
analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .
anatomic extent of qualifying event  n ( % . ) x
anatomical extent of qualifying event — no . ( % ) : t
anatomy
ancova result
and after pci  median ( iqr )  d
and either an ace inhibitor or angiotension receptor blocker
and infusion
and microalbuminuria or macroalbuminuria
and physical examination
and vfx status
and / or aza at baseline
and / or discharge
anemia  %
anemia  no . / total ( % ) ”
anesthesiad  n ( % )
angina class iii or iv prior
angina or acute mi
angina or positive stress test
angina with documented ischemia
angina .
angioedema ( adjudicated )  n ( % )
angioedema present  n ( % ) {
angioedema present  n ( % ) $nmbr$
angiographic characteristics  no . ( % )
angioplasty
angiotensin -
angiotensin - converting - enzyme inhibitor or angiotensin -
angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population )
angiotensin - converting enzyme inhibitor / angiotensin receptor blocker
angiotensin - converting enzyme inhibitors
angiotensin - converting enzyme inhibitors ^
angiotensin - eonverting enzyme inhibitors
angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers
angiotensin - receptor
angiotensin ii antagonists
angiotensin ii receptor blockers
angiotensin il - receptor blocker
angiotensin receptive blocker
ankle - brachial index £ $nmbr$ . $nmbr$
ankle edema
annanginal drugs ( $nmbr$ / l / s » $nmbr$ ) ^
annual asthma exacerbation rates
annual exacerbation rate
anorexigen use
anterior infarct location
anterior mi
anterior myocardial infarction — no . / total no . ( % )
anterior or non - anterior ml
anthropometrics  mean ( sd )
anti - anaemics
anti - ccp antibodies *
anti - ccp antibody - positive  n ( % )
anti - ccp positive
anti - dsdna ( > $nmbr$ iu / ml )  %
anti - dsdna positive
anti - gad negative
anti - gad negative ( n = $nmbr$ )
anti - gad positive
anti - gad positive ( n = $nmbr$ )
anti - histamines
anti ‐ hyperglycaemic agent  n ( % )
anti - hypertensive
anti - hypertensive treatment history  n ( % )
anti - hypertensives
anti - p $nmbr$
anti ‐ platelet agents  n ( % )
anti - thrombotics
anti - tnf
anti ‐ tnf ‐ na ï ve    n   ( % )
anti - tnf ir
antiarrhythmic drugs    n   ( % )
antiarrhythmics
antibody binding level at baseline
anticholinergic drug
anticholinergic use  n ( % )
anticholinergics
antidepressant
antidiabetic drug
antidiabetic drug ‘ i “ j ‘
antihyperglycaemic medication at baseline
antihyperglycemic medications
antihypertensive agent use
antihypertensive agents ( n per patient )
antihypertensive medication
antihypertensive medication use  n ( % )
antihypertensive medication )
antihypertensive medication $nmbr$ '
antihypertensive randomization  no . ( % ) a
antihypertensive treatment  n ( % )
antihypertensive treatments
antihypertensive use
antihypertensives ' *
antihypertensives  n ( % )
antimalarial
antiplatelet agent n ( % )
antiplatelet at randomization
antiplatelet use
antiplatelets agents
antiplatelets  any
antiplateletsa
antithrombin
antithrombotic
antithrombotic medications  n ( % )
antithrombotic use before enrollment  no . ( % )
antithrombotic ! i
any ( including corticosteroid )
any acuity bleeding
any adverse event ( ae )
any adverse event leading to study drug discontinuation  n ( % )
any ae
any ae leading to discontinuation  n ( % )
any ae  n ( % ) ‡
any aes
any albuminuria
any anti - hypertensive agent
any antianginal drug !
any anticoagulant
any antihypertensive agent
any antihypertensive drug
any bleeding
any blood
any blood product transfusion
any bp - lowering agents ^
any cardiovascular disease
any cardiovascular diseased
any cause
any copd medication
any cough
any cvd history ( % )
any drug - related ae  n ( % )
any dynamic st - segment shift
any early adverse event
any electrocardiographic abnormality — no . ( % )
any glycoprotein iib / iiia inhibitor use
any gusto bleeding
any hba $nmbr$ c
any lipid - lowering agent use
any llt other than nutraceuticals  n ( % )
any llt other than statins  n ( % ) b
any mi
any other lipid ‐ lowering therapy  n ( % )
any overt bleed
any peripheral revascularization
any placebo
any prerandomization failure of an antiarrhythmic drug — no . ( % )
any pulmonary medication  n ( % )
any revascularization
any sae
any secukinumab ( n   = $nmbr$ )
any serious ae  n ( % )
any serious teaes
any severity
any site
any stroke
any sulfonylurea
any teae
any teaes
any therapy — no . ( % )
any thiazide diuretic
any thiazolidinedione
any timi bleeding
any treatment - emergent ae
any ulcerative colitis medication
any vascular diasease
any vascular disease
any vascular *   efficacy
any vte - related death
any vte or vte - related death — no . ( % )
aortic
aortic - valve replacement
aortic valve disease ( n = $nmbr$ $nmbr$ )
ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .
ap = $nmbr$ . $nmbr$  bp $nmbr$ . $nmbr$  cp = $nmbr$ . $nmbr$ . * the study - speci ﬁ c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg ( or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm ) . the ldl - c target was $nmbr$ mg / dl or $nmbr$ mg / dl  depending on risk factor status at baseline in accordance with ncep atp iii guidelines . odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site . an interaction between treatment effect and dm status was observed for bp goal attainment ( p = $nmbr$ . $nmbr$ ) and dual bp / ldl - c goal attainment ( p = $nmbr$ . $nmbr$ ) among patients with or without dm calculated based on a mixed - effects linear model ( not adjusted for differences in baseline values ) . abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure
apasp ( per mmhg )
apixaban $nmbr$ . $nmbr$ mg bid
apixaban $nmbr$ mg bid
aplxaban $nmbr$ . $nmbr$ mg bid
apo a - i ( mg / dl ) *
apo a $nmbr$ ( mg / dl )
apo a $nmbr$  mean ( sd )
apo a $nmbr$  mg / dl  mean ( sd )
apo b ( mg / dl )
apo b ( mg / dl ) * *
apo b  mean ( sd )
apo b  mg / dl  mean ( sd )
apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol
apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [ standard deviation for medians calculated by ( q $nmbr$ q $nmbr$ ) / $nmbr$ . $nmbr$ ] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .
apoa - i
apoa $nmbr$  mg / dl
apoal
apoal ( mg / dl ) *
apob  g / l  mean ( sd )
apob : apoa - i
apob : apoa - i ratio
apob : apoa $nmbr$
apob : apoa $nmbr$ ratio
apob $nmbr$
apoe e $nmbr$ carriers  no . ( % )
apoe   ε $nmbr$ carrier
apolipoprotein
apolipoprotein b $nmbr$  mg / dl
apolipoprotein b  mg / dl
aqlq score  mean
aqlq score  mean ( sd )
aqlq ( s ) + $nmbr$ score  mean ( sd ) c  f
aqlq ( s ) + $nmbr$ score : §
aqlq ( si + $nmbr$ score ’
arb ( n  % )
arb + ccb ( n = $nmbr$ )
arb = angiotensin ii receptor blocker  ccb
arb or ace inhibitor
arb or ace inhibitor  n ( % )
arbs or ace inhibitors
ard ( $nmbr$ % cl ) per $nmbr$ patient - years
ard per $nmbr$ $nmbr$ patient - years ( $nmbr$ % ci )
area of fluorescein leakage within the grid  mean ( sd )  dab
area of retinal hemorrhage within the grid  mean ( sd )  dab
area of retinal thickening within the grid  mean ( sd )  dab
areas
arr ( % )
arteriai access
arterial hypertension  no . ( % )
arthritis characteristics
arthritis mutilans
arvfac ( per $nmbr$ % )
as
as duration  y  mean ( sd )
as major component — no . ( % )
asa  n ( % )
asas $nmbr$ / $nmbr$    %
asas $nmbr$ / $nmbr$    n   ( % )
asas partial remission  %
asas partial remission    n   ( % )
asas $nmbr$
asas $nmbr$  %
asas $nmbr$    %
ascvd no prior ml
ascvd * . n ( % )
ascvd  b no . ( % )
asdas - crp δ   ≥   $nmbr$ . $nmbr$
asdas - crp *
asdas - crp   <   $nmbr$ . $nmbr$
asdas inactive disease  %
asia - pacific and south africa
asia - pacific region and south africa
asia ( excluding japan )
asia ( n = $nmbr$  $nmbr$ )
asia and pacific islands
asia pacific ( n = $nmbr$ )
asia pacific and africa
asia pacific and south africa
asia #
asian ( n   = $nmbr$ )
asian ( n = $nmbr$  $nmbr$ )
asian itt population by treatment group
asian itt population total ( n = $nmbr$ )
asian / pacific islander  n ( % )
asians ( n = $nmbr$ )
aslan
aspartate aminotransferase increased
aspartate aminotransferase  u / l
aspirin ( % )
aspirin ( any dose )
aspirin ( n  % )
aspirin ( n = $nmbr$ ) no . of participants with events ( % )
aspirin $nmbr$  $nmbr$
aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
aspirin at baseline
aspirin before admission
aspirin dose at baseline  mg
aspirin dose  mg / d
aspirin group ( n = $nmbr$ )
aspirin or other antiplatelet drug
aspirin or other antiplatelet or anticoagulant agent
aspirin orother antiplatelet drug
aspirin plus clopidogrel ( n = $nmbr$ )
aspirin plus placebo ( n = $nmbr$ )
aspirin use ( % )
aspirin use ( p = $nmbr$ . $nmbr$ t )
aspirin use at randomization
aspirin use at randomization - n ( % )
aspirin use before screening — no . { % )
aspirin use n ( % )
aspirin  no . ( % )
aspirin / antiplatelet medication
aspirin + dipyridamole
aspirin + thienopyridine
asqol  ls mean change ± se
asqol  ls mean change from baseline   ±   se
assessment of physical function ( $nmbr$ - $nmbr$  haq - di )
assigned to placebo
assigned to topiramate
assigned treatment by sex interaction
associated with an atrial septal defect
ast > $nmbr$ x uln on two consecutive visits
ast increased
asteria i / ii
asthma - control status at randomization — no . ( % )
asthma - related health -
asthma exacerbations
asthma symptoms in the past $nmbr$ weeks
asubset of the ≥ $nmbr$ years subgroup .
asui score  mean
asui score  mean ( sd )
asymmetric peripheral arthritis
at
at $nmbr$ years
at any time
at baseline
at baseline — no . ( % )
at c change ( % ) *
at c data
at end of follow - up
at end of follow - up — no . ( % )
at end of follow - up — no . / total no . ( % )
at femoral neck  mean ( sd )
at increased fall risk ( n - $nmbr$ )
at index event : no . ( % )
at or above median
at screening
at week $nmbr$
at weeks $nmbr$ and $nmbr$
atenoioi ( n = $nmbr$ )
atenolol
atenolol ( n = $nmbr$ )
atenolol ( n = $nmbr$  $nmbr$ )
atenolol ( no . = $nmbr$ )
atenolol use at $nmbr$ month
atherectomy
atherosclerosis
atherosclerotic cardiovascular disease *
atherosclerotic cvd
atherosclerotic cvd §
atherosclerotic cvdj
atherosclerotic vascular disease — no .
atherosclerotic vascular disease history  n ( % ) t
atherosclerotic vascular disease history  no . ( % ) ‡
atherosclerotic vascular disease history †
atherosclerotic vascular disease  n ( % ) §
atherothrombotic infarction  n ( % )
atherothrombotic stroke  n ( % )
atients with event
atm - locm
atm - locus
atonic
atopic
atopic at baseline : yes
atopy ( n = $nmbr$  $nmbr$ )
atopy ( specific ige ) c  n ( % )
atopy by phadiatop test  n ( % )
atorvastatin ( n = $nmbr$  $nmbr$ )
atorvastatin { n = $nmbr$  $nmbr$ )
atorvastatin $nmbr$ mg and simvastatin $nmbr$ - $nmbr$ mg ( zi = $nmbr$ )
atorvastatin $nmbr$ mg ( zi = $nmbr$ )
atorvastatinb
atrial fibrillation — no . ( % )
atrial fibrillation on baseline ecg  n ( % )
atrial fibrillation type  n ( % )
atrial fibrillation    n   ( % )
atrial fibrillation . no . ( % )
attack ( % )
attain
atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment   [ expressed as number of patients reaching ldl - c goal at week $nmbr$ / number of patients above goal at baseline  ^ treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg .
atwo ‐ sample t ‐ test .
atypical absence
augment copd
aunivariate logistic regression .
austral ia / new zealand
australia / new zealand / south africa
autonomic neuropathy
available data
average daily dose
avp pg / ml
aza ( n = $nmbr$ )
azathioprine monotherapy
azl - m
azl - m + hctz ( n = $nmbr$ )
azl - m $nmbr$ mg ( n = $nmbr$ )
azl - m $nmbr$ mg + cld $nmbr$ mg
azl - m $nmbr$ mg $nmbr$ - cld $nmbr$ mg ( n = l $nmbr$ )
azl - m / cld ( n = $nmbr$ )
azl - m + cldb
azl - ma
b - blockers at baseline
b - blockers  n ( % )
b - natriuretic peptide . pg / ml
b includes both ex - smokers and nonsmokers .
b mace
b major cardiovascular events
b nonsevere hypoglycemia
b pooled new and worsened vertebral fractures ( mfas )
b postbronchodilator fevl ( % predicted )
b reslizumab $nmbr$ . $nmbr$ mg / kg n / n
b ) those on inhaled corticosteroids and long - acting bronchodilators as previous treatment use .
b  vhd ( n = $nmbr$ )
b . acr $nmbr$
b . benralizumab $nmbr$ mg q $nmbr$ w
b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fev $nmbr$    forced expiratory volume in $nmbr$   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd
b . myocardial infarction
b : u . s . black and non - black patients
b + a ( n = $nmbr$ )
b + h ( n = $nmbr$ )
background aha therapy at screening  n
background aha therapy at screening  n ( % ) §
background aha therapy at screening  a
background aha therapy at screening  a   n ( % )
background laba use
background laba use - yes  n ( % )
background lipid - lowering therapy
background lipid therapy per acc / aha definition    n   ( % ) a
background therapy
bacterial pneumonia
bail ‐ out use of glycoprotein iib / iiia inhibitors
barc types $nmbr$  $nmbr$  or $nmbr$
baricitinib $nmbr$ / $nmbr$ mg
baricitinib $nmbr$ mg qd
basal
basal alone
basal insulin
basal insulin doset
basal only
basal plus bolus
basdai question $nmbr$ score ( $nmbr$ - $nmbr$ )  mean ( sd )
basdai responses at week $nmbr$
basdai score ( $nmbr$ - $nmbr$ )  mean ( sd )
basdai score  mean ( sd )
basdai  ls mean change from baseline   ±   se
basdai  mean change from baseline
basdai  total  mean ± sd
basdai ⁎ ⁎
basdai $nmbr$  n ( % )
basdai $nmbr$  %
base
baseiine acei / arb
baseiine aspirin
baseiine ccb
baseiine diuretic
baseiine statin
baseline - adjusted hr
baseline - - mdrd
baseline - ckd - epi
baseline ( mmol / l )
baseline ( sd )
baseline ^ ste  mm
baseline £ std  mm
baseline $nmbr$ - hour mean sbp  mm hg
baseline $nmbr$ - mlnute walk distance :
baseline a $nmbr$ c ( % )
baseline a $nmbr$ c ( % ) [ lsm ( se ) ]
baseline abi  affected limb
baseline adas - cog $nmbr$
baseline age
baseline albuminuria
baseline alc < $nmbr$ . $nmbr$ %
baseline alc category
baseline anti - hyperglycemic medications  n ( % )
baseline asdas - crp
baseline aspirin use
baseline aspirin use strata
baseline basdai
baseline basfi
baseline bii  mean ( sd )
baseline bmi
baseline bmi ( kg / m ^ )
baseline bmi ( kg / m $nmbr$ )
baseline bnp concentration ( pg / ml )
baseline bp  mean ( sd ) *
baseline bsa  mean ( sd )
baseline cardiovascular assessment
baseline cardiovascular medications  n ( % )
baseline cdai  mean ( sd )
baseline cdr - sb ( n   = $nmbr$ + $nmbr$ )
baseline cha $nmbr$ ds $nmbr$ - vascb  c
baseline chads $nmbr$ a  c
baseline characteristics  mean ( sd ) a
baseline ckd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
baseline ckd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
baseline concentration
baseline concomitant cardiovascular medications
baseline crcl  ml / min
baseline creatinine  median ( range ) mg / dl
baseline crohn ' s disease medications
baseline crp
baseline crp category ( mg / l )
baseline crp levels < $nmbr$ mg / l
baseline crp levels ≥ $nmbr$ mg / l
baseline dad ( n   = $nmbr$ + $nmbr$ )
baseline das $nmbr$  mean ( s . e . )
baseline data
baseline daytime nasal symptoms score  mean ± sd
baseline dbp
baseline dbp  mean ± sd  mm hg
baseline demographics
baseline diabetes mellitus therapy  n ( % )
baseline diastolic blood
baseline diastolic blood pressure  mean ( sd )  mm hg
baseline dipeptidyl peptidase $nmbr$
baseline dlqi  mean ( sd )
baseline ecg with lvh  n ( % )
baseline ecrcl $nmbr$ $nmbr$ ml / min
baseline ecrcl k $nmbr$ to < $nmbr$ ml / min
baseline ecro < $nmbr$ mumin
baseline ecrq $nmbr$ $nmbr$ to < $nmbr$ ml / min
baseline ed severity * * :
baseline egfr ( ml / min per $nmbr$ « $nmbr$ m ’ )
baseline egfr < $nmbr$
baseline egfr ≥ $nmbr$ to < $nmbr$
baseline egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
baseline egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$
baseline eosinophil < $nmbr$ cells / pl
baseline eosinophil $nmbr$ cells / pl
baseline estimated gfr
baseline factor
baseline fasting plasma glucose
baseline fasting tgs  mg / dl
baseline fc - ldl - c
baseline feature
baseline fev $nmbr$  median ( range )  l
baseline fpg  mg / dl
baseline free pcsk $nmbr$ level
baseline geometric mean ( $nmbr$ ® / l )
baseline gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )
baseline glycated
baseline glycated hemoglobin ( % )
baseline glycemic control
baseline haq mean ( s . e . )
baseline hba ^ c
baseline hba $nmbr$ c < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )
baseline hba $nmbr$ c ≤ median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )
baseline hba $nmbr$ c ≥ $nmbr$ mmol / mol ( ≥ $nmbr$ . $nmbr$ % )  n ( % )
baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % to < $nmbr$ . $nmbr$ % ( $nmbr$ – $nmbr$ mmol / mol )
baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )
baseline hba $nmbr$ c > median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )
baseline hba $nmbr$ c concentration
baseline hba $nmbr$ c subgroup
baseline hba $nmbr$ c ^
baseline hbalc
baseline hbalc < $nmbr$ %
baseline hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % )
baseline hbalc > $nmbr$ % to < $nmbr$ %
baseline hbalc > $nmbr$ %
baseline hbalc ^
baseline hbalc ’
baseline hbi  mean ( sd )
baseline hdl - c
baseline hdl - c level ( n = $nmbr$ » $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl
baseline hdl - c level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl
baseline hdl - c level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl
baseline hdl - c level ( n = s $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl
baseline hdl - c  mg / dl
baseline hdl ‐ c  mg / dl
baseline height ( cm )
baseline hemoglobin aj ^ values
baseline high - density lipoprotein cholesterol ( mg / dl )
baseline hstni
baseline ics
baseline ics > $nmbr$ pg per day ( fluticasone propionate dpi or equivalent ) and laba
baseline ics dose  n ( % )
baseline if have $nmbr$ yr follow - up *
baseline ifg ( fpg $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l ) - n
baseline in - check * ’ pifr ( l / min )
baseline inflammation markers
baseline insulin
baseline insulin dose ( u = kg ) [ lsm ( se ) ]
baseline ldl - c  mg / dl
baseline ldl ‐ c  mg / dl
baseline ldl ( mg % )
baseline ldl cholesterol ( derived )
baseline ldlc level ( n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mgzdl
baseline ldlc level ( n = $nmbr$  $nmbr$ ) ^ $nmbr$ . $nmbr$ mg / dl
baseline ldlc level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl
baseline ldlc level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl
baseline lipid and apolipoprotein levels
baseline lipid parameters  mg / dl  mmol / l or g / l
baseline lipid profile  mg / dl  mean ( sd )
baseline lipid therapy
baseline lipids
baseline lipids  mg / dl
baseline lipoprotein ( a ) ( nmol / l )  median ( iqr )
baseline los angeles grade of eo  n ( % )
baseline lp ( a )  mg / dl
baseline luts severity * :
baseline luts severity  n ( % ) :
baseline mayo score
baseline mdrd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
baseline mdrd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
baseline mean ( sd )
baseline mean ambulatory sbp  mm hg ( sd ) *
baseline mean fev $nmbr$ ( sd )  ml
baseline mean seated sbp  mm hg ( sd )
baseline mean serum uric acid  pmol / l ( sd )
baseline median
baseline medical therapy  n ( % )
baseline medications ( % )
baseline medications  n ( % )
baseline metformin
baseline microalbumin : < $nmbr$
baseline monthly pos seizure rate
baseline mtss subgroup
baseline mwd  m
baseline nbp
baseline non - hdl - ca
baseline normoglycaemia ( fpg < $nmbr$ . $nmbr$ mmol / l ) - n
baseline normoglycemia
baseline numberf of adm classes  n ( % )
baseline ocs use : yes
baseline of induction
baseline of induction )  n ( % )
baseline outcomes
baseline parameter
baseline pasi  mean ( sd )
baseline pava
baseline pcsi < $nmbr$ a
baseline pfd  m
baseline pos frequency per $nmbr$ days
baseline post - bronchodilator fev $nmbr$   ( sd )  ml
baseline ppasi score  mean ( sd )
baseline prediabetes
baseline prednisone or oral prednisone equivalent daily dose
baseline presence of nasal polyps
baseline procedure  n ( % )
baseline pssi score  mean ( sd )
baseline ptga
baseline pulmonary medication  b n ( % )
baseline pulmonary medications
baseline renal function ( eclcr )
baseline risk factors
baseline rst - segment
baseline rst - segment elevation  mm
baseline sbp
baseline sbp ( mm )
baseline sbp { p = o - $nmbr$ )
baseline sbp  mean ± sd  mm hg
baseline sedbp  mean ( sd )  mm hg §
baseline serum calcium level  n ( % )
baseline serum mg < $nmbr$ . $nmbr$ mmol / l
baseline serum mg > = $nmbr$ . $nmbr$ mmol / l
baseline serum urate ( mg / dl ) a
baseline sesbp  mean ( sd )  mm hg §
baseline shs ( $nmbr$ - $nmbr$ )
baseline sildenafil dose mg
baseline sitosterol / cholesterol
baseline sitosterol / lathosterol
baseline sitting dbp  * mm hg
baseline sitting sbp  $nmbr$ mm hg
baseline sjc  mean ( s . e . )
baseline skin pain vas  mean ( sd )
baseline smoking status
baseline spga  mean ( sd )
baseline spirometry
baseline statin
baseline statin intensity
baseline statin use
baseline ste in worst lead  mm
baseline sua  mean ± sd mg / dl
baseline subgroup
baseline sulfonylurea yes
baseline symptom days perweek
baseline systolic blood pressure  mean ( sd )  mm hg
baseline t - score at femoral neck  n ( % )
baseline tava
baseline tbp
baseline tc  mg / dl
baseline tg
baseline tg < $nmbr$ . $nmbr$ mmol / l
baseline tg > $nmbr$ . $nmbr$ mmol / l
baseline tg level ( n = $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl
baseline tg level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl
baseline tg level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl
baseline tg level { n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl
baseline tg  ( mg / dl )  median ( iqr )
baseline tjc  mean ( s . e . )
baseline to eom placebo ( n = $nmbr$ )
baseline to year $nmbr$
baseline tophusa
baseline total ipss
baseline total ipss  mean ( sd )
baseline total pcsk $nmbr$ level
baseline triglycerides
baseline triglycerides > $nmbr$ mg / dl and
baseline uas $nmbr$
baseline upgr > $nmbr$ gm / gm ( $nmbr$ mg / mmole )
baseline upgr  mg / mmole ( n = $nmbr$  $nmbr$  $nmbr$ )
baseline use of adm  n ( % )
baseline variable
baseline vertebral fracture
baseline vfx
baseline vitamin - d
baseline weekly iss
baseline who function class
baseline  % ( n )
baseline  mg / dl ( mmol / l )
baseline  no . ( % )
basfi *
batellna c - reective protein
bb
bdi focal score $nmbr$
beam values ( mg / dl )  mean ( sd )
beam   <   $nmbr$   mg / dl at week $nmbr$  n ( % )
because of ae
because of drug ‐ relateda   ae
because of drug ‐ relateda   sae
because of sae
before a change to the enrollment form was implemented in august $nmbr$ . bnp
before admission )  %
before bronchodilation — liters §
before bronchodilator use
below median
bempedoic
bempedoic acid ( n = $nmbr$ )
benazepril - amlodipine group ( n = $nmbr$ )
benazepril - hydrochlorothiazide group ( n = $nmbr$ )
benralizumab
benralizumab $nmbr$ mg q $nmbr$ w
benralizumab q $nmbr$ w ( n - $nmbr$ )
benralizumab q $nmbr$ w ( n = $nmbr$ )
benzodiazepine or bzra ‡
beta - blocker n ( % )
beta blocker use ( % )
beta blocker users
beta blocker  %
beta blocker  n ( % )
beta bloekers
betablocker
between - treatment comparison of percentage change from baseline in total hip bmd
bi ( $nmbr$ . $nmbr$ )
biack
biack hispanic
biack non - hispanic
biasp $nmbr$ bid
bifurcation lesion with side branch ≥ $nmbr$ . $nmbr$ mm stented
bifurcation per lesion ‡
biguanide
biguanide use at baseline
biguanides ¶
bii ( mean ± sd )
bii score
bilag a  b or c domain score  n ( % )
biochemical events
biochemical measures  mean ( sd )
biochemical parameters at randomization  mean
biolimus a $nmbr$ - eluting stent ¶
biologic
biological
biomarker high
biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl ) t
biomarker levels
biomarker low
biomarkers at baseline
biometric parameters
bivalirudin ( n = $nmbr$  $nmbr$ )
bivalirudin alone ( n = $nmbr$ )
bivalirudin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ )
bivalirudin used
bl
bl alc < $nmbr$ . $nmbr$ %
bl bm $nmbr$ < $nmbr$ kg / m ^
bl bmioo kg / m ^
bl bml < $nmbr$ kg / m ^
bl bml > $nmbr$ kg / m ^
bl bml > $nmbr$ ke / m ^
black ( n   = $nmbr$ )
black ( n = $nmbr$ )  adjusted hazard ratio *
black hispanic
black hispanic - n ( % )
black non - hispanic
black non - hispanic - n ( % )
black or african
black or african ‐ american
black or african heritage
black or asian
black participants
black region or country ( % )
black *
black  no . ( % )
black  non - hispanic
black /
black / af rican american
black / african
black / non - black
bladder
blaek
blaek / afriean - ameriean
blaic < $nmbr$ . $nmbr$ %
blaic > $nmbr$ . $nmbr$ %
bleeding
bleeding end points
bleeding events during first $nmbr$ days of treatmen
bleeding events during the entire study
bleeding outcomes
blisibimod ( n = $nmbr$ )
blocker
blood - glucose control
blood bilirubin increased
blood eosinophil count — cells / mm ’
blood eosinophil count cells / mm $nmbr$ no .
blood eosinophil count  geometric mean ( sd loge scale ) cells / ll
blood eosinophils  cells / ml
blood eosinophils  mean ( range )  cells / ml
blood eosinophils  mean ( range )  cells / mlb
blood glucose - lowering drugs  excluding insulin  n ( % )
blood glucose - lowering treatments  n ( % )
blood glucose lowering treatment
blood pressure ( mm hg ) systolic
blood pressure ( mm hg ) *
blood pressure < $nmbr$ / $nmbr$ mmhg  n ( % )
blood pressure < $nmbr$ mm hg
blood pressure > $nmbr$ mm hg
blood pressure at baseline :
blood pressure at entry ( mm   hg )
blood pressure control *
blood pressure eontrolt
blood pressure in mm hg  mean ( sd )
blood pressure while seated — mm hg
blood pressure  mean ( sd )  mm hg systolic
blood pressure  mean ( sd )  mm hgt
blood pressure  mm hg  mean ( sd )
blood pressure  mmhg systolic
blood pressure  mmhg  mean ( sd )
blood pressure : systolic / diastolic ( mm hg ) ( mean  sd )
blood urea nitrogen  mg / dl
bm $nmbr$  kg / m $nmbr$ ( mean ± s . d . )
bmi - kg / m $nmbr$
bmi ( . kg / m - ) *
bmi ( kg / ( m ) $nmbr$ )
bmi ( kg / m ^ )
bmi ( kg / m ^ )  mean ( sd )
bmi ( kg / m ^ )  mean ± s . d .
bmi ( kg / m ’ )
bmi ( kg / m $nmbr$ ) ( mean ± sd )
bmi ( kg / m $nmbr$ ) ( sd )
bmi ( kg / m $nmbr$ ) [ mean - sd ]
bmi ( kg / m $nmbr$ )  mean ( sd ) a
bmi ( kg / m $nmbr$ )  median ( range )
bmi ( kg / m $nmbr$ ) : mean ± sd
bmi ( kg / m $nmbr$ ) a
bmi ( kg = m $nmbr$ )
bmi ( sd )  kg / m $nmbr$
bmi [ kg / m $nmbr$ ]
bmi £ $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )
bmi < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ )
bmi < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )
bmi < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ )
bmi < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ )
bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure
bmi > $nmbr$  n ( % )
bmi > = $nmbr$ kg / m $nmbr$ population ( n = $nmbr$ )
bmi > $nmbr$ — no . { % ) $
bmi > $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ )
bmi > $nmbr$ kg / m $nmbr$ *
bmi > $nmbr$ kg / m $nmbr$  n ( % )
bmi > $nmbr$ obese
bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation
bmi $nmbr$ - < $nmbr$ kg / m - ( n = $nmbr$ / $nmbr$ )
bmi $nmbr$ - < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ )
bmi $nmbr$ - < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )
bmi $nmbr$ - < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ )
bmi $nmbr$ - < $nmbr$ kg / ni - ( n = $nmbr$ / $nmbr$ )
bmi $nmbr$ – $nmbr$ overweight
bmi $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$
bmi $nmbr$ $nmbr$ - $nmbr$ $nmbr$
bmi $nmbr$ - $nmbr$ - $nmbr$ $nmbr$
bmi $nmbr$
bmi a $nmbr$
bmi categories  n ( % )
bmi category ( kg / m $nmbr$ )
bmi category  no . ( % )
bmi distribution  n ( % )
bmi group ( kg / m ^ )
bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .
bmi kg · m − $nmbr$
bmi o $nmbr$ kg / m $nmbr$  n ( % )
bmi   kg · m − $nmbr$
bmi # kg - m “ $nmbr$
bmi * ( kg / m $nmbr$ )  median ( q $nmbr$  q $nmbr$ )
bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < $nmbr$ . $nmbr$ for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than $nmbr$ mg / dl . dblood pressure control defined as < $nmbr$ / $nmbr$ or < $nmbr$ / $nmbr$ in patients with diabetes or a history of renal insufficiency .
bmi  kg per m $nmbr$
bmi  kg / m ^
bmi  kg / m ^ *
bmi  kg / m ^  mean ( sd )
bmi  kg / m ^  mean ( sd ) ’
bmi  kg / m ’
bmi  kg / m $nmbr$ ( mean $nmbr$ sd )
bmi  kg / m $nmbr$ ( sd )
bmi  kg / m $nmbr$ cholesterol  mg / dl
bmi  kg / m $nmbr$  mean
bmi  kg / m $nmbr$  median ( iqr )
bmi  kg / m $nmbr$  n ( % )
bmi  mean ( sd ) ( kg / m $nmbr$ )
bmi  mean ( sd ) kg / m $nmbr$
bmi  mean ( sd )  kg / m ^
bmi  mean ( sd )  kg / m $nmbr$ c
bmi  mean ( sd )  kg / rn $nmbr$
bmi  mean ± sd kg / m $nmbr$
bmi  mean ± sd  kg / m $nmbr$
bmi  mean  kg / m $nmbr$
bmi  mean  kg / m $nmbr$ ( ± sd )
bmi  median ( iqr )  kg / m $nmbr$
bmi  n ( % )
bmi  no . ( % )
bmi : < $nmbr$ kg / nr
bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom $nmbr$ h urine was collected ( see materials and methods section ) .
bmi > $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )
bmi > $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ )
bmia
bmij
bmit
bmp kg - m “ $nmbr$
bmultivariate logistic regression with variables forced in the modela
bnp — pg / ml
bnp — pg / ml  i
bnp ( n = $nmbr$ )
bnp < $nmbr$ pg / ml n = $nmbr$
bnp > $nmbr$ pg / ml or nt pro - bnp > $nmbr$ pg / ml  n ( % )
bnp > $nmbr$ pg / ml n = $nmbr$
bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$
bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$
bnp indicates brain natriuretic peptide  and nyha  new york heart association .
bnp  * median ( iqr )  pg / ml
bnp / nt - probnp
bnp / ntbnp ( n = $nmbr$ )
bocf - iike imputation ( random . ) ( n = $nmbr$ )
body - mass index - ! '
body - mass index — no . ( % ) : i :
body - mass index ( kg / cm $nmbr$ )
body - mass index ( kg / m   $nmbr$ )
body - mass index ( kg / m ’ )
body - mass index ( kg / m $nmbr$ ) ( mean  sd )
body - mass index ( kg / m $nmbr$ ) *
body - mass index ( kg / mq
body - mass index \ kg / m $nmbr$
body - mass index > $nmbr$ kg / nrn
body - mass index ) '
body - mass index  kg / m $nmbr$
body - mass index  kq / nrn
body - mass index : ! : blood pressure — mm hg
body - mass index ^
body - mass index ^ :
body - mass index ”
body height ( cm )
body mass index - mean ( sd )
body mass index ( bmi  kg / m $nmbr$ )  n ( % ) < $nmbr$ kg / m $nmbr$
body mass index ( kg / m )
body mass index ( kg / m ^ )
body mass index ( kg / m ^ ) ^
body mass index ( kg / m ’ ) ^
body mass index ( kg / m “ ) ^
body mass index ( kg / m $nmbr$ ) baseline systolic blood
body mass index ( kg / m $nmbr$ ) ∗
body mass index ( kg / m $nmbr$ )  mean ( sd ) c
body mass index ( kg / ma )
body mass index ( kgm _ $nmbr$ )
body mass index ( median
body mass index ( mg / m $nmbr$ )
body mass index [ kg / m $nmbr$ ]  mean ± sd
body mass index > $nmbr$ kg / m  n ( % )
body mass index > $nmbr$ t
body mass index blood pressure — mmhg
body mass index group ( ≥ $nmbr$ kg / m $nmbr$ ) — no . ( % )
body mass index group ( kg / m $nmbr$ ) ≥ $nmbr$ kg / m $nmbr$ — no . ( % )
body mass index mean kg / m $nmbr$ ( sd )
body mass index  kg / m ^
body mass index  kg / m ^ ( meanisd )
body mass index  kg / m ^ mean ( sd )
body mass index  kg / m ^ ^
body mass index  kg / m ’
body mass index  kg / m $nmbr$ ( mean ± sd )
body mass index  kg / m $nmbr$   ( sd )
body mass index  kg / m $nmbr$  mean ( sd ) §
body mass index  kg / rn \ mean ( sd )
body mass index  mean ( sd ) ( kg m ) $nmbr$ )
body mass index  mean ( sd ) kg / m $nmbr$
body mass index  mean ( sd )  kg / m $nmbr$
body mass index  mean kg / m ^ ( sd )
body mass index / mean ( sd )
body mass index ^
body mass indexa
body mass indexb
body mass indexf
body mass indexf  < $nmbr$
body mass indext
body weight ( change from baseline )
body weight ( kg ) *
body weight ( kg )  mean ( sd )
body weight ( kg )  mean ± sd
body weight at randomization
body weight at randonization { ixrs )
body weight reduction > $nmbr$ %
body weight *
body weight  kg ( mean ± sd )
body weight  kg ( sd )
body weight  kg ^
body weiqht
bodyweight  kg
bolus
bolus alone
bolus and corrections
bolus and infusion
bolus insulin doseh
bolus of heparin given
bone erosion score  mean ( sd )
bone fracture
bone fracture due to fall
bone mineral density ( g / cm $nmbr$ )  mean ( sd )
bonferroni - adjusted p value  b vs a
bonferroni - adjusted p value  c vs a
bonferroni - adjusted p value  d vs a
boost intensify all ( pan - asian patient population )
boost intensify premix i ( global patient population )
borg dyspnea score who functional class  n ( % )
bosentan use :
both adalimumab groups ( n = $nmbr$ )
both adalimumab groups ( n = $nmbr$ ) no baseline cd - related antibiotic use
both adalimumab groups ( n = $nmbr$ ) baseline immunosuppressant use
both adalimumab groups ( n = $nmbr$ ) baseline cd - related antibiotic use
both iv vasodilator and inotrope
both unfractionated heparin and low - molecular - weight heparin
bowel stricturing  ' n ( % )
bp - lowering treatment ( n = $nmbr$ )
bp - lowering treatments  n ( % )
bp < $nmbr$ / $nmbr$  n ( % )
bp = blood pressure  egfr = estimated glomerular filtration rate ( men : $nmbr$ en : $nmbr$ x cr $nmbr$ . $nmbr$ x age $nmbr$ . $nmbr$ x $nmbr$ . $nmbr$ )  hdl = high - density lipoprotein .
bp and fasting glucose results
bp component ( mm hg )
bp control
bp goal attainment
bp goal  no . ( % )
bp in pre - treated patients
bp variable  mm hg
bp : blood pressure  ci : confidence interval  esrd : end - stage renal disease  hr  hazard ratio . all patients ( except patients with other race ) were included with missing covariates imputed . event : no . of patients with esrd  rate : event rate per $nmbr$ years of follow - up  pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or x $nmbr$ g / g ) as strata  adjusted : a multivariate cox model with treatment group  time - varying systolic and diastolic bp as covariates . pre - specified analysis and adjusted for time - varying bp
bpearson ' s chi ‐ square test .
bph - luts severity
bph - related health status
brain volume  cm '
brandomization was stratified by diabetic status .
breakfastb
bronchial reversibility %
brv > $nmbr$ mg / day
brv $nmbr$   mg / day
brv $nmbr$ mg / day ( n =
brv overall
brv overall ( n = $nmbr$ )
brv overalla ( n = $nmbr$ )
bsa ( % )
bsa ( % )  mean ( sd )
bsa affected  %
bsa involved  % $nmbr$
bsl hb  gl - $nmbr$
bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per $nmbr$ patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .
bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per $nmbr$ patient - years of follow - up  rrr  relative risk reduction  yr  year . ^ treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < $nmbr$ or > $nmbr$ g i - $nmbr$ ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year $nmbr$ as covariates .
bud $nmbr$ ptg n = $nmbr$
bud / fm $nmbr$ / $nmbr$ atg n = ^ $nmbr$
budesonide - formoterol ( n = $nmbr$ )
budesonide - formoterol $nmbr$ ^ g + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ )
budesonide - formoterol $nmbr$ + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ )
budesonide ( n = $nmbr$ )
budesonide ( symptom days a week )
budesonide { symptom days a week )
budesonide $nmbr$ ^ g ( n = $nmbr$ )
budesonide mmx $nmbr$ mg  ( n = $nmbr$ )
budesonide  n ( % )
budesonide / formoterol fdc
bundle branch block
bw  kg
by baseline diabetic status
by cause of death
by genotyping
by gfr stratum for all participants  ml / min per $nmbr$ . $nmbr$ m ’ !
by gfr stratum for diabetic participants  mt / min per $nmbr$ . $nmbr$ m ’ §
by gfr stratum tor all participants  ml / min per $nmbr$ . $nmbr$ m ^ !
by gfr stratum tor diabetic participants  ml / min per $nmbr$ . $nmbr$ m ’ §
by treatment arm
by who / simon broome criteria
bypass graft §
c - peptide  median ( q $nmbr$  q $nmbr$ )  nmol / l
c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < $nmbr$ . $nmbr$  § p = $nmbr$ . $nmbr$  * p = $nmbr$ . $nmbr$ . nteractions were not statistically significant ( p > $nmbr$ . $nmbr$ ) .
c - reactive protein concentration ( mg / l )
c - reactive protein  u / l
c - reactive proteinc
c clinical fractures ( fas )
c group ( n = $nmbr$ )
c peptide  nmol / l * '
c  right - sided vhd ( n = $nmbr$ )
c . das $nmbr$ - crp < $nmbr$ . $nmbr$
c $nmbr$ ml decrease in trough fev $nmbr$
c $nmbr$ - unit sgrq total score increase
c $nmbr$ e $nmbr$ fab bolus
c $nmbr$ e $nmbr$ fab bolus ( n = $nmbr$ )
c $nmbr$ e $nmbr$ fab bolus and infusion ( n = $nmbr$ )
ca - channel blockers  n ( % )
cabg — no . { % )
cabg history
cabg or angioplasty
cabg or ptca ( % )
cabg or valve
cabg performed during index hospitalization
cabg surgery by no . of vessels $nmbr$
cabg :
cad death
cad *
caffeine
caffeine consumption ( yes ) ( n )
caffeine consumption *
caffeine user
caffeine user  n ( % )
caffeine users  n ( % )
calcitonin
calcium - channel blocker *
calcium - channel blockersubgroup
calcium channel blocker ( % )
calcium channelantagonist
calcium level
calculated annual decline  mean ± se
caleitonin  ng / l  females mean ± sd
caleitonin  ng / l  males mean ± sd
caleium ehannel bloekers ( ccb )
calima japan ( n = $nmbr$ )
calima japandhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ) y
calima overall ( n = $nmbr$ )
calima overalldhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ )
cana
cana $nmbr$ mg ( n $nmbr$ $nmbr$ )
cana $nmbr$ mg ( n - $nmbr$ )
cana $nmbr$ mg ( n = $nmbr$ ) *
cana $nmbr$ ( n = $nmbr$ )
cana $nmbr$ / met ( n = $nmbr$ )
canada or united states
canagiiflozin
canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg
canakinumab $nmbr$ mg
canakinumab dose
canakinumab  $nmbr$ - month on - treatment il - $nmbr$ below the median value ( < $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ )
canakinumab  $nmbr$ month on - treatment il - $nmbr$ above the median value ( ≥ $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ )
canakinumab  il - $nmbr$ lowest tertile
canakinumab  il - $nmbr$ middle tertile
canakinumab  il - $nmbr$ top tertilec
cancer — no . ( % )
cancer n ( % )
cancer surgery
cancer *
cancer  fatal and nonfatal
cancert
cangrelor dyspnoea vs no dyspnoea *
cangrelor n / n ( % )
canrenone ( n z $nmbr$ )
canvas ( n = $nmbr$ ) : placebo ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )
cardiac - biomarker status 一 no . / total no . ( % ) $
cardiac arrhythmia
cardiac arrhythmia  n ( % )
cardiac biomarker elevation
cardiac biomarker  n ( % )
cardiac catheterisation or pci for index event
cardiac diseasec
cardiac disorder
cardiac disorder  n ( % ) §
cardiac disorders ( soc )
cardiac enzyates raised
cardiac failure —
cardiac failurec
cardiac index  l • mn ' • m $nmbr$
cardiac medications during index hospitalization
cardiac medications during index hospitalization — no . ( % )
cardiac parameters
cardiac procedure :
cardiac resynchronization therapy n ( % )
cardiac rhythm disorder at baseline no
cardiac therapy
cardio - renal risk
cardioembolic infarction  n ( % )
cardiogenic shock during first $nmbr$ hr after randomization
cardiomyopathy
cardiothoracic ratio > $nmbr$ . $nmbr$
cardiovascuiar mortaiity
cardiovascular and oral hypoglycemic drugs - no . ( % )
cardiovascular death ( n = $nmbr$ )
cardiovascular death and hospital admission for heart failure
cardiovascular death or heart failure hospitalization
cardiovascular death or hospitalization for heart failure
cardiovascular death or hospitalized hf
cardiovascular death or nonfatal myocardial infarction
cardiovascular death *
cardiovascular death  mi  or stroke
cardiovascular death  myocardial infarction  or stroke
cardiovascular death  nonfatal myocardial infarction  nonfatal stroke
cardiovascular death  nonfatal myocardial infarction  or nonfatal stroke
cardiovascular death / hospitalization for heart failure
cardiovascular death ®
cardiovascular disease ( n = $nmbr$ )
cardiovascular disease history  n ( % ) *
cardiovascular disease history ‡
cardiovascular disease n ( % )
cardiovascular disease risk category
cardiovascular disease *
cardiovascular disorder
cardiovascular disorder  n ( % )
cardiovascular events
cardiovascular history — no . ( % )
cardiovascular hospitalisation §
cardiovascular metabolic syndrome risk lactors
cardiovascular mortality ( per $nmbr$ person - years )
cardiovascular mortality or mi
cardiovascular mortality  mi  or revascularization
cardiovascular risk factor — no . { % )
cardiovascular risk factors — no . { % )
cardiovascular risk factors alone ( n = $nmbr$ )
cardiovascular risk factors and history
cardiovascular risk factors and history — no . ( % )
cardiovascular risk factors and history ( % )
cardiovascular risk  n ( % )
cardiovascular therapies — no . { % )
care use
caribbean
carisbamate $nmbr$  $nmbr$ mg ( n = $nmbr$ )
carisbamate $nmbr$ mg ( n = $nmbr$ )
carotid artery disease
carotid artery stenosis  n ( % )
carotid bulb sites
carotid endarterectomy
carotid imt
carrier ( n = $nmbr$ )
carvedilol
carvedilol  % ( n )
cases
casual plasma glucose ( mg / dl )
cat > = $nmbr$ ( n = $nmbr$  $nmbr$ )
cat > = $nmbr$
cat score  mean ( sd )
cat total score $nmbr$
cat . $nmbr$ n / n ( % )
cataract
cataract removal
catecholamines or corticosteroids without hospitalization
categorical variables
categorical variables . no . ( % ) * ’
categories of urinary acr  ^ g / mg
category
category — no . / total no . ( % )
catheter site — femoral
catheterization laboratory in
catheterization laboratory in center
caucasian $nmbr$
caucasian eze / simva ( n = $nmbr$ )
caucasian n = $nmbr$  $nmbr$
caucasian race
caucasian race ( % )
caucasian simva ( n = $nmbr$ )
caucasian  n ( % ) *
caucasians ( n = $nmbr$ )
causaslan
cause of death unknown
causes of dvt or pe — no . ( % ) ^ |
causes of dvt or pe  n ( % )
cbz - exposed
cbz - naive
cc
cclear < $nmbr$
cclear $nmbr$ - $nmbr$
cclear $nmbr$ +
ccq total score
cd [ gemini $nmbr$ ] * ’
cd complications
cd duration  y
cdai ( $nmbr$ - $nmbr$ )
cdai > $nmbr$  n [ % ]
cdai score
cdai score  mean ( s . d . )
cdai score  mean ± sda
cdai score  median ( min  max )
cdai  mean [ sd ]
cdai §
cdmard experience  n ( % )
celecoxib
center
center - level ihr percent time in therapeutic range for warfarin subjects
center level ttr
central and eastern europe
central and south america
central and south america and mexico
central eosinophil count
central or south america
central / eastern
central / south
central / south america
central / south america and mexico
centrally acting sympathomimetics
centre
centrilobular emphysema
cerebral
cerebral infarction
cerebral ischemia
cerebrovascuiar disease
cerebrovascular accident / tia
cerebrovascular disease n ( % )
cerebrovascular disease  %
cerebrovascular or peripheral arterial disease
cerebrovascular or peripheral arterial disease    n   ( % )
certolizumab group
cfb at week $nmbr$
cfisher ' s exact test .
cgfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
cgfrby ckd - epi  ml / min / $nmbr$ . $nmbr$ m $nmbr$  median ( iqr )
cgi - s  n ( % ) z :
cgm use
cha $nmbr$ s $nmbr$ score
cha $nmbr$ ds $nmbr$ - vasc < $nmbr$
cha $nmbr$ ds $nmbr$ - vasc $nmbr$ - $nmbr$
cha $nmbr$ ds $nmbr$ - vasc $nmbr$ $nmbr$
cha $nmbr$ ds $nmbr$ - vasc score
cha $nmbr$ ds $nmbr$ - vasc score  mean ± sd
cha $nmbr$ ds $nmbr$ - vasc score    n   ( % )
cha $nmbr$ ds $nmbr$ - vasc  mean ± sd
cha $nmbr$ ds $nmbr$ vasc score
cha $nmbr$ ds $nmbr$ vasc score ( % )
chad $nmbr$ > $nmbr$
chads - $nmbr$ score
chads score  n ( % )
chads $nmbr$ risk factors  n ( % )
chads $nmbr$ score > $nmbr$
chads $nmbr$ score $nmbr$
chads $nmbr$ score $nmbr$ - $nmbr$  n ( % )
chads $nmbr$ score per outcome stroke or systemic embolism
chads $nmbr$ score  mean ( ± sd )
chads $nmbr$ score  mean ± sd
chads $nmbr$ score  n ( % )
chads $nmbr$ scoret
chads $nmbr$   score    n   ( % )
chads $nmbr$  mean ± sd
chads $nmbr$ < $nmbr$
chads $nmbr$ components  n ( % )
chads $nmbr$ scoref
chadsa < $nmbr$
chadsj < $nmbr$
chadsj > $nmbr$
chajdsa - vasc $nmbr$ - $nmbr$
chajdsj - vasc > $nmbr$
chajdsj - vasc $nmbr$ - $nmbr$
chajdsrvasc $nmbr$ - $nmbr$
change
change from baseline in
change from baseline in acq - $nmbr$
change from baseline in acq - $nmbr$ score
change from baseline in aqlq { s ) score
change from baseline in fevj ( mb )
change from baseline in mean $nmbr$ - h dbp  mmhg
change from baseline in mean $nmbr$ - h sbp  mmhg
change from baseline in morning pef during weeks $nmbr$ - $nmbr$  mean l / min ( se )
change from baseline in post - bd
change from baseline in pre - bd
change from baseline in rescue medication use ( puffs per day )
change from baseline in sgrq
change from baseline to final apbm
change from baseline to week $nmbr$ in dlqi scorez
change from baseline to week $nmbr$ in uas $nmbr$
change from baseline to week $nmbr$ in weekly iss
change from baseline to week $nmbr$ in weekly no . of hives score
change from baseline to week $nmbr$ in weekly size of largest hive score
change from baseline to week $nmbr$
change from baseline  median ( iqr )
change from baseline  mg / dl  mean ( sd )
change from baseline  mmhg
change in das $nmbr$ > $nmbr$ . $nmbr$
change in femoral neck bmd from fit baseline to flex baseline
change in fpg $nmbr$ to month $nmbr$ ( mg / dl )
change in hba $nmbr$ c $nmbr$ to month $nmbr$ ( % )
change in hbalc after $nmbr$ weeks etd ( $nmbr$ % cl )
change in hdl ‐ c
change in ldl ‐ c
change in lp ( a )
change in nt - probnp at $nmbr$
change in pav  mean ( $nmbr$ % cl )  %
change in psa ‐ modified shs  baseline to week $nmbr$ ‡
change in psa ‐ modified shs  baseline to week $nmbr$
change in retinal pathology
change in sbp
change in sedbp  ls mean ( se )
change in sesbp  ls mean ( se )
change in tc
change in tg
change to week $nmbr$
change to week $nmbr$ *
change to week $nmbr$ * ’ ’
change to   week $nmbr$
change  mg / dl ( mmol / l )
changes at baseline
changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p $nmbr$ . $nmbr$ vs $nmbr$ y .
changes in serum creatinine  pmol / l
changes in shs
characteristic ( a )
characteristic age
characteristic age — yr
characteristic age mean ± sd — yr
characteristic and treatment
characteristic at baseline
characteristic *
characteristic  no . ( % )
characteristic / outcome
characteristic ^
characteristic_level
characteristic_name
characteristic †
characteristica
characteristics no . of participants
characteristics *
characteristicsa
charlson
charlson comobility score  n ( % )
charlson comorbidity index
charlson comorbidity index  mean ( sd )
charlson index ( % )
charm
chd ( nonfatal mi + fatal chd )
chd ( primary outcome )
chd + cl all
chd at baseline
chd deaths
chd disease death
chd eze / simva ( „ = $nmbr$ )
chd plus cerebral infarction
chd risk factors #
chd simva ( „ = $nmbr$ )
chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease
chd  total
chest discomfort
chest x - ray
chf score ( u )
chi - square p value
china / japan
china / tjapan
chl
chlor
chloroquine
chlorthalidone
chlorthalidone ( n = $nmbr$ )
chlorthalidone $nmbr$
chlorthalidone group
chlorthalidone vs amlodipine
chlorthalidone vs doxazosin
chlorthalidone vs lisinopril
cholesterol
cholesterol - mean ( sd  n )
cholesterol ( ng / ml )
cholesterol ( nmol / l )
cholesterol  mg / dl
cholesterol  mg / dl total
cholesterol  mg / dl  mean ( sd ) §
cholinesterase inhibitor use at baseline  no . ( % )
chondroitin
chondroitin sulfate
chronic bronchitis ( itt ) ( n = $nmbr$ )
chronic bronchitis ( n = $nmbr$ )
chronic bronchitist
chronic cardiovascular disease  no . ( % )
chronic kidney disease ( % )
chronic kidney disease  no . ( % ) t
chronic kidney disease †
chronic obstructive pulmonary
chronic obstructive pulmonary disease — no . ( % )
chronic renal disease
chronic renal disease — no . ( % )
chronic renal insufficiency
chronic renal insufficiency  %
chronic sinusitis + nasal polypsd  n ( % )
chronic treatment with aspirin
chylomicron cholesterol
chylomicron triglycerides
ci = confidence interval  na = not applicable or not analyzed .
ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the $nmbr$ genotype groups ) .
ciass i
ciass ll - iv
cigarette - smoking status — no . ( % )
cigarette - smoking status ( % )
cigarette smoker *
cigarette smoker  no . ( % )
cigarette smoking  n ( % )
ck > $nmbr$ x uln $nmbr$
ck > $nmbr$ xuln
ckd ( egfr < $nmbr$ )  n ( % )
ckd n
ckd prognosis by kdigo ' '
ckd rate ( # events )
ckd stage $nmbr$
ckd stage $nmbr$ ( % )
ckd stages
ckd *
cl - $nmbr$ ]
class > ii
class $nmbr$
class i or no symptoms
class ii ( b - blockers )
class iii / iii - v
class iv glomerulonephritis
class iv only
class iv / iv - v
class ll - iv
class v only
classification of epilepsy type  n ( % )
cld $nmbr$ mg
cld $nmbr$ mg ( n = l $nmbr$ )
clean  n ( % ) a
clinic research experience  n ( % )
clinical and patient reported outcomes  % ( observed n ) unless otherwise indicated
clinical atherosclerotic disease *
clinical characteristics ( % )
clinical characteristics  n ( % )
clinical dementia rating sum of boxes  mean ( sd ) f
clinical disease activity index
clinical efficacy at week $nmbr$
clinical endpoint
clinical fracture
clinical or lesion rf for st
clinical outcome
clinical remissione
clinical responsed
clinical variables  median ( iqr )
clinically relevant non
clonic
clopidogrel %
clopidogrel ( n = $nmbr$ $nmbr$ )
clopidogrel dyspnoea vs no dyspnoea *
clopidogrel n / n ( % )
clopidogrel n / n { % )
clopidogrel or ticlopidine
clopidogrel  $nmbr$ mg loading doset
closure
clow - potency stratum : simvastatin $nmbr$ mg  pravastatin $nmbr$ mg  fluvastatin $nmbr$ mg  atorvastatin $nmbr$ mg  high - potency stratum : simvastatin $nmbr$ mg  atorvastatin
cluster $nmbr$ : diuretic ( n = $nmbr$ )
cluster $nmbr$ : reversible  no diuretic ( n = $nmbr$ )
cluster $nmbr$ : not reversible  no diuretic ( n = $nmbr$ )
cluster seizures
cm
cmann whitney u test / wilcoxon sum rank test .
cns systemic embolism
co - morbidities  n ( % )
cochranemantelehaenszel ( repeated $nmbr$ . $nmbr$ % ci ) c
coefficient
coenzyme q $nmbr$ p  g / ml #
cognitive
cognitive subscale on alzheimer ' s disease assessment scale  mean ( sd ) e
coiticosieroids at baseline
colchicine ( n = $nmbr$ )
colectomy ( partial or total )
colesevelam ( n = $nmbr$ )
colesevelam hydrochloride group ( n = $nmbr$ )
college degree or higher
college graduate or more
colombia
colon ' ses - cd score  mean ( sd )
colon only  ' n ( % )
colon only  n ( % )
colon or rectum
colonic area involved
colonoscopy
combination
combination ( n = $nmbr$ )
combination treatment ifx + aza
combinationf
combinations of aspirin and ppi use ( p = $nmbr$ . $nmbr$ t )
combined
combined ( dutasteride / ta msu losi n )
combined cardiac failure  cardiomyopathy or other cardiac disorder  n ( % ) luts severity  n ( % )
combined cardiac failure  cardiomyopathy or other cardiac disorders
combined chd
combined cvd
combined end point
combined end poir
combined fatal / nonfatal outcomes
combined golimumab groups
combined infliximab
combined insulin / oral hypoglycaemic agent use
combined ischaemic heart disease and / or cerebrovascular disorder *
combined major macrovascular events  neohrodathv . and all - cause mortalitv ■
combined major macrovascular events .
combined statin and other lipid - lowering agent use
combined therapy ( / v = $nmbr$ )  $nmbr$ / $nmbr$
combined therapy vsdutasteride
combined therapy vsta msu iosin
combo - facilitated pci
combo vs . primary
commercially available fondaparinux
common carotid artery sites
comorbid conditionsb
comorbid illnesses
comorbidities ( % )
comorbidities and concomitant medications
comorbidities  no . ( % )
comorbidities / concomitant medications
comorbidity  no . ( % )
comparator
comparison
comparison : cat . $nmbr$ vs . cat . $nmbr$
complete healinga
complete mayo clinic score  median ( min  max }
completed previous febuxostat study
completed prior febuxostat studya
component . for all instruments  higher scores indicate more severe disease . ara denotes american rheumatism association ( now called
components
components of primary composite end point — secondary end points
components of the first cid
composite
composite endpoint
composite endpoint ( a $nmbr$ c < $nmbr$ . $nmbr$ %  bp
composite index of insulin sensitivity ( isi )
composite microvascular end point *
composite ocular end point ^
composite of $nmbr$ % reduction in egfr  end - stage kidney disease  or death from renal causes
composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis
composite of death / mi / urg ent revasc
composite of doubling of serum creatinine  end - stage kidney disease  or death from renal causes
composite physiologic index §
composite vascular endpoint
concentrations at baseline
concern
concomitant
concomitant aeds  n ( % )
concomitant aedsb  n ( % )
concomitant aedsb    n   ( % )
concomitant antibiotic use  n [ % ]
concomitant anticoagulant  antithrombotic or nsaid  n ( % )
concomitant antiplatelet
concomitant aspirin use
concomitant cardiovascular therapy
concomitant drug therapies  n ( % )
concomitant drug therapy at discharge
concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % )
concomitant dvt  n ( % )
concomitant lipid - lowering therapy ( any )
concomitant lipid - modifying therapy — no . { % )
concomitant medication — no . { % ) | ace inhibitor
concomitant medication ( > $nmbr$ % )
concomitant medication use
concomitant medication  n ( % ) d
concomitant medication  n [ % ]
concomitant medication  no . ( % )
concomitant medications — no . ( % )
concomitant medications ( % )
concomitant medications ( yes )  n ( % }
concomitant medications after randomization
concomitant medications at baseline
concomitant medications in > $nmbr$ % of subjects  no . ( % )
concomitant medications  no . ( % )
concomitant methotrexate use  n ( % )
concomitant oads  n ( % )
concomitant oral anti - dm drugs  no . ( % ) a
concomitant oral glucose - lowering agents  zz ( % )
concomitant pd medications at baseline  n ( % ) c  d
concomitant therapy  n [ % ]
concomitant treatment 一 no . ( % )
concomitant treatments at randomization
concomitant use of bosentan  n ( % )
concomitant use of conventional synthetic dmard up to $nmbr$ mo — no . { % ) methotrexate
concomitant use of corticosteroids
concomitant use of mtx to week $nmbr$
concomitant use of nsaids to week $nmbr$
concurrent illness
concurrent medications
concurrent prednisolone
concurrent treatment at study entry — no . ( % ) * *
condition $nmbr$ ( $nmbr$ . $nmbr$ )
congestion *
congestive heart
congestive heart failure — no . ( % ) |
congestive heart failure at randomisation
congestive heart failure §
congestive heart failure †
congestive hf
conieosieroids and / or $nmbr$ - mp
connective - tissue disease
connective tissue disease
conservative strategy ( n = $nmbr$  $nmbr$ )
constipation
continue thienopyridine n = $nmbr$
continued use of gpa
continuous
continuous lvef $nmbr$ treatment interaction
continuous variables  mean ( sd ) ^
contrast angiography
contrast used ( ml ) *
contrast volume > $nmbr$ ( ml )
contrast volume > $nmbr$ ml
control = warfarin
control group
control n = $nmbr$
controlled : acq - $nmbr$ < $nmbr$ . $nmbr$
controllertreatment before entry *
contusion
conventional agents *
converting enzyme inhibitor
convulsion
copd - placebo ( $nmbr$ pt ) n . ( % )
copd - rosuvastatin ( $nmbr$ pt ) n . ( % )
copd ( % )
copd duration  mean ( sd )  yr *
copd exacerbation history in the previous year  n ( % )
copd history yrs
copd medication taken for at least $nmbr$ months before study entry
copd severity stage ( gold )
copd severity  %
copd severitya    n   ( % )
copd severityy
copd type
copd worsening
copd    n   ( % )
coping
core cardiovascular endpoint
core study to first infusion
corneii product  mm - ms
cornell index  pv
cornell voltage - duration product ( mmxmsec ) *
cornell voltage - duration product  mm × ms
cornell voltage - duration product  mm x ms
cornell voltage duration ( mv × ms )
cornell voltage x duration product  mm x ms
coronar y - artery bypass grafting
coronar y artery disease
coronarv arterv disease
coronary - artery bypass grafting §
coronary artery
coronary artery bypass
coronary artery bypass graft — no . ( % )
coronary artery bypass graft  n ( % )
coronary artery bypass grafting n ( % )
coronary artery disease — no . ( % )
coronary artery disease — no . ( % ) : c
coronary artery disease ( n = $nmbr$ $nmbr$ )
coronary artery disease *
coronary artery disease  %
coronary artery disease    n   ( % )
coronary artery disease §
coronary artery stenosis > $nmbr$ %
coronary artery treated  no . ( % )
coronary bypass surgery
coronary events $nmbr$
coronary heart disease — no . ( % )
coronary heart disease  n ( % ) cardiovascular risk ( per protocol )  n ( % ) very high
coronary procedure ( % of group )
coronary revascularisation §
coronary syndrome . ci = confidence interval  hr = hazard ratio .
corticosteroid - free remissioni
corticosteroid dose ( prednisone
corticosteroid use at randomization
corticosteroid use at randomization    n   ( % )
corticosteroid use  %
corticosteroid use  n ( % )
corticosteroids ' $nmbr$
corticosteroids ( excluding budesonide )
cortteosterom relrsclory status
cough ( investigator reported )
cough ( leading to study drug discontinuation )
cough  n ( % )
covariate
covariates
cox - $nmbr$ selective inhibitor use
cr + crpnorr
cr + mh
cr + mh + crpnorr
cr imputation ( random . ) ( n = $nmbr$ )
crcl ( ml / min )
crcl ( ml / min ) at randomization
crcl ( sd ) ml / min
crcl > $nmbr$ - < $nmbr$ ml / min
crcl $nmbr$ - $nmbr$
crcl at baseline  ml / min
crcl at randomization - ml / min
crcl at randomization  ml / min
crcl of $nmbr$ - $nmbr$ ml min '  n ( % )
crcl  mean  ml / min ( ± sd )
crcl  median ( iqr )  ml / min
crcl  ml / min
crcl  ml / min mean ( sd )
creatine clearance category
creatine clearance category $nmbr$ to < $nmbr$ ml / min $nmbr$ / $nmbr$
creatinine
creatinine ( ^ mol / l ) ( median  iqr )
creatinine ( µ mol / l )
creatinine ( mg / dl )  mean ( sd )
creatinine ( p  mol / l )
creatinine > $nmbr$ . $nmbr$ x baseline and above uln
creatinine > $nmbr$ x baseline
creatinine $nmbr$ . $nmbr$ mg / dl medications
creatinine ciearance
creatinine clearance — ml / min
creatinine clearance ( ml / min )  mean ± sd
creatinine clearance < $nmbr$ ml / min — no . ( % ) weight < $nmbr$ kg — no . ( % )
creatinine clearance < $nmbr$ ml / min  no . / total ( % )
creatinine clearance > $nmbr$ to < $nmbr$ ml / min — no . ( % ) f
creatinine clearance at randomization
creatinine clearance at randomization ( ixrs )
creatinine clearance category [ ml / min ]
creatinine clearance  ml / min - $nmbr$ *
creatinine clearance  no . ( % )
creatinine clearance  an   ( % )
creatinine clearanceb  ml / min
creatinine ratio
creatinine  mg / dl ( sd )
creatinine  mg / dl  mean
creatinine  mmol 八
creatinine  pmol / l
criterion
criterion reached first  n ( % )
critical site
crj
crohn ' s disease duration
cromoglicate
cross - clamp
crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .
crp ( mg / dl  per unit )
crp ( mg / l )
crp ( mg / l ) ( cv )
crp ( mg / l ) [ b ]  median ( min - max )
crp ( mg / l )  mean ( sd )
crp ( mg / l )  n
crp ( normal < $nmbr$ . $nmbr$ mg / dl )
crp [ mg / l ]  median
crp > $nmbr$ . $nmbr$ mg / dl  n ( % )
crp > $nmbr$ mg / $nmbr$  n [ % ]
crp level  mean ± sd mg / dl
crp  mean [ sd ] mg / $nmbr$
crp  mean mg / l ( sd )
crp  median ( range ) mg / literl
crp  median  mg / dl
crp  mg / dl
crp  mg / dl  mean ( sd )
crp  mg / dl  median
crp  mg / l *
crp   ≤   uln
crp   >   uln
crpnonr ?
crt - p + d  n ( % )
crude
crude model hr ( $nmbr$ % ci )
crude rate
crusade bleeding score  mean ( sd ) ^
crusade score
cryptogenic
cryptogenic localization - related
cs
cs and im
cs and imm
cs and is
cs only
csdmard otherthan methotrexate
csdmard use at baseline ^
csii
ct
ct ratio ( % )
ct ratio > $nmbr$ . $nmbr$
ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  h $nmbr$  histamine $nmbr$  iqr  interquartile range  n  number of patients  sd  standard deviation .
ct + tt
ctd population subgroup
ctn - i  ng / ml
cu index test  n ( % ) $nmbr$
cuban
culprit vessel
cumulative events
cumulative incidence $nmbr$ years
cumulative incidence lyear
cumulative nsaid score  mean   ±   sd
current ( n   = $nmbr$  $nmbr$ )
current alcohol drinking  n ( % )
current alcohol  n ( % )
current alendronate use
current angina
current angina ( % )
current cigarette smoker  n ( % )
current cigarette smoking  no . ( % )
current cigarette use
current cigarette  n ( % )
current corticosteroid use  n
current dactylitis  n
current enthesitis  n ( % ) ’
current inhaled corticosteroid use
current laba use
current lama use
current lra use
current medication use
current or former smoker
current or prior smoking  %
current oral corticosteroid use
current smoker — no . { % )
current smoker — no . ( % ) blood pressure — mm hg
current smoker — no . / total no . ( % )
current smoker »
current smoker ( n = $nmbr$  $nmbr$ ) former smoker ( n = $nmbr$  $nmbr$ )
current smoker at baseline    n   ( % )
current smoker at screening  n ( % )
current smoker at screeninga  n ( % )
current smoker  n ( % of patients )
current smoker  n ( % ) post - bronchodilator screening
current smoker  n ( % }
current smoker  n [ % ]
current smoker  n / n ( % )
current smoker  no . ( % )
current smokers ( itt ) ( n = $nmbr$ )
current smokers ( n = $nmbr$ )
current smokers  n ( % ) medicai history  n ( % )
current smokers    n   ( % )
current smoking ( % )
current smoking  %
current tobacco smoker
current tobacco smoker ( % ) qualifying event ( % )
current use of hormone therapy
current xanthine derivative use
currentd
currently on aha therapy
currently smoker
currently smokes
cutoffs
cv
cv death or hf hosp .
cv death or hhf
cv death or ml
cv death  mi  or stroke
cv death  mi  stroke
cv death  mi  stroke  or urgent coronary revascularization
cv death  mi  stroke  recurrent ischemia
cv death  ml or ischemic stroke
cv death  ml  ischemic stroke  hospitalization for unstable angina  revascularization or heart failure
cv death  myocardial infarction  stroke
cv death  non - fatal mi or non - fatal stroke
cv disease
cv disease history  no . ( % ) §
cv endpoints n ( % )
cv historya
cv medication
cv risk factors
cv risk factors and history
cvd deaths
cvd mortality
cvd risk factors ( age > $nmbr$ ) ^ “ ^
cvd without mi or stroke ( n = $nmbr$ )
cvd without miatroke
cvd without ml / stroke
cvd without ml ^ troke
cvd  total
cvd / mi / stroke
cvd / mi / stroke / revascularization / urgent vascular hospitalization
cvd / mi / stroke / urgent coronary revascularization
cvd / mi / stroke / urgent vascular hospitalization
cvd / stroke / see
cvdeath  ml  or ischemic stroke
cwt  mean ( se )  mm
cyp $nmbr$ a $nmbr$
cyp $nmbr$ a $nmbr$ inhibitors
cystitis
cystoscopic procedure
czech repumc
czp $nmbr$ mg
czp $nmbr$ mg ( n = $nmbr$ )
czp $nmbr$ mg ( n = lll )
czp $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ )
czp $nmbr$ mg q $nmbr$ w
czp baseline
czp combined arms ( n = $nmbr$ )
d
d - value
d ( $nmbr$ % ci )
d $nmbr$ mg vs . warfarin
d includes cardiac glycosides  antiarrhythmics classes i and iii  vasodilators used in cardiac disease and other cardiac preparations .
d non - vertebral fragility fractures ( fas )
d population
d  mitral stenosis vhd ( n = $nmbr$ )
d / mi / idfvst
d $nmbr$ % ( n / n )
d $nmbr$ vs warfarin
d $nmbr$ vs warfarin rr ( $nmbr$ % ci  p value )
dabigatran
dabigatran ( n = $nmbr$ )
dabigatran $nmbr$ mg
dabigatran $nmbr$ mg ( n = $nmbr$ )
dabigatran $nmbr$ mg $nmbr$ mg % per yr
dabigatran $nmbr$ mg bid
dabigatran $nmbr$ mg bid ( n = $nmbr$ )
dabigatran $nmbr$ mg bid events / n ( % / y )
dabigatran $nmbr$ mg bid vs warfarin
dabigatran $nmbr$ mg versus warfarin
dabigatran $nmbr$   mg b . i . d .
dabigatran $nmbr$ mg versu swarfarin
dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid
dabigatran $nmbr$ mg ( n = $nmbr$  $nmbr$ )
dabigatran group
dabigatran  $nmbr$ mg
dabigatran  $nmbr$ mg bid
dabigatran  $nmbr$ mg twice daily
dabigatran  $nmbr$ mg  vs . warfarin
dabigatran $nmbr$ vs . warfarin p ( inter )
dactylitis in > $nmbr$ digit
dactylitis score
dactylitis score ( $nmbr$ - $nmbr$ )
dactylitis score ( $nmbr$ - $nmbr$ )  mean ( sd )
dactylitis score ( $nmbr$ – $nmbr$ scale )
dactylitis score at baseline  median ( iqr ) week $nmbr$
dactylitis severity score ) score > $nmbr$ — no . { % )
dactylitis  % #
daily “ off ” time  mean ± sd  h / dayf
daily bowel movements
daily dose of inhaled glucocorticoid — no . ( % ) §
daily dose of study medication prescribed
daily dose of vitamin d ( iu / day )
daily exercise ( % )
daily total dose of insulin — lu / kg
dalteparin ( n = $nmbr$ )
dapaglifloiin  n *
dapaglifloz . in  n
dapagliflozin
dapagliflozin ( n = $nmbr$ )
dapagliflozin $nmbr$ mg + insulin ( n   = $nmbr$ )
dapagliflozin $nmbr$ mg + insulin ( n = $nmbr$ )
dapagliflozin placebo no . of events / no . of patients
dapagliflozin  n *
das $nmbr$ ‐ crp
das $nmbr$ - esr  mean ( sd )
das $nmbr$ - esr  mean ± sd das $nmbr$ - esr remission  %
das $nmbr$ - hscrp  mean ( sd )
das $nmbr$ ( crp )  mean ( sd )
das $nmbr$ score
das $nmbr$  mean ( sd )
das $nmbr$  mean ± sd
das $nmbr$  range $nmbr$ - $nmbr$  mean ( sd )
data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation  † at discharge . ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .
data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation
data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme  arb = angiotensin - receptor blocker . chf = congestive heart failure . * any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery .
data are mean ( sd ) or number ( % ) . bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . lvef = left ventricular ejection fraction . hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .
data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids  bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . nyha = newyork heart association . lvef = left ventricular ejection fraction . hf = heartfailure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter defibrillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .
data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p
data are number of patients ( % ) or hazard ratio ( $nmbr$ % cl )  p values are forthe test of heterogeneity . cad = coronary artery disease . bmi = body - mass index  which is weight in kg divided by the square of height in metres . ldl = low - density lipoprotein . hdl = high - density lipoprotein . there is a deficit of clinical data in some patients with the events .
data are number of patients ( % ) or mean ( sd )  unless otherwise indicated . cabg = coronary - artery bypass grafting . ptca = percutaneous transluminal coronary angioplasty  ldl = low - density lipoprotein . hdl = high - density lipoprotein . iqr = i nterquarti le range  hmg coa ri = $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a reductase inhibitor . bmi = body - mass index  which is weight in kg divided by the square of height in metres  * median ( iqr ) .
data are presented as mean sd . * n $nmbr$ for ldl cholesterol . † n $nmbr$ for ldl cholesterol . ‡ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . § signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . ¶ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ .
data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at $nmbr$ year . * cardiovascular ( cv ) death  myocardial infarction ( mi )  or recurrent ischemia . † cv death  mi  or severe recurrent ischemia
data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < $nmbr$ . $nmbr$ vs . ng . † p < $nmbr$ . $nmbr$ vs . ng .
data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < $nmbr$ . $nmbr$ vs . non - epa . § p < $nmbr$ . $nmbr$ vs . non - epa
data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ]  gold $nmbr$ [ $nmbr$ ]    bon a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status  the mcid is a change of $nmbr$   units  on a scale of $nmbr$ – $nmbr$  with higher scores indicating more severe dyspnea  on a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status
data represent number of patients ( % ) or mean ( standard deviation )  unless otherwise indicated . a self - reported information . bc physician - diagnosed diabetes or fasting plasma glucose ≥ $nmbr$ mg / dl or hemoglobin a $nmbr$ c ≥ $nmbr$ . $nmbr$ % . d physician - diagnosed hypertension or systolic blood pressure ≥ $nmbr$ mmhg or diastolic blood pressure ≥ $nmbr$ mmhg . median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .
data  ' ' n
dates of recruitment
day $nmbr$ oral glucocorticoid use — no . { % )
days between acs and rand
days from acs to randomization
days with heartburna ( days )
daytime mean dbp ( abpm ) at week $nmbr$  mmhg
daytime mean sbp ( abpm ) at week $nmbr$  mmhg
daytime nasal symptoms score change from baseline  mean ± se
daytime symptoms more than twice per week
dbp
dbp ( mean over $nmbr$ h )  mmhg
dbp ( mmghg )  mean ( sd )
dbp ( mmhg )  mean ( sd )
dbp ( office measurement )  mmhg
dbp ( sd )
dbp ( sd )  mm   hg
dbp < $nmbr$ mmhg
dbp ≥ $nmbr$ mmhg
dbp > $nmbr$ or sbp > $nmbr$ mm hg laboratory determinations
dbp $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) baseline lipid profile  mg / dl  mean ( sd )
dbp at visit $nmbr$
dbp during the follow - up period ( mmhg )
dbp mm hg
dbp  mean ( sd )
dbp  mean ( sd ) mm hg
dbp  mm hg ( mean $nmbr$ h )  mean ( sd )
dbp  mm hg ( office measurement )  mean ( sd )
dbp  mm   hg
dbp  mm   hg ( sd )
dbp . mean ( sd ) mm hg
dcct a $nmbr$ c
de
de ( n = $nmbr$ )
de $nmbr$ mg bid ( n - $nmbr$  $nmbr$ )
de $nmbr$ n = $nmbr$
dead ( n = $nmbr$ )
death due to renal failure or sustained esrd
death due to renal failure ®
death from
death or disabling stroke
death or ich
death *
death  mi  idr  st  or gusto mod / sev bleeding
death  n ( % )
death  with pe not
death / mi / idr / st
death / q - ml / stent thrombosis
death / q - mi / idr
death / udmi / idr
deaths  n ( % )
deathsb
decline #   ml · yr − $nmbr$
deep - vein thrombosis only
definite acute stent thrombosis
definite stent thrombosis
definite / probable stent thrombosis
delayed
delayed - eptifibatide group ( n = $nmbr$ )
delayed eptifibatide
delighted
demographic $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )
demographic and clinical
demographic characteristic
demographic characteristics  mean ( sd )  unless otherwise stated
demographic characteristics  mean ± sd unless otherwise indicated
demographic data
demographic factors
demographic variable
demographic / disease characteristics at baseline
demographics age ( years )
demographics and clinical characteristics
denosumab ( n = $nmbr$ ) n ( % )
denotes angiotensin - converting enzyme .
dense calcium
dense calcium  mm ’
dental procedure
depression ®
dermal
dermatitis atopic
des implantation for restenosis  n ( % )
des type at index procedure
descent
detected during tumor evaluation
deterioration in renal function ( investigator reported )
deviation  mm
deviation  tg  triglyceride .
device = watchman filter
dexlansoprazole mr
dexlansoprazole mr ( n = $nmbr$ )
dexlansoprazole mr $nmbr$ mg  n = $nmbr$
dexlansoprazole mr $nmbr$ mg qd
dfisher ' s exact test .
dha ( n = $nmbr$ )
dha intake on food frequency questionnaire  mean ( sd )  mg / d
diabetes - related medication use    n   ( % )
diabetes ( n [ % ] ) *
diabetes ( n = $nmbr$ )
diabetes ( p = . $nmbr$ )
diabetes ( p = . o $nmbr$ )
diabetes ( p = . oo $nmbr$ )
diabetes at baseline
diabetes bl
diabetes classificationa
diabetes duration
diabetes duration ( y )
diabetes duration ( years ) *
diabetes duration at baseline
diabetes duration mean ± sd
diabetes duration  y
diabetes duration  ycars “
diabetes duration  years ( mean ± sd )
diabetes duration  years ^
diabetes etiology
diabetes history  mean ( sd )  years
diabetes medication
diabetes melitus
diabetes mellitus — no . / total no . ( % )
diabetes mellitus ( type $nmbr$ )  n ( % )
diabetes mellitus [ n ( % ) ]
diabetes mellitus 一 no . ( % )
diabetes mellitus classification
diabetes mellitus duration ( sd )  y
diabetes mellitus duration  y
diabetes mellitus duration  y ( sd )
diabetes mellitus n = $nmbr$  $nmbr$
diabetes mellitus yes ( n  % ) hypertension
diabetes mellitus  n ( % ) yes
diabetes mellitus  n / n ( % )
diabetes mellitus  n = $nmbr$
diabetes mellitus  no . ( % )
diabetes mellitus  no . / total no . ( % )
diabetes mellitust
diabetes n ( % )
diabetes t
diabetes therapy at baseline ( alone or in combination )
diabetes type ii  n ( % )
diabetes with no use of diabetes drugs
diabetes with use of oral diabetes drugs
diabetes  no . ( % ) c
diabetes ^
diabetes | |
diabetes | | yes
diabetesc
diabetese
diabetesh yes
diabetesz
diabetic ( no )
diabetic ( yes )
diabetic eye disease
diabetic participants
diabetic participants !
diabetic status  n ( % )
diabetic subjects  n = $nmbr$
diabetic therapy use  n ( % ) * no therapy
diabetic  n ( % )
diabetics - no ( n = $nmbr$  $nmbr$ )
diabetics - yes ( n = $nmbr$  $nmbr$ )
diabetics ( n = $nmbr$ )
diabetics • no ( n = $nmbr$  $nmbr$ )
diagnoses / risk factors  n ( % ]
diagnosis — yr
diagnosis ( years )
diagnosis at study entry — no . ( % )
diagnosis of diabetes  n ( % )
diagnosis of hefh  n ( % )
diagnostic catheterization
diarrhoea
diary variables  mean ( sd )
diastoiic biood pressure  mm hg
diastolic blood pressure > $nmbr$ mm hg
diastolic blood pressure mmhg  mean ( sd )
diastolic blood pressure  ( mm hg )
diastolic blood pressure  mm hg ( sd )
diastolic blood pressure  mm hg ^
diastolic blood pressure  mm hq
diastolic blood pressure  mm   hg
diastolic blood pressure  mmhg  mean ( sd )
diastolic blood pressure  and lp ( a )
diastolic bp
diastolic bp ( mmhg ) *
diastolic bp  mm hg  mean ( sd )
diastolic bp  mm   hg  mean ( sd )
diastolic bp  mmhg
diastolic pressure  mm hg
diastolic  mean ( sd )  mm hg
diastolic  total
diastolic  treated at baseline
diclofenac ( n = $nmbr$ )
diclofenac $nmbr$ mg ( n = $nmbr$ ) n ( % )
diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . n . . . ( . % . . ) . . . . . . . . . . .
diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . ( . % . . ) . . . . . . . . . . .
diclofenac $nmbr$ mg  n = $nmbr$  n ( % )
diclofenac group ( n = $nmbr$ $nmbr$ )
did not enrol into osler
did not meet atopy and ige $nmbr$ - $nmbr$ ku / lcriteriaa ( n = $nmbr$  $nmbr$ )
diet - controlled ( % )
diet - i - pravastatin ( n = $nmbr$ )
diet diet + pravastatin event / patients ( $nmbr$ ooo / pt - y )
diet ( n = $nmbr$ )
diet $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )
diet group
diet + pravastatin $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )
dietary calcium intake  mean ( sd )  mg / d
diff_measure
diff_measure ( dm added this as table had multiple headings )
difference ( $nmbr$ % ci  p value )
difference ( glargine - standard care ) lsm ± se ( mm / year )
difference ( n - $nmbr$ fa - placebo ) lsm ± se ( mm / year )
difference $nmbr$ years - baseline
difference $nmbr$ years - baseline *
difference ff / vi versus uc  %
difference from placebo ( $nmbr$ % cl )
difference in ls mean vs placebo ( $nmbr$ % ci )  %
difference in ls mean vs placebo ( $nmbr$ % ci )  mmol / mol
difference in ls means ( $nmbr$ % ci )
difference in ls means ( $nmbr$ % ci ) versus placebo
difference in ls means ( $nmbr$ % ci ) a
difference in means
difference in means ( $nmbr$ % cl )
difference in sbp between treatment
difference mepo - pbo ( $nmbr$ % ci )
difference vs ff $nmbr$ pg ( $nmbr$ % ci )
difference vs pbo
difference vs pbo ( $nmbr$ % ci )
difference vs placebo ( $nmbr$ % ci )
difference vs . placebo  % ( $nmbr$ % cl )
difference vs . placebo  kg ( $nmbr$ % cl )
differences between indacaterol + tiotropium versus tiotropium + placebo
differencevs . pbof
diffusion capacity of the lung for carbon monoxide  % predicted !
digoxin n ( % )
digoxin n = $nmbr$ ( $nmbr$ % )
digoxin or digitalis glycoside
digoxin or digitalis preparation
digoxin or digitalis preparations
digoxin scd  no . ( % / y )
digoxin  %
digoxin  % ( n )
dihydropyridine ccbs
dip joint arthritis
dipeptidyl peptidase $nmbr$ inhibitor
dipeptidyl peptidase $nmbr$ inhibitors
dipyridamole alone
direct stenting per lesion ‡
direction of hr
disabling or fatal
disabling or fatal stroke
disabling stroke
discontinu - ation
discontinuation of ics / laba prior to baseline  n ( % )
discontinuation of lama prior to baseline  n ( % )
disease activity ( n ( % ) )
disease and quality - of - life scores  mean ( sd )
disease characteristics duration of psoriatic arthritis — yr
disease characteristics  n ( % )  unless otherwise stated
disease duration
disease duration ( y )  median ( m / n  max )
disease duration ( years )  mean ± s . d .
disease duration [ year ]  mean ± sda
disease duration > $nmbr$ years  $nmbr$ [ % ] disease activity ‘ s
disease duration  mean [ sd ] years
disease duration  y
disease duration  y  mean ± sd
disease duration  year ( median )
disease duration  yrs  mean ( sd )
disease extent  n ( % )
disease history
disease localization ' ’  n ( % )
disease localization  n ( % )
disease severity
disease site — no . ( % ) ^
disease site  n [ % ]
disorders ( soc )
disposition index
disseminated tuberculosis
distal
distal forearm
distal lower
distance to ldl - c goal
distribution — no . { % )
distribution of metformin dose at randomization  n ( % )
diuretic ( any )
diuretic agents
diuretic agents ( excluding antialdosterone )
diuretic n ( % )
diuretic subgroup
diuretic therapy
diuretic use at baseline
diuretics  %
diuretics ^
diureties
dlqi
dlqi ( $nmbr$ - $nmbr$ )  mean ( sd )
dlqi ( patients with £ $nmbr$ % bsa psoriasis )
dlqi improvement from baseline to week $nmbr$
dlqi score
dlqi §
dm ( n = $nmbr$  $nmbr$ )
dm duration
dm duration  years
dm or ckd *
dm or diabetic complications
dm  n ( % )
dmab ( n = $nmbr$ )
dmard − ( n   =   $nmbr$ )
dmard - biologic ir
dmard - ir
dmard - ir / anti - tnf - ir
dmard at baseline
dmard + ( n   =   $nmbr$ )
documented hypoglycaemiac
documented mi
door - to - balloon time — hr
dopa and dopa derivativese
dopamine agonist use  no . ( % )
dose ( iu )
dose ( mg / day )
dose ( mg / week )
dose adjusted
dose adjustment n ( % )
dose adjustment reason < $nmbr$ kg
dose equivalent  mg ( sd ) )
dose ratio at week $nmbr$ ( $nmbr$ % cl )
dose reduced at randomization *
dose reduction at randomization
dose reduction at randomization — no . ( % )  i
dose reduction at randomization  %
dose reduction  n ( % )
dose  mg
dose / weight ( iu / kg )
dosing
double - dummy phase * *
doubling of baseline serum creatinine or esrd rr ( ci ) “
doubling of creatinine
doubling of creatinine level
doubling statin dose
doxazosin
doxazosin group
dpp - $nmbr$
dpp ‐ $nmbr$ inhibitors
draining fistulae  n ( % )
drinker ( $nmbr$ - $nmbr$ drinks / week )
drinker ( $nmbr$ to $nmbr$ drinks / week )
drinker  n ( % )
drinking
drinking  n ( % ) lipid values  mmol / l
dronedarone
dronedarone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .
drug - related saes
drug - related teaes
drug ‐ relateda
drug - relateda
drug and insulint
drug naive
drug therapy
drug therapy at admission — no . ( % ) aspirin
drug therapy  n ( % )
drug therapy  no . ( % )
drugs and toxins
dual antiplatelet therapy
dual bp / ldl - c goal attainment
dual i extension
dual ii
dual iv
due to ae
due to drug - relateda ae
due to drug - relateda sae
due to ecg changes
due to sae
due worsening angina
dulaglutide $nmbr$ . $nmbr$ mg
dulaglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
dulaglutide $nmbr$ . $nmbr$ mgf
dulaglutide $nmbr$ · $nmbr$ mg ( n = $nmbr$ )
dulaglutide $nmbr$ . $nmbr$ mg *
dupiiumab  $nmbr$ mg ( n = $nmbr$ )
dupilumab $nmbr$
durable clinical remissionh
durable clinical responseg
duration
duration — yr
duration < $nmbr$ year  n ( % )
duration > $nmbr$ to < $nmbr$ years  n ( % )
duration > $nmbr$ years  n ( % )
duration alendronate use  years ( meanisd )
duration antiplatelet use as % of study duration ( sd )
duration dm in dm ( years )
duration of alendronate use  mean ( sd )  y
duration of as  n ( % )
duration of as  years
duration of asthma — yr
duration of asthma ( years )
duration of asthma > $nmbr$ years
duration of asthma
duration of asthma  y
duration of chf ( months )
duration of chronic kidney disease * ( years )
duration of clopidogrel pretreatment — hr median
duration of copd ( yr ) f
duration of crohn ’ s disease ( yrs )
duration of current flare  median ( range ) months ( n = $nmbr$  $nmbr$  $nmbr$ )
duration of diabetes — yr ^
duration of diabetes < $nmbr$ yrs
duration of diabetes ( years )  mean ( sd )
duration of diabetes ( years )  mean  ( sd )
duration of diabetes in years  median ( iqr )
duration of diabetes mellitus
duration of diabetes mellitus  median ( iqr )  y
duration of diabetes mellitus  y  mean ( sd ) §
duration of diabetes microvascular disease — no . ( % )
duration of diabetes  y
duration of diabetes  y  mean ( sd )
duration of diabetes  years  mean ( sd )
duration of diabetes  years  median ( iqr )
duration of disease — yr ^ mean
duration of disease ( y )  median ( min  max }
duration of disease ( years )
duration of disease ( yr )
duration of disease before baseline
duration of disease since
duration of disease  n ( % )
duration of disease  y
duration of dm - years
duration of epilepsy  mean ( sd )  years
duration of epilepsy  years
duration of heart failure ( years )
duration of hf  y
duration of infusion after pci — hr
duration of infusion before cabg — hr
duration of infusion before pci — hr
duration of infusion during medical management — hr
duration of macular edema  mo
duration of oral antidiabetic treatment  y  mean ( sd )
duration of paod ( years )  mean ± sd
duration of pci ( min )  median
duration of previous use of vka  months
duration of prior alendronate use  months
duration of prior statin therapy ^
duration of procedure
duration of psoriasis ( years )  mean ( sd )
duration of qualifying atrial fibrillation » $nmbr$ days — no . ( % )
duration of ra
duration of ra  mean ± sd years
duration of rat  years
duration of study - drug administration — hr
duration of sulphonylurea use ( months )  mean ± s . d .
duration of symptoms > $nmbr$ min
duration of t $nmbr$ d  y
duration of total exposure to study treatment  weeks
duration of treatment in the healing study  n
duration of type $nmbr$ diabetes
duration of type $nmbr$ diabetes categories  n ( % )
duration of type $nmbr$ diabetes mellitus  years
duration of type $nmbr$ diabetes  years
duration since diagnosis ( years )
during overall study period
dutasteride
dutasteride ( n = $nmbr$ )
dutasteride ( w = $nmbr$ )  $nmbr$ / $nmbr$
dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only
dysfunction  ef = erectile function  iief = i
dysglycaemia or mets
dysglycemic categories  n ( % )
dyslipidaemia — no . ( % )
dyslipidaemia including hypercholesterol — no . ( % )
dyslipidaemiaj
dyslipidemia — no . { % )
dyspnea
dyspnea – mmrc grade  n ( % )
dyspnea t
dyspnea  % ( frequent / continuous )
dyspnea  frequent / continuous
dyspnoea ( n = $nmbr$ )
e - rs total scoreb
e ( characteristic n
e europe
e major non - vertebral fragility fractures ( fas )
e / a ratio
e / e ' ( septal )
e $nmbr$ + a $nmbr$
e $nmbr$ ( n = $nmbr$ )
e $nmbr$ / s $nmbr$ ( n = $nmbr$ )
e $nmbr$ / s $nmbr$ vs e $nmbr$
e $nmbr$ / s $nmbr$ vs s $nmbr$
eacit - e total score ) |
early
early - eptifibatide group ( n = $nmbr$ )
early clopidogrel intended
early crohn ' s disease *
early death
early eptifibatide
early ichaem ic stroke
early invasive strategy ( n = $nmbr$  $nmbr$ )
early invasive *
early invasive $nmbr$
early load
early routine
early use intended
early  n ( % )
ease - $nmbr$
east asia
east asian
eastern and central europe
eastern europe ( n   = $nmbr$  $nmbr$ )
eastern europe and africa
eastern europe  africa
ecfr ( ml / min per $nmbr$ - $nmbr$ m ’ )
ecfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$
ecg - lvh ( cornell )
ecg - lvh ( sokolow - lyon )
ecg abnormality at entry
ecg and imaging data
ecg at time of qualifying symptoms
ecg atrial fibrillation  n ( % )
ecg changes ( % ) t
ecg left ventricular
eczema
ed > $nmbr$ yr  no . ( % )
ed characteristics
ed duration
ed duration > $nmbr$ yr  n ( % )
ed duration  visit $nmbr$ * *
ed etiology  no . ( % )
ed history  n ( % yes )
ed severity * *  n ( % ) :
ed severity  no . ( % ) a
ed severity  visit $nmbr$ * *
ed therapy
ed visit related to exacerbation  n ( % )
eda  %
edema peripheral
edema  % z
edema  n ( % )
edo
edoxaban
edoxaban ( n = $nmbr$ )
edoxaban at randomization  n ( % )
edoxaban dose adjusted at randomisation  n ( % ) *
edoxaban higher dose vs warfarin
edoxaban lower dose vs warfarin
edoxaban n = $nmbr$
edoxaban n = $nmbr$ n / n ( % )
edoxaban n / n  rate ( % )
edoxaban vs . warfarin
edoxaban warfarin
edss stratification . no . ( % )
educ > $nmbr$ y
educ $nmbr$ - $nmbr$ y
educ ssy
education
education — no . ( % )
education ( % )
education ( years )
education < $nmbr$ y
education > $nmbr$ y
education > $nmbr$ yr ( % )
education $nmbr$ to $nmbr$ y
education in years  mean
education in years  mean ( sd )
education level
education  mean ( sd ) years
education  mean ( sd )  y
education  mean ( sd )  ya
education  y
education  y  mean ( sd )
education  years  mean ( sd )
education  yrs  mean ( sd )
eduglinozin $nmbr$ mg vs placebo / glimepiride
ef ( % )  mean ( sd )
ef < $nmbr$ % ( n $nmbr$ $nmbr$ )
ef < $nmbr$ % ( n = $nmbr$  $nmbr$ )
ef < $nmbr$ % n = $nmbr$
ef > $nmbr$ % ( n = $nmbr$  $nmbr$ )
ef > $nmbr$ % n = $nmbr$
ef > $nmbr$ % ( n $nmbr$ $nmbr$ )
ef $nmbr$ - $nmbr$ . $nmbr$ % ( n $nmbr$ $nmbr$ )
ef b $nmbr$ %
ef domain
effect estimate
effect of covariates on slopes
effect of ranolazine compared with placebo on angina and recurrent ischemia
effect size !
effect size ^
efficacy end points
efficacy endpoint
efficacy endpoints *
efficacy measures
efficacy parameter
efficacy variable
efficacy    n   ( % ) a
egfr — mean ( sd  n )
egfr — ml / min / $nmbr$ . $nmbr$ m ^
egfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr ( mdrd )  ml min − $nmbr$ $nmbr$ . $nmbr$   m − $nmbr$
egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m * *
egfr ( mdrd )  n ( % )
egfr ( ml / min per $nmbr$ - $nmbr$ kg / m ^ )
egfr ( ml / min per $nmbr$ - $nmbr$ m ^ )
egfr ( ml / min per $nmbr$ - $nmbr$ m ’ )
egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
egfr ( ml / min per $nmbr$ ^ $nmbr$ m ' )
egfr ( ml / min per $nmbr$ + $nmbr$ m ”
egfr ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ )
egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd )
egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )
egfr < $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ )
egfr < $nmbr$ ml / min  n ( % )
egfr < $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m '
egfr < $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$
egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
egfr ≥ $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$
egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )
egfr > $nmbr$  n ( % )
egfr > $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m '
egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
egfr > $nmbr$ ml / min  n ( % )
egfr $nmbr$ ml / min / $nmbr$ . $nmbr$
egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$
egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m *
egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )
egfr $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ )
egfr $nmbr$ to < $nmbr$ ml / min  n ( % )
egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ’
egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
egfr and albuminuria
egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ )
egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] )
egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] )
egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  mean [ se ] )
egfr category
egfr category ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % )
egfr crcl ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$
egfr from the mdrd equation ( sd )  ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$
egfr in ml / min / $nmbr$ . $nmbr$ m ^  median ( iqr )
egfr s $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^
egfr s $nmbr$ o ml / min / $nmbr$ . $nmbr$ m ^
egfr   < $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr   ≥ $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$
egfr  mean ± sd
egfr  ml • mn ' • $nmbr$ . $nmbr$ m $nmbr$
egfr  ml / kg per $nmbr$ . $nmbr$ m $nmbr$
egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$
egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$  mean ( sd )
egfr  ml / min per $nmbr$ · $nmbr$ m $nmbr$
egfr  ml / min / $nmbr$ . $nmbr$ m ^
egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )
egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )  mean ( sd )
egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( sd )
egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$
egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  ‡
egfr  ml / min / bsa
egfr  ml / minute / $nmbr$ . $nmbr$ m $nmbr$
egfr  n ( % ) normal ( egfr > $nmbr$ ml / min / em ^ )
egfr_p_interaction
egfr +  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mean ± sd )
egfr ‡ ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ )
either ocs use  nasal polyps  pre - bd fvc < $nmbr$ % of predicted or age at diagnosis sl $nmbr$ years
ejection fraction — mean ± sd
ejection fraction ( % )
ejection fraction ( mean )
ejection fraction group
ejection fraction *
ejection fraction  %
ejection fraction  mean ( sd )  %
el  n ( % )
elderly
elderly patients ( n — $nmbr$ )
elective peripheral revascularization
elective procedure
elective surgery
electrocardiogram
electrocardiograph results  no . ( % )
electrocardiography
elevated baseline crp
elevated biomarkers and st - segment changes
elevated bnp
elevated bnp  > $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ )
elevated cholesterol
elevated crp  n ( % )
elevated high - sensitivity crp — no . { % ) * *
elevated natriuretic peptide level ( n = $nmbr$ )
elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) $
elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) : ! :
elevated non - hdl cholesterol
elevated serum creatinine ( > $nmbr$ . $nmbr$ mg / dl_ )
elevated serum creatinine  > $nmbr$ . $nmbr$ mg / dl
elevated symptomatic serum creatinine  hypotension > $nmbr$ . $nmbr$ mg / dl
elevated troponin — %
elevated vs normalb
elevated vs . normalb
elevated vs . normalc
elevation of cardiac biomarker levels — no . / total no . ( % )
elevation of cardiac biomarker levels or st - seg - ment deviation > $nmbr$ mm — no . / total no . ( % )
elevation of troponin levels — no . / total no . ( % )
eligibility risk factors
eligibility risk factors — n ( % ) :
eligibility risk factors !
eligibility risk factors  % t ascvo
eligibility risk factors  no . ( % ) t
eligibility risk factors /
eligibility risk factors :
eligibility risk factors ’ )
eligibility risk factorsa
eligibility strata
eligibility stratum
elms  n ( % )
embolism
emotional function
empa
empagiiflozin $nmbr$ mg
empaglifiozin $nmbr$ mg ( w = $nmbr$ )
empaglifiozin $nmbr$ . $nmbr$ mg ( w = $nmbr$ )
empagliflozin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
empagliflozin ( n   =   $nmbr$ )
empagliflozin $nmbr$ mg / day ( n = $nmbr$ )
empagliflozin n with event / n
empagliflozin pooled ( n = $nmbr$ )
empagllflozin
empagllflozln
emphysema ( itt ) ( n = $nmbr$ )
emphysema ( n = $nmbr$ )
empty
end - point ( sd )
end - stage renal disease
end of trial
endoscopic disease severity
endoscopy subscore  n ( % )
endpoint *
endpoints
enox
enoxaparin ( n = $nmbr$  $nmbr$ )
enoxaparin $nmbr$ mg ( n = $nmbr$  $nmbr$ )
enoxaparin only
enrolled from re - cover ii study — no . ( % )
enrolled from re - cover study — no . ( % )
enrolled in russia or georgia
enrolled in the americas
enrolled into osler
enrollment in lmwh substudy
enrollment strata : prior hospitalization
enrollment to randomization
enrolment through hf
enrope + sonth afriea
entacapone
enthesitis score ( mases  $nmbr$ - $nmbr$ )  mean ( sd )
enthesitis score at baseline  median ( iqr ) week $nmbr$
enthesitis score *
enthesitis  % §
entire evaluable cohort
entocort ec ( n = $nmbr$ )
entry category
entry criteria ( % )
entry hip fracture location  n ( % )
environmental stimuli
eo
eo severity by la classification at baseline ( baseline of the healing study )  n ( % )
eos count ( cells / pl )
eosinoohil count
eosinophil counf cells pl '
eosinophil count
eosinophil count ( cells / pl )  median ( range ) c
eosinophil high
eosinophil low
eosinophils
eosinophils ( cells / ll ) inclusion criteria  n ( % )
eosinophils £ $nmbr$ % ( itt ) ( n = $nmbr$ )
eosinophils £ $nmbr$ % ( n = $nmbr$ )
eosinophils < $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / l ( n = $nmbr$ )
eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ )
eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ )
eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( itt ) ( n = $nmbr$ )
eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ )
eosinophils < $nmbr$ % ( itt ) ( n = $nmbr$ )
eosinophils < $nmbr$ % ( n = $nmbr$ )
eosinophils > $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / $nmbr$ ( n = $nmbr$ )
eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ )
eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ^ ( itt ) ( n = $nmbr$ )
eosinophils > $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ )
eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ^ ^ ( itt ) ( n = $nmbr$ )
eosinophils > $nmbr$ % ( itt ) ( n = $nmbr$ )
eosinophils > $nmbr$ % ( n = $nmbr$ )
eosinophils $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ )
eosinophils $nmbr$ % ( itt ) ( n = $nmbr$ )
eosinophils $nmbr$ % ( n - $nmbr$ )
epilepsy drug
epilepsy with grand mal seizures on awakening
epistaxis
eplerenone ( n   = $nmbr$ )
eq - $nmbr$ d - $nmbr$   l  no pain or discomfortc
eq - $nmbr$ d - $nmbr$   l  no pain or discomfortf
eq - $nmbr$ d mobility
eq - $nmbr$ dprofile - mobility  n ( % )
eq $nmbr$ da health index status score
er visit
era
era and pde - $nmbr$ i
erd *  n ( % )
erectile dysfunction
erectile function  ipss
erlugliflozin $nmbr$ mg vs placebo / glimepiride
erosion score ( $nmbr$ – $nmbr$ scale )
erosion score  mean ± sd
erosion  mean ± sd
ertuglifldzin $nmbr$ mg vs placebo / glinepiride
ertugliflozin
ertugliflozin $nmbr$ mg ( n $nmbr$ $nmbr$ )
ertugliflozin $nmbr$ mg vs placebo / giimepiride
ertugliflozin $nmbr$ mg vs placebo / glimepiride
ertugliflozin $nmbr$ mg vs placebo / glirneplride
ertugliflozin $nmbr$   mg
ertugliflozin $nmbr$   mg ( n   =   $nmbr$ )
ertugliflozin $nmbr$ mg ( n   =   $nmbr$ )
ertugliflozin $nmbr$ mg vs placebo / glinepiride
ertuglrflozin $nmbr$ mg vs placebo / glimepiride
erysipelas
erythrocyte sedimentation rate ( mm / h )
esophageal hiatal hernia *
esr
esr ( mm / h )  mean ( sd )
esr ( mm / h )  median ( min - max )
esr ( mm / hour )
esr ( mm / hour  per unit )
esr  mean ± sd mg / dl
esr  median ( range ) mm / hour
esrd '
esrd only rr ( ci ) “
esrd or $nmbr$ % decline in gfr
esrd or $nmbr$ % dedine in gfr
esrd *
established atherosclerotic cardiovascular disease — no . { % )
established atherosclerotic disease — no . { % )
established cvd / chronic kidney disease ( age > $nmbr$ ) ^ * ’
established maerovaseular disease and albuminuria
established renal disease ( egfr $nmbr$ - < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ with any uacr mg / g or egfr > $nmbr$ - $nmbr$ ml / inin / l $nmbr$ m $nmbr$ with an uacr > $nmbr$ mg / g ) without previous maerovaseular and albuminuria disease
established renal disease *
estimate
estimate ( $nmbr$ % ci )
estimate ( $nmbr$ % cl )
estimated creatinine clearance — ml / min  i
estimated creatinine clearance — ml / min §
estimated creatinine clearance ( ml / min )
estimated creatinine clearance < $nmbr$ ml / mint
estimated creatinine clearance  !
estimated creatinine clearancet
estimated cv risk at baseline
estimated gfr — ml / min / $nmbr$ . $nmbr$ m ^ |
estimated gfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$
estimated gfr — no . ( % ) ^ |
estimated gfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd )
estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) lipid baseline lipid profile
estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd )
estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . ( % )
estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  no . ( % )
estimated gfr at baseline  ml • min $nmbr$
estimated gfr  mean ( sd )  mlvmin per $nmbr$ . $nmbr$ m ^ *
estimated gfr  ml / min
estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$   of body - surface area
estimated gfr ^
estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m ^
estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$
estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area §
estimated glomerular filtration rate — no . ( % )
estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$
estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$ *
estimated glomerular filtration rate < $nmbr$
estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$
estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ) §
estimated glomerular filtration rate ^
estimated glomerular filtration rate | |
estimated glomerular filtration rate §
estimated mean
estimated mean $nmbr$ % cl
estimated means and treatment differences ( % )
estimated number of pack - years
estimated proportions ( % ) and odds ratios
estimated treatment difference ( % )
estradiol ( e $nmbr$ ) ( pmol / l )
estradiol ( pmol / l )
estradiol quartiles
estrogen
estrogen ( ' % ? )
estrogen supplementation
estrogen supplementation -
etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$
etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$
etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$
ethnic background
ethnic minority group — no . ( % )
ethnic origin white
ethnic origin *
ethnicity - - hispanic or latino
ethnicity t
ethnicity  %
ethnicity  hispanic / latino  n ( % )
ethnicity  n ( % ) *
ethnicity  n ( % ) :
ethnicity  n ( % ) b
ethnicity  not hispanic / latino    n   ( % )
ethnicity $nmbr$ '
ethnieity
etiology
etiology ( % )
etiology  n ( % )
etiology    n   ( % )
etoricoxib ( n = $nmbr$ )
etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . .
etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . .
etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .
etoricoxib $nmbr$ mg  n = $nmbr$  n ( % )
etoricoxib group ( n = $nmbr$ $nmbr$ )
etr : $nmbr$ . $nmbr$ [ $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$
eu
europe ( including south africa )
europe ( plus south africa )
europe $nmbr$ ( n = $nmbr$  $nmbr$ )
europe $nmbr$ ¶
europe $nmbr$ +
europe and russia
european or arab
evening
evening mealb
event ( p = $nmbr$ . $nmbr$ o + )
event during on -
event during overall
event incidence / n
event number
event rate ( per $nmbr$
event rate ( % / vr )
event rate ( % / year )
event rate ( per $nmbr$ person - years )
event rate ( per $nmbr$ person years )
event rates per $nmbr$ patient - years ( $nmbr$ % ci )
event  n ( % )
event / patients in group ( incidence / $nmbr$ person - year )
event { n ( % )
events consistent with genital infection
events consistent with uti
events consistent with volume depletion
events requiring assistance
events  n ( % )
events  n ( % / y )
events / patient - year ( n )
ever
ever been on a vka
every day
evolocumab
evolocumab ( n = $nmbr$ )
evolocumab + soc ( n = $nmbr$ )
evomab
evomab + soc
ex - drinker
ex - smokers ( itt ) ( n = $nmbr$ )
ex - smokers ( n = $nmbr$ )
ex - smokers : qvai $nmbr$ - sfc
exacerbation historyh  n ( % )
exacerbation in previous year
exacerbation rate per year
exacerbation within $nmbr$ mo  %
exacerbation within previous $nmbr$ mo  no . ( % )
exacerbations in past $nmbr$ mo — no . ( % )
exacerbations in previous $nmbr$ mo ( n )  mean ( sd )
exacerbations in previous year requiring hospitalization and / or ed visit  n ( % )
exacerbations in previous year requiring hospitalization  n ( % )
exacerbations in the past $nmbr$ months n
exacerbations in the prev . year : $nmbr$
exacerbations in the year before study
exacerbations requiring hospitalisation ( past year ) ( % )
exacerbations requiring oral steroids / antibiotics ( past year ) ( % )
exact - pro total score  mean ( sd )
exact ( b )
exenatide ± oad
exenatide er
exercise status
exercise  n ( % )
exlertl ot disease
expanded cv endpoint
expanded mace
experience ( n  % )
experienced
experimental intervention group ( n = $nmbr$ )
experimental treatment group
exploratory cardiovascular and death outcomes
exploratory kidney and microvascular outcomes
exposed
exposure to study drug — days
exsmoker
extended - release niacin plus statin ( n = $nmbr$ )
extended cardiovascular endpoint
extensive  n ( % )
extensive / pancolitis
extenswe
extent of index dvt ' ( n  % of dvt patients ' )
extent of index pe ' ( n  % of pe patients )
extracranial
ez / simva $nmbr$ / $nmbr$ mg
eze = ezetimibe $nmbr$ mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .
eze / simva ( n = $nmbr$ )
eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ) '
eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ )
eze / simva  $nmbr$ / $nmbr$ mg dn = $nmbr$ c $nmbr$ )
eze / simva  $nmbr$ / $nmbr$ mg dr = $nmbr$ )
ezetimibe $nmbr$ mg ( n — $nmbr$ )
ezetimibe  n ( % )
ezetimibe / simvastatin group
f - plasma glucose  mmol / l
f $nmbr$ vs placebo
facial psoriasis  n ( % )
facilitated pci ( n = $nmbr$ )
facit - f
facit - f score
factor
factor absent
factor at baseline
factor present
factor *
factors dabigatran
factors dabigatran event incidence / n
factors that confer a
failure
fair control ( $nmbr$ - $nmbr$ . $nmbr$ )
fair or poor
fair / poor
fall in last $nmbr$ mo
fall in last $nmbr$ months ( % )
familial
familv historv of cad
family history of diabetes mellitus — no . ( % )
family history of diabetes mellitus — no . { % )
family history of myocardial infarction prior to age $nmbr$  %
family history of premature chd * *
family history of premature coronary heart disease
family history of premature heart disease
family history ot chd  n ( % )
famotidine $nmbr$ mg ( n = $nmbr$ )
fas
fas  range $nmbr$ - $nmbr$  mean ( sd )
faster aspart
faster aspart ( mealtime )
faster aspart   +   basal
fasting
fasting blood glucose > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l )
fasting blood glucose  mean ( sd )  mg / dlt
fasting c - peptide ( ng / ml )
fasting glucose
fasting glucose > $nmbr$ mg / dl  n ( % )
fasting glucose > $nmbr$ mg / dl *
fasting glucose level  mg / dl
fasting glucose mg / dl diabetes classification
fasting glucose *
fasting glucose  mean ( sd )  mg / dl
fasting glucose  mg / dl
fasting glucose  mg / dl '
fasting glucose  mg / dl  mean ( sd ) §
fasting indices
fasting insulin ( miu / ml )
fasting insulin  iiiu / ml  mean ± sd
fasting insulin  pmol / l ( mean ± sd )
fasting insulin  * median ( iqr )  gu / ml
fasting lipids ( mmol / $nmbr$ )
fasting plasma glucose — mmol / liter
fasting plasma glucose ( change from baseline )
fasting plasma glucose ( mg / dl ) $nmbr$
fasting plasma glucose ( mmol / l ) $nmbr$
fasting plasma glucose categories  n ( % )
fasting plasma glucose in mmol / l ( median ( q $nmbr$  q $nmbr$ ) [ n ] )
fasting plasma glucose *
fasting plasma glucose  mg / dl
fasting plasma glucose  mg / dl  mean ( sd )
fasting proinsulin ( pmol / l )
fasting serum glucose — mg / dl * *
fasting serum glucose ( mg / dl )
fasting serum glucose level  mean ( sd )  mg / dl
fasting serum glucose  mean ( sd ) mg / dl
fasting serum glucose  mmol / l  median ( q $nmbr$  q $nmbr$ )
fasting tgs  median ( q $nmbr$ : q $nmbr$ )
fasting triglyceride level  mean ( sd )  mg / dl
fasting triglycerides
fasting triglycerides > $nmbr$ mg / dl *
fasting triglycerides  mean ( sd ) mg / dl
fasting triglycerides  mean ( sd )  mg / dl
fasting triglycerides  mg / dl
fatal
fatal & nonfatal ccvd
fatal & nonfatal hospitalized heart failure
fatal & nonfatal hospitalized stroke
fatal aes
fatal bleed
fatal bleeding
fatal chd + nonfatal ml
fatal chd and nonfatal mia
fatal myocardial infarction
fatal or non - fatal myocardial infarction
fatal or non - fatal stroke
fatal or nonfatal myocardial infarction
fatal or nonfatal stroke
fatal or nonlatal myocardial inlarctlon
fatal or nonlatal stroke
fatal stroke
fatal / nonfatal mi  n ( % )
fatal / nonfatal ml
fatal / nonfatal stroke
fatal / nonfatal stroke  n ( % )
fatigue ( range $nmbr$ - $nmbr$ )
fatty acid group ( n = $nmbr$ )
favors favors amlodipine chlorthalidone
favors favors lisinopril chlorthalidone
favors amlodipine favors chlorthalidone
favors comparator
favors dabigatran
favors ff / vi favors placebo
favors ffa / i favors placebo
favors lisinopril favors chlorthalidone
fbg ( mg / dl )
fbg ( mmol / l )
fbg baseline
fbg  mmol / l
fc > $nmbr$ mg / dl ( > _ $nmbr$ . $nmbr$ mmol / l ) or history of diabetes
fcal  mg / g  mean ± sd
fdc $nmbr$ / $nmbr$ pg
fdc $nmbr$ / $nmbr$ pg vs aclidinium $nmbr$ pg
fdc $nmbr$ / $nmbr$ pg vs formoterol $nmbr$ pg
fdc $nmbr$ / $nmbr$ pg vs placebo
fdc $nmbr$ / $nmbr$   μ g ( n   =   $nmbr$ )
feature
febuxostat
febuxostat $nmbr$ mg
febuxostat $nmbr$ mg ( n = $nmbr$ )
febuxostat $nmbr$ mg daily n = $nmbr$
febuxostat $nmbr$ mg n = $nmbr$
febuxostat $nmbr$ mg daily n = $nmbr$ % ( n / n )
febuxostat $nmbr$ mg daily n = $nmbr$ n ( % )
feet
femaie
female - n ( % )
female — no . ( % )
female ( n   = $nmbr$  $nmbr$ )
female ( n = lll $nmbr$ )
female $nmbr$
female acr definition  ^ g / mg
female eze / simva ( n = $nmbr$ )
female gender ( % )
female gender n ( % )
female n ( % )
female participants who are ≥ $nmbr$ years postmenopausal
female patients ^
female race white
female sex — no . { % )
female sex — %
female sex — no . ( % ) race — no . ( % ) f
female sex  n ( % of patients )
female sex  no . ( % )
female sex  no . / total ( % )
female simva ( n = $nmbr$ )
female subjects ( n = $nmbr$ )
female  n ( % ) race  n ( % )
female / male ( % )
female : ≥ $nmbr$ years postmenopausal
female : perimenopausal or < $nmbr$ years postmenopausal
female : premenopausal
females ( itt ) ( n = $nmbr$ )
females ( n = $nmbr$ )
females only
females  < $nmbr$ . $nmbr$
females  < $nmbr$
females  > $nmbr$ . $nmbr$
females  > $nmbr$
females  n ( % )
femalesex
femoral access
femoral neck ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd )
femoral neck bmd ( g / cm $nmbr$ )
femoral neck bmd t - score
femoral neck f - score at flex baseline
femoral neck t - score
femoral neck t - score ( mean = sd )
femoral neckc
femoralneck t - scorebybaselinevfxstatus
feno — ppb
feno  $nmbr$ dn = $nmbr$ )
feno  $nmbr$ mg dn = $nmbr$ )
fenofibrate ( n = $nmbr$ )
fenofibric acid - $nmbr$ - low - dose statin
fenofibric acid - i - moderate - dose statin
fenofibric acid - i - low - dose statin
fenofibric acid   n   =   $nmbr$
fev auc i $nmbr$ h
fev
fev  % predicted
fev  < $nmbr$ % predicted
fev  > $nmbr$ % predicted
fev $nmbr$
fev $nmbr$ % predicted at baseline
fev $nmbr$ % predicted normal
fev $nmbr$ ( l ) pre - bronchodilator
fev $nmbr$ ( l )  mean ( sd )
fev $nmbr$ at week $nmbr$  mean ml ( se ) difference mepo - pbo ( $nmbr$ % ci )
fev $nmbr$ auc $nmbr$ mine $nmbr$ h
fev $nmbr$ pre - bronchodilator ( % predicted normal )  mean ( sd ) c  d
fev $nmbr$ pre - bronchodilator ( l )  mean ( sd ) c
fev $nmbr$ prebronchodilator [ % pn ]  mean ± sd
fev $nmbr$ prebronchodilator [ l ]  mean ± sd
fev $nmbr$   % of predicted normal post - bronchodilator
fev $nmbr$   at baseline ( randomization ) ∗
fev $nmbr$   at screening ∗
fev $nmbr$ % predicted ( sd )
fev $nmbr$ % predicted < $nmbr$ %
fev $nmbr$ % predicted ≥ $nmbr$ %
fev $nmbr$ % predicted  mean ( sd )
fev $nmbr$ % reversibility ( sd )
fev $nmbr$  % predicted  mean ( sd )
fev $nmbr$  l prebronchodilator fev $nmbr$  % predicted
fev $nmbr$  l  mean ( sd )
fev $nmbr$  mean ( sd ) pre - bd fev $nmbr$ / fvc
fev $nmbr$  mean  % predicted
fev $nmbr$  mean  l
fev $nmbr$ / fvc at baseline ( randomization ) ( % ) ∗
fev $nmbr$ / fvc prebronchodilator  mean ± sd
fev $nmbr$ / fvc ratio  %
fev $nmbr$ / fvc  mean ( sd )
fevi percent predicted ( % )
fevi reversibility — %
fevi  l
fevi / fvc ( % )
fevi $nmbr$ l
fevj % predicted !  t
fevt : fvc ratio — % |
ff - $nmbr$ % ( - $nmbr$ %  $nmbr$ % )
ff – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )
ff $nmbr$ % ( - $nmbr$ %  $nmbr$ % )
ff $nmbr$   µ g
ff $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )
ff mdi
ff / vi
ff / vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )
ff / vi ( n   =   $nmbr$ )
ff / vi $nmbr$ . $nmbr$
ff / vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % )
ff / vi $nmbr$ / $nmbr$   µ g
ff / vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % )
ff / vi $nmbr$ % ( $nmbr$ %  $nmbr$ % )
ffa / i
fg > $nmbr$
fgf - $nmbr$ high / < $nmbr$ elevated biomarkers
fgf - $nmbr$ high / > $nmbr$ elevated biomarkers
fgf - $nmbr$ high / egfr < $nmbr$
fgf - $nmbr$ high / egfr > $nmbr$
fgf - $nmbr$ low / < $nmbr$ elevated biomarkers
fgf - $nmbr$ low / > $nmbr$ elevated biomarkers
fgf - $nmbr$ low / egfr < $nmbr$
fgf - $nmbr$ low / egfr > $nmbr$
fibrate or other lipid - lowering agent
fibrillation / flutter )
fibrin - specilic
fibrinolysist
fibrinolytic
fibrinolytic agent — no . ( % ) : t
fibrinolytic agent before randomisation
fibrinolytic agents before or after entry
fibrinolytic therapy — no . ( % )
fibrinolytics
fibrofatty
fibrofatty  mm ^
fibrous
fibrous  mm ’
figure $nmbr$ least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fev $nmbr$ in the itt population and subpopulations . copd  chronic obstructive pulmonary disease  fev $nmbr$  forced expiratory volume in $nmbr$ s  ics  inhaled corticosteroid  itt  intent to treat  laba  long - acting b $nmbr$ - agonist .
final
final ( mg / dl )
final a $nmbr$ c ( % )
final analysis ( all patients )
final mean
final timi flow grade < $nmbr$
first co - primary
first cv hospitalization
first diagnosed
first disease - progression outcome to occur §
first dose admin . $nmbr$ - $nmbr$ h / $nmbr$ - $nmbr$ h post onset of symptoms
first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f
first hospitalization for chf or cv death
first medical contact in ambulance
first serum creatinine
first year *
fistula  ' n ( % )
fl ( $nmbr$ . $nmbr$ )
fl ( $nmbr$ b )
flecainide
flex ain ' ’
flex aln ^
flex baseline bmd t - score at femoral neck ( meanisd )
flex baseline bmd t - score at lumbar spine ( meanisd )
flex baseline bmd t score
flex baseline bmd  g / cm ^ ( meanisd )
flex baseline bmd  mean ( sd )  g / cm $nmbr$
flex fn f - score < - $nmbr$ . $nmbr$
flex pbo ®
fluticasone - salmeterol ( n = $nmbr$ )
fluticasone alone ( n = $nmbr$ )
fluticasone propionate / salmeterol fdc
fn t - score < — $nmbr$ . $nmbr$
fn t - score < = - $nmbr$ . $nmbr$ ( % )
focal
follow - up
follow - up in - trial at $nmbr$ yr
fondaparinux — no . ( % )
fondaparinux ( n = $nmbr$  $nmbr$ )
fondaparinux ( n = $nmbr$ )
for baseline hemoglobin $nmbr$ g $nmbr$ ’
for baseline hemoglobin < $nmbr$ g $nmbr$ '
for combined hemoglobin groups
for patients not using personal cgm
for patients using personal cgm
forearm
former ( n   = $nmbr$  $nmbr$ )
former smoker — no . ( % )
former smoker — no . { % )
former smoker ( n = $nmbr$  $nmbr$ )
former smokers
former / current smoker ( n = $nmbr$ $nmbr$ )
formoterol $nmbr$ gg ( n = $nmbr$ )
formoterol $nmbr$ pg
formoterol $nmbr$ pg vs placebo
formoterol $nmbr$   μ g ( n   =   $nmbr$ )
formoterol tiotropium n = $nmbr$ non - tiotropium n = $nmbr$
fp
fp ( n   = $nmbr$  $nmbr$ )
fp versus no ics
fp versus other ics
fpci vs . ppci in men
fpci vs . ppci in women
fpg
fpg ( mmol / $nmbr$ )
fpg ( mmol / l )  mean ( sd )
fpg ( mmol / l )  mean ± s . d .
fpg change ( mg / dl ) *
fpg data '
fpg month $nmbr$ ( mg / dl )
fpg ( mg / dl ) x
fpg  ( mg / dl )
fpg  ( mmol / l )
fpg  mean ( sd )  mg / dlf
fpg  median ( q $nmbr$  q $nmbr$ )  mmol / l
fpg  mg / dl  mean ± sd
fpg  mmol / l ( mean ± sd )
fpg  mmol / l  mean ( sd )
fpg  mmol / la
fpi  gu / ml ( pmol / l )
fpi  m - u / ml ( pmol / l )
fpi  mean ( sd )  pu / rnff
fracture history  n ( % )
fracture status prevalent vertebral fractured
fractures
framingham risk score
framingham risk score ( % )
framingham risk score *
framingham risk score  arbitrary units
freedom from gtc seizures  n ( % )
freqency of events
frequency of events
frequent exacerbator
frequent or continuous
fsg ( mg / dl )
fsg  mg / dl ( mean ± sd )
fsn score  mean ± sd
full analysis set  n
furosemide equivalent  mg / kg
fvc
fvc % predicted !  t
fvc < $nmbr$ % predicted
fvc > $nmbr$ % predicted
fvc change
fvc ∗
fvc  % predicted
fvc  % predicted  mean ( sd )
fvc  l  mean ( sd )
fvc  ml
g
g - blockers
g + c
ga
ga / a
gained bmd
gait
gamma glutamyltransferase  u / l
gastroenteritis
gastrointestinal ( gi ) disorders
gastrointestinal area involved  n / total n ( % )
gastrointestinal bleeding
gastrointestinal disorders
gastrointestinal event
gastrointestinal major bleed
gaviscon da ( n = $nmbr$ )
gemfibrozil ( n = $nmbr$
gendar
gender - male  n ( % )
gender - n ( % )
gender ( female : male  % )
gender ( m / f )  ( % )
gender ( male )  n ( % )
gender ( male / female ) ( number )
gender [ n ( % ) ]
gender female
gender n ( % )
gender  male ( % )
gender  male  n ( % )
gender  male / female
gender  n ( % ]
gender    n   ( % men )
gender    n   ( % )
gender :
gender : male    n   ( % )
gene
gene / chr / snp
general allergic events
general alone
general anaesthesia
general health ( self - reported )
general health  self - reported
generalized
genetic subgroup
genital mycotic infections male $nmbr$
genotype
genotype - by - treatment interaction p values *
genotype - specific treatment effect hazard ratio ( $nmbr$ % ci )
gentype
geo graphic region : asia
geographic region  n ( % )
geographic region ?
geographic region ^
geographical location  n ( % )
geometric anti - dsdna antibody binding level
geometric c $nmbr$ concentration  mg / dl
geometric mean blood eosinophil count on loge scale — cells / ^ ljj
geometric mean ige on loge scale — u / ml
geometric mean ofcrp — mg / liter ( range )
geometric mean uacr
gertder
getgoal - l - asia
getgoal - s
gff mdi
gfr ( ckd - epi )
gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
gfr < $nmbr$
gfr > $nmbr$
gfr $nmbr$ $nmbr$
gfr $nmbr$ - $nmbr$
gg
ggt increased
gi bleed
gi major bleeding
giargine
giimepiride ± oad
glacial $nmbr$
glargine $nmbr$
glargine allocation
glargine n ( n / loopy )
glatiramer acetate  no . ( % )
glimepiride
glipizide ( n = $nmbr$ )
global trial population
glp - $nmbr$ analogue
glp - $nmbr$ receptor agonist
glp - $nmbr$ receptor agonists
glu $nmbr$ asp g . t
glucagon - like peptide - $nmbr$ receptor agonist
glucocorticoid ]
glucocorticoids at baseline
glucocorticoids combined with immunosuppressive agents
glucosamine
glucosamine + chondroitin sulfate
glucose - lowering medication
glucose - lowering medications
glucose - lowering therapies — no . { % )
glucose - lowering therapy
glucose - lowering therapy - no . ( % )
glucose - lowering therapy  n ( % )
glucose — mmol / liter
glucose in urine    ≥ $nmbr$ +
glucose  mg / dl  mean
glucose  non - fasting or random ( nmol / l )
glulisine + oad
glulisine monotherapy
gly
gly ( $nmbr$ . $nmbr$ pg b . i . d . ) n = $nmbr$
gly $nmbr$ μ g bid
glycaemic control ( hba $nmbr$ c )  n ( % )
glycaemic control group
glycaemic parameters
glycated haemoglobin  %
glycated hemoglobin — % -
glycated hemoglobin  %  mean ( sd )
glycated hemoglobin | |
glycemic characteristics
glycemic indexes
glycemic status
glycemic status f
glycemic variability  mmol / lc
glyceryl trinitrate infusion
glycohemoglobin  %
glycohemoglobin  %  mean ( sd )
glycoprotein iib / iiia inhibitor use before angiography
glycoprotein iib / iiia inhibitort
glycoprotein llb / illa inhibitor
glycoprotein llb / llia inhibitor
glycoprotein llb / llla receptor inhibitor
glycopyrrolate / glycopyrrolate / eflow cs $nmbr$ meg eflow cs $nmbr$ meg ( n = $nmbr$ ) ( n = $nmbr$ )
glycopyrrolate / eflow cs $nmbr$ meg ( n = $nmbr$ )
glyeated haemoglobin
gm
gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : $nmbr$ x ( $nmbr$ — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .
gmi ( men )
gmi ( women )
gmr
goal
gold $nmbr$ ( « = $nmbr$ )
gold $nmbr$ - $nmbr$
gold $nmbr$ - $nmbr$ ( « = $nmbr$ )
gold $nmbr$ - $nmbr$ ( n = $nmbr$ )
gold classification
gold grade $nmbr$
gold grade $nmbr$ and ics non - users at screening
gold grade $nmbr$ and ics users at screening
gold grades $nmbr$ - $nmbr$ ( percent - predicted fev ( )  n
gold group
gold group a
gold group b
gold group c
gold group d
gold group  n ( % )
gold groups a - d using mmrcb
gold stage ( % ) : c
gold stage  n ( % )
gold stage  nf * ( % )
golden - $nmbr$ and - $nmbr$
golden - $nmbr$
golimumab
golimumab $nmbr$ mg ( n = $nmbr$ )
golimumab $nmbr$ mg / kg + mtx
golimumab $nmbr$ / $nmbr$ mg
golimumab $nmbr$ mg ( n = $nmbr$ ) †
golimumab $nmbr$ mg / $nmbr$ mgt
golimumab combined ( n = $nmbr$ )
goncomitant treatment with age inhibitors / angiotensin
good
good control ( < $nmbr$ )
good / moderate response
gout history  mean ± sd years
gp iib / iiia inhibitor before pci — no . ( % )
gp iib / iiia inhibitor used
gp iib / iiia inhibitors
gp mdi
gpifo ' llia inhibitor use before angography
gpiib - iiia inhibitors
grade > $nmbr$
grade $nmbr$ ( moderate copd )  n ( % )
grade $nmbr$ ( severe copd )  n ( % )
grade of hypertension
graft
graft  pci  percutaneous coronary intervention  tia  transient
granulating  n ( % ) a
grip strength < meidan
grip strength > = median
group
group b ( low risk  more symptoms )  n ( % )
group d ( high risk  more symptoms )  n ( % )
group difference
groups
grs
gt
gt + tt
gusto - bleeding severe / moderate
gusto moderate bleeding / ich
gusto moderate or severe
gusto moderate / severe bleed
gusto moderate / severe bleeding
gusto severe bleed
gusto severe or
gusto severe / moderate
h
h dl cholesterol < $nmbr$ mg / dl
h pylori serology *
h . pylori status  n ( % )
h $nmbr$ - receptor antagonist
h $nmbr$ blocker ( n  % ) long - term vka therapy
h $nmbr$ receptor antagonist
haematological
haemoglobin ( mg / dl )
haemorrhagic stroke
haemorrhagic stroke — no . ( % )
hale
hand
hands
haplotype
haq - di ( $nmbr$ - $nmbr$ )
haq - di ( range $nmbr$ - $nmbr$ )
haq - di improvement from baseline to week $nmbr$
haq - di mcide
haq - di score ( $nmbr$ - $nmbr$ )  mean ( sd )
haq - di  mean [ sd ]
haq - di  range $nmbr$ - $nmbr$  mean ( sd )
haq alternative disability score
haq di
haq di ( range $nmbr$ - $nmbr$ )
haq di score ( $nmbr$ - $nmbr$ )
haq di score ( range $nmbr$ - $nmbr$ )  mean ± sd
haq pain scale  mean
haq pain score
haq score
haq score ( $nmbr$ – $nmbr$ scale )
hard mace
harzar ratio ( $nmbr$ % ci )
harzard ratio ( $nmbr$ % ci )
has - bled > $nmbr$
has - bled $nmbr$ - $nmbr$
has - bled score
has - bled score > $nmbr$
has - bled score ’
has - bledo
hazard inleraction
hazard interaction
hazard ratio ( $nmbr$ % c
hazard ratio ( $nmbr$ % ci ) - j -
hazard ratio ( $nmbr$ % ci ) for adjudicated type $nmbr$ diabetes
hazard ratio ( $nmbr$ % ci ) vs . placebo
hazard ratio ( $nmbr$ % ci ) $nmbr$ with vs . without psoriasis
hazard ratio ( $nmbr$ % cl ) nateglinide vs . placebo
hazard ratio ( $nmbr$ % cl ) valsartan vs . placebo
hazard ratio ( $nmbr$ % cl ) *
hazard ratio ( $nmbr$ % cl ]
hazard ratio [ $nmbr$ % cl ]
hazard ratio [ $nmbr$ % ci ]
hazard ratio $nmbr$ )
hazard ratio and $nmbr$ % confidence interval
hazard ratio for cardiovascular death
hazard ratio glp - $nmbr$ analogue vs placebo [ $nmbr$ % cl ]
hazard ratio vs . placebo
hazard ratio with
hazard ratio with dabigatran  $nmbr$ mg ( $nmbr$ % cl )
hazard ratio with high ( $nmbr$ % cl )
hazard ratio with low ( $nmbr$ % cl )
hazard ratio * ( and $nmbr$ % ci )
hazard ratio  umec / vi vs . tio ( $nmbr$ % ci )
hazard ratio $nmbr$
hazard . ratio . ( $nmbr$ % ci ) . . . . . . . . . .
hb decrease ≥ $nmbr$ g / dl
hb  g / dl
hba   ( % )
hba $nmbr$ c — % cholesterol — mmol / l
hba $nmbr$ c % ( range )
hba $nmbr$ c ( % patients < $nmbr$ . $nmbr$ % )
hba $nmbr$ c ( % ) *
hba $nmbr$ c ( % )  mean ( sd )
hba $nmbr$ c ( change from baseline )
hba $nmbr$ c ( mmol / mol [ se ] )
hba $nmbr$ c ( sd )  %
hba $nmbr$ c ( sd )  mmol / mol
hba $nmbr$ c \n
hba $nmbr$ c < $nmbr$ . $nmbr$ %
hba $nmbr$ c < $nmbr$ . $nmbr$ %  bp < $nmbr$ / $nmbr$ mm hg  ldl - c < $nmbr$ mg / dl
hba $nmbr$ c < $nmbr$ % level
hba $nmbr$ c ≤ $nmbr$ . $nmbr$ %
hba $nmbr$ c ≤ $nmbr$ . $nmbr$ % without gi adverse reactions
hba $nmbr$ c > $nmbr$ . $nmbr$ %
hba $nmbr$ c > $nmbr$ % level
hba $nmbr$ c > $nmbr$ · $nmbr$ %
hba $nmbr$ c $nmbr$ weeks
hba $nmbr$ c at baseline
hba $nmbr$ c at baseline :
hba $nmbr$ c categories  n ( % )
hba $nmbr$ c category
hba $nmbr$ c distribution at baseline
hba $nmbr$ c in % ( median ( q $nmbr$  q $nmbr$ ) [ n ] )
hba $nmbr$ c month $nmbr$ ( % )
hba $nmbr$ c strata
hba $nmbr$ c tx difference vs pbo  median change from baseline ( se ) $nmbr$
hba $nmbr$ c   ( % )
hba $nmbr$ c   ( mmol / mol )
hba $nmbr$ c   at randomization
hba $nmbr$ c   baseline ( % )
hba $nmbr$ c ( % ) ( median ( iqr )
hba $nmbr$ c  % ( mean ± sd ) [ range ]
hba $nmbr$ c  % ( mean $nmbr$ sd )
hba $nmbr$ c  % [ mmol / mol ]
hba $nmbr$ c  % *
hba $nmbr$ c  %  median ( q $nmbr$  q $nmbr$ )
hba $nmbr$ c  % d
hba $nmbr$ c  ( % )
hba $nmbr$ c  ( mmol / mol )
hba $nmbr$ c  < $nmbr$ . $nmbr$
hba $nmbr$ c  > $nmbr$ . $nmbr$
hba $nmbr$ c  $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$
hba $nmbr$ c  baseline mean hba $nmbr$ c  % ( sd )
hba $nmbr$ c  difference vs placebo ( $nmbr$ % cl )
hba $nmbr$ c  mean ( sd )
hba $nmbr$ c  median ( q $nmbr$ – q $nmbr$ )
hba $nmbr$ c  median ( q $nmbr$  q $nmbr$ )  %
hba $nmbr$ c  mmol / mol ( mean )
hba $nmbr$ c  mmol / mol  mean ( sd )
hba $nmbr$ c  mmol / mol  median ( q $nmbr$  q $nmbr$ )
hba $nmbr$ c  mmol / mold
hba $nmbr$ c  mmol / mole
hba $nmbr$ c  n
hba $nmbr$ ca  %  mean ± sd
hbai
hbaic ( % )  mean ± s . d .
hbaic group ( % )
hbaie ( % )
hbaie ( % ) mean ± sd
hbaie  %
hbaj ( - ( %  mmol / mol )
hbajc ( mmol / mol ) mean ± sd
hbalc
hbalc ( mmol / mol )
hbalc £ $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc £ $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc £ $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) at week $nmbr$
hbalc < $nmbr$ % ( $nmbr$ mmol / mol )
hbalc < $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc < $nmbr$ %
hbalc > $nmbr$ - < $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc > $nmbr$ %
hbalc a $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )
hbalc in %  median ( iqr )
hbalc  %  mean ( sd )
hbalc  mmol / mol
hbau  %
hc
hcru ( a )
hctz - hydrochlorothiazide . * data were missing for some patients .
hctz = hydrochlorothiazide . * based on a ' / _ $nmbr$ test  t data were missing for some patients .
hd ( n = $nmbr$ )
hd edoxaban vs warfarin
hder *
hdl - c ( mg / dl ) *
hdl - c < $nmbr$ mg / dl
hdl - c < $nmbr$ mg / dl  no . ( % )
hdl - c < $nmbr$ mg / dl_
hdl - c > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l )
hdl - c at baseline .
hdl - c level  < $nmbr$ mg / dld
hdl - c level  mean ( sd )  mg / dl
hdl - c level  mg / dl
hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .
hdl - c  mg / dl  mean ( sd )
hdl - c  mmol / l  mean ( sd )
hdl - c  $nmbr$ mg / dl  n ( % )
hdl - c < $nmbr$ mg / dl . n ( % )
hdl - cholesterol  mean ( sd ) mg / dl
hdl - cholesterol  mg / dl  mean ( sd )
hdl - cholesterol  mmol / l
hdl - cholesterol  mmol / le
hdl — female
hdl — male
hdl < $nmbr$ mg / dl
hdl cholesterol ( mmol / l ) ( median  iqr )
hdl cholesterol ( mmol / l )  mean ( sd )
hdl cholesterol ( sd )  mg / dl
hdl cholesterol < $nmbr$ mg / dl *
hdl cholesterol level
hdl cholesterol mean
hdl cholesterol  mean ( sd )  mg / dl
hdl cholesterol  mmol / lt
hdl cholesterol ^ :
hdl  mean ( sd )  mg / dl
hdl $nmbr$
hdlcholesterol
hdm n = $nmbr$
health - care use rate ( peryear )
health practices
healthy weight
heart - rate group at baseline
heart failure — no . / total no . ( % )
heart failure ( nyha ii ‐ iii )  n ( % )
heart failure ( treated / hospitalized / fatal )
heart failure $nmbr$ yr before admission
heart failure at entry  no . ( % )
heart failure history
heart failure hospitalisation or cv death
heart failure hospitalizations
heart failure  hospitalized or fatal
heart failure  n ( % )
heart failure  no . / total no . ( % )
heart failure  ci  confidence interval .
heart failure ‡
heart rate ( bpm ) *
heart rate ( bpm $nmbr$ ) *  * *
heart rate ( median $nmbr$ . $nmbr$ }
heart rate ( min − $nmbr$ )
heart rate ( sd )
heart rate ( sd )  bpm
heart rate ( sd )  bpm blood pressure  mm hg
heart rate 一 beats / min
heart rate at baseline ( bpm
heart rate at baseline  bpm
heart rate at rest — beats / min
heart rate  / min
heart rate  beats per minute
heart rate  bpm  mean ( sd )
heart rate  mean ( sd )
heart rate  mean ( sd )  bpm ( n = $nmbr$ $nmbr$ )
heart rate  min_ $nmbr$ ( mean )
heartburn severity during the run - in periodt
heat failure
height '  cm
height ( cm ) ( mean ± sd )
height ( cm )  mean ( s . e . )
height ( cm )  mean ( sd ) a
height in meters .
height loss
height loss ( cm )
height  cm ( mean ± s . d . )
height  cm  mean ( sd )
height  mean ( sd )  cm
helicobacter pylori - negative  n ( % )
helicobacter pylori infection ( + ) ( n )
hematocrit  %
hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy
hemoglobin - a $nmbr$ c ( % ) ' • ■ * *
hemoglobin level  %
hemoglobin ( < $nmbr$ men  ， : : $nmbr$ women )
hemoglobin ( g / l )
hemoglobin 一 g / dl
hemoglobin a    ( % )
hemoglobin a ^ c  %
hemoglobin a $nmbr$ c
hemoglobin a $nmbr$ c ( % )
hemoglobin a $nmbr$ c  %
hemoglobin a $nmbr$ c  mean ( sd )  %
hemoglobin aj ^ ( % )
hemoglobin ale *
hemoglobin ale  %  median ( iqr )
hemoglobin category
hemorrhagic
heparin + tirofiban ( n = $nmbr$ )
heparin ± tirofiban ( n = $nmbr$ )
heparin alone ( n = $nmbr$ )
heparin at randomization
heparin dose regimen
heparin plus a gpi ( n = $nmbr$ )
heparin plus gpi ( n = $nmbr$  $nmbr$ )
heparin plus tirofiban ( n = $nmbr$ )
heparin use
heparin  fondaparinux or brvalirudin use between - oex event
heparins and fondaparinux
hepatic disorders
heterogeneity or trend p vaiue
heterogeneity or trend p value
heterozygous familial hypercholesterolemia
heterozygous familial hypercholesterolemia †
hf
hf ' without known reduced ef
hf cause
hf duration  y  n ( % )
hf hosp .
hf hospitalisation
hf signs and symptoms
hf symptoms and signs
hf without known reduced ef
hf without known reduced ef ( n = $nmbr$ )
hf  total
hfref
hfref ( n = $nmbr$ )
hhf ( n = $nmbr$ )
hiatal hernia ( yes ) ( n )
high - density lipoprotein cholesterol — mg / dl
high - density lipoprotein cholesterol metabolic syndrome  patients were to
high - density lipoprotein cholesterol  mg / dl
high - density lipoprotein ]
high - dose arb ( n = $nmbr$ )
high - dose edoxaban
high - dose edoxaban ( n = $nmbr$ )
high - dose edoxaban vs warfarin
high - intensity statin use
high ‐ intensity statins ‡
high - risk
high - school graduate
high - school graduate or ged
high - sensitivity c - reactive protein — mg / liter |
high - sensitivity c - reactive protein ( mg / l )
high - sensitivity c - reactive protein stratification
high - sensitivity c - reactive protein  mg / l
high ( >   uln and   ≤   $nmbr$ xuln ) ( n   =   $nmbr$ )
high ( > $nmbr$ % )
high ( > $nmbr$ )
high ( > $nmbr$ kg / m ^ ) baseline bmi
high ( > $nmbr$ )  %
high ( > $nmbr$ . $nmbr$ u / ml )
high ( > $nmbr$ % ) baseline hbalc
high ( > uln )
high ( $nmbr$ % )
high ( $nmbr$ - $nmbr$ )
high ( i $nmbr$ kg / m $nmbr$ ) baseline bmi
high ( i $nmbr$ % ) baseline hba $nmbr$ c
high ( n = $nmbr$ )
high blood pressure
high cardiovascular risk  n ( % ) ^
high crp and esr
high crp or esr
high cv risk
high dose
high fracture risk stratum
high microalbuminuria to macroalbuminuria ( n = $nmbr$ )
high nafld fibrosis score ( nfs > $nmbr$ . $nmbr$ )
high nfs nfs > $nmbr$ . $nmbr$ ( n = $nmbr$ )
high normal ( n = $nmbr$ )
high risk ( - ics )
high risk ( ? ics )
high risk ( > $nmbr$ )
high risk ( n $nmbr$ $nmbr$ )
high risk for diabetes *
high risk of diabetes
high risk *  %
high trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )
high tt > $nmbr$ . $nmbr$ ( n = $nmbr$ )
high vs . normalb
high vs . normalc
higher - dose
higher - dose edoxaban ( n = $nmbr$ )  n ( % / y )
higher - dose edoxaban vs warfarin
higher - target group ( n = $nmbr$ )
higher dose
higher dose edoxaban regimen
higher risk ( n = $nmbr$ )
highest
highjj
highly sensitive
highly sensitive responder ( n = $nmbr$ )
highly sensitive responders ( n = $nmbr$ )
hip
hip + $nmbr$ vertebral fractures
hip + nonvertebral + vertebral
hip + other nonvertebral fractures
hip fracture + > $nmbr$
hip fracture only
hip  femur
hip  wrist  or spine *
hispanic ( n = $nmbr$ l $nmbr$ )
hispanic ethnic group — no . { % ) ’ i '
hispanic ethnic group — no . ( % ) : t
hispanic ethnicity  n ( % )
hispanic or non - hispanic ethnic group — no . ( % ) f
hispanic / latino ( n = $nmbr$ )
hispanic / latino ethnicity
hispanic / non - hispanic
hispanie / latino
histamine - $nmbr$ - receptor antagonist
histor y of congestive heart failure — no . ( % )
histor y of heart failure
histor y of myocardial infarction
histor y of stable angina
histor y of unstable angina
history chd
history congestive heart failure
history coronary
history coronary revascularization
history mi or stroke
history of ( % )
history of > $nmbr$ previous vte ( excluding index event )
history of amputation  n ( % )
history of amputation  no . ( % )
history of asthma - related intubation — no . ( % )
history of atrial fibrillation and / or flutter
history of atrial fibrillation or flutter
history of bowel resection ( ref )
history of bowel resections  n ( % )
history of cad / mi
history of cardiovascular disease — no . ( % )
history of cardiovascular disease — no . { % )
history of carotid disease - n ( % )
history of cerebrovascular disease — no . { % )
history of chd at baseline
history of chd at baseline d  g
history of chd at baseline  no . ( % )
history of chd at baseline §
history of chf - n ( % )
history of chf before index event
history of chf  nyha class ii or iii — no . ( % )
history of clinical fracture ( > $nmbr$ years old )
history of clinical fracture ( > $nmbr$ years )
history of coronary
history of coronary arteiy disease
history of coronary artery disease
history of coronary artery disease - n ( % )
history of coronary artery disease — no . { % )
history of coronary heart disease at
history of coronary heart disease  no . ( % )
history of coronary revascularization d
history of coronary revascularization  no . ( % )
history of crohn ' s disease surgery  n ( % )
history of cvd
history of cvd and of cv risk factors - no . ( % )
history of cvd  n ( % )
history of diabetes - n ( % )
history of diabetes { p = $nmbr$ * $nmbr$ )
history of diabetes mellitus ( n = $nmbr$ )
history of diabetes mellitus  no . ( % )
history of diabetes nyha class
history of diagnosed hypertension n ( % )
history of diagnosed hypertension prior to randomization  n ( % )
history of disease refractory to treatment with tnf antagonist — no . ( % )
history of dyslipidaemia
history of dyslipidemia
history of elms  n ( % )
history of extra - intestinal manifestations of ibd
history of falls
history of falls in year before randomization
history of fistulising disease  n [ % ]
history of fistulizing disease  n ( % )
history of fistullzing disease  n ( % )
history of h pylori eradication *
history of heart failure — no . { % )
history of heart failure at baseline
history of heart failure  no . ( % )
history of hf hospitalization
history of hf or lvef b $nmbr$ % with index event  no . ( % )
history of htn  %
history of hypertension - n ( % )
history of hypertension  no . ( % )
history of hypertension . no . ( % )
history of hypertension ^  %
history of impaired renal function  no . ( % )
history of lvh on echocardiogram
history of lvh on electrocardiogram
history of macrovascular disease at baseline  n ( % )
history of mi or stroke
history of mi or stroke d
history of mi or stroke history of coronary
history of mi or stroke  n ( % )
history of mi or stroke  no . ( % )
history of ml at baseline
history of ml before index event
history of ml or stroke
history of non - hemor - rhagic stroke
history of omalizumab treatment :
history of osteoporotic fracture  n ( % ) a
history of oxygen use - yes  n ( % )
history of parental myocardial
history of pci or cabg before index event
history of peripheral arterial disease
history of peripheral artery disease — no . { % )
history of postmenopausal fracture *
history of pvd
history of pvd  no . ( % )
history of smoking
history of stroke at baseline
history of stroke or tia - n ( % )
history of stroke * *
history of stroke / see / tia  n ( % )
history of stroke / see / tia
history of stroke †
history of strokea
history of thyroid disease  n ( % )
history of tnf antagonist treatment failure — no . ( % ) * *
history of upper
history of upper gi events ( perforations  ulcers and bleeding ) n ( % )
history of upper gl events ( perforations  ulcers  bleeding )  n ( % )
history of venous
history ol chd at baselines
history ol coronary revascularization *
history ol mi or stroke
history ot chd  n ( % )
history / presence of tophi
hit - $nmbr$ score
hl 土 $nmbr$ . $nmbr$
hla - b $nmbr$
hla - b $nmbr$ positive at baseline  n ( % )
hla ‐ b $nmbr$ positive    n   ( % )
hla - b $nmbr$  n ( % ) ⁎ ⁎
hmg - coa reductase inhibitors
ho
ho active cancer
hoehn & yahr stage
hoehn & yahr stage ( “ off ” )  n ( % )
hoehn & yahr stage ( “ on ” )  n ( % )
hoehn and yahr stage ( baseline )  mean ( sd )
homa - b
homa - ir index
homa - ir score
homa - ir  mean ( sd )
homa_ % b  median ( q $nmbr$  q $nmbr$ )  %
homa_ir tx difference vs pbo  median change from baseline ( se ) $nmbr$
homa_ir  median ( q $nmbr$  q $nmbr$ )  % / $nmbr$
hong kong
hordic
hormone therapy use
hormones
hospitaiization for angina
hospitaiization for heart faiiure
hospital admission for heart failure
hospitalisation
hospitalisation for heart failure
hospitalisation related to exacerbation  n ( % )
hospitalization for acute limb ischemia
hospitalization for heart failure n ( % )
hospitalization for heart failure or cv
hospitalization for heart failure or cv death
hospitalization for unstable ap
hospitalization for / due to
hospitalization in previous year with management of heart failure
hospitalization in previous year with management of heart failure as major component — no . ( % )
hospitalization in the past $nmbr$ months prior to baseline
hospitalization stratum  n ( % )
hospitalization to enrollment
hospitalization  n ( % )
hospitalizations
hospitalized
hospitalized angina
hospitalized exacerbation rates
hospitalized for an exacerbation
hospitalized heart failure
hospitalized hf
hospitalized hf !
hospitalized pneumonia events  n
hospitalized without airway compromise
hospitalized !
hospitalized / fatal heart failure
hot climate subset
hr ( $nmbr$ % c ! )
hr ( $nmbr$ % ci ) *
hr ( $nmbr$ % ci )  multivariate cox proportional - hazard regression
hr ( $nmbr$ % ci )  univariate cox proportional - hazard regression
hr ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$  $nmbr$ )
hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ b ( $nmbr$  $nmbr$ . $nmbr$ )
hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ )
hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$  $nmbr$ . $nmbr$ )
hr ( $nmbr$ % cl ) pvalue
hr ( $nmbr$ s % a )
hr ( $nmbr$ s % ci )
hr ( adjusteda )
hr ( b . p . m . )
hr ( bpm )
hr [ $nmbr$ % ci )
hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ )
hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$ )
hr $nmbr$ . $nmbr$
hr $nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$ *
hr and $nmbr$ % ci *
hr is < $nmbr$ if pravastatin is better than diet alone
hr vs control ( $nmbr$ % cl ) *
hr vs placebo ( $nmbr$ % ci )
hr vs . warfarin ( $nmbr$ % ci )
hr with edoxaban ( $nmbr$ % ci )
hr * or rr †
hr * or rr † ( $nmbr$ % ci )
hr  ( $nmbr$ % ci )
hr  ( $nmbr$ % cl )
hr  bpm
hr  bpm ( sd )
hr : $nmbr$ . $nmbr$ ( $nmbr$ % cl : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$
hr ‡
hradj ( $nmbr$ % ci )
hradjusted ( $nmbr$ % ci ) b
hrg
hrql mean ( sd )
hrt use
hs - crp mg / l
hs - crp _ = $nmbr$ . $nmbr$ mg / l
hs - crp < $nmbr$ . $nmbr$ nlg l
hs - crp j $nmbr$ . $nmbr$ mg / l
hs graduate / ged
hscrp ( mg / l )  median ( first  third quartiles )
hscrp ( mg / l )  median ( min – max )
hscrp ( mg / l )  median ( minimum ‒ maximum )
hscrp ( post - baseline / baseline ratio )  ls mean   ±   se
hscrp at baseline
hscrp level
hscrp range  mg / l
hscrp  exp ls mean change ± se ‡
hscrp  mean ( sd )
hscrp  median ( iqr )  mg / l
hscrp  mg / l  median ( min – max )
hvpercholesterolemia
hvpertension
hx cabg
hx mi or stroke
hx of diabetes  n ( % )
hydroxychloroquine
hydroxychloroquine treatment §
hypercholesterolaemia ( % )
hypercholesterolemia ( % )
hypercholesterolemia  no . ( % )
hyperkalaemia
hyperkalaemia ( investigator reported )
hyperkalaemia ( serum potassium > $nmbr$ . $nmbr$ mmol / l )
hyperkalemia * ’
hyperkalemia  n ( % )
hyperlipidaemia therapy use  n ( % ) * no lipid - lowering agent therapy
hyperlipidaemia  n ( % ) yes
hyperlipidemia — no . / total no . ( % )
hyperlipidemia | |
hyperlipidemia | | yes
hyperlipidemia  n / n ( % )
hyperlipidemia §
hyperlipidemia § yes
hyperlipidmemia
hypersensitivity  n ( % )
hypertension ( > $nmbr$ / $nmbr$ mm hg or taking
hypertension ( bp > $nmbr$ / $nmbr$ mmhg or using antihypertensive medication )
hypertension 一 no . ( % )
hypertension at baseline
hypertension n ( % )
hypertension requiring medical treatment
hypertension requiring treatment
hypertension severity at baseline  n ( % )
hypertension  n ( % ) yes
hypertension  n / n ( % )
hypertension  no . / total no . ( % ) medications in use at baseline  no . / total no . ( % )
hypertension  receiving treatment  n ( % )
hypertension    n   ( % )
hypertension / yes
hypertension ^
hypertension § yes
hypertrophy per ecg ( n = $nmbr$ $nmbr$ )
hypertrophy  n ( % )
hypoglycaemiad  %
hypoglycaemic therapy
hypoglycemia ^
hypoglycemiat
hypoglycemic agent
hypokalaemia
hyponatremia
hyponatremic ( < $nmbr$ meq / l ) at baseline
hypotension  n ( % )
hypovolaemia
hzard ratio
i - $nmbr$ mg / d ( n = $nmbr$ )
i - ^ w « - i - $nmbr$
i - h
i ( $nmbr$ . i )
i $nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$
i amiodarone
i intensive  $nmbr$ mg of atorvastatin ( n = $nmbr$ )
i lisinopril ( n = $nmbr$ )
i moderate  $nmbr$ mg of pravastatin ( n = $nmbr$ )
i no . of events
i or ii
i placebo
i placebo ( n = $nmbr$ )
i rosuvastatin ( n = $nmbr$ )
i u - uj
i vitamin e
i vitamin e ( n = $nmbr$ )
i with mets ( n = $nmbr$ )
i without mets ( n = $nmbr$ )
i . $nmbr$ ( $nmbr$ . $nmbr$ - i . $nmbr$ )
i . $nmbr$ i ( $nmbr$ . $nmbr$ - i . $nmbr$ )
i $nmbr$ ( i $nmbr$ . $nmbr$ )
i $nmbr$ ( i $nmbr$ . i )
i $nmbr$ i $nmbr$ ± $nmbr$
i $nmbr$ ± $nmbr$ i
i $nmbr$ ± $nmbr$ ii
i $nmbr$ i ( i $nmbr$ . $nmbr$ )
i $nmbr$ ± i $nmbr$
i $nmbr$ years of age
i $nmbr$ i ± i $nmbr$
i $nmbr$ i
ib ( $nmbr$ . $nmbr$ )
ibdq total score
ibs ( $nmbr$ . $nmbr$ )
ibuprofen
ica stenosis $nmbr$ % - $nmbr$ % f
icd or crt - d
icd vs . placebo
icd  %
icd / crt - d  n ( % )
ich
icosapent ethyl ( events / n ( % ) )
ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ )
ics ? laba ( free or fdc )
ics dose of stable maintenance treatment ( μ g ) ∗  †
ics no laba
ics non - users
ics non - users at screening
ics non - users : qvai $nmbr$ - sfc
ics nonusers  n ( % )
ics plus laba
ics subset
ics use at enrollment  mean  mg / d
ics use at screening
ics use at screeningg  n ( % )
ics use no
ics use yes
ics users
ics users at baseline  %
ics users at screening
ics users : qvai $nmbr$ - sfc
ics  n ( % )
ics  no laba  n ( % )
ics / laba subset
ics / laba therapy  n ( % )
ics / labd
ics  no laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ )
icsa plus laba  n ( % )
icsf
ideg
idegasp – biasp $nmbr$
idegasp bid
ideglira
idiopathic / familial
idiopathica
idm
iee at baseline : < $nmbr$ iu / l
ifg pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )
ifx treatment
ig ( n = $nmbr$ )
iga $nmbr$ / $nmbr$
iga mod $nmbr$ score  n ( % )
ige ( ku / l )  median ( range ) c
ige high ( > $nmbr$ ku / l  n = $nmbr$  $nmbr$ )
igehigh ( > i $nmbr$ ku / l  n = i  $nmbr$ )
igelow ( < $nmbr$ ku / l  n = $nmbr$  $nmbr$ )
igelow ( < i $nmbr$ ku / l  n = i  $nmbr$ )
igelow ( n = $nmbr$  $nmbr$ )
igg ( > $nmbr$ . $nmbr$ g / l )  %
igl ( n = $nmbr$ )
iglar ( n   =   $nmbr$ )
iglarlixi ( n   =   $nmbr$ )
igt or ifg
igt / ifg
ihd
ii $nmbr$ amlodipine - lisinopril - chlorthalidone chlorthalidone
ii ( $nmbr$ )
ii = $nmbr$
ii chiorthaiidone amiodipine
ii lisinopril
ii lisinopril i
ii . $nmbr$ ( $nmbr$ . $nmbr$ ) $nmbr$
ii / iii
ii $nmbr$ ( i $nmbr$ . $nmbr$ )
ii $nmbr$ ( ii . $nmbr$ )
ii $nmbr$ ± $nmbr$
iief - ef domain score  visit $nmbr$ * *
iief - ef domain score  visit $nmbr$ y
iii ( $nmbr$ )
iii and iv
iii or iv
ijb ^
il - $nmbr$ range  ng / l
ileocolonic ( both ileum and colon )
ileum and colon  ' n ( % )
ileum and colon  n ( % )
ileum only  n ( % )
ileum ses - cd score  mean ( sd )
ill -
im - uniti
im on ] y
image only
imaged artery
imaging data  mean ( sd )
imm
imm only
immobilization — no . ( % )
immunomodulators
immunomodulatory drugs
immunosuppressant ^
immunosuppressive agents at baseline
immunosuppressive use  n ( % )
impacts
impaired cognitive
impaired cognitive function ( spmsq > $nmbr$ ) . n - $nmbr$ n ( % ) participants with the event of interest
impaired fasting giucose levei ( n = $nmbr$ )
impaired fasting glucose
impaired fasting glucose ( > $nmbr$ mg / dl ) ( % )
impaired fasting glucose §
impaired fasting glucosex
impaired renal function §
impaired renal function †
implantable cardioverter - defibrillator n ( % )
implanted cardioverter defibrillator
improvement from baseline ≥   $nmbr$
imputed
in
in - clinic uas $nmbr$
in - clinic uask
in - hospital medication
in - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk
in - trial and post - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk
in - trial nonfatal or fatal stroke n = $nmbr$  $nmbr$
in extension study
in hospital ticagrelor
in patients with a history of chronic angina who have presented with an acute
in previous year  mean ( sd )
in remission at maintenance study baseline
in the spironolactone group and $nmbr$ patients in the placebo group .
in therapeutic range for warfarin subjects
in thirds
inadequate response ' ^
inadequate response ' ’ '
inadequate response ( > $nmbr$ months mmf / ggs )
inadequate response or intolerance to > $nmbr$ anti - tnfdrug
inappropriate
incidence of each outcome
incidence rate ( n )
incidence rate ( n ) a
incidence rate ( per $nmbr$ person - yr )
incidence rate difference  linagliptin - placebo ( $nmbr$ % cl )
incidence rate no . ( / $nmbr$ person - years )
incidence rate of cv events  n ( % )
incidence rate per $nmbr$ person years
incidence rate *
incidence  ° / o ( $nmbr$ / $nmbr$ cl )
incidence  $nmbr$ person - year
incidence ^
incident dm or change in
incident or worsening nephropathy
included in analysis
included in this study ( n = $nmbr$ )
inclusion criteria
inclusion findings ( % )
inconsistent fao ( n [ $nmbr$ )
incontinence episodes / $nmbr$ h
increase in serum creatinine
increased - risk for thrombotic cardiovascular
increased risk for falls
increased risk for thrombotic cardiovascular event ^  n ( % )
indacaterol / glycopyrronium $nmbr$ / $nmbr$   μ g o . d .
indeterminate nfs - $nmbr$ . $nmbr$ < nfs < $nmbr$ . $nmbr$ ! n = $nmbr$ )
index acs — no . ( % )
index acs ( % )
index acute coronary syndrome — no . { % )
index event information
index event  n / n ( % )
index events
index events : dvt n ( % )
index events : pe ± dvt n ( % )
index inclusion acute coronary syndrome
index pe : event during
index percutaneous coronary intervention
indian subpopulation
indication
individual endpoints
individuals with normoglycaemia
individuals with pre - diabetes  n ( % )
individuals with prediabetes
individuals with t $nmbr$ dm ( scale diabetes )
individuals with type $nmbr$ diabetes  n ( % )
indomethacin
inducing
induction study treatment
infarct - related vessel ( % )
infarct location anterior
infarct on brain imaging ^
infarct size
infarct territory ( % )
infarction ( yr ) history of congestive heart failure ( % )
infected  n ( % ) a
infections
infections and infestations
inferior mi *  %
inflammatory bowel disease
infliiimab i
infliximab combination therapy
infliximab monotherapy
inflotmas io mgluj versus piecew
influenza
infrequent exacerbator
inguinal hernia repair
inhaled corticosteroid
inhaled corticosteroid - yes  n ( % )
inhaled ^
inhaledb
inhibitor
inhibitors — no . { % ) se - $nmbr$ physical functioning score ^ ^
inhixanab $nmbr$ mgikg versus piacom
initial heparin — no . ( % ) §
initial heparin treatment duration
initial heparin treatment duration on or after randomization
initial symptomatic pe
initial timi flow grade $nmbr$
initial treatment randomization
initial type of heparin treatment received
initiated use during double - blind treatment period
injectable anti ‐ hyperglycaemic  n ( % )
injection - site reaction  n ( % )
inotropic agent
insufficient
insuiin giargine ± oad
insulin - dependent diabetes mellitus
insulin - naive  n ( % )
insulin - requiring diabetes
insulin - treated diabetes  %
insulin - treated dm
insulin — / tu / ml
insulin ( % )
insulin + metformin
insulin + oral antidiabetic medication ( s )
insulin administration
insulin aspart
insulin aspart ( mealtime )
insulin at baseline
insulin detemir
insulin dose — lu / day
insulin dose ( iu / day )  median
insulin dose ( lu / day )
insulin dose ( u )
insulin dose  u
insulin glargin arm
insulin glargine + insulin lispro ( award - $nmbr$  n = $nmbr$ )
insulin glargine dose at screening visit  iu
insulin glargine slope lsm ± se ( mm / year )
insulin glargine   ±   oad
insulin glargine   ±   oad   +   > bd prandial
insulin glargine   ±   oad   +   bd prandial
insulin glargine   ±   oad   +   od prandial
insulin lispro mix $nmbr$
insulin secretagogue
insulin therapy  n ( % )
insulin therapy  n ( % ) 本
insulin treatment
insulin treatment  n ( % )
insulin type  n ( % )
insulin use at baseline
insulin use    n   ( % )
insulin  median ( q $nmbr$  q $nmbr$ )  pmol / l
insulin  n ( % )
insulin + metformin + sulphonylureas
insulin + sulphonylureas
insulinogenic index ( dinsulino_ $nmbr$ o min / dglucoseo - $nmbr$ o min )
insulins
insulins and analogs
integrated analysis set ( n = $nmbr$ )
intensification of antianginal therapy
intensity of rest pain ( mmvas )  mean ± sd
intensity of statin therapy
intensity of statin therapy at baseline — no . { % )
intensity $nmbr$
intensive ( n = $nmbr$ )
intensive blood glucose control
intensive bp lowering  < $nmbr$ mm hg ( n = $nmbr$ )
intensive glycemia lowering
intensive therapy ( n = $nmbr$ )
intent - to - treat population
intent to use direct thrombin
intent to use glycoprotein iib / iiia inhibitor
intention to treat
inter . p - value
interaction
interaction between treatment and baseline bmi category
interaction j $nmbr$ - valuet
interaction p - vaiue
interaction p - value *
interaction p - valuef
interaction p = $nmbr$ . $nmbr$
interaction p vaiue
interaction p value $nmbr$ . $nmbr$
interaction p value !
interaction p value ∗
interaction p value *
interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . lisinopril vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .
interaction pf
interaction : treatment by psoriasis p valueb
intercourse satisfac -
interim analysis
interim analysis ( all patients )
intermediate - acting
intermediate ( $nmbr$ )  %
intermediate ( $nmbr$ - $nmbr$ )
intermediate / long - acting + fast - acting
internal carotid artery sites
interquartile range — ml / min
intertrochanteric
interval between clinical evaluation and initiation of treatment — no . ( % )
interval from symptom onset to qualifying ecg obtained in the er — hr
interval of > $nmbr$ yr since diagnosis of type $nmbr$ diabetes — no . ( % )
intervention .
interventional or surgical procedures
intestinal area involved — no . ( % )
intolerance
intolerance '
intolerance ®
intra - abdominal abscess ( past )
intracerebral
intracranial
intracranial bleed
intracranial bleeding
intracranial disease of major artery disease t
intracranial hemorrhage
intracranial hemorrhage  n ( % )
intracranial hemorrhage †
intravenous ( n = $nmbr$ )
intravenous anticoagulant during hospitalisation *
intravenous anticoagulant prior to pre - pci angiography
intravenous vasoactive drugs  % y
inversion
investigations
investigator - defined drug - related aes
investigator - reported aes
involved gastrointestinal
involved gl areas
iop - lowering medication
iop  mm hg
ipeated - measures state examinatioi
ipf
ipss
ipss - s
ipss - v
ipss ( ls mean ± se )
ipss ( mean ± sd )
ipss ( unit )
ipss categories
ipss hrql
ipss qol
ipss qol ( ls
ipss storage subscore
ipss total score
ipss voiding subscore
ipss  “ / o
iqr
irr = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$
irregular or ulcerated ica plaquef
irritative subscore
is domain luts severity ( % )
is only
ischaemic ( n = $nmbr$ )
ischaemic dilated cardiomyopathy
ischaemic etiology n ( % )
ischaemic heart disease or cerebrovascular disorder  n ( % )
ischaemic or unknown stroke
ischaemic skin lesions
ischaemic stroke
ischaemic stroke  n ( % )
ischemia on cecg ( % )
ischemic
ischemic cause
ischemic etiology
ischemic etiology ( % )
ischemic etiology  %
ischemic heart disease ( % )
ischemic heart disease *
ischemic heart disease  no . ( % )
ischemic heart failure etiology
ischemic hf etiology
ischemic hf  % ( n )
ischemic outcomes
ischemic stroke ( % )
ischemic stroke ( incl . uncertain )
ischemic stroke or see
ischemic stroke subtype
isehemie heart disease
ish
ish status  n ( % )
isoiated systoiic hypertension *
isolated systolic hypertension
isolated systolic hypertension  n ( ' % >
isolated systolic hypertension ^
isolated systolic hypertension ⁎
isolated upper gastrointestinal disease behavior  n ( % )
it $nmbr$ . $nmbr$
itca $nmbr$ $nmbr$ mg / day ( n = $nmbr$ )
itch nrs
itch nrs $nmbr$ ( v = $nmbr$ )
itch nrs $nmbr$ - $nmbr$ ( at = $nmbr$ )
itch nrs $nmbr$ - $nmbr$ ( v = $nmbr$ )
itch nrs $nmbr$ - $nmbr$ ( . \ ' = $nmbr$ )
itch nrs $nmbr$ - $nmbr$ ( a ' = $nmbr$ )
item
ith vs . without )
itt cohort  overall study period
itt patients  n ( % )
itt population  n
iuss score  mean ( sd )
iv - $nmbr$ mg
iv ( $nmbr$ )
iv inotropic drug
iv vasodilator
ivabradine
ivc ( n = $nmbr$ )
ixekizumab every $nmbr$ weeks ( n = $nmbr$ )
ization — no . ( % )
j $nmbr$ - blocker  % ( n )
j $nmbr$ - blocker
j $nmbr$ coefficient
japanese subgroup ( n = $nmbr$ )
japanese subpopulation
joint space narrowing score  mean ( sd )
joint swelling  effusion  or both on clinical examination
js $nmbr$ - agonists
jsn score
jsn score ( $nmbr$ – $nmbr$ scale )
jsn  mean ± sd
jugular venous distension  n ( % )
jugular venous distention > $nmbr$ cm
juvenile myoclonic epilepsy
jvd $ $nmbr$ cm h $nmbr$ o  %
jvp $ $nmbr$ cm h $nmbr$ o
jvp ( 〉 $nmbr$ cm )
k - m % n
k  mmol / l
kaplan - meier rates  %
kaplan - meier rates  % i i
key secondary end points
key : fc = fasting glucose  bp = * this category did not include ar have $nmbr$ of the indicated charac
kg
kg / m $nmbr$
kg / m $nmbr$ )
kidney disease ( usrds )
killip ciass
killip class — no . / total no . ( % ) i
killip class > $nmbr$  no . ( % )
killip class > i  %
killip class $nmbr$
killip class $nmbr$ / $nmbr$
killip class ii - iv  n ( % )
killip class ii  iii  or iv — %
killip class iv at randomization
killip class *
killip class  n ( % ) i
kl $nmbr$ ( % )
km event ( % ) at $nmbr$ y
km rate ( % )
km rates { % ) e / s
km rates { % ) p / s
knee
knees ( n )
known duration
known duration of t $nmbr$ dm  y
known duration of type $nmbr$ diabetes
l
l ( < l )
l compared wi
l compared wit
l eft anterior descending
l vs . c
l . i ( $nmbr$ . $nmbr$ )
l . l ± $nmbr$ . $nmbr$
l / c
l $nmbr$ - $nmbr$ vs placebo
l $nmbr$ - $nmbr$ vs l $nmbr$ - $nmbr$ - $nmbr$
la diameter
la grade a  n ( % ) f
la grade b  n ( % ) f
laa closure ( n = $nmbr$ )
laba ( inhaled )  d   n ( % )
laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ )
laba or lama
laba plus ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ )
laba plus ics  n ( % )
laba use at enrolment
laba  n ( % )
laba  no ics  n ( % )
laba / ics #
laba / lama / ics
laba   +   ics
labd alone
laboratory determinations
laboratory evaluations
laboratory investigations
laboratory parameters  median ( iqr )
laboratory testing
laboratory tests
laboratory values in patients with history of diabetes
labs at randomization
lack of effectiveness
lack of efficacy
lack of efficacy with > $nmbr$ anti - interleukin $nmbr$
lack of efficacy with > $nmbr$ bdmard
lacunar infarction  n ( % )
lad artery
lama ( tiotropium )  b   n ( % )
lama use  n ( % )
lamad
lansoprazole ( n = $nmbr$ )
lansoprazole $nmbr$ mg qd
laparoscopic cholecystectomy
large / very large
last infusion in the horizon - pft
last study visit
late load
lathosterol ( jimol / l )
lathosterol / total c ( | imol / mmol )
latin
latin american subgroup
latin ameriea
latino
lav ( ml )
lavolta $nmbr$
lavolta ii
lb
lc  n = $nmbr$
lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - $nmbr$ — parkinson disease questionnaire .
lce  n = $nmbr$
lcl
lcz $nmbr$
lcz $nmbr$ treatment  n ( % )
ld
ld edoxaban vs warfarin
ldi - b > $nmbr$ ( n = $nmbr$ )
ldi  mean ( sd ) a
ldi  mean [ sd ] b
ldi $nmbr$
ldl - c ( calculated )  mean ( sd )
ldl - c ( calculated )  mg / dl  mean ( sd )
ldl - c ( measured )  mean ( sd )
ldl - c ( mg / dl ) * *
ldl - c < $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l )
ldl - c > $nmbr$ mg / dl
ldl - c $nmbr$ - $nmbr$ mg / dl
ldl - c at baseline :
ldl - c goal attainment
ldl - c in mmol / l ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] )
ldl - c in mmol / l ( mean ± sd for baseline [ n ]  mean ± se for week $nmbr$ [ n ] )
ldl - c level  mean ( sd )  mg / dl
ldl - c level  mg / dl
ldl - c   *   ( mmol / l )
ldl - c  mg / dl *
ldl - c  mmol / l ( sd )
ldl - c  mmol / l  mean ( sd )
ldl - c / hdl - c ratio  mean ( sd )
ldl - c < $nmbr$ mg / dl  no . ( % )
ldl - cholesterol  mean ( sd ) mg / dl
ldl - cholesterol  mg / dl  mean ( sd )
ldl - cholesterol  mmol / l
ldl - cholesterol  mmol / lf
ldl - to - hdl cholesterol ratio  mean ( sd )
ldl cholesterol - lowering therapy
ldl cholesterol ( mmol / l ) ( median  iqr )
ldl cholesterol ( mmol / l )  mean ( sd )
ldl cholesterol ( sd )  mg / dl
ldl cholesterol level
ldl cholesterol mean
ldl cholesterol  mean ( sd )  mg / dl
ldl cholesterol  mmol / l  mean ( sd ) §
ldl cholesterol  mmol / lt
ldl cholesterol ^ :
ldl / hdl cholesterol ratio  mean ( sd ) §
ldl : hdl ratio
ldlc
ldlc : hdlc
leader
leading to death
leading to discontinuation
leading to study drug discontinuation
leading to study withdrawal
least - squares mean difference ( $nmbr$ % ci ) *
least - squares mean difference ( $nmbr$ % cl )
least squares mean between - treatment difference ( $nmbr$ % ci )
lebrikizumab $nmbr$ mg
lebrikizumab $nmbr$ mg ( n = $nmbr$ )
lebrikizumab $nmbr$ - $nmbr$ mg
lebrikizumab $nmbr$ - $nmbr$ mg ( n = $nmbr$ )
leeds dactylitis index - basic  mean ( sd ) ’ ' ^
leeds enthesitis index  mean ( sd ) ’ ’ * ’
leeds enthesitis index ^ score > $nmbr$ — no . { % )
leflunomide
left
left anterior descending artery
left main coronary artery bifurcation
left main disease  n ( % )
left main treated
left shoulder
left side  n ( % )
left ventricular ejection fraction — % §
left ventricular ejection fraction ( % )
left ventricular ejection fraction within previous $nmbr$ mo — no . / total no . ( % ) $nmbr$
left ventricular ejection fraction  %
left ventricular ejection fraction  % *
left ventricular hypertrophy * *
left ventricular systolic dysfunction  n ( % )
legend
legs only
lei > $nmbr$ ( n = $nmbr$ )
lei  mean ( sd )
lei  mean [ sd ] c
lei $nmbr$
lelt ventricular hypertrophy *
lesion length ≥ $nmbr$ mm
lesion ( s )
lesions treated per patient
less severe oa symptoms at baseline
less than $nmbr$ y ears
less than $nmbr$
less than $nmbr$ kg / m $nmbr$
less than $nmbr$ . $nmbr$ %
less than high school
less than median
leukopenia
leukotriene modifier
lev - exposed
lev ( n   =   $nmbr$ )
lev status
level of renal impairment '
level of thyroperoxidase antibody at baseline
levodopa dose  mean ± sd  mg / day
levosimendan ( n   = $nmbr$ )
li $nmbr$ ( $nmbr$ . $nmbr$ )
lieum only  n ( % )
life - threatening
life - threatening bleed
life - threatening bleeding  disabling stroke  and death
lifestyle behaviors
lifestyle behaviours
likelihood test
limb
limb amputation
limited
limited to left side of colon
linagliptin ( n = $nmbr$ ) '
linear regression
lioid trial participants
lipc
lipid - lowering drug * *
lipid - lowering drugs  n ( % )
lipid ‐ lowering therapies  n ( % )
lipid - modulating drug
lipid concentrations
lipid concentrations total cholesterol ( mmol / l )
lipid levels — mg / dlj total cholesterol
lipid lowering agent n ( % )
lipid lowering agents
lipid lowering drugs
lipid lowering therapy
lipid measure *
lipid measures at baseline — mg / dl
lipid medication  n ( % )
lipid modifiers
lipid parameters
lipid parameters  mg / dl  mean ( sd )
lipid treatment
lipid trial participants
lipid trial participants - n ( % )
lipid trial participants #
lipid trial participants  no . ( % )
lipid trial participantsk
lipid trial participantss
lipid values
lipid values  mean ( sd )
lipids
lipids — mg / dl
lipids medications
lipids  mean ( sd )  mg / dlf
lipoprotein ( a )  median ( qi  q $nmbr$ )  nmol / l
lira
liraglutide ( « = $nmbr$ )
liraglutide ( $nmbr$ . $nmbr$ mg ) ± oad
liraglutide $nmbr$ - $nmbr$ mg mean ( n )
liraglutide n ( % )
lis
lisinopril
lisinopril ( n = $nmbr$ )
lisinopril cvd total
lisinopril vs amlodipineb
lisinopril vs chlorthalidone
lisinopril vs chlorthalidone normal
lisinopril vs chlorthalidone obese
lisinopril vs chlorthalidone overweight
lisinopril / chlorthalidone
lisrs
lithe
lived alone
liver disorder
lixi
lixisenatide
lixisenatide ( n = $nmbr$ )
lixisenatide ( n = $nmbr$ o )
ll ( $nmbr$ )
ll  n ( % )
ll $nmbr$ ( $nmbr$ )
lll / iv
llpasi $nmbr$
llraglutide $nmbr$ - $nmbr$ mg mean ( n )
lm $nmbr$ $nmbr$
lm $nmbr$ bid ( n = $nmbr$ )
lmwh within $nmbr$ days before randomization — no . / total no . ( % )
lo ( lo - lo )
loading dose of clopidogrel or ticlopidine
local eosinophil count
local eosinophil count [ cells / µ l ]  median ( range )
local eosinophil count [ cells / ml ]  median ( range )
locally advanced
location of infarction — no . ( % ) §
log - rank
log - rank p value
logistic regression
lone atrial fibrillation — no . ( % ) §
long - acting nitrate agents
long - acting  intermediate / long - acting + fast - acting
long - acting ^
long - standing persistent
long - term treatment with aspirin — no . / total no . ( % )
long - term vitamin k antagonist
long - term vka therapy
long - term warfarin ( n = $nmbr$ )
long ( > $nmbr$ years ) duration of diabetes
long ( > $nmbr$ mm ) stenting yes ( n = $nmbr$ )
long ( i $nmbr$ years ) duration of diabetes
long term ( n = $nmbr$ ) +
long term vka therapy
long term *
loop diuretic use
loop diureties
loop or thiazide diuretic ^
lor ii
losartan ( n = $nmbr$  $nmbr$ )
losartan ( n = $nmbr$ )
loss of response
loss of response ‘ s
loss of response ®
lost bmd
low - ceiling diuretic
low - density lipoprotein choles -
low - density lipoprotein cholesterol — mg / dlf
low - density lipoprotein ^
low - dose aspirin use at baseline
low - dose aspirin use strata * n ( % )
low - dose aspirin use . strata *  n ( % )
low - dose edoxaban
low - dose edoxaban ( n = $nmbr$ )
low - dose edoxaban vs warfarin
low - medium microalbuminuria ( n = $nmbr$ )
low - molecular - weight heparin — no . ( % )
low - molecular - weight heparin only
low - molecular - weight only
low - trauma fracture since age $nmbr$  n ( % )
low ( < $nmbr$ kg / m ^ ) baseline bmi
low ( < $nmbr$ kg / m $nmbr$ ) baseline bmi
low ( < $nmbr$ % )
low ( < $nmbr$ % ) baseline hba $nmbr$ c
low ( < $nmbr$ % ) baseline hbalc
low ( > $nmbr$ . $nmbr$ and < $nmbr$ )
low ( $nmbr$ - $nmbr$ )  %
low ( $nmbr$ - $nmbr$ )
low ( n = $nmbr$ )
low { < $nmbr$ % )
low body weight ( < $nmbr$ kg )
low c $nmbr$ ( < $nmbr$ . $nmbr$ g / l )
low c $nmbr$ ( < $nmbr$ mg / dl )  %
low c $nmbr$ / c $nmbr$ and anti - dsdna
low complement / anti - dsdna positive ( n = $nmbr$ )
low dose
low dose combination therapy
low hdl - c
low hdl cholesterol * |
low nafld fibrosis score ( nfs < - $nmbr$ . $nmbr$ )
low nfs nfs < - $nmbr$ . $nmbr$ ( n = $nmbr$ )
low normal ( n = $nmbr$ )
low or moderate
low renin ( pra < $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ )
low risk ( - ics )
low risk ( ? ics )
low risk ( n $nmbr$ $nmbr$ )
low to medium microalbuminuria ( n = $nmbr$ )
low trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )
low tt < $nmbr$ . $nmbr$ ( n = $nmbr$ )
lower - dose
lower - limb angioplasty or bypass surgery
lower - target group ( n = $nmbr$ )
lower dose
lower dose edoxaban regimen
lower limbs
lower risk ( n = $nmbr$ )
lower tertile : b $nmbr$ . $nmbr$
lowest
lowest activated clotting
lowest normal ( n = $nmbr$ )
lowest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl )
lp ( a ) ( μ mol / l )
lp ( a )  median ( q $nmbr$ : q $nmbr$ )
lp ( a )  mg / dl  median ( q $nmbr$ : q $nmbr$ )
lp ( a )  nmol / l  mean ( sd )
lpa  mg / dl
lrg
ls - mean difference between treatment groups ( $nmbr$ % ci )
ls - mean difference ® ( $nmbr$ % cl )
ls mean ( $nmbr$ % ci )
ls mean ( $nmbr$ % ci )  %
ls mean ( $nmbr$ % ci )  mmol / mol
ls mean ( $nmbr$ % ci ) a
ls mean [ $nmbr$ % ci ] treatment difference vs placebo
ls mean ± se
ls mean change
ls mean change ( se )
ls mean change from baseline
ls mean change from baseline ( se )
ls mean change from baseline ( se )  %
ls mean change from baseline  ml ( se ) a
ls mean difference ( $nmbr$ % cl )
ls mean difference ( se )
ls mean difference vs placebo ( $nmbr$ % ci )
ls mean treatment difference ( $nmbr$ % ci )
ls means difference ( $nmbr$ % ci ) a
ls t - score < — $nmbr$ . $nmbr$
ls / ul $nmbr$ $nmbr$
lsm difference ( $nmbr$ % cl )
lta ( max response to $nmbr$ pm adp ) defined hpr ( % patients )
ltg - exposed
ltg - naive
ltg subgroup  n = $nmbr$
ltt other than statin
lue for interaction
lumbar
lumbar spine bmd t -
lunchb
lung
lung infection
lung neoplasm malignant
luts = lower urinary tract symptoms  is =
luts severity
luts / bph characteristics
lv diastolic dysfunction  n ( % )
lv ejection fraction > $nmbr$ % and < $nmbr$ %
lv ejection fraction  % ( n = $nmbr$ )
lv ejection fractionb
lv function
lv function > $nmbr$ . $nmbr$ and < $nmbr$ . $nmbr$  n ( % ) medications  n ( % of patients )
lv heart structure
lv hypertrophy per ecg
lv mass index ( mg / m $nmbr$ )
lv systolic dysfunction  n ( % )
lvedv ( ml )
lvef — no . ( % )  i
lvef ( mean ± sd )
lvef ( u )
lvef < $nmbr$ . $nmbr$
lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ a
lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ ) a
lvef ^ $nmbr$ . $nmbr$ and nyha class ii  iii at baseline
lvesv ( ml )
lvh - n = $nmbr$
lvh ( from echocardiogram )
lvh ( from electrocardiogram )
lvh + n = $nmbr$
lvh by ecg
lvh by ecg ( minnesota code )
lvh by ecg or echo . n ( % )
lvh by ecg or echocardiography  no ( % )
lvh by ecg or echocardiographyd
lvh by ecg / echo
lvh by ecgt blood pressure  mm hg
lvh by echo or ecg
lvh by echocardiogram
lvh by echocardiography
lvh by electrocardiogram
lvh by electrocardiogram  n ( % )
lvh by minnesota code
lvh by minnesota code  no . ( % )
lvh on ecg
lyear mean change from baseline
lymphadenopathy
m $nmbr$ s
mab
macce ( % ) abciximab placebo
macce ( death  mi  stroke )
mace category  n ( % ) [ ir ]
mace +
macroalbuminuria — no . ( % ) drug therapy — no . ( % )
macroalbuminuria ( uacr > $nmbr$ )
maf
main effect baseline hormone
main etiology of heart failure
maintenance ocs use  n ( % )
maintenance use — no . ( % )
major adverse cardiovascular events
major amputationsb
major and crnm bleeds
major bleed
major bleeding ( mb )
major bleeding $nmbr$ to $nmbr$
major coronary disease event ( fatal / non - fatal mi )
major coronary event
major gl bleeding
major macrovascular events
major or clinically relevant non - major bleed
major or clinically relevant non - major bleeding
major secondary end pointf
major st depression or
major st depression or t - wave
major st depression or t - wave inversion
major surgery
major / crnm bleed
male ( n   = $nmbr$  $nmbr$ )
male acr definition  ^ . g / mg
male eze / simva ( n = $nmbr$ )
male gender    n   ( % )
male patients *
male sex — no . { % )
male sex — no . ( % ) medical history — no . / total no . ( % )
male sex ( % ) race or ethnic group ( % ) f
male sex \ no . ( % )
male sex  n [ % ]
male sex  no . / total no . ( % )
male sex ^
male simva ( n = $nmbr$ )
male subjects ( n = $nmbr$  $nmbr$ )
male vs . female
male *  n ( % )
male  % ( n )
male  n
male    n   ( % )
males ( itt ) ( n = $nmbr$ )
males ( n = $nmbr$ )
males [ n ( % ) ]
males  %
males  < $nmbr$ . $nmbr$
males  < $nmbr$
males  > $nmbr$ . $nmbr$
males  > $nmbr$
males  n ( % )
malignancy death
management distribution
mar ( itt ) ( n = $nmbr$ )
mar imputation ( random . ) ( n = $nmbr$ )
married
mass index
mate !
maximum
mayo clinic score  mean ± sd
mayo clinic scoreb
mayo score ( $nmbr$ - $nmbr$ )
mbes / crbesb  n / n ( % )
mbes / crbesc
mbesb  n / n ( % )
mbesc  n / n ( % )
mcs score
mcs score ( $nmbr$ – $nmbr$ scale )
mdi
mdrd - egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
mdrd egfr geometric mean ( cv % )  a  b ml /
mdrd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
mean — %
mean — mg / dl
mean — ml / min
mean — ml / min / $nmbr$ . $nmbr$ m ^
mean — mm hg
mean % change in fn bmd
mean % predicted value prebronchodilation
mean ( = sd ) days since
mean ( ± s . d . )
mean ( ± sd ) baseline score
mean ( ± sd ) change from
mean ( $nmbr$ th to $nmbr$ thquartile ) bnp ( pg / ml )
mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  %
mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  % ‐ points
mean ( median ) mtx dose  mg / week
mean ( s . d . ) baseline fpg  mmol / l
mean ( s . d . ) baseline hba $nmbr$ c  %
mean ( s . d . ) duration of t $nmbr$ dm  years
mean ( s . d . ) metformin dose †  mg / day
mean ( s . d . ) weight  kg
mean ( sd on loge scale ) u / ml
mean ( sd ) % of predicted normal eevi
mean ( sd ) % of predicted normal fev $nmbr$
mean ( sd ) % of predicted normal fevi
mean ( sd ) % reversibility fev $nmbr$ at
mean ( sd ) ( years )
mean ( sd ) [ range ] duration of epilepsy  years
mean ( sd ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )
mean ( sd ) age
mean ( sd ) age  y
mean ( sd ) age  y race  n ( % ) *
mean ( sd ) anthropometry
mean ( sd ) baseline
mean ( sd ) bmd in g / cm $nmbr$
mean ( sd ) bmi  kg / m $nmbr$
mean ( sd ) calcium intake in mg daily
mean ( sd ) change from pre - to post - bronchodilator fev $nmbr$  l
mean ( sd ) change from pre - to post - bronchodilator fevi  ml
mean ( sd ) change from pre - to post - bronchodilator fevi  nil
mean ( sd ) duration of smoking  pack - years
mean ( sd ) duration of t $nmbr$ dm  y
mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent )
mean ( sd ) eevi  ml
mean ( sd ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$
mean ( sd ) fev $nmbr$  l
mean ( sd ) fev $nmbr$ / fvc  %
mean ( sd ) fev $nmbr$ postbronchodilator  l
mean ( sd ) fevi  ml
mean ( sd ) fevi / evc  %
mean ( sd ) fevi / fvc  %
mean ( sd ) hba $nmbr$ c level  %
mean ( sd ) hba $nmbr$ c  %
mean ( sd ) improvement from baseline to week $nmbr$ in basdai
mean ( sd ) improvement from baseline to week $nmbr$ in basdai questions *
mean ( sd ) nonstudy eye e - etdrs visual acuity letter score
mean ( sd ) postbronchodilator fev $nmbr$ % predicted
mean ( sd ) postbronchodilator fev $nmbr$ reversibility  %
mean ( sd ) postbronchodilator fev $nmbr$ / fvc  %
mean ( sd ) values are presented for all variables  except medical history  race or ethnic group  and sex ( n  % ) and urinary albumin / creatinine ratio ( median ( range ) ) . abody mass index is the weight in kilograms divided by the square of the height in meters . bto convert values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . estimated using the modified equation from the modification of diet in renal disease study . dto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . eto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ^ to convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ .
mean ( sd ) years daily ocs use  n ( % )
mean ( sd ) % predicted normal fev $nmbr$
mean ( sd )  kg / m $nmbr$
mean ( sd )  mg / kg $nmbr$
mean ( sd )  mmhg
mean ( sd )  ng / ml £
mean ( sd ) d
mean ( se ) $nmbr$ - year rates per $nmbr$ population
mean ( se ) auc ^ p l
mean ( se ) auc $nmbr$ - $nmbr$  l
mean ( se ) trough l
mean ( se ) trough  l
mean ± s . d .
mean ± sd age ( y ) mean bmi category ( % )
mean ± sd mg ( n = $nmbr$  $nmbr$  $nmbr$ )
mean ± sd unless otherwise indicated
mean ± se
mean ± se ) bii ( ls mean ± se )
mean ±   sd
mean $nmbr$ - h dbp +
mean $nmbr$ - h sbp *
mean acq - $nmbr$ score at randomization  !
mean acq - $nmbr$ scores
mean age — yr ( range )
mean age ( range ) — yr
mean age ( sd )
mean age ( sd )  yr
mean age ( y )
mean age ( years  sd )
mean age ( yr )
mean age 士 s . d .  year
mean age ± s . d .  year
mean age ± s . d .  years
mean age  y
mean age  y ( range )
mean age  y : ( range )
mean age  years ( range )
mean age  years ± sd
mean age ± sd ( years )
mean alc  %
mean aqlq total score t
mean arterial pressure  baseline
mean arterial pressure  difference
mean arterial pressure  last
mean asui scored
mean baseline ( n )
mean baseline bmi
mean baseline ei score
mean baseline nasal congestion score
mean baseline ucdai score
mean blood eosinophil count ( cells per pl )
mean blood pressure at screening visit ( mm hg )
mean blood pressure  mm hg
mean bm $nmbr$ ± s . d .  kg / m $nmbr$
mean bmd ( = sd )  g / cm $nmbr$
mean bmi ( sd )
mean bmi ( sd )  kg / m $nmbr$
mean bmi ± s . d .  kg / m ^
mean bmi ± s . d .  kg / m $nmbr$
mean bmi  kg / m $nmbr$ ± sd
mean bmi ± sd ( kg / m $nmbr$ )
mean bmii 士 s . d .  kg / m $nmbr$
mean body - mass index ( = sd )  kg / m $nmbr$
mean body - mass index ( kg / mq
mean body - mass index  kg / m $nmbr$ ( sd ) *
mean body - mass index  kg / m $nmbr$   ( sd ) *
mean body - mass indexj
mean body weight  kg ( range )
mean change from baseline in acq overall score ( sd ) *
mean change from baseline in fev $nmbr$ % predicted  % ( sd ) *
mean change from baseline in the number of
mean change from baseline  %
mean change from baseline  % ‐ points
mean change in acq score
mean change in dbp from baseline  mg / dl  mean ( sd )
mean change in fev $nmbr$
mean change in radiographic end points shs  mean ± sd
mean change in sbp from baseline  mmhg  mean ( sd )
mean change in sgrq
mean change in total updrs scores adjusted according to baseline updrs
mean change ‘ s in fasting blood glucose [ mg / dl ( mmol / l ) ]
mean copd duration  y ( sd )
mean crp level  mg / l ( sd )
mean daily dose ( range ) — mg  i
mean diastolic blood pressure ( sd )  mm hg
mean difference ( $nmbr$ % cl )
mean dose ' ’
mean dose ( sd ) ( mg / day )
mean dose ( sd ) ( mg / week )
mean doseb
mean duration of pd  yr
mean duration of surgery ± sd  min
mean duration offollow - up ( years ) *
mean fecal calprotectin level  mg / g stool ( sd )
mean femoral neck t score
mean fpg  mmol / l
mean glycated hemoglobin reduction during characteristic follow - up ( $nmbr$ % ci ) percent
mean hba $nmbr$ c ± s . d .  %
mean hba $nmbr$ c  %
mean hba $nmbr$ c  mmol / mol †
mean hbaic = • = s . d .  %
mean ics ( fluticasone propionate dpi or equivalent  pg per day )
mean ics use at enrolment ( pg ) *
mean iief ef score mean iief domain score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ )
mean ipss qol ( sd )
mean ipss  storage sub - score ( sd )
mean ipss  voiding subscore ( sd )
mean lipid difference ( mg / dl ) hdl - c
mean lumbar spine t score
mean lvef
mean mmrc grade  units ( sd )
mean mmse score
mean no . agents ( sd ) other medications
mean number of antihypertensive medication at last visit   ‡
mean number of antihypertensive medications at $nmbr$ year   *
mean number of caes in past $nmbr$ months ( number per patient ) ] |
mean number of clinically significant asthma exacerbations †
mean number of combined visits / hospitalizations †
mean number of exacerbations in previous y ( sd )
mean number of puffs per day
mean of jsw ( mm )
mean of maximum cimt  mean ( sd )  mm
mean of mean cimt  mean ( sd )  mm
mean or n
mean percentage change from baseline to final visit
mean pga score ± sd
mean postbronchodilatora fev $nmbr$  % predicted ( sd )
mean prebronchodilation ( l )
mean proportion ( % )
mean pulmonary artery pressure  mm hg
mean qmax score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ )
mean reversibility ( % )
mean score ( min  max range )
mean selena - sledai score ± sd
mean serum cholesterol  mg / dl
mean serum creatinine  mg / dl
mean serum potassium  mg / dl
mean sgrq total score
mean sitting diastolic blood pressure
mean sitting systolic blood pressure
mean slicc damage index score ± sd
mean stent diameter per lesion  mm ( sd ) †
mean stents per lesion ( sd ) ‡
mean systolic blood pressure ( sd )  mm hg
mean systolic blood pressure  mm hg ( sd )
mean systolic pressure gradient
mean time since as diagnosis  years  mean ± sd
mean time since asthma
mean time since diagnosis ( years )
mean time since diagnosis  y
mean time to first oral dose postsurgeryh  hr
mean time to first subcutaneous injectiong  h in relation to surgery  hr
mean total ipss ( sd )
mean total ipss mean ipss by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ )
mean total serum psa
mean total stent length per lesion  mm ( sd ) ‡
mean treatment exposure  wk
mean wall thickness ( cm )
mean years since menopause
mean   ±   sd
mean  mg / dl
mean  ml ( sd )
mean  sd
mean_delta
mean 土 sd ( n )
mean ± sd  n ( % )
measure
measures
measures ( % )
measures ( mmol / l )
measures of lung function
medal
meddra smq
median — ml / min
median — ml / min / $nmbr$ . $nmbr$ m $nmbr$
median ( $nmbr$ th  $nmbr$ th percentile )
median ( $nmbr$ % ci ) time to weekly iss mid response up to week $nmbr$ ( wk ) f
median ( interquartile range )
median ( interquartile range ) — yr
median ( iq range )
median ( iqr ) — yr
median ( iqr ) change from baseline to week $nmbr$ in psa - modified total shs score
median ( iqr ) mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use : weight
median ( iqr )  h
median ( minimum – maximum ) focal seizure frequency / $nmbr$   days at baseline
median ( q $nmbr$ – q $nmbr$ )
median ( range ) duration of asthma ( y )
median ( range ) duration of asthma ( years )
median ( range ) duration of hospital stayi  d
median ( range ) total ige level ( iuml ~ ’ ) $nmbr$
median ( range ) treatment duration  d
median age — yr
median age [ interquartile range ] — yr
median age  y ( range )
median age  years ( iqr )
median blood eosinophil count ( cells per pl ) t
median bnp ( iqr ) – pg / ml
median body mass index  kg / m $nmbr$ ( range )
median body weight ( kg )
median c - reactive protein — mg / liter
median cardiac troponin t ( iqr ) 一 pg / ml
median crcl — ml / min
median crohn ' s disease duration  y ( range )
median delay ( h ) §
median dose ( range ) ' ’
median dose ( range ) b
median duration of chf — mo
median duration of diabetes ( yr )
median duration of study - drug administration ( iqr ) — days
median duration oftype $nmbr$ diabetes ( iqr ) — yr
median egfr ( interquartile range )
median fecal calprotectin — mg / kg gi areas involved — no . ( % )
median feno ( ppb ) f
median infusions — no . ( range )
median m / kg $nmbr$ ( iqr )
median nt - probnp ( iqr ) – pg / ml
median of jsw
median pasi score { range ) ' i  i '
median seconds
median serum periostin ( ng / ml ) t
median time delay ( interquartile range ) — min
median time from index acute coronary syndrome to randomization ( iqr ) — mo
median time in therapeutic range for warfarin recipients  %
median time to event ( weeks )
median triglyceride ( mg / dl )
median  iqr )
median  mg / dl
median  ml
median  range
median  y ( range )
median §
medians ( iqr )
medical and lifestyle history
medical historv
medical history — %
medical history and risk factors  no . / total ( % ) *
medical history at randomization — no . ( % )
medical history before index acute coronary syndrome — no . { % )
medical history of cv disease or heart failure  n ( % )
medical history  n ( % of patients )
medical history    n   ( % )
medical history . no . ( % )
medical history : cancer
medical management only — no . { % )
medical therapy before admission
medical therapy before randomization — no . / total no . ( % )
medical therapy during index hospitalization — %
medical treatment  n ( % )
medication $nmbr$ ( $nmbr$ . $nmbr$ )
medication at entry ( % )
medication at randomization
medication at randomization  %
medication at randomization  n ( % )
medication at time of randomization
medication at time of randomization — no . ( % )
medication continued into double - blind treatment period
medication in use at the baseline
medication use — no . { % )
medication use ( % )
medication use ( % ) aspirin
medication use at baseline - n ( % )
medication use at entry ( % )
medication use before enrollment  no . ( % )
medication use  n ( % )
medication use  no . / total no . ( % )
medication useb
medications — no . ( % )
medications — no . { % ) * *
medications ( % )
medications antihypertensive drugs
medications at baselinet
medications at enrollment  n ( % ) :
medications at enrolment
medications at the time of randomization — no . ( % )
medications at time of randomization — no . ( % )
medications during hospitalization or at discharge
medications for crohn ' s disease taken at baseline — no . ( % )
medications in the hospital after randomization — no . ( % )
medications in use at baseline — no . ( % )
medications in use at baseline — no . / total no . ( % )
medications in use at baseline  n ( % )
medications  n
medications  n ( % of patients )
medium normal ( n = $nmbr$ )
meglitinides ( glinides )
meloxicam
memantine use at baseline  no . ( % )
men ( n [ % ] )
men ( n 二 $nmbr$ )
men ( n  % )
men with ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
men without ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
men  n ( % ) *
men  no . ( % )
men  total ( n = $nmbr$ )
men    n   ( % )
men : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l )
men : qvai $nmbr$ - sfc
menopausal status and hormone therapy use
menopausal status and hormone therapy use premenopausal
mensa
ment
mental activities updrs subscore ( baseline )  mean ( sd )
mental status
mental status ( baseline spmsq scores )  n ( % )
mepo ( n = $nmbr$ )
mepolizumab
mepolizumab $nmbr$ mg ( n = $nmbr$ )
merformin
mesalamine use  n ( % ) a
met atopy and ige $nmbr$ - $nmbr$ ku / l criteria  ( n = $nmbr$ )
met / su / tzd
met / tzd
metabolic syndrome — no . ( % ) !
metabolic syndrome — no . ( % ) ^
metabolic syndrome — no . ( % ) $nmbr$
metabolic syndrome  n / n ( % ) *
metabolic syndromeb
metabolism and nutrition
metastatic
metformin - dose
metformin ( hdm )
metformin ( n $nmbr$ $nmbr$ )
metformin ? pioglitazone
metformin ? su
metformin + su
metformin + su + tzd
metformin ± other oral anti - dm drugs
metformin • pioglitazone
metformin alone
metformin dose
metformin monotherapy
metformin only
metformin open - label *
metformin use  n ( % )
metformin  n ( % )
metformin + sulphonylureas
metforminmonotherapy
method of assessing ejection fraction
method of insulin administration
methotrexate alone ^
methotrexate dose on day $nmbr$ — mg per wl < $nmbr$
methotrexate dose | |  mg
methotrexate plus other csdmardfl
methotrexate treatment !
methotrexate use at baseline
methotrexate use at randomization
methotrexate use at randomization    n   ( % )
methylxanthines
metoprolol ( n = $nmbr$ $nmbr$ )
mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )
mets  n ( % )
mexican
mexico  central / south america
mfns ( n = $nmbr$ )
mg daily )
mg / day
mg / dl fpg ( mmol / l )
mg / dl  mean ± sd
mg / g
mg / mmol
mh + crpnorr
mhi
mi — no . ( % )
mi ( fatal / nonfatal )
mi *
mi  n ( % )
micral test result
micro - or macroalbuminuria  n ( % ) §
micro - or macroalbuminuria  no . ( % )
micro / macroaibuminuria
micro / macroalbuminuria
microalbuminuria — no . ( % )
microalbuminuria ( uacr $nmbr$ – $nmbr$ )
microalbuminuria or macroalbuminuria §
microalbuminuria  mg / g cr
microvascular complicationsb
microvascular disease history
microvascular disease history  n ( % )
microvascular disease history  no . ( % )
microvascular disease *
microvascular outcome
micturitions / $nmbr$ h
midas score
middle
middle east  africa  or asia - pacific
middle tertile : > $nmbr$ . $nmbr$ to b $nmbr$ . $nmbr$
migraine duration ( h )
migraine occurrence ( days / month )
migraine severity score
mild - to - moderate ( ipss < $nmbr$ )
mild ( < $nmbr$ )
mild ( $nmbr$ - $nmbr$ )
mild ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )
mild ( fev  > $nmbr$ % predicted )
mild ( iief - ef $nmbr$ - $nmbr$ )
mild ( ipss < $nmbr$ )
mild ( n = $nmbr$ )
mild ( n $nmbr$ = $nmbr$ ) $nmbr$
mild decrease ( $nmbr$ - < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
mild decrease in gfr ( $nmbr$ - $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ )
mild dysfunction ( crcl > $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] )
mild ed
mild ed severe ed
mild impairment
mild impairment ( £ $nmbr$ to
mild impairment ( $nmbr$ to $nmbr$ ml / min )
mild impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ )
mild impairment ( egfr $nmbr$ – $nmbr$ )  n ( % )
mild impairment  < $nmbr$ to < $nmbr$
mild or no dysfunction ( crcl > $nmbr$ ml / min  n = $nmbr$ $nmbr$  [ $nmbr$ . $nmbr$ % ] )
mild reduction in egfr
mild to moderate renal impairment *
mild / moderate ( ipss < $nmbr$ )
mildlydecreased baseline gfr ( $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
min - ’
min - max
min – max
min per $nmbr$ . $nmbr$ m $nmbr$
mineralcorticoid receptor antagonist
mineralocorticoid receptor antagonist n ( % )
mini - mental state examination  mean ( sd ) d
minimum
minimum — maxim um
minimum — maximum
minimum  maximum
minimum / maximum
minor bleed
minor surgery
minor / major
minority
minutes from pre - pci angiography to post - pci angiography  median ( iqr )
minutes from prehospital ecg to pci  median ( iqr )
minutes from symptom onset to prehospital ecg  median ( iqr )
missing ed duration ( y )
missing *
missing  n ( % ) a
mitral valve disease ( n = $nmbr$ $nmbr$ )
mitt population ( n = $nmbr$ )
mixed
mixed ( itt ) ( n = $nmbr$ )
mixed ( n = $nmbr$ )
mixed hispanic
mmf ( n = $nmbr$ )
mmol / l [ n ]
mmol / l )
mmp - $nmbr$  median ( iqr )  gg / l
mmrc dyspnea scale score : t : t
mmrm estimates  ls mean ( se )  [ $nmbr$ % ci ]
mmse = mini - mental state examination  adas — cog = alzhei -
mn - na ï ve population
mn population
mn population  n
mnapsi
mnapsi  mean ( sd )
mnapsi  mean [ sd ] d
mod / sev exacerbation rate
mod / sev exacerbation rates
model  n
model $nmbr$
model $nmbr$ +
model $nmbr$ t
model $nmbr$ §
moderate - intensity statin
moderate - intensity statin use
moderate - to -
moderate - to - severe copd exacerbation
moderate severe ( n = $nmbr$ ) ( n = $nmbr$ )
moderate ( > $nmbr$ and < $nmbr$ )
moderate ( > $nmbr$ % . < $nmbr$ % )
moderate ( $nmbr$ % . < $nmbr$ % )
moderate ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )
moderate ( $nmbr$ % < fev  < $nmbr$ % predicted )
moderate ( $nmbr$ - $nmbr$ )
moderate ( $nmbr$ < ipss < $nmbr$ )
moderate ( iief - ef $nmbr$ - $nmbr$ )
moderate ( iief - ef $nmbr$ - $nmbr$ )  n ( % )
moderate ( ipss < $nmbr$ ) ( n = $nmbr$ )
moderate ( n = $nmbr$ )
moderate ( n $nmbr$ = $nmbr$ )
moderate ( s $nmbr$ % . < $nmbr$ % )
moderate chronic kidney disease
moderate copd
moderate cord * : qva $nmbr$ - sfc
moderate decrease ( $nmbr$ - < $nmbr$ mlymin per $nmbr$ . $nmbr$ m $nmbr$ )
moderate disease
moderate dysfunction ( crcl $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] )
moderate impairment
moderate impairment ( $nmbr$ to $nmbr$ ml / min )
moderate impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ )
moderate impairment ( egfr $nmbr$ – $nmbr$ )  n ( % )
moderate impairment  < $nmbr$ to < $nmbr$
moderate or severe decrease in gfr ( < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
moderate or severe decrease in gfr { < $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ )
moderate or severe impairment
moderate or severe renal disease  n ( % )
moderate or severe renal disease  b   n ( % )
moderate renal impairment  n ( % ) *
moderate risk ( > $nmbr$ - $nmbr$ )
moderate severity
moderate trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )
moderate  gold $nmbr$
moderate / low
moderate / severe exacerbation
moderate / severe exacerbations  patient subgroups  n ( % )
moderate / severe reduction in egfr
moderatex
moderatez
modi fied la grade *
modified hachinski ischemia scale  mean ( sd ) c
modified has - bled > $nmbr$
modified has - bled score  mean ± sd
modified total sharp score
monoamine oxidase b inhibitors
monotherapy $nmbr$
monteiukast
monteiukast ( n = $nmbr$ )
monteiukast vs placebo
month $nmbr$ subgroup x treatment interaction p - value
months from qualifying stroke *   ( % )
morning
morning peak expiratory flow — liters / min
morning stiffness duration  min
morning stiffness severity  $nmbr$ - $nmbr$ scale
morphometric vertebral
mortality
mortality outcomes
most common aes in any group
most common aes ‡
most frequent aesa
most frequent gi disorders
most frequent infections
most frequent non - infectious teaesb
most frequent serious teaes
mostly dissatisfied
mostly satisfied
motor updrs subscore ( baseline )  mean ( sd )
mouth ulceration
mra regimen ( n - $nmbr$ )
mra use
mras
mrf
ms < $nmbr$  n [ % ]
ms $nmbr$ - $nmbr$  n [ % ]
ms  mean [ sd ]
msdbp ( mm hg )
msdbp ± sd  mmhg
msfc timed $nmbr$ - foot walk test .
mssbp ( mm hg )
mssbp ± sd  mmhg
mtss at
mtss at baseline observed case
mtss  mean ( sd )
mtx - ir
mtx ( n )
mtx + other csdmards
mtx + other csomards
mtx + othetcsdmards
mtx < $nmbr$ mg / week
mtx ≤ $nmbr$ mg / week
mtx ≥ $nmbr$ mg / week
mtx > $nmbr$ – $nmbr$ mg / week
mtx > $nmbr$ and si $nmbr$ mg / week
mtx at baseline
mtx at baseline  n ( % )
mtx average weekly dose  mg / week  mean ( sd )
mtx dose > $nmbr$ mg / week  %
mtx ir
mtx naive or free
mtx only
mtx plus infliximab
mtx plus placebo
mtx sio mg / week
mtx use at baseline
mtx use at randomization  n ( % )
mucosal healingc n / n ( % )
mucosal healingf
multiple risk factors
multiracial or other
multivariable
multivariable adjusted hr ( $nmbr$ % ci )
multivariable adjusted model hr ( $nmbr$ % ci )
multivariable or ( $nmbr$ % ci )  p value *
multivariate logistic modelb
multivessel coronary - artery bypass grafting
multivessel disease — no . ( % )
multivessel disease  no . ( % )
multivitamin use yes
multivitamins
mycophenolate ( any derivative )
myocardiai infarction
myocardial infarction ( % )
myocardial infarction before index acs — no . ( % )
myocardial infarction n ( % )
myocardial infarction / cabg / pci
myocardial infarction :
myocardial infarction §
myoclonic
n - $nmbr$ allocation
n - $nmbr$ fatty acids
n - $nmbr$ fatty acids slope lsm ± se ( mm / year )
n - $nmbr$ fatty acit
n - terminal pro - bnp — pg / ml §
n ( % of patients )
n ( % ) blood pressure - mean ( sd ) mm hg
n ( % ) liraglutide $nmbr$ placebo
n ( % ) patients with risk faetors for cv disease aged > $nmbr$
n ( % ) responders
n ( % ) unless otherwise specified
n ( iqr )
n ( lesions )
n ( stented lesions )
n = $nmbr$ t
n america
n events ( % )
n events / n subjects
n events / n at risk
n nt
n observed
n participants
n t % )
n . a .
n / a
n / n   ( % )
n / n ( % / yr )
n / r
n + v ( n = $nmbr$ )
n = $nmbr$ lesions
na
nail involvement  %
naire can range from $nmbr$ to $nmbr$ for the alternative disability portion and from $nmbr$ to $nmbr$ for the pain portion . scores for the medical outcomes
naive
naive ( no treatment for current flare )
nap
naproxen
napsi score ( $nmbr$ - $nmbr$ ) of target fingernail
napsit
nasal polyposis or chronic rhinosinusitis — no . { % )
nasal polyps at baseline : yes
nasal polyps  n ( % )
nateglinide ( n = $nmbr$ )
nateglinide and repaglinide
nateglinide n / n
native american or alaska native
native american or alaskan native
native hawaiian or
native hawaiian or other pacific
native hawaiian / pacific islander
nausea and / or vomiting adverse events
nbp
nc
nc group ( n = $nmbr$ )
ncep atp - iii metabolic syndrome features  n ( % )
nct $nmbr$
nd
nd not due to swelling or ich
ne
nebivolol ( n = $nmbr$ )
necessitating hospitalization in previous year — no . ( % )
necrosis  n ( % ) a
necrotic core
necrotic core  mm ^
need for $nmbr$ ng edoxaban dose at
negative ctnl ( n = $nmbr$  $nmbr$ )
neither cs nor imm
neither deep - vein thrombosis nor pulmonary embolism ^
neither deep - vein thrombosis nor pulmonary embolism §
neither pe nor dvt
neither unfractionated heparin nor low - molecular - weight heparin
neohrodathv . and all - cause mortalitv
nerd
nesiritide ( n = $nmbr$ )
nesiritide  % z
net clinical benefit *
net clinical benefit : cv death  mi  stroke  gusto moderate / severe bleeding
net clinical benefit : on - treatment vte or major bleeding
net composite
net ep $nmbr$
network
neuraxial alonee
neuraxial anaesthesia
neurocognitive disorders
neurologicai events
neuropathy — no . ( % )
neutropenia
never been on a vka
never drink
never nsaid
never or past
never smoked — no . ( % )
never took alendronate
new - onset atrial fibrillation
new - onset diabetes
new - onset diabetes §
new diabetes
new hf medication
new or worsenina neohrodathv
new or worsentna neohrodathv
new use of gpa
new york heart association class
newly diagnosed asthma ( n )
nfs < - $nmbr$ . $nmbr$ ( low )
nfs > $nmbr$ . $nmbr$ ( high )
niacin ( n = $nmbr$ )
niacin  n ( % )
niacin + statin
nice classification of copd severity of obstruction  n ( % ) [ $nmbr$ ]
night - time awakenings in past $nmbr$ weeks ( sd ) *
night - time awakenings in past $nmbr$ weeks prior to baseline
nighttime mean dbp ( abpm ) at week $nmbr$  mmhg
nighttime mean sbp ( abpm ) at week $nmbr$  mmhg
nih stroke scale
nihss score
nilvadipine
nintedanib ( n   =   $nmbr$ )
nintedanib ( n = $nmbr$ )
nitrate ( oral or intravenous )
nitrate ( oral or topical )
nitrates ( % )
nitratesf
nkf stage
no - ckd intensive ( n = $nmbr$ )
no - ckd standard ( n = $nmbr$ )
no $nmbr$  $nmbr$
no ( $nmbr$ . $nmbr$ )
no ( reference )
no ace inhibitor / arb
no active cancer center - level inr percent time
no alcohol consumption  on average
no amiodarone
no antihypertensive medication
no apparent heart disease
no asa
no aspirin at baseline
no atopy ( n = $nmbr$ )
no atrial fibrillation
no baseline characteristics
no baseline immunosuppressant use
no body weight at randomization ( ixrs )
no cad / mi
no cardiovascular disease ( n = $nmbr$ )
no cardiovascular disorder $nmbr$ '
no cases
no chd at baseline
no chd eze / simva ( n = $nmbr$ )
no chd simva ( „ = $nmbr$ )
no ckd
no ckd ( % )
no ckd n
no ckd rate ( # events )
no colchicine ( n = $nmbr$ )
no concomitant antiplatelet
no cs and imm
no cs and is
no culprit vessel identified
no cv event ( n = $nmbr$  $nmbr$ )
no cvd
no diabetes ( n = $nmbr$  $nmbr$ )
no diabetes ( p = . $nmbr$ )
no diabetes ( p = . o $nmbr$ )
no digoxin n = $nmbr$ $nmbr$ ( $nmbr$ % )
no digoxin scd  no . ( % / y )
no diuretic therapy
no dm
no dm ( n = $nmbr$  $nmbr$ )
no draining fistulas *
no dysglycaemia or mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )
no dyspnoea ( n = $nmbr$ )
no ef data | |
no estrogen
no gi bleed
no glucocorticoids at baseline
no glucose lowering drugs
no heart failure
no history of bowel resections
no history of extra - intestinal manifestations of ibd ( ref )
no history of heart failure at baseline
no history of hf
no history of tnf antagonist treatment — no . ( % )
no hospitalization in the past $nmbr$ months prior to baseline ( ref )
no hx of hf ( n = $nmbr$ )
no ics
no immunosuppressive agents at baseline
no in - trial stroke n = $nmbr$  $nmbr$
no incident dm or change in fg > $nmbr$
no increased risk for falls
no inducer at core study entry
no infarct visible
no laba  no ics  n ( % )
no laba  no ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ )
no longer met study criteria
no metabolic syndrome
no methotrexate  hydroxychloroquine  or sulfasalazine treatment
no mtx at baseline
no mtx use at baseline
no nasal polyps
no new a or and no more than $nmbr$ new bilag b domain score  %
no new erosions among patients with ≥ $nmbr$ uninvolved joint at baseline ¶
no new jsn among patients with ≥ $nmbr$ uninvolved joint at baseline ¶
no nonsevere hypoglycemia
no oam
no ocs
no ocs use  no nasal polyps  pre - bd fvc s $nmbr$ % of predicted and age at diagnosis < $nmbr$ years
no of events / total n ( % )
no op  no vfx
no op  vfx
no oral antidiabetic medication
no p value for ischemia ischemia hr ( $nmbr$ % ci ) interaction
no pah - specific therapy
no polyvascular disease ( n = $nmbr$ $nmbr$ )
no polyvascular disease * ( n = $nmbr$ $nmbr$ )
no ppi
no pretreatment
no previous cd related surgery $nmbr$
no previous copd medication
no previous diagnosis of diabetes mellitus
no previous ischemic stroke / tia ( n = $nmbr$ $nmbr$  $nmbr$ . $nmbr$ % )
no previous myocardial infarction $nmbr$ / $nmbr$
no previous stroke or tia ( n = $nmbr$ )
no previous stroke ortia
no previous stroke / tia
no previous treatment with infliximab
no prior admc
no prior angina ( n = $nmbr$  $nmbr$ )
no prior cvd
no prior dm
no prior hf ( n = $nmbr$  $nmbr$ )
no prior hf hospitalization ( n   = $nmbr$  $nmbr$ )
no prior hf n = $nmbr$
no prior htn ( n = $nmbr$  $nmbr$ )
no prior mi ( n = $nmbr$  $nmbr$ )
no prior mi n = $nmbr$
no prior oma use
no prior oma use ( n = $nmbr$ )
no prior revascularization ( n = $nmbr$  $nmbr$ )
no prior stroke ( n = $nmbr$ )
no prior tnf inhibitor exposure
no reperfusion
no resistant htn n = $nmbr$  $nmbr$
no revascularisation
no revascularization for index acs event  no . ( % )
no severe hypoglycemia
no statin group
no steroid use at baseline ( ref )
no stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ )
no treatment or antihistamines only
no vhd
no vhd event rate / year ( n )
no vka at randomization
no worsening in pga  %
no . ( % ) '
no . ( % ) $nmbr$ ( $nmbr$ )
no . ( % ) of individuals *
no . ( % ) of patients with ≥ $nmbr$ % bsa affected
no . ( % ) of patients with atrial tachyarrhythmia
no . ( % ) of patients with fingernail involvement
no . ( % ) of patients with stroke
no . *
no . copies gly $nmbr$ - glu $nmbr$ - $nmbr$ c
no . fingernails
no . japanese
no . needed to treat ( $nmbr$ % cl ) *
no . of
no . of ' signs or symptoms of chff
no . of $nmbr$ - mg tablets of acetaminophen
no . of agents
no . of background glucose - lowering therapies  no . ( % )
no . of cardiovascular events ( cardiovascular events / $nmbr$ person - years )
no . of deaths
no . of diseased vessels ( % of group )
no . of drugs
no . of events ( rate )
no . of events / patients % / yr
no . of events / sample size
no . of events / sample size i i
no . of events / total no . $nmbr$ % )
no . of events / totol no . ( % )
no . of exacerbations in past year
no . of hospitalised patients
no . of infusions
no . of moderate or severe exacerbations in previous
no . of pack - yr
no . of participants
no . of participants ( % )
no . of patients with events ( % )
no . of patients / no . of events ( % ) $nmbr$ / $nmbr$ ( $nmbr$ ) $nmbr$ / $nmbr$ ( $nmbr$ )
no . of previous biologic dmards — no . ( % )
no . of previous ciu / csu medications
no . of previous ciu / csu medications  mean ( median )
no . of previous csdmards  n ( % )
no . of previous tne inhibitors
no . of prior aeds  n ( % ) $nmbr$ - $nmbr$
no . of prior aedsd
no . of risk factors for venous thromboembolism  no . ( % )
no . of strokes / no . of patients in category ( and % )
no . of vessels treated
no . of vessels with > $nmbr$ % stenosis
no . patients ( % )
no . patients with
no . previous alpha - blocker use
no . previous dmard  mean ( sd )
no . randomized
no . with visit
no . women
no . / total
no . / total no . ( % )
no . / total no . ( % ) t
no . / total 	 no . ( % )
no . a
nocad / mi
nocturia episodes / $nmbr$ h
nocturnal back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd
nocturnal symptoms in past week
noirecerving
noliecervrig
nominal change
nominal p vs placebo
non - / ex - drinker
non - / ex - tobacco user
non - asian
non - asian ( n = $nmbr$ $nmbr$ )
non - biological systemic
non - black participants
non - cabg related bleeding at $nmbr$ h
non - cana ( n = $nmbr$ )
non - cardiovascular mortality
non - carrier ( n = $nmbr$ )
non - caucasian eze / simva ( n = $nmbr$ )
non - caucasian simva ( n = $nmbr$ )
non - cvd deaths
non - cvd mortality
non - diabetic ( n = $nmbr$ )
non - diabetic subjects  n = $nmbr$
non - diabetics ( n = $nmbr$ )
non - dihydropyridine ccbs
non - early crohn ' s disease
non - east asian §
non - east asianf
non ‐ elderly
non - fatal ml
non ‐ haemorrhagic stroke — no . ( % )
non - hdl - c ( mg / dl ) * *
non - hdl - c  mean ( sd )
non - hdl - c  mg / dl  mean ( sd )
non - hdl - c  mmol / l  mean ( sd )
non ‐ hdl cholesterol
non - hdl cholesterol j
non - hdlc
non - hishnic
non - hispanic and latino
non - hispanic black or african - american
non - hispanic or latino
non - hispanic  non - latino
non - hispanicwhite
non - inhaled steroid use  n ( % )
non - insulin treated dm
non - ischaemic ( n = $nmbr$ )
non - ischaemic dilated cardiomyopathy
non - ischemic
non - lad artery
non - mets
non - mtx csdmards
non - pci intravenous unfractionated heparin
non - q - wave myocardial infarction
non - rheumatic valvular heart disease
non - rollover
non - severe hypoglycaemia
non - smokers receiving lipid - lowering drugs  p blockers  and either an ace inhibitor or angiotension receptor blocker
non - smokers receiving lipid lowering drugs  ( $nmbr$ blockers  and either an ace inhibitor or angiotension receptor blocker
non - spondylitis
non - st - segment elevation
non - statin ( n = $nmbr$ )
non - steroidal anti - inflammatory drugs
non - tiotropium
non - transient risk factors for recurrent vte  n ( % )
non - trial antiplatelet
non - trial p blocker
non - trial treatment during hospital stay
non - united states
non - us
non - user $nmbr$
non cns embolism
non stent thrombosis - related mi
non usa
non white
nonblack
nonblack ( n = $nmbr$ )
nonblack ( n = $nmbr$ )  adjusted hazard ratio *
nonblack participants
nonblack race — no . ( % ) f
noncardiac death
noncardiovascular death
noncompliant
noncurrent smoker
nondiabetes
nondiabetic participants !
nondisabling  nonfatal stroke
none ( n = $nmbr$ )
none at baseline
none or diet
none or seldom
nonfatai myocardiai infarction
nonfatal
nonfatal mi ( n = $nmbr$ )
nonfatal mi + fatal chdt
nonfatal myocardiail infarction
nonfatal myocardial infarction
nonfatal myocardial infarction ®
nonfatal stroke ( n = $nmbr$ )
nonfatal stroke ®
nonglycemic cardiovascular risk factors
noninducing
nonischemic
nonischemic cardiomyopathy — no . ( % )
nonobese ( < $nmbr$ kg / nr )
nonreversible
nonsevere hypoglycemia
nonsmoker  n ( % )
nontraumatic leg or foot amputation
nonuser
nonvertebral
noppi
nordic
nordic countries
normai fasting giucose levei ( n = $nmbr$ )
normal - high renin ( pra > $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ )
normal ( £ $nmbr$ ml / minute )
normal ( < $nmbr$ . $nmbr$ u / ml )
normal ( ≤   uln ) n   =   $nmbr$
normal ( ≥ $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )
normal ( > $nmbr$ ml / min )
normal ( > $nmbr$ mlvmin per $nmbr$ . $nmbr$ m $nmbr$ )
normal ( bmi < $nmbr$ )
normal ( egfr ≥ $nmbr$ )  n ( % )
normal acr ( < $nmbr$ mg / mg ) at baseline to albuminuria ( acr > $nmbr$ mg / g )
normal albuminuria ( uacr < $nmbr$ )
normal baseline crp
normal bnp  ^ $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ )
normal cognitive
normal cognitive function ( spmsq < $nmbr$ ) . n - $nmbr$ . $nmbr$ n ( % ) participants with the event of interest
normal coronary angiography
normal crp and
normal egfr ( $nmbr$ < egfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
normal function ( crcl > $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] )
normal function or mild impairment
normal hba $nmbr$ c  n = $nmbr$
normal left ventricular ejection fraction — no . ( % ) j
normal or high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to low egfr ( < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )
normal or increased baseline gfr ( > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
normal or increased egfr
normal or increased gfr ( > $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ )
normal or mild ( iief - ef $nmbr$ - $nmbr$ )  n ( % )
normal responder
normal responder ( n = $nmbr$ )
normal responders ( n = $nmbr$ )
normal study termination
normal weight ( bmi < $nmbr$ )
normal  < $nmbr$
normalfunction or mild impairment
normalized volume measures
normalized womac score
normoalbuminuria
normoalbuminuria — no . ( % )
normoalbuminuria ( uacr < $nmbr$ mg / g )
normoalbuminuria  no . ( % )
normoalbuminuria §
normoglycaemic individuals  n ( % )
normoglycemia
normoglycemic
normoglycemic ^
normoglycemic {
normonatremic ( > $nmbr$ meq / l ) at baseline
normotensive ( n = $nmbr$ )
north
north america ( n = $nmbr$ )
north america ( plus america and new zealand )
north america *
north america / oceania
north ameriea
nos $nmbr$ $nmbr$ c . t  n ( % )
nos $nmbr$ $nmbr$ a . g  n ( % )
nos $nmbr$ glu $nmbr$ asp g . t  n ( % )
not assessable
not collected ^
not estimable
not hispanic
not hispanic / latino ( n = $nmbr$  $nmbr$ )
not hispanie / latino
not on an aha
not on metformin
not perfused
not present at screening  but within previous year
not receiving
not severe
not tested
notatincreased fall risk ( n - $nmbr$  $nmbr$ )
notes :
nothfref
np tercile $nmbr$ ( bnp < $nmbr$ pg / ml  nt - probnp < $nmbr$ pg / ml ) ( n - $nmbr$ )
np tercile $nmbr$ ( bnp > $nmbr$ pg / ml  nt - probnp > $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ )
nph
nptercile $nmbr$ ( bnp $nmbr$ - $nmbr$ pg / ml  nt - probnp $nmbr$ - $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ )
nsaid   at   least   once
nste acs
nstemi ( n = $nmbr$  $nmbr$ )
nt - pro - bnp
nt - pro - bnp — pmol / literf
nt - probnp — pg / ml
nt - probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum
nt - probnp  median pg / ml
nt - probnp  pmol / h
nt - probnp $nmbr$ pmol - l - $nmbr$
nt estimated
nt probnp > $nmbr$ ng / ml n ( % ) §
ntbnp ( n = $nmbr$ )
nteraction p value
nternational index of
ntprobnp ( pg / ml )
numab
number ( % ) of patients
number and % of participants with events  and incidence rate per $nmbr$ person - year
number of “ off ” periods
number of agents
number of antihypertensive agent reported
number of antihypertensive medications at study entry
number of antihypertensive medications used  n ( % ) no antihypertensive therapy
number of antihypertensive medications  n ( % )
number of arterial beds involved
number of clinically significant asthma exacerbations in last year prior to baseline
number of co - aeds  n ( % )
number of concomitant aedsc
number of copd exacerbations in the previous year    n   ( % )
number of copd exacerbations within $nmbr$ months  mean ( sd )
number of diseased vessels  mean ( sd )
number of draining fistulae per patient  n
number of er visits in last year prior to baseline
number of events
number of events ( annualised rate [ % ] )
number of events  event per $nmbr$ person - years
number of exacerbations in previous $nmbr$ months
number of exacerbations in previous $nmbr$   months
number of exacerbations in previous year  mean ( sd )
number of exacerbations in the $nmbr$ months before screening
number of exacerbations in the last $nmbr$ months
number of exacerbations in the last $nmbr$ months  mean ± sd
number of hospitalizations in last year prior to baseline
number of implanted stents  n  mean ( sd )
number of lesions  n ( % ) a
number of medications  n ( % )
number of pack years
number of participants with an event
number of patients ( % ) or mean ± sd
number of patients randomized
number of patients with available data
number of patients with dose available
number of patients with events
number of patients with exacerbations in the previous $nmbr$ months  n ( % )
number of people ( n )
number of prevalent vertebral fractures
number of previous anti - tnf treatments for psa  n ( % )
number of previous reported aeds
number of previous tnfa inhibitors
number of prior aeds
number of prior aeds    n   ( % )
number of subjects in analysis
number of swollen joints ( $nmbr$ - $nmbr$ )
number of swollen joints ( $nmbr$ - $nmbr$ )  mean ( sd )
number of swollen joints ( $nmbr$ assessed )
number of target vessels
number of tender joints ( $nmbr$ - $nmbr$ )
number of tender joints ( $nmbr$ - $nmbr$ )  mean ( sd )
number of tender joints ( $nmbr$ assessed )
number of treated lesions ( per patient )
number of treated patients
number of visits  mean ± sd
number of visits  median
number ol ( % ) patients > $nmbr$ years
number randomized
numbera
numbers of events ( % ) :
nutraceuticals  n ( % )
nvf at flex baseline - $nmbr$ < flex fn t - score
nx *
nyha
nyha chf class
nyha class ( when patient was last in stable condition
nyha class ii ( n = $nmbr$ )
nyha class iii or iv  n ( % )
nyha class iii  % ( n )
nyha class iii / iv
nyha classes iii - iv
nyha functional class ( % )
nyha functional class $nmbr$
nyha functional class at randomization
nyha functional class i
nyha functional class iii
nyha functional class iii ( % )
nyha functional classification — no . ( % )
nyha functional classification — no . ( % ) i
nyha iii or iv § ( n = $nmbr$ $nmbr$ )
nyha iv  %
nyha ll / lll patients with lvef < $nmbr$ . $nmbr$ at baseline
nyha_class
o
o - oi $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )
o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )
o $nmbr$ o ( oo $nmbr$ - o - $nmbr$ o )
o $nmbr$ kg  n ( % )
oab - q score  mean ( sd )
oab therapy
oac experienced  bn   ( % )
oad at screening  n ( % )
oad history  years
oad use  n ( % )
oam
oam use [ n ( % ) ]
oascvd
oat
oat ( n   =   $nmbr$ )
obese ( > $nmbr$ kg / m ^ $nmbr$ )
obese ( > $nmbr$ kg / m $nmbr$ ) b
obese ( bmi £ $nmbr$ )
obese ( bmi > $nmbr$ kg / m $nmbr$ )
obesity ( bmi £ $nmbr$ kg / m $nmbr$ )
obesity *
obesity * ( bm $nmbr$ > $nmbr$ kg / m $nmbr$ )
observation
observed
observed case
obstructive subscore
ocn
ocs at baseline
ocs dose *  mean ( sd )
ocs maintained / increased
ocs reduced / stopped
ocs use
ocs  n ( % )
oct center point thickness  pm
octi
octi & mate $nmbr$
odds ‐ ratio ( $nmbr$ % ci )
odds ratio and $nmbr$ % cl
odds ratios ( $nmbr$ % ci )
of patients meeting criterion / total no . of patients
of t $nmbr$ dm ( years )
of variation )  iu
off - pump
ohs graduate
oil
ol / l )
olaemia  n ( % )
older subjects ( aged > $nmbr$ years '
olmesartan along with ccb ( n - $nmbr$ )
olmesartan along with diuretic ( n - $nmbr$ )
olmesartan medoxomil $nmbr$ mg ( n = $nmbr$ )
olmesartan medoxomil $nmbr$ mg / hctz $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
olodaterol
olodaterol $nmbr$ $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$
olodaterol $nmbr$ gg ( n = $nmbr$ )
olodaterol $nmbr$ jig
olodaterol $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$
olodaterol $nmbr$ pg
olodaterol sgg
om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg
om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ )
om $nmbr$ mg / aml $nmbr$ mg ( n = $nmbr$ )
om $nmbr$ mg / hctz $nmbr$ mg ( n = $nmbr$ )
om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg
om $nmbr$ / aml $nmbr$ / hctz $nmbr$ mg
om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg *
oma / oat
oma / oat ( n   =   $nmbr$ )
omalizumab
omalizumab $nmbr$ mg ( n [ $nmbr$ )
omega - $nmbr$ fa ( n = $nmbr$ )
omega - $nmbr$ fatty acids
omeract - oarsi response
on - pump
on antihypertensive medication at baseline  n ( % ) ‡
on antihypertensive treatment  n ( % )
on aspirin at baseline
on bp medication  n ( % )
on maximum tolerated medications ( % ) median ( $nmbr$ th to $nmbr$ th quartile ) sua ( mg / dl )
on metformin ir or metformin xr $nmbr$   mg / d
on non ‐ metformin aha
on oac at time of randomisation  n ( % )
on or after e ^ andomization
on statins at baseline
on step - $nmbr$ drug  %
on steroid at baseline
one antihypertensive medication
one at baseline
one lesion
one or more exacerbations
one or more medications
ongoing atopic or allergic condition — no . { % )
onset $nmbr$ [ $nmbr$ ]
ontario and mcmaster universities osteoarthritis index ( womac ) can range from $nmbr$ to $nmbr$ for the pain subscale  $nmbr$ to $nmbr$ for the stiffness
op concomitant medications ( % )
op  no vfx
op  vfx
opaqb physical function score
open - label phase ( baseline = week $nmbr$ )
open - label population
operative procedure
ophthalmologic events
option
or
or ( $nmbr$ % ci ) a
or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ )
or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ . $nmbr$ )
or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )
or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ $nmbr$ )
or ( itt ) ( n = $nmbr$ )
or [ $nmbr$ % cl ]
or death
or esrd
or for cana vs pbo ( $nmbr$ % ci ) | |
or for cana vs pbo ( $nmbr$ % ci ) §
or morbidity and mortality
or no microalbuminuria or macroalbuminuria
or per unit for continuous variables
or primary outcome
or raloxifene
or severe
or taking antihypertensive medication
or ulcerations  ® n ( % )
or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )
or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ — $nmbr$  $nmbr$ )
or : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )  p = $nmbr$ . $nmbr$
or 、 ( $nmbr$ % ci )
or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) < $nmbr$ . $nmbr$
or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$
oradj ( $nmbr$ % ci )
oral ( % )
oral agent
oral agent and / or insulin therapy
oral anti - dm drug status  no . ( % )
oral anticoagulant n ( % )
oral antihyperglycaemic  n ( % )
oral corticosteroid dose ( mg / day )
oral corticosteroid use at baseline
oral corticosteroid use at enrolmentt
oral corticosteroid use  n ( % )
oral diabetic agent
oral fi - blockers
oral glucocorticoid dose  mg ( prednisone equivalent )
oral glucocorticoid use
oral hypoglycemic agents
oral hypoglycemic agentsj
oral hypoglycemics hormone replacement
oral or other systemic corticosteroid
oral β - adrenergics  n ( % )
oralb
organic
origin [ n ( % ) ]
original dabigatran protocol
oropharyngeal pain
ors ( $nmbr$ % cis ) :
orthopnea
orthopnea  frequent / continuous
orthostatic test *
os domain
osmotic diuresis - related aes
osteoporosis drug
osteoprotegerin decreased
other ' i '
other ( % ) diabetes ( interaction : p = $nmbr$ . $nmbr$ )
other ( n   = $nmbr$ )
other ( n = $nmbr$  $nmbr$ )
other ( n = $nmbr$  $nmbr$ ]
other { n = $nmbr$ )
other anti - hypertensive
other antihypertensive drug
other antihypertensive medications
other antithrombotic medication for index event — no . ( % )
other ascvd
other ascvd  no . ( % )
other atherosclerotic
other atherosclerotic cvd
other atherosclerotic cvd st depression on
other atherosclerotic cvd * *
other atherosclerotic cvdd  e
other blood glucose - lowering agents
other blood pressure - lowering drugs
other bp drug
other bph - luts therapy
other climate subset
other clinical characteristics
other combination
other diagnostic procedure *
other diuretic
other dmards
other drug therapy  n ( % )
other end points
other glucose - lowering drugs
other glucose status
other hypoglycemic agent  n ( % )
other ics
other ics versus no ics
other individual and exploratory end points
other lipid - lowering medication
other lipid lowering drugs
other medical history  no . ( % )
other medications
other medications at enrollment
other n ( % )
other osteoporosis medication
other outcomes
other pacific islander
other plain vitamin preparations
other prespecified end points
other race
other race  n ( % )
other selected aes
other stent
other steroids
other treatment assignment
other uc - related gi surgical procedure
other vascular disease ( cvd or pad )  %
other vasodilators §
other * ( n = $nmbr$ )
other * ’
other  no . ( % )
other / mixed ( n = $nmbr$ )
other / multiple
other : :
other ^
other ® region — no . ( % )
other †
othera
otherc
otherd
otherf
otherj ^ :
others  classes i and iiic
othert
othery ethnicity  n ( % )
othery ethnicity  n ( % ) *
outcome - variant
outcome ( n  % }
outcome according to no . of risk factors for vte
outcome according to primary cancer site — no . / total no . ( % )
outcome according to renal function level ( in ml / min )
outcome according to stage of cancer — no . / total no . ( % )
outcome and metabolizer phenotype
outcome measure
outcome severity
outcome type
outcome_subgroup
outcomes
outcomes by treatment ( spironolactone vs placebo )
outcomes during accord
ovary
over past $nmbr$ years  n ( % )
overaii
overaii ( n = $nmbr$ )
overal event rate
overall ( $nmbr$  $nmbr$ )
overall ( itt ) ( n = $nmbr$ )
overall ( per protocol ) ( n = $nmbr$ )
overall ( pp ) ( n = $nmbr$ )
overall ( w = $nmbr$ )  $nmbr$ / $nmbr$
overall analysis
overall cohort ( post hoc analysis excluding metformin users )
overall cohort ( primary analysis )
overall ctd
overall dlqi score
overall dlqi score $nmbr$
overall early - morning copd symptom severity scorec
overall efficacy
overall freedom population ( n = $nmbr$ )
overall mortality
overall n ( n / loopy )
overall night - time copd symptom severity scorec
overall pea population
overall population ( n - $nmbr$ )
overall population ( n = $nmbr$ $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )
overall population ( n = $nmbr$ )
overall study period
overall study population
overall treatment effect
overall vero population
overall  n = $nmbr$
overall  qvai $nmbr$ - sfc
overall ® $nmbr$ . $nmbr$
overally
overweight
overweight ( bmi £ $nmbr$ to < $nmbr$ )
overweight ( bmi = $nmbr$ - $nmbr$ . $nmbr$ )
oxypurinol ( n = $nmbr$ )
p ' value
p - blocker intake at randomisation ( n = $nmbr$ )
p - blocker use
p - blockers ( % )
p - blocking agents  selective
p - for interaetion
p - gp inhibitor
p - gp use
p - heterogeneity
p - int .
p - inte faction
p - inter
p - sitosterol / lathosterol
p - sitosterol / total c ( | imol / mmol )
p ‐ value
p - value ( ■ nt )
p - value ( ancova treatment difference ) a
p - value ( interaction ) ≠
p - value ( overall )
p - value ( trend )
p - value ( vs placebo )
p - value d $nmbr$ mg vs . warfarin
p - value for
p - value for east asian versus non - east asian *
p - value for interaction $nmbr$ :
p - value for trend across categories
p - value low vs . high nfs ^
p - value n / n ( % )
p - value vs . placebo
p ‐ value *
p - value }
p - value ‘ ’
p - value ¶
p - value $nmbr$
p - valueb
p ( $nmbr$ % cl )
p ( inter - action )
p ( women vs men )
p . b * int
p . b “ int
p $nmbr$ interaction women vs men
p between age groups
p blocker before admission
p blocker *
p blockersubgroup
p for inter - act
p for interaction between rhtn and no rhtn and treatmenta
p for trend
p for trend -
p int . f
p inter
p interaction = $nmbr$ . $nmbr$
p j $nmbr$ * trend
p vaiue
p vaiue ( interaction )
p value ( inter )
p value ( interaction )
p value ( nominal )
p value ( vs . previous time point )
p value between groups
p value by gt
p value f
p value for
p value for dm vs . no dm
p value for heterogeneity （ rosiglitazone versus glyburide ）
p value for heterogeneity （ rosiglitazone versus metformin ）
p value for interaction - dosage with dabigatran  $nmbr$ mg
p value for interaction ( age continuous )
p value for interaction ( age groups ) *
p value for interaction by region
p value for interaction  dosage with dabigatran  $nmbr$ mg
p value for interaction ®
p value for interaction ® vertebral fracture at flex baseline :
p value for trend *
p value heart failure vs no heart failure
p value interaction
p value within category
p value *  placebo group p value *  hyponatremia normonatremic group  tolvaptan vs hyponatremic vs placebo
p value ∥
p value § ® ( w
p valueb
p valuec
p valuej '
p valuer
p   value
p   value for interaction
p   values for interaction
p   values of interaction
p   vs . placebo
p ( inter )
p ) atients with > $nmbr$ exacerbations resulting in emergency department visit
p . o )
p / interaction
p < $nmbr$ . $nmbr$ ) between the study groups in any of the baseline characteristics . ace
p $nmbr$ vs no treatment $nmbr$
p $nmbr$ y $nmbr$ antagonist
p $nmbr$ y $nmbr$ antagonists
p $nmbr$ min twice / week
p $nmbr$ z $nmbr$ ( n = $nmbr$ )
p $nmbr$ vs placebo
p $nmbr$ vs usual care
pacemaker — no . ( % )
pacemaker or icd
pacific
pack - years ( iqr )
pack years
paclitaxel - eluting stent use  n ( % )
pad details  n ( % )
pah - ctd
pah - mctd / ctd - other
pah - sle
pah - ssc
pah etiology
pah etiology :
pah therapy at baseline
pain vas ( range $nmbr$ - $nmbr$ )  mean ± sd
pain vas  mean change from baselinea
pain vas  mean change from baselined
pain vas  range $nmbr$ - $nmbr$ mm  mean ( sd )
pain  $nmbr$ - $nmbr$ mm vas
pain  mm
pairwise comparison
pancreas
panel a
panel b
parameter ( mg / dl )
parameter at baseline
parameter mean ± s . d .
parameter statistics
parameter  % ( $nmbr$ % ci )
parameter  n ( % )
parameter / variable
parameters
parameters at baseline
parental history of mi before age $nmbr$ y
parental history of ml before age $nmbr$ y yes
parental history of myocardial infarction before age $nmbr$ y
parental history of myocardial infarction before age $nmbr$ y yes
parenteral anticoagulation
paresthesia
paroxysmal ( n  % )
paroxysmal atrial fibrillation — no . ( % )
paroxysmal nocturnal dyspnea
paroxysmal !
paroxysmal  n ( % )
partial mayo score
participant - reported hypertension — no . { % )
participants
participants at baseline  n
participants randomized
participants taking insulin
participants with a history of cabg
participants with an event per $nmbr$ patient - years
participants with heart failure
participants with hf at baseline
participants with metabolic syndrome
participants without a history of cabg
participants without heart failure
participants without hf at baseline
participants without metabolic syndrome
participants  n
participants  no . ( % )
participated in a previous febuxostat studyb  n ( % )
partner  n ( % yes )
pasi
pasi # $nmbr$ at week $nmbr$
pasi [ c ]  median ( min - max )
pasi $nmbr$
pasi response by baseline mtx use  no . / total no . ( % ) * pasi $nmbr$
pasi response by baseline weight  no . / total no . ( % ) * pasi $nmbr$
pasi score
pasi score ( $nmbr$ - $nmbr$ )
pasi score ( $nmbr$ - $nmbr$ )  mean ( sd )
pasi score ( $nmbr$ - $nmbr$ ) d
pasi score ( $nmbr$ – $nmbr$ scale )
pasi score  mean ( sd )
pasi score $nmbr$
pasi  mean ( sd )
pasi  median ( range ) * *
pasi $nmbr$ a
pasi $nmbr$  no . / total no . ( % ) $nmbr$
pasia
passive smoker
past cardiovascular history  no . ( % )
past or nonsmoker ( n = $nmbr$ )
past smoker
past treatment for paod
patient ' s ga  $nmbr$ - $nmbr$ mm vas
patient ' s global assessment of disease status score
patient ' s global assessment of response to therapy score
patient ' s history of :
patient - reported hypertension — no . { % )
patient - reported outcomes
patient - years ) hr ( unadjusted )
patient assessment of arthritis pain  mm
patient assessment of disease activity  mm
patient assessment of pain ( $nmbr$ - $nmbr$ cm  vas )
patient assessment of pain ( $nmbr$ - $nmbr$ mm )  mean ( sd )
patient characteristic
patient characteristics at randomization
patient classification
patient demographics age — yr
patient global assessment of disease
patient global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas )
patient global assessment of disease activity  mean ( sd )
patient population
patient status after wake - up  % of days patient woke :
patient years
patients ( full analysis sety )  n
patients ( treated set * )  n
patients < $nmbr$ y
patients < $nmbr$ y *
patients > $nmbr$ y
patients > $nmbr$ y *
patients aged > $nmbr$ y  no  ( ss )
patients analyzed  n
patients assessed
patients in analysis  n
patients in the placebo group  nt - probnp values were reported for $nmbr$ patients
patients included in analysis
patients meeting the criteria to receive $nmbr$ mg of
patients not receiving mtx  n =
patients not receiving statin
patients on antihypertensive medications  n ( % ) | |
patients on atorvastatin  rosuvastatin  or simvastatin at
patients per $nmbr$ patient - years
patients randomised  n
patients randomized  n
patients randomized  no .
patients randomly assigned
patients receiving $nmbr$ mg of edoxaban at randomization — no . ( % ) f
patients receiving any uc medication  n ( % )
patients receiving immunotherapy  no . ( % )
patients receiving mtx
patients receiving mtx  n =
patients receiving statin
patients taking mtx  n ( % )
patients taking mtx  no . ( % )
patients taking oral corticosteroids at baseline  n ( % )
patients total no .
patients treated and operated  n ( % )
patients treated with atenoloi ( n = $nmbr$ )
patients treated with losartan ( n = $nmbr$ )
patients who did not use insulin pump
patients who had ulcerations at
patients who received $nmbr$ drug
patients who received $nmbr$ or $nmbr$ drugs
patients who used insulin pump
patients with $ $nmbr$ dactylitis digit at week $nmbr$ enthesitis
patients with $ $nmbr$ % bsa at baseline  no .
patients with > $nmbr$ exacerbation in previous $nmbr$ months
patients with > $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening
patients with > $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening
patients with > $nmbr$ co - aeds
patients with > $nmbr$ % bsa
patients with > $nmbr$ % bsa psoriasis skin involvement  n ( % )
patients with $nmbr$ co - aed
patients with $nmbr$ co - aeds
patients with a prior mi or stroke at baseline
patients with an event per $nmbr$ patient - years
patients with ascvd but no prior ml hr ( $nmbr$ % cl )
patients with bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt
patients with cardiac disorders  n ( % ) §
patients with cardiac disorders  n ( % ) c
patients with change from baseline in psa - modified total shs score # $nmbr$
patients with change from baseline in total psa ‐ modified shs ≤ $nmbr$
patients with clinically evident vascular disease
patients with dactylitis
patients with dactylitis at baseline  no .
patients with dactylitis at week $nmbr$  n ( % )
patients with dactylitis  no . ( % )
patients with dactylitisa
patients with deep - vein thrombosis only
patients with diabetes
patients with diabetes mellitus ( n = $nmbr$ )
patients with digits with dactylitis  n ( % )
patients with dm ( n = $nmbr$ )
patients with dm vs . patients without dm
patients with draining fistulae at baseline [ n = $nmbr$ ]
patients with early cd ( n = $nmbr$ )
patients with eligible ses - cd score
patients with endpoin t  n ( % )
patients with enthesitis
patients with enthesitis ( lei > $nmbr$ )
patients with enthesitis at baseline  no .
patients with enthesitis at week $nmbr$ radiographic progression § change from baseline to week $nmbr$ in psa - modified total shs score
patients with enthesitis at week $nmbr$  n ( % )
patients with enthesitis  n ( % )
patients with enthesitis  no . ( % )
patients with eot data  n
patients with established cv disease aged > $nmbr$ years .
patients with evaluable endoscopy
patients with event ( n  % )
patients with event / patients analysed
patients with event / analyzed
patients with fingernail involvement
patients with glycated hemoglobin < $nmbr$ . $nmbr$ % and no severe hypoglycemia or diabetic ketoacidosis
patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode of severe hypoglycemia *
patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode ofdiabetic ketoacidosis *
patients with hospitalized pneumonia events  n ( % )
patients with improvement $ $nmbr$ . $nmbr$
patients with level > $nmbr$ pg / ml
patients with low ( < $nmbr$ mg / dl ) c $nmbr$
patients with measurement
patients with microvascular complications  n ( % )
patients with mild pain ( womac pain score  $nmbr$ - $nmbr$ )
patients with moderate - to - severe pain ( womac pain score  $nmbr$ - $nmbr$ )
patients with nail psoriasis ( mnapsi > $nmbr$ )
patients with negative anti - dsdna
patients with no prior cvd ( primary
patients with only mrf hr ( $nmbr$ % cl )
patients with perianal fistulae  n [ % ]
patients with pneumonia event  n ( % ) #
patients with pneumonia events  n ( % ) #
patients with pneumonia resulting in death  n ( % )
patients with possible new dm at randomization ( fpg > $nmbr$ - $nmbr$ )
patients with possible new dm at randomization ( hba $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ % )
patients with prior dmard use  n ( % ) a
patients with prior ml hr ( $nmbr$ % cl )
patients with psoriasis ( bsa ≥   $nmbr$ % )
patients with psoriasis > $nmbr$ % of body surface area
patients with pulmonary embolism
patients with radiographic erosion  n / n ( % )
patients with remission
patients with serum $nmbr$ ( oh ) d ≥   $nmbr$ . $nmbr$ and <   $nmbr$   ng / ml    n / n   ( % )
patients with specific disease characteris -
patients with specific disease characteristics  n ( % )
patients with supplemental vitamin d dose of $nmbr$ iu / day starting at screeningc    n   ( % )
patients with weekly iss mid response  n ( % ) v
patients without
patients without a prior mi or stroke at baseline
patients without clinically evident vascular disease
patients without diabetes
patients without diabetes mellitus ( n = $nmbr$ )
patients without dm ( n = $nmbr$  $nmbr$ )
patients without dm ( n = $nmbr$ )
patients without draining fistulae at baseline [ n = $nmbr$ ]
patients  n ( % )
patients  n / n ( % ) a
patients  no .
patients    n   ( % )
patients / events n
patientswith bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt
patientswith bp  $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  n §
pb
pbo - adjusted ls mean change
pbo - adjusted ls mean change ( se )
pbo - sc every other week ( n = $nmbr$ )
pbo ( n - $nmbr$ )
pbo ( n   =   $nmbr$ )
pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ ( n = $nmbr$ )
pbo n = $nmbr$
pbo to czp week $nmbr$ dose combined
pbo  no . ( % ) ^
pbo  no . ( o / o ) ^ ’
pci — no . { % )
pci alone ( n = $nmbr$ )
pci duration
pci history
pci indication
pci performed
pci postindex event
pci / thrombolysis at randomization
pci :
pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > $nmbr$ mg / l  for europa > $nmbr$ mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .
pcr after acs
pcs score
pcs score ( $nmbr$ – $nmbr$ scale )
pde - $nmbr$ i
pde - $nmbr$ i monotherapy
pde $nmbr$ inhibitors
pdq - $nmbr$
pe and dvt
pe only
pe with / without dvt
peak fev $nmbr$ ( $nmbr$ - $nmbr$ h )   response
peak systolic pressure gradient
pedal edema  slight / moderate / marked
pef at baseline  l_ / min
pef !
pefam   ( l / min ) ∗
pefpm   ( l / min ) ∗
penetrating no . of resections  n ( % )
people with diabetes n = $nmbr$
people without diabetes n = $nmbr$
pepsinogen i / ii ratio
per body weight  u / kg
percent activity impairment due to asthma
percent atheroma volume at baseline
percent change from baseline at week $nmbr$
percent change from baseline to week $nmbr$ in auc ( mean  sem )
percent impairment while working due to asthma
percent improvement  baseline to week $nmbr$  median ( iqr )
percent of predicted normal value
percent of predicted value before bronchodilation ^
percent of the time that inr was in the therapeutic range
percent overall work impairment due to asthma
percent stenosis [ core lab ]
percent stenosis [ investigator ]
percent work time missed due to asthma
percentage
percentage of bsa involved
percentage of females
percentage of fevj reversibility
percentage of p
percentage of patients receiving dose adjustment
percentage of patients with event
percentage of predicted pre - bronchodilator fev ^
percentage points
percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < $nmbr$ mg / dl . tbased on participant history or review of chart .
percentages
percentages of patients with event
percutaneous coronary intervention done *
percutaneous coronary intervention n ( % )
percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % )
percutaneous coronary intervention  n ( % )
percutaneous coronary intervention §
percutaneous transluminal coronary angioplasty
peri - operative cabg participants :
perianal gi tract
perianal  n ( % )
perindopril - indapamide
period ii
periostin
periostin high
periostin low
peripherai arteriai disease
peripheral - artery stenosis
peripheral angioplasty
peripheral arterial disease — no . ( % )
peripheral arterial disease ( n = $nmbr$ $nmbr$ )
peripheral arterial disease §
peripheral arterial stenosis
peripheral artery disease - -
peripheral artery disease 一 no . ( % )
peripheral artery diseaseb
peripheral limb vascular efficacy
peripheral revascularisation
peripheral sensory neuropathy
periprocedural medications  n ( % )
permanent ( n  % )
permanent af
permanent users
permanent users  n
permanent  n ( % )
persisent
persistent ( n  % )
persistent af  n ( % )
persistent faod ( n [ $nmbr$ )
persistent faol ( n [ $nmbr$ )
persistent *
persistent  n ( % )
persistent / permanent
person - years
pervious cerebrovascular event
pfor trend
pga score ( range )
pga score  mean ( sd )
pgi - s  n ( % ) y :
phakic
pharmacological therapy for hf
pharyngitis
phenobarbital
phosphatase  mean ( sd )  ng / ' mlf
phototherapy
phototherapy previous systemic treatment  n ( % )
physical activity ( hours walking / wk )
physical activity  kcal / wk < $nmbr$
physical characteristics
physician ' s assessment of disease activity ( vas )  mm
physician ' s ga  $nmbr$ - $nmbr$ mmvas
physician ' s global assessment of disease status score
physician global assessment of disease
physician global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas )
physician global assessment of disease activity  mean ( sd )
pi
piacebo
piacebo ( n = $nmbr$ ) no . of participants with events ( % )
pifr l / min
pinteraction for treatment and history of heart failure
pinteraction = $nmbr$ . $nmbr$
pioglitazone dose  mean ( sd )  mg
pioglitazone group ( n = $nmbr$ )
pioglitazone only
piroxicam
pla « = $nmbr$
pla n = $nmbr$
place !
placebo - control study
placebo ‐ controlled period
placebo |
placebo $nmbr$ o $nmbr$
placebo  ( n = $nmbr$ )
placebo ( « = $nmbr$ )
placebo ( » = $nmbr$ )
placebo ( $nmbr$ = $nmbr$ )
placebo ( $nmbr$  $nmbr$ . $nmbr$ % )
placebo ( events / n ( % ) )
placebo ( n — $nmbr$ )
placebo ( n : $nmbr$ )
placebo ( n = $nmbr$ ) †
placebo ( n = $nmbr$ ) i -
placebo ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
placebo ( n = $nmbr$ ) '
placebo ( n = $nmbr$ ) n ( % )
placebo ( n = $nmbr$ i $nmbr$ )
placebo ( n $nmbr$ $nmbr$  $nmbr$ )
placebo ( n   = $nmbr$  $nmbr$ )
placebo ( n   = $nmbr$ )
placebo ( n   =   $nmbr$ )
placebo ( n   =   $nmbr$  $nmbr$ )
placebo ( n   =   $nmbr$ )
placebo ( n   =   $nmbr$ ) a
placebo ( n   =   $nmbr$ ) b
placebo ( n = l $nmbr$ )
placebo ( symptom days a week )
placebo ( w = $nmbr$ )
placebo + glimepiride
placebo + insulin ( n   = $nmbr$ )
placebo + insulin ( n = $nmbr$ )
placebo + insulin glargine ( award - $nmbr$  n = $nmbr$ )
placebo + pioglitazone ( n = $nmbr$ )
placebo $nmbr$ . $nmbr$
placebo $nmbr$  $nmbr$
placebo analysed ( % )
placebo arm
placebo diabetes n = $nmbr$
placebo dn = $nmbr$ )
placebo dr = $nmbr$ )
placebo events / patients (
placebo group ( n = $nmbr$ ) ’ j '
placebo km %
placebo mdi
placebo mean
placebo mean change ( sd )
placebo mortality rate  events per $nmbr$ person - y
placebo n
placebo n ( rate ) $nmbr$
placebo n / n
placebo no diabetes n = $nmbr$
placebo no . ( $nmbr$ - y km % )
placebo patients / events n
placebo plus statin ( n = $nmbr$ )
placebo slope lsm ± se ( mm / year )
placebo tiotropium n = $nmbr$ non - tiotropium n = $nmbr$
placebo to ustekinumab $nmbr$ mgt
placebo tolvaptan ( $nmbr$ mg ) ( n $nmbr$ $nmbr$ ) ( n $nmbr$ $nmbr$ )
placebo ( n = $nmbr$ )  n ( % )
placebo * ( add on to basal insulin )
placebo  $nmbr$ . $nmbr$ ml ( n = $nmbr$ )
placebo  n
placebo  n = l $nmbr$
placebo  n *
placebo  n   =   $nmbr$
placebo /
placebo / rosu vastatin
placebo / simva
placebo + statin
placebo → golimumab $nmbr$ mg / $nmbr$ mga  b
placebo §
placebofigolimumab $nmbr$ mg / $nmbr$ mgt
plaeebo
plasma cholesterol — mg / dl
plasma creatine  mg / dl
plasma dha  mean ( sd ) weight  %
plasma glucose — mmol per liter
plasma glucose $nmbr$ hr after glucose load — mmol / liter
plasma lipids ( mg / dl ) $nmbr$ total cholesterol mean
plasma lipoproteins  mmol / l
plasma triglyceride — mg / dl
platelet aggregation inhibitors excluding heparin
platelet aggregation inhibitors  n ( % )
platelets xlooo / mm ^
pleased
plus – minus values are means ± sd . cabg denotes coronary - artery by - pass graft  ptca percutaneous transluminal coronary angioplasty  and ace angiotensin - converting enzyme . hypertension and diabetes were de - fined by clinical history . a more complete list of base - line characteristics is given in rubins et al . $nmbr$ † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$ . to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ .
pnd
pneumonia
pneumonia events  n
pollen exposure
pollent < $nmbr$
pollent s $nmbr$
polyarticular arthritis  no rheumatoid nodules
polyvascular disease ( n = $nmbr$ )
polyvascular disease and no type $nmbr$ diabetes ( n = $nmbr$ )
polyvascular disease and type $nmbr$ diabetes ( n = $nmbr$ )
polyvascular disease * ( n = $nmbr$ )
polyvascular disease * and type $nmbr$ diabetes status
polyvascular disease * status
pool of fh i and ii studies
pool of long term ( hefh patients only ) and high fh
pooled analysis of sustain $nmbr$ — $nmbr$ trials
pooled analysis sample
pooled itt
pooled non - canvas studies ( n = $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )
pooled pah - mctd and pah
pooled placebo
pooled secukinumab
pooled trials * n = $nmbr$
poor compliance / noncompliance
poor outcome at $nmbr$ months
population
positive atopic status
positive ctnl ( n = $nmbr$ )
positive cu index test
positive cu index test  z n ( % )
positive for hla - b $nmbr$  n ( % )
positive hla - b $nmbr$ status  n ( % )
positive orthostatic test }
positive troponin i or t  no . ( % )
positive troponin or ck - mb
positive vs . negative
post - albuterol % predicted fev $nmbr$ mean ( sd ) e
post - bronchodilator fev i reversibility  % b
post - bronchodilator fev  % predicted
post - bronchodilator fev  ( l )
post - bronchodilator fev  reversibility
post - bronchodilator fev  / fvc
post - bronchodilator fev $nmbr$ at screening
post - bronchodilator fev $nmbr$ ml
post - bronchodilator fev $nmbr$ % predictedb
post - bronchodilator fev $nmbr$  % predicted of normal value
post - bronchodilator fev $nmbr$  % predicted  mean ( sd )
post - bronchodilator fev $nmbr$  % predicted  mean ( sd ) c
post - bronchodilator fev $nmbr$  l  mean ( sd )
post - bronchodilator fev $nmbr$  l  mean ( sd ) c
post - bronchodilator fev $nmbr$  mean ( sd )  l
post - bronchodilator fev $nmbr$ / fvc ratio  mean ( sd )
post - bronchodilator fevi  n ( % )
post - bronchodilator fevi $nmbr$ % predicted
post - bronchodilator fevx ( l )
post - bronchodilator screening
post - dose
post - procedure
post - salbutamol fev $nmbr$ ( l ) b  mean ( sd )
post - salbutamol fev $nmbr$ / fvcb  mean ( sd )
post erior - anterior spine
post fev $nmbr$
post fev $nmbr$   % pred
post fvc
post fvc % pred
post hoc analysis
post svc
postbaseline binding antibodies
postbaseline new - onset diabetes - n ( % )
postbronchodilator $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )
postbronchodilator fevj ( % predicted )
postdose fev / fvc at screening
postoperative use of p - blocker
postprandial indices
potassium - sparing diuretic
potassium — mg / dl
potassium ( mg / dl )
potassium at admission  mmol / l - $nmbr$
potassium  meq / dl  mean
potassium  meq / l
potent phosphorylated glycoprotein inhibitor use
potential injection site reactions
potential predictor
ppbc score  mean ( sd )
ppci
ppg post - meal test  mmol / l
ppi
ppi or h $nmbr$ receptor antagonist  n ( % )
ppi use
ppi use ( p = $nmbr$ . $nmbr$ t )
ppi use at baseline
ppi use within $nmbr$ months of randomization
pr / virgin islands  n ( % )
pra  median ( min  max )  ng / ml / h
pravastatin ( n = $nmbr$ )
pravastatin n = $nmbr$
pravastatin sodium
pravastatin vs usual care
pre - bd fvc < $nmbr$ % of predicted
pre - bd fvc s $nmbr$ % of predicted
pre - bronchodilator fef $nmbr$ . $nmbr$ ( ml / s ) baseline blood eosinophil count
pre - bronchodilator fev i ( l )
pre - bronchodilator fev  % predicted
pre - bronchodilator fev  ( l )
pre - bronchodilator fev ^ ( l )
pre - bronchodilator fevi change
pre - bronchodilator fevi / fvc  %
pre - bronchodilator fevj
pre - bronchodilator fevr % pred
pre - bronchodilator fevr l
pre - bronchodilator fvc ’ % pred
pre - bronchodilator mean ( sd ) fev $nmbr$  . l
pre - bronchodilator screening
pre - dose
pre - hospital ticagrelor ( n = $nmbr$ )
pre - procedure
pre - specified trial endpoints
pre - treatedforhypertension [ n ( % ) ]
pre - treatment [ n ( % ) ] c
pre – diabetes mellitus
pre – diabetes mellitus  n = $nmbr$
pre fev $nmbr$
pre fev $nmbr$   % pred
pre fvc
pre fvc % pred
pre hospital ticagrelor
pre svc
prebronchodilator fev $nmbr$
prebronchodilator fev $nmbr$ ( %
prebronchodilator fev $nmbr$  mean ( sd )  l
prebronchodilator fevi — liters
prebronchodilator fevi ( % predicted )
prebronchodilator fevj ( % predicted )
prediabetese
predicted normal ) t
predictive factor
prednisone - equivalent dose  mg
prednisone or equivalent dose ( mg / day )
predominant cardiac diagnosis — no . ( % )
predose fev -  at randomization
predose fev / fvc
predose fev ^ at screening
predose fev $nmbr$ ( l ) *
predose fvc ( l )
predose fvc ( l ) *
preferred term  %
pregnancy
premature discontinuation
premature treatment discontinuation
premenopausal  %
premixed insulin only ( % )
premixed insulin with oads ( % )
preoperative p - blocker use yes
preoperative use p - blocker
prerandomization pci
presence of angioedema at baseline
presence of dactylitis
presence of enthesitis
presence of tophi
presence of tophi  n ( % )
present at screening
presentation to tertiary care hospital — %
presentation *
presenting condition  n ( % )
presenting history or diagnosis — no . ( % )
prespecified medical conditions  n ( % ) f
prespecified subgroup analyses
prespecified subgroups
pressure ( mm hg )
pressure
prestudy treatment ( % ) a
prestudy treatment status
pretreatment hdl - c
pretreatment triglycerides
prevalent cvd
prevalent kidney disease ( egfr < $nmbr$ ml / min / usm ^ or maeroalbuminuria uacr > $nmbr$ mg / g )
prevalent vertebral fracture
prevalent vertebral fracture status
prevalent vertebral fracture  n ( % )
prevention )  n ( % ) patients on llt ( other than statin )  n ( % )
previous $nmbr$ - ari use ( % )
previous $nmbr$ ari use
previous a - blocker
previous a - blocker use
previous af
previous analgesic products n ( % )
previous anti - inflammatory / antirheumatic products n ( % )
previous antihypertensive treatment
previous antihypertensive treatment — no . ( % )
previous antiparkinson medication  no . ( % )
previous bdmard received
previous cad  n ( % )
previous cancer — no . ( % )
previous cardiovascular event — no . ( % )
previous cardiovascular event ( % )
previous cd related surgery ( ref ) a
previous chf  n ( % )
previous chronic kidney disease
previous clinical stroke or tia
previous clinical stroke or transient ischemic attack ( % )
previous congestive heart failure — no . ( % )
previous congestive heart failure ( % )
previous coronary artery bypass graft
previous coronary artery bypass grafting
previous coronary artery bypass surgery  no . ( % )
previous coronary heart disease
previous coronary procedure ( % of group )
previous cv events
previous cvd ^
previous diabetes mellitus
previous diagnosis
previous digoxin use
previous digoxin use ( % )
previous disease and drug use
previous dm
previous dm  n ( % )
previous dmards  mean ± sd
previous events  no . ( % )
previous exposure to a vitamin k antagonist — no . ( % ) current or former never
previous exposure to biologic systemic psoriasis therapyb ( yes )  n ( % )
previous exposure to non - biologic systemic psoriasis therapyb ( yes )  n ( % )
previous exposure to systemic psoriasis therapyb ( yes )  n ( % )
previous heart failure — no . ( % )
previous history of cardiovascular events
previous hospital admission for heart failure
previous hospitalization for heart failure
previous hospitalization for unstable angina
previous htn  n ( % )
previous hypersensitivity reaction — no . ( % )
previous ics alone
previous ics only
previous ics / labd
previous infarction
previous infarction ( % of group )
previous infliximab therapy | |
previous intervention ( % )
previous ischemic heart disease — no . ( % )
previous ischemic stroke / tia ( n = $nmbr$  $nmbr$ . $nmbr$ % )
previous labd alone
previous labd only
previous lev only
previous mi ( % )
previous mi  %
previous ml or abnormal angiogram
previous myocardial infarction  no . ( % )
previous myocardiaunfarction
previous number of ciu / csu medications
previous oral antidiabetic medication use  n ( % )
previous pde $nmbr$ - i therapy  no . ( % )
previous pde $nmbr$ inhibitors
previous percutaneous coronary intervention  %
previous renal disease  n ( % )
previous revascularization
previous segments resection ( s ) *
previous smoker
previous smokers
previous stroke 一 no . ( % )
previous stroke or tia ( n = $nmbr$ )
previous stroke or tia  n ( % )
previous stroke or tl a
previous stroke or tl a $nmbr$ - $nmbr$
previous stroke or transient ischemic attack — no . / total
previous stroke or transient ischemic attack  no . / total no . ( % )
previous stroke ortia
previous stroke ortia $nmbr$ - $nmbr$
previous stroke yes ( n  % ) previous myocardial infarction
previous stroke / tia
previous systemic treatment  n ( % )
previous therapies  n ( % )
previous therapy
previous treatment in the healing study  n ( % )
previous treatment with infliximab
previous treatment ?
previous use of biologic systemic therapy  n ( % )
previous use of niacin or niaspan §
previous use of nonbiologic systemic therapy  n ( % )
previous use of other biologic agents in addition to tne
previous use of systemic steroids for ciu / csu
previous use of systemic steroids  n ( % )
previous use of vitamin k antagonist for > $nmbr$ days — no . ( % )
previous vka use
previous vka use ( stratified randomization )
previous vte
previous vte n ( % )
previous vte  n ( % )
previously failed anti - tnf treatment  no . ( % )
previously untreated isolated systolic hypertension
primary - prevention cohort
primary analysis
primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  $nmbr$ % cl  $nmbr$ % confidence interval  tia  transient ischemic attack .
primary cardiovascular endpoint
primary cause of chf
primary cause of heart failure
primary composite end point ‡
primary composite end points
primary composite endpoint ‡
primary composite ^
primary cv endpoint
primary efficacy outcome
primary end - point
primary end point |
primary end point *
primary end points
primary endpoint :
primary endpoint ^
primary endpoint ’
primary endpoint $nmbr$
primary hemorrhagic stroke
primary indication
primary ischemic stroke
primary mace endpoint
primary nonresponse
primary outcome ( $nmbr$ - point mace )
primary outcome plus revascularization or nonfatal hf
primary outcome ! ( n = $nmbr$ )
primary outcome : $nmbr$ % decrease in womac pain score
primary pcit
primary safety outcome -
primary study joint  n ( % )
primary target vessel ( % )
primary / key efficacy endpoint
prior a - blocker use
prior acbi or arb use
prior admb
prior aeds  ≥ $nmbr$  n ( % )
prior analgesic products  n ( % )
prior angina ( n = $nmbr$  $nmbr$ )
prior angina pectoris
prior angina pectoris — no . / total no . ( % )
prior angina  n / n ( % )
prior angiography showing stenosis ≥ $nmbr$ %  n   =   $nmbr$   $nmbr$ a
prior anti - tnf exposure
prior anti - tnf failure
prior anti - tnf treatment
prior antiinflammatory / antirheumatic products  n ( % )
prior aortocoronary bypass surgery — no . ( % )
prior aspirin use
prior bb plus acbi plus arb use
prior bisphosphonate usage
prior bp use
prior cabg surgery
prior cabg  %
prior cad
prior cardiovascular event
prior chf
prior chf  %
prior clinical fracture ( since age $nmbr$ )
prior conventional synthetic dmards  n ( % )
prior copd medication
prior copd medicationa  n ( % )
prior coronary intervention or coronary artery bypass grafting
prior coronary revascularization — no . { % )
prior coronary revascularization  n / n ( % )
prior coronary revascularization  no . ( % )
prior corticosteroid treatment
prior cv history
prior cvd
prior ed therapy
prior electrical cardioversion for af ( n = $nmbr$ $nmbr$ )
prior gestational diabetes
prior heart failure — no . { % )
prior heart failure  n / n ( % )
prior hf ( n = $nmbr$  $nmbr$ )
prior hf hospitalization
prior hf hospitalization ( n = $nmbr$ )
prior hf n = $nmbr$
prior history of bleeding on oac
prior hospitalization for hf  %
prior hospitalizations  n ( % )
prior htn ( n = $nmbr$  $nmbr$ )
prior hypertension
prior immunosuppressant failure
prior immunosuppressant failurec
prior immunosuppressive exposure  n ( % )
prior infarction
prior insulin use ( years )
prior lev
prior lev treatment    n   ( % )
prior medication use  n ( % )
prior mesalazine use *
prior mi ( n = $nmbr$  $nmbr$ )
prior mi diagnosis :
prior mi n = $nmbr$
prior mi within $nmbr$ y  no . ( % )
prior mi  %
prior mi  n / n ( % )
prior ml or stroke at baseline
prior ml / stroke
prior ms treatment with ifn - beta or glatiramer acetate . no . ( % )
prior myocardial infarction — no . { % )
prior myocardial infarction — no . / total no . ( % )
prior myocardial infarction ( % )
prior myocardial infarction  no . / total no . ( % )
prior myocardial intarction
prior non - cns se
prior non - haemorrhagic stroke
prior nonvertebral fracture
prior nonvertebral fracture at age > $nmbr$ years
prior nsaid use
prior nsaid  n ( % ) a
prior oabg surgery
prior oac
prior oad :
prior oma use
prior oma use ( n = $nmbr$ )
prior pad
prior pci or cabg
prior pci  %
prior percutaneous coronary intervention — no . / total no . ( % )
prior ptca or cabg
prior revascularization ( % )
prior revascularization ( n = $nmbr$  $nmbr$ )
prior statin use ( n = $nmbr$ )
prior stroke ( % )
prior stroke ( n = $nmbr$ )
prior stroke or tia  %
prior stroke or tza
prior stroke / mi  n ( % )
prior sulfasalazine use *
prior surgery for cd  n ( % )
prior surgery for cd  n [ % ]
prior therapy with omalizumab : yes
prior thienopyridine ( - )
prior thienopyridine ( + )
prior tia
prior tnf antagonist failure  n [ % ]
prior tnf antagonist failure  n ( % ) b
prior tnf antagonist  n [ % ] ‘ *
prior tnf inhibitor exposure
prior tnf inhibitor exposure  no . ( % )
prior transient ischaemic
prior transient ischemic attack
prior treatment — no . ( % )
prior urate lowering therapies  n ( % )
prior use of osteoporosis medications
prior use of osteoporosis medications  n ( % )
prior use of synthetic dmards
prior use of synthetic dmards  n ( % )
prior vka experience
prior vka use for > $nmbr$ d  %
pro - active intervention
probable stent thrombosis
probenecid
procedures after discharge — no . ( % )
procedures in the hospital — no . ( % )
progression of albuminuria
progression to diabetes
propafenone
propionic acid derivatives
proportion
proportion ( % ) of individuals • control alirocumab
proportion ( % ) of individuals a alirocumab • placebo
proportion of angioedema - free days from week $nmbr$ to week $nmbr$ x
proportion of patients who achieved acr $nmbr$ n / n ( % )
proportion of patients with trough fevi > $nmbr$ ml above baseline  n ( % )
proportion of responders n / n ( % )
proportion taking pulmonary medications ( % ) b
proportions  n ( % )
prostate biopsy
prostate volume ( cm $nmbr$ )
prostate volume ( ml )
protein in urine    ≥ $nmbr$ +
proteinuria ( > $nmbr$ g / $nmbr$ h )  %
proton pump inhibitor
proton pump inhibitor ( n  % )
proximal
proximal gi tract
proximal gl tract  n ( % )
psa - modified mases score ( $nmbr$ - $nmbr$ )
psa ‐ modified mases score ( $nmbr$ – $nmbr$ scale )
psa - modified shs of hands & feet $nmbr$ ( $nmbr$ - $nmbr$ )
psa ‐ modified shs of hands and feet
psa - modified shs ( $nmbr$ - $nmbr$ )
psa ( ng / ml )
psa duration ( years )
psa duration ( years )  mean ( sd )
psa level  ng / ml
psa pain ( vas )
psa reported  n ( % )
psa subtypes  n ( % )
psa  ng / ml  mean ( sd )
psaqol
psoriasis ( n =
psoriasis > $nmbr$ % of bsa
psoriasis bsa > $nmbr$ %  n ( % )
psoriasis characteristics
psoriasis duration ( years )  mean ( sd )
psoriasis duration  years
psoriatic arthritis
psychoactivesd
psychogenic
psycholeptics
pt . years = $nmbr$
ptga ( $nmbr$ - $nmbr$ cm vas )
ptga of disease activity ( $nmbr$ ‒ $nmbr$ mm )  mean ( sd ) †
ptga ⁎ ⁎ ⁎
ptrend across doses
pts
ptx $nmbr$ ( ng / ml )
puerto rican
pulmonary congestion ( cxr )
pulmonary embolism only
pulmonary embolisma  n / n ( % )
pulmonary embolismb  n / n ( % )
pulmonary function tests ( post - bronchodilator )  mean ( sd )
pulmonary medication during baseline ! '
pulmonary medications ( % )
pulmonary vascular resistance  dyne • s • cm $nmbr$
pulse — beats / min
pulse in beats / minute  mean ( sd )
pulse pressure ( median $nmbr$ . $nmbr$ ]
pulse pressure ( mm hg )
pulse pressure ( mmhg )
pulse rate ( mean $nmbr$ h )  bpm *
pulse rate  bpm ( mean $nmbr$ h )  mean ( sd ) *
pulse  beats / min
pump
pure motor hemiparesis
pure sensory stroke
pv  ml
pvalue ∗
pvaluefor interaction $nmbr$ - $nmbr$
pvaluefor trend
pvr volume  ml  mean ( sd )
pvr  ml
pyrexia
q ( q $nmbr$ \
q wave in the infarct territory at baseline *  %
q waves in the infarct territory at baseline *  %
q $nmbr$ - q $nmbr$
q $nmbr$ ( n   = $nmbr$ )
q $nmbr$ w ( n $nmbr$ $nmbr$ )
q $nmbr$ w ( n = $nmbr$ )
qids - sr $nmbr$
qmax ( ml / s )
qmax category  n ( % ) :
qmax  ml / s
qmax  ml / s  mean ( sd )
qmaxi rn l / s
qol
qol due to urinary symptoms
qrs $ $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$ )
qrs < $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$  $nmbr$ )
qrs > $nmbr$ ms  % ( n )
qrs duration  ms
qrs width  ms
qtc > $nmbr$ n = $nmbr$
qtc < $nmbr$ n = $nmbr$
qualifying acs event — no . ( % )
qualifying events
qualifying high - risk features — %
qualifying index event as pe
qualifying risk factor
qualifying risk factor — no . ( % )
qualifying risk factor  n ( % )
qualifying risk factors — no . ( % )
qualifying symptomatic event  n ( % ) a
quartiles of fgf - $nmbr$ ( ru / ml )
question $nmbr$ ( fatigue / tiredness )
question $nmbr$ ( neck / back / hip pain )
question $nmbr$ ( pain / swelling in joints other than neck / back / hips )
question $nmbr$ ( discomfort from any areas tender to touch / pressure )
question $nmbr$ ( morning stiffness since arising )
question $nmbr$ ( length of morning stiffness since arising )
quintile ( n )
quintile $nmbr$ ( $nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ % ) ( n = $nmbr$ )
quintile  range  mg / dl
qva $nmbr$ / $nmbr$ pg once daily ( n = $nmbr$ )
qveral
r - tpa
r ight coronary
r wave in avl ( mm )
ra - beam
ra duration ( years )  mean ( s . e . )
ra ndosii zat ion
raas inhibitor
raas inhibitors
race - nonwhite
race - n ( % )
race — no . ( % ) : t
race — no . { % ) ' i '
race — no . { % ) - i -
race — no . / total no . ( % ) f
race ( % white )
race ( % ) white
race ( % ) *
race ( non - white ) ( % )
race ( p = o - $nmbr$ )
race ( white  n [ % ] )
race or ethnic group — no . ( % ) : t
race or ethnic group — no . { % ) ■ ' ( white
race or ethnic group ( % ) f
race or ethnic group  n ( % ) *
race or ethnic origin
race or ethnicity
race white
race  % white
race  asian  n ( % )
race  black or african - american  n ( % )
race  n ( % ) white
race  n ( % ) *
race  n ( % ) :
race  n ( % ) ’
race  n ( % ) +
race  n ( % ) a
race  n ( % ) t
race  n ( % ) y
race  n ( % ]
race  no . ( % ) white
race  no . ( % ) *
race  no . ( % ) b
race  no . ( % ) c
race  no . / total ( % )
race  white ( % )
race  white  n ( % of patients )
race  white    n   ( % )
race    n   ( % )
race  * ’ n ( % )
race / ethnicity  % white non - hispanic
race / ethnicity  no . ( % ) *
race / ethnicity  zz ( % )
race :
race : white
race_white  %
race §
racec  n ( % )
racey  z
racial category
radiate
radiographic progression based on change from baseline > sdc
radionuclide ventriculography
raee
rales
ramus
randomised patients ( n )
randomised patients with > $nmbr$ % bsa psoriasis skin involvement at baseline
randomised patients with basdai assessment at baseline and week $nmbr$  n
randomised patients with dactylitis at baseline
randomised patients with enthesitis at baselinet
randomised patients with spondylitis at baseline  n
randomization - to - angiography
randomization - to - angiography distribution time
randomization group
randomization to
randomization to end of study
randomization to first balloon inflation  min
randomization )
randomization  n ( % )
randomize
randomized < $nmbr$ hr after presentation — %
randomized group by subgroup interaction
randomized patients
randomized to canakinumab $nmbr$ mg
randomized to receive aspirin yes
randomized to receiveaspirin
randomized treatment
randomized treatment  % ( n )
randomized treatments  n ( % )
randomized  double - blind reversal phase ( baseline = week $nmbr$ )
randomly assigned to ace
randomly assigned to calcium channel blocker
randomly assigned to diuretic
range ed etiology ( n )
range iga modified $nmbr$ score  n ( % )
range of sbp
range race  n ( % )
rank based on treatment   =   placebo
rankin scale ≥ $nmbr$
ranolazine ( n $nmbr$ $nmbr$ )
ranolazine n = $nmbr$
ranolazine  n   =   $nmbr$
ranotazine vs . placebo km failure rate
rash
rate
rate - control group ( n = $nmbr$ )
rate ( % per year )
rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )
rate difference ( events / year )
rate difference ( lebrikizumab - placebo )
rate estimate ( $nmbr$ % ci )
rate in all participants  % / y
rate of non - progression ( defined as cfb in mtss £ $nmbr$ )  n / n ( % ) *
rate of non - progression ( defined as cfb in mtss £ $nmbr$ . $nmbr$ )  n / n ( % ) *
rate of oral or systemic corticosteroid
rate of sares
rate per $nmbr$ - patient - years ( control vs alirocumab ) *
rate per $nmbr$ - patient - years ( control vs alirocumab ) i
rate per $nmbr$ patient - years
rate ratio ( lebrikizumab vs placebo  $nmbr$ % cl )
rate ratio { $nmbr$ % cl )
rate ratio mepo / pbo ( $nmbr$ % ci )
rate ratio vs placebo ( $nmbr$ % ci )
rate reduction ( % )
rate ( % / year )
rate  % / y
rate / $nmbr$ pyo
rate †
rate ‡
rates
ratet
ratet n ( % )
ratio mepo / pbo ( $nmbr$ % ci )
ratio of fev $nmbr$ to fvc ( % )
ratio of ldl to hdl cholesterol
ratio of urinary albumin ( mg ) to creatinine ( g )
ratio of urinary albumin ( mg ) to creatinine ( g ) median
ratio to baseline in eosinophil count at week $nmbr$  geometric mean ( se on loge scale ) cells / ll
ratio to baseline in total ige at week $nmbr$  geometric mean ( se on loge scale ) u / ml
re - cover $nmbr$ dabigatran
re - cover $nmbr$ warfarin
re - cover ii
re - cover / re - cover ii
re - medy
reason for discontinuation of previous tnfa inhibitor
rec . ischemia
rec . ischemia leading to hosp
received antihypertensive within last $nmbr$ days  n ( % )
received drug - eluting stent
received first loading dose
receiving antihypertensive
receiving antihypertensive treatment -
receiving antihypertensive treatment  n ( % ) blood pressure  mm hg  mean ( sd )
recent cardiovascular eventf
recent cardioversion ( within $nmbr$ days before randomization ) — no . ( % )
recent treatment ( < $nmbr$ months mmf / ggs )
recent use of allopurinol ( within $nmbr$ days of
receptor blocker
receptor blockers
receptor blockers  n ( % )
recervini }
recervng
recurrent hf
reduced hdl cholesterol
reduction in odds %
reduction in risk % ( $nmbr$ % ci )
reduction of hba $nmbr$ c from baseline ≥ $nmbr$ . $nmbr$ %
ref .
ref §
reference
referent
refractory to corticosteroids  n ( % )
regadenoson ( n = $nmbr$ )
region - north america
region - n ( % )
region — no . { % )
region north america
region ( us )
region 一 no . ( % )
region n ( % )
region of enrollment — no . ( % )
region of residence ( p = $nmbr$ $nmbr$ )
region of the world
region of world — no . ( % )
region ofenrollment — %
region ofthe world
region united states
region *
region  n ( % ) a
region  no . ( % )
region  no . ( % ) c
region  no . / total ( % )
region    n   ( % )
region :
regions  n ( % )
regiont
related to study druga
relative risk ( $nmbr$ % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *
relative risk { $nmbr$ % ci )
relative risk comparing icd therapy and placebo
relative risk vs . placebo ( $nmbr$ % cl )
relative risk * ( $nmbr$ % cl )
relative risk ® ' ( $nmbr$ % cl )
relative risk ® ( $nmbr$ % cl )
relative wall thickness
remaining patients
remission by : baseline duration of steroid
remission by : baseline steroid doses
remission component of variable
renal biopsy class
renal composite *
renal disease
renal disease )
renal failure
renal function ( egfr ) according to mdrd  n ( % )
renal function ( ml / min )
renal function at randomization
renal function *
renal function  bn ( % )
renal function : ! : n ( % )
renal functiona
renal functionb
renal functionc  n ( % )
renal impairment ( crcl < $nmbr$ ml / min )
renal impairment *
renal impairmentf
renal insufficiency *
renin - angiotensin - aldosterone system blocker
renin - angiotensin system inhibitor use
renin – angiotensin system inhibitor
renin inhibitor
repaired congenital shunts
repaired s - p shunts
required corticosteroid and / or antibiotic ( without hospitalization )
required hospitalization
requiring assistance
rescue medication use  inh / d {
rescue medication use  mean inhalations / previous $nmbr$ d
rescue use : mean no . of inhalations / d
resection performed — no . { % )
residence in asia  n ( % )
resistant htn n = $nmbr$
resistant htn : placebo n = $nmbr$
resistant htn : spiro n = $nmbr$
reslizumab
reslizumab ( n = $nmbr$ )
reslizumab $nmbr$ . $nmbr$   mg / kg ( n   = $nmbr$ )
reslizumab $nmbr$ . $nmbr$ mg / kg ( n = $nmbr$ )
resllzumab
respiratory medication taken at baseline  n ( % )
responder analyses ( achieving alc < $nmbr$ . $nmbr$ % )
rest angina but not past $nmbr$ h
rest angina past $nmbr$ h
rest ofthe world
rest ofworld
restriction in normal activities in the past $nmbr$ weeks
retinopathy — no . ( % )
revascularisation  n ( % )
revascularization history
revascularization in $nmbr$ days
reversibility — %
reversibility ( % )  median ( range ) c
reversibility [ % ]  median ( range )
reversibility < $nmbr$ % ( itt ) ( n = $nmbr$ )
reversibility < $nmbr$ % ( n = $nmbr$ )
reversibility > $nmbr$ % ( itt ) ( n = $nmbr$ )
reversibility > $nmbr$ % ( n = $nmbr$ )
reversibility s $nmbr$ % ( itt ) ( n = $nmbr$ )
reversibility stratum *
reversibility to salbutamolc  d  mean ( sd )
reversibility ’ ' %
reversible
reversible to albuterolc  d  n ( % )
reversible to bronchodilator  b %
revive i
revive ii
rf - positive  > $nmbr$ iu / ml  %
rf ( mg / dl )
rf ( mg / dl  per unit )
rf and acpa negative  n ( % )
rf and acpa positive  n ( % )
rf negative and acpa positive  n ( % )
rf positive
rf positive and acpa negative  n ( % )
rf positive  no . ( % )
rf  % positive
rhabdomyolysis  myopathy  or elevated creatine phosphokinase > $nmbr$ x upper limit of normal ( n = $nmbr$ )
rheumatoid factor and acpa positive
rheumatoid factor or acpa positive  or both
rheumatoid factor !
rhinitis
rhythm - control group ( n = $nmbr$ )
rib
right ventricular dysfunction — no . / total no . ( % ) §
right ventricular dysfunction  n / n ( % ) j
risedronate ( n   =   $nmbr$ )
risedronate ( n = $nmbr$ )
risedronate n / n ( % )
risk ratio [ $nmbr$ % cl ]
risk at
risk categories
risk factor
risk factor for venous thromboembolism  no . ( % )
risk factors — no . ( % )
risk factors ( % of group )
risk factors ( % )
risk factors and diabetes status ( % )
risk factors and medical history
risk factors for stroke
risk factors  no . ( % )
risk level at admission
risk marker and model
risk model endpoint
risk of moderate / severe exacerbations
risk stratum
rivaroxaban ( n   = $nmbr$ )
rivaroxaban $nmbr$ . $nmbr$ mg bid + aspirin $nmbr$ mg od
rivaroxaban alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
rivaroxaban plus
rivaroxaban plus aspirin ( $nmbr$ % cl )
rivaroxaban plus aspirin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$
rivaroxaban +
rofecoxib
roflumilast ( n = $nmbr$  $nmbr$ )
rolofylline ( n = $nmbr$ )
rolofylline $nmbr$ mg ( n = $nmbr$ )
rolofylline n
rolofylline rx
rosigiitazone ± oad
rosiglitazone $nmbr$ mg daik
rosiglitazone $nmbr$ mg daily
rosiglitazone versus glyburide
rosiglitazone versus metformin
rosuva  rosuvastatin  sd  standard deviation  t $nmbr$ dm  type $nmbr$ diabetes mellitus .
rosuvastain + fenofibric acid   n   =   $nmbr$
rosuvastatin ( n = $nmbr$  $nmbr$ )
rosuvastatin ( n = $nmbr$ . $nmbr$ )
rosuvastatin + fenofibric acid
rosuvastatin n ( rate ) $nmbr$
rosuvastatin   n   =   $nmbr$
rotablator use  n ( % )
rotigotine ( n = $nmbr$ )
rotigotine n = $nmbr$
row * n = $nmbr$
row §
rr ( $nmbr$ % ci ) c
rr ( $nmbr$ % cl ) p value
rr ( $nmbr$ % cl ) [ / ’ value ]
rr $nmbr$ - $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$  $nmbr$ ) ’
rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *
rr $nmbr$ . $nmbr$ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *
rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )
rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )
rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ }
rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) * *
rr $nmbr$ . $nmbr$
rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$
rr reduction  $nmbr$ / $nmbr$ ( $nmbr$ / $nmbr$ cl )
rr ( $nmbr$ aci ) [ p value ]
rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$ . $nmbr$ . $nmbr$ ) *
rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$  $nmbr$ . $nmbr$ )
rro . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )
rro $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )
rs - breathlessnessb
rs - chest symptomsd
rs - cough & sputumc
rs - totala
rs $nmbr$
rs $nmbr$ & rs $nmbr$
rs $nmbr$ ( aa ) & rs $nmbr$
rs $nmbr$ ( ac ) & rs $nmbr$
rs $nmbr$ ( cc ) & rs $nmbr$
ruled out non - fatal pe with or
russia and georgia
russia / georgia
rv and pulmonary vascular
rvalue
rvalue for interaction
rvfac ( % )
rvw
s - asa compounds at baseline
s ( s $nmbr$
s $nmbr$ mmhg
s $nmbr$ yrs
s arm
s fs $nmbr$
s median
s wave in v $nmbr$ ( mm )
s / se  mb or death
s $nmbr$ ( n = $nmbr$ )
s $nmbr$ mg / mmol
s $nmbr$ - $nmbr$ vs placebo
s $nmbr$ kg / m ^
s $nmbr$ exacerbations
s $nmbr$ vs placebo
s $nmbr$ . $nmbr$ mg / mmol
s $nmbr$ years ( n = $nmbr$ )
s $nmbr$ years
s $nmbr$ ml / min
s $nmbr$ ( $nmbr$ . s )
s $nmbr$ - $nmbr$ - s $nmbr$ . $nmbr$ %
s $nmbr$ months
sa acs
saba ( inhaled )  c   n ( % )
saba use in past $nmbr$ days
saba use  occasions / weekt
sabae
sack
sacral and / or lumbar
saes
safety population
safety variable
safety  %
safety    n   ( % ) b
sal ( n   = $nmbr$  $nmbr$ )
salbutamol  %
salmeterol
salmeterol ( n = $nmbr$ )
salmeterol / fluticasone $nmbr$ / $nmbr$ pg twice daily
salmeterol / fluticasone $nmbr$ / $nmbr$   μ g b . i . d .
sama  b   n ( % )
samac
sample size
sample size ( n )
sample size  n
sample size  n ( % ) by treatment
sample sizea
sample statistics
saudi arabia
saxa $nmbr$ mg ( n $nmbr$ $nmbr$ )
saxa $nmbr$ mg $nmbr$ metformin ( n $nmbr$ $nmbr$ )
saxagiiptin
saxagliptin ( n = $nmbr$ )
sbp
sbp ( mean over $nmbr$ h )  mmhg
sbp ( mmghg )  mean ( sd )
sbp ( mmhg ) *
sbp ( mmhg )  mean ( sd )
sbp ( office measurement )  mmhg
sbp ( sd )
sbp ( sd )  mm   hg
sbp < $nmbr$ mm hg
sbp < $nmbr$ mmhg
sbp < $nmbr$ mm hg and dbp < $nmbr$ mm hg $nmbr$ / $nmbr$
sbp ≥ $nmbr$ mmhg
sbp > $nmbr$ mmhg n = $nmbr$
sbp > $nmbr$ mm hg and / or dbp > $nmbr$ mm hg $nmbr$ / $nmbr$
sbp > $nmbr$ mmhg
sbp > $nmbr$ mmhg or dbp > $nmbr$ mmhg
sbp at baseline
sbp at visit $nmbr$
sbp during the follow - up period ( mmhg )
sbp  baseline
sbp  difference
sbp  last
sbp  mean ( sd ) mm hg
sbp  mm hg ( mean $nmbr$ h )  mean ( sd )
sbp  mm hg ( office measurement )  mean ( sd )
sbp  mm   hg
sbp  mm   hg
sbp  mm   hg ( sd )
sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .
sbp  difference vs placebo ( $nmbr$ % cl )
sbp . mean ( sd ) mm hg
sbp / dbp ( mmhg )
sbp / dbp mean
sbp < $nmbr$ mmhg n = $nmbr$
sbp < median ( n = $nmbr$ o $nmbr$ )
sbp > median ( n = $nmbr$ )
sbp > $nmbr$ mm hg
sbp > $nmbr$ mnn hg
sc belimumab $nmbr$ mg ( n = $nmbr$ )
scale — cognitive portion  ldl — low -
scalp psoriasis  n ( % )
scarring on renal biopsy
scd ( % )
scdbp  mean ( sd )  mmhgf
schwab & england score
score
score ( > $nmbr$ ) at $nmbr$ monthsb unadjusted or
score > $nmbr$ . $nmbr$
score $nmbr$ . $nmbr$
score at week $nmbr$  mean ( se ) difference mepo - pbo ( $nmbr$ % ci )
score distribution :
score improvement  baseline to week $nmbr$  median ( iqr )
score on asthma control questionnaire * *
score on st . george ' s respiratory questionnaire ^ ^
screening ( visit $nmbr$ )
screening and baseline lung function characteristics
screening fev $nmbr$   % predicted
screening  l
screening  mean ( sd ) morning pef  mean
scsbp  mean ( sd )  mmhge
sd = standard deviation  bmi = body mass index  ed = erectile
sd of sbp
sd or %
sd  standard
sdai ( $nmbr$ - $nmbr$ )
sdc ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml )
sdc ( ng / ml )
se
seated sbp  n
second co - primary
second serum creatinine
second year !
secondary - prevention cohort
secondary cardiovascular endpoint
secondary end points
secondary end points $nmbr$
secondary end points ii
secondary end points iii
secondary endpoints :
secondary iii *
secondary ip
secondary kidney composite outcome
secondary mace endpoint
secondary nonresponse
secondary outcome
secondary p
section $nmbr$ a
section $nmbr$ b
section $nmbr$ c
secukinumab $nmbr$ mg ( n $nmbr$ $nmbr$ )
secukinumab $nmbr$   mg
secukinumab $nmbr$   mg ( n   =   $nmbr$ )
secukinumab $nmbr$   mg no load ( n   =   $nmbr$ )
secukinumab pooled †   ( n   = $nmbr$ )
sedbp ( mmhg ) [ mean _sd ] d
sedbp ( mmhg ) [ mean_ sd ] a
seizure frequency during $nmbr$ ‐ week baseline  median ( range )
seizure history  n ( % )
seizure types reported during baselinee
selected clinical characteristics
selected key secondary efficacy endpoints
selective vascular history
selena - sledai > $nmbr$  %
selena - sledai activity  n ( % )
selena - sledai mean score ( sd )
selena - sledai total score
selexipag patients / events n
selexipag vs placebo hazard ratio ( $nmbr$ % cl )
self - rated health status
self - reported descent  n ( % )
semaglutide
semaglutide ( n = $nmbr$ )
semaglutide $nmbr$ . $nmbr$ mg
semaglutide exposure  nmol / l
semuloparin ( n = $nmbr$ )
sensitive
sensitive responder ( n = $nmbr$ )
sensitive responders ( n = $nmbr$ )
sensitivity analyses
sensorimotor stroke
serious
serious aes
serious decline in kidney function *
serious decline in kidney function $nmbr$
serious gi disorder
serious infections
serious teaes
serms
seropositivity status  n
sertraline
serum $nmbr$ - hydroxyvitamin d  ng / ml
serum $nmbr$ ( oh ) d concentrations  ng / ml  mean ( sd )
serum albumin - adjusted calcium ( mg / dl )
serum albumin concentration  g / l
serum albumin  g / l
serum biochemistry potassium  mmol / l
serum bone - specific alkaline
serum c - terminal telopeptide of
serum calcium  mmol / l
serum cholesterol  mean ( sd ) mg / dl
serum cholesterol  mean ( sd )  mg / dl
serum cholesterol  mg / dl
serum creatinine - mean ( sd  n )
serum creatinine — mg / dl | |
serum creatinine > $nmbr$ / xmol / l  n ( % ) | |
serum creatinine concentration and randomization to losartan
serum creatinine level
serum creatinine level  mean ( sd )  mg / dl
serum creatinine  / xmol / l | |
serum creatinine  ≥ $nmbr$ . $nmbr$ mg / dl
serum creatinine  μ mol / l
serum creatinine  gmol / ' l  mean ( sd )
serum creatinine  mean ( sd ) mg / dl
serum creatinine  mean ( sd )  mg / dl
serum creatinine  mg / dl  mean ( sd )
serum creatinine . mg / dl
serum ctx - $nmbr$  ng / ml  median ( iqr )
serum ctx i ( ng / ml )
serum fg  mg / dl
serum gastrint  pg / ml
serum glucose ( mmol / l )
serum glucose ( mg / dl )
serum mg < $nmbr$ . $nmbr$ mmol / l ( hypomagnesemia )
serum mg > $nmbr$ . $nmbr$ mmol / l ( normal mg / hvpermagnesemia )
serum n - propeptide of type $nmbr$ collagen
serum pepsinogen i / iit
serum phosphate  mmol / l
serum potassium 一 mmol / liter
serum potassium level  mean ( sd )  meq / l
serum potassium  > $nmbr$ . $nmbr$ mmol / l
serum potassium  mean ( sd ) mmol / l
serum sodium — mmol / liter
serum sodium  meq / l
serum sodium . meq / l
serum total ige  iu / ml
serum urate ( mg / dl )
serum urate ( mg / dl )  n ( % )
serum urea nitrogen  mg / dl
serum uric acid  difference vs placebo ( $nmbr$ % cl )
serum uric acid  n
serum values
serum values ^
serum vitamin d ( nmol / l )
ses - cd  mean ( sd )
sesbp ( mmhg ) [ mean - sd ] d
sesbp ( mmhg ) [ mean _sd ] a
severe ( < $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )
severe ( > $nmbr$ )
severe ( fev  < $nmbr$ % predicted )
severe ( iief - ef < $nmbr$ )
severe ( iief - ef $nmbr$ - $nmbr$ )  n ( % )
severe ( ipss > $nmbr$ )
severe ( ipss > $nmbr$ ) age group
severe ( ipss > $nmbr$ ) ( n = $nmbr$ )
severe ( itt ) ( n = $nmbr$ )
severe ( n $nmbr$ = $nmbr$ )
severe aes
severe copd
severe cord * : qvai $nmbr$ - sfc
severe disease
severe ed
severe episodes in previous year — no . / patient
severe exacerbations
severe hyperkalemia ' s
severe hyperkalemia ‘ s
severe hypoglycemia
severe impairment ( egfr < $nmbr$ ml / min / m ^ )
severe impairment ( egfr < $nmbr$ )  n ( % )
severe oa symptoms at baselined
severe oab subgroup
severe or very severe smoking status
severe recurrent ischemia
severe to end - stage impairment ( $nmbr$ ml / min )
severe  gold $nmbr$
severe / life threatening
severe / life ttireatening
severe / lite threatening
severe / moderate
severity of copda  airflow limitation  n ( % )
severity of copda  combined assessment of copd  n ( % )
severity of heartburnb
severity ofhypertension [ n ( % ) ] b
severitya
sex — no . / total no . ( % )
sex ( male )
sex ( male )  %
sex ( male  % )
sex ( male / female )
sex ( male / female ) ( n )
sex ( men / women )
sex ( no . )
sex ( p = $nmbr$ )
sex ( women  men )
sex ( women  n [ % ] )
sex m / f
sex  %
sex  % male
sex  female  %
sex  female    n   ( % )
sex  n ( % ) *
sex  n ( % ) b
sex  no  ( % )
sex  no . ( % ) male
sexually active
sexually active with female
sexually active $nmbr$ ( % )
sexy
sf - $nmbr$ mcs score
sf - $nmbr$ pcs score
sf - $nmbr$ bodily pain  mean change from baselineb
sf - $nmbr$ bodily pain  mean change from baselinee
sf ‐ $nmbr$ health survey
sf - $nmbr$ mcs
sf - $nmbr$ pcs
sf ‐ $nmbr$ pcs  ls mean change ± se
sf - $nmbr$ pcs  ls mean change from baseline   ±   se
sf - $nmbr$ summary scores
sfc ( n   = $nmbr$  $nmbr$ )
sfc $nmbr$ / $nmbr$ pg twice daily ( n = $nmbr$ )
sgrq - c total scoreb
sgrq responder ( % )
sgrq score  mean ( sd )
sgrq scores  mean ( sd )
sgrq total score $nmbr$
shared epitope  a % positive
shfm annual mortality
short ( < $nmbr$ years ) duration of diabetes
short term ( n = $nmbr$ ) +
short term ^
shs ( $nmbr$ - $nmbr$  per $nmbr$ score )
shs  mean ± sd
si . gni . fi . canr ecg changes  positive biomarkers  and age < $nmbr$ vrs
significant worsening in kccq clinical
significant worsening in kccq clinical score ( ≥ $nmbr$ ) at $nmbr$ mo †
sildenafil ( n = $nmbr$ )
silodosin $nmbr$ mg ( n = $nmbr$ )
simva ( n = $nmbr$ )
simvastatin ( n = $nmbr$ . $nmbr$ )
simvastatin ( n = $nmbr$  $nmbr$ )
single - vessel disease
single vessel coronary artery disease †
single vessel coronary artery diseasea
sinus tracts / perforation  ' ^ n ( % )
sirius
sirolimus - eluting stent use  n ( % )
sita $nmbr$ mg ( n = $nmbr$ )
sitagliptin $nmbr$
sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ $nmbr$ - h postprandial plasma glucose ( ppg ) ( mmol / l )
sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ fasting plasma glucose ( fpg ) ( mmol / l )
sitagliptin ± oad
sitting blood pressure — mmhg
sitting diastolic blood pressure ( mm hg )
sitting systolic blood pressure ( mm hg )
six - minute walk distance  m
six - study placebo - controlled set
size ( cm $nmbr$ ) ( mean ± standard deviation )
size of left atrium normal — no . ( % ) £
sjc  mean ( sd )
sk . $nmbr$
sl $nmbr$ mm hg
sle markers  n ( % )
sleep
sleeping problems in the past $nmbr$ weeks ( % )
small / medium
smedian prednisone dose  n ( % )
smi :
smmse
smmse < $nmbr$
smoker at baseline
smoker or ex - smoker  n ( % )
smoker  %
smoker  n ( % )
smokers  no . ( % )
smokers : qva $nmbr$ - $nmbr$ fc
smoking ' ! '
smoking ( % )
smoking ( current )
smoking ( during the previous month )
smoking classification  n ( % )
smoking consumption pack - years
smoking history ( pack - years ) ∗
smoking history  r ( % )
smoking history    n   ( % )
smoking pack - yearsa
smoking pack - yearsb  n ( % )
smoking pack year ( years ) ^
smoking status — no . { % )
smoking status ( ongoing ) ( n )
smoking status ( previous ) ( n )
smoking status current
smoking status current smoker ( n = $nmbr$ )
smoking status  n ( % ) *
smoking status  n [ % ] ®
smoking status . no . ( % )
smoking * ( > $nmbr$ pack - years )
smoking  mean
smoking  n ( % )
smokingb
snp
so
so $nmbr$ %
soc
socalone ( n = $nmbr$ )
social interaction
sodium - glucose cotransporter $nmbr$ inhibitor
sodium  meq / l
sokoiow - lyon voitage  mv
sokolow - lyon ( mm ) *
sokolow - lyon voltage  mm
sokolow - lyon  mm
sokolow – lyon voltage ( mv )
solifenacin ( n = $nmbr$ )
some college
some college / tech
some walking
somnolence
sotagliflozin
sotagliflozin ( n = $nmbr$ )
sotagliflozin $nmbr$ mg ( n = $nmbr$ )
source
south africa / south america
south america ( n = $nmbr$ )
south asia
south or central america
south or central american
south ! central america
south  n ( % )
southern europe
southern hemisphere
spain
spain ( n = $nmbr$ )
special interest categories
specific syndromes
spga > $nmbr$
spine
spine *
spirometric values at baseline
spirometry
spirometry after bronchodilation §
spirono ( n = $nmbr$ )
spondylitis
spondylitis with peripheral arthritis
sprint acr < $nmbr$ - $nmbr$
sprint acr > $nmbr$ - $nmbr$
sri ‐ $nmbr$ response rate  %
β - blocker
β ‐ blocker
β - blockers
β blocker
β blockers
ss years
ssed as ls means
ssomgdayp . eq .
st - depression and t - wave inversion
st - depression only
st - segment depression > $nmbr$ mm
st - segment depression > $nmbr$ mm — no . ( % )
st - segment depression or t - wave inversion on ecg
st - segment deviation > $nmbr$ mm — no . / total no . ( % )
st - segment deviation timi risk score  %
st - segment elevation
st ‐ str ≥ $nmbr$ % post pci
st ‐ str ≥ $nmbr$ % pre ‐ ci
st - t wave
st - t wave abnormality d
st - t wave changes
st - t wave  n ( % )
st - t wave  no . ( % )
st - t waveft
st - t wavett
st depression ( without st elevation )
st depression > $nmbr$ mm
st elevation
st george ' s respiratory questionnaire total score !
st segment depression
st segment elevation
st / t wave
stable angina ( n = $nmbr$  $nmbr$ )
stable angina  n ( % )
stable coronary artery disease
stage $nmbr$ ckd egfr > $nmbr$ ml / ( n = $nmbr$ )
stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml / min ( n = $nmbr$ )
stage $nmbr$ a ckd cohort ( post hoc analysis excluding metformin users )
stage $nmbr$ a ckd cohort ( secondary analysis )
stage i ( gfr > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) and stage v ( gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) were not considered because they included only $nmbr$ and $nmbr$ patient  respectively . chf  congestive
stage ii
stage iii
stage iv
stage of pda
standard
standard allocation
standard bp lowering  < $nmbr$ mm hg ( n = $nmbr$ )
standard care slope lsm ± se ( mm / year )
standard therapy ( n = $nmbr$ )
standard treatment ( n - $nmbr$ )
standardized mean difference
standardized total hip bmd ( g / cm $nmbr$ )
statin ( % )
statin + ezetimibe
statin + ezetimibe ( n = $nmbr$ . $nmbr$ )
statin + ezetimibe { n = $nmbr$  $nmbr$ )
statin + fibrate or niacin
statin and / or ezetimibe
statin and / or other lipid - lowering agent therapy
statin group
statin intensity per acc / ahac
statin intolerant *
statin medication
statin only ( n = $nmbr$  $nmbr$ )
statin potency medium ( n = $nmbr$ )
statin use — no . { % )
statin use ( % )
statin use at baseline :
statin users
statin ( s )
statin  % ( n )
statin + er niacin ( n = $nmbr$ )
statin + placebo ( n = $nmbr$ )
stating
statins used during follow - up
statins  n ( % )
statins  no . ( % )
statistic * *
statisticd
statistics
status ( spmsq < $nmbr$
status ( spmsq > $nmbr$
std n ( n / loopy )
stent thrombosis - related mi
stent thrombosis arc definite / probable
stent thrombosis or mi
stented lesions
stented vessel
steroid - free cr - $nmbr$
steroid - free remission
steroid - sparing remission *
steroid use at baseline ( mg / day )
steroid use  %
steroids  n ( % )
still taking alendronate at study entry  n ( % )
stomach
storage subscore
strain ( % )
strata modelb hr  $nmbr$ % ci  p value
stratification factor : menopausal status  n ( % )
stratification factors
stratified by
stratified hazard ratio ( $nmbr$ % ci )
stratified log - rank p value
stratified log - rank   p   value
stratum
stratum $nmbr$ : inadequate response or intolerance to $nmbr$ - $nmbr$ bdmards of same moa
stratum $nmbr$ : inadequate response or intolerance to > $nmbr$ bdmards of same moa or > $nmbr$ of multiple moa
stratum *
stratum  n ( % )
stroke ( fatal / nonfatal )
stroke and tia  n ( % )
stroke any
stroke at entry
stroke deaths
stroke n ( % )
stroke non - fatal
stroke of atherosclerotic origin
stroke or
stroke or cerebrovascular disease
stroke or se ( s / se )
stroke or see
stroke or systemic
stroke or systemic embolism
stroke ortia
stroke subtype
stroke  fatal and nonfatal
stroke  see  or cv death
stroke  see  or death
stroke  total
stroke / embolism
stroke / m $nmbr$
stroke / m l / hf hospitalization
stroke / non -
stroke / se
stroke / see
strokezsee
structural
structural heart disease — no . ( % ) f
stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ )
study $nmbr$ . $nmbr$
study $nmbr$ - item short - form general health survey ( sf - $nmbr$ ) can range from $nmbr$ to $nmbr$ for the physical component and from $nmbr$ to $nmbr$ for the mental
study drug
study druga
study eye characteristics
study medication  pre - dose
study period fatal pe
study population
study treatment
study treatment — no . / total no . ( % )
su
su monotherapy
su  n ( % )
su / met
su / tzd
sua < $nmbr$ . $nmbr$
subcutaneous ( n = $nmbr$ )
subcutaneous injections
subcutaneous unfractionated heparin
subdural / epidural
subgoup_name
subgroup $nmbr$
subgroup analyses
subgroup analysis : change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category
subgroup based on :
subgroup level
subgroup levels
subgroup name / level
subgroup no .
subgroup overall
subgroup p - value $nmbr$
subgroup p value !
subgroup sex
subgroup statistics
subgroup treatment
subgroup w . r . t . re - cover
subgroup_level
subgroupt
subject disposition  n ( % )
subject group
subjects
subjects ( n )
subjects n
subjects stratified by baseline pra
subjects who did not receive labd prior to the study
subjects who did receive labd prior to the study
subjects with imputed value for end ‐ of ‐ treatment body weight
subjects with prevalent vertebral fracture  n ( % ) prevalent vertebral fracture
subpopulation
subpopulation analyses according to baseline hba $nmbr$ c
subpopulation analyses according to bmi
subscale  and $nmbr$ to $nmbr$ for the function subscale  normalized scores can range from $nmbr$ to $nmbr$ . scores for the health assessment question -
subsets
subtrochanteric
sudden cardiac death §
sudden death
sufficient
suit index  nmol / mmol
suit quartile $nmbr$ ( b $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ )
suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ )
suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ )
sulfasalazine treatment
sulfasalazine use at randomization
sulfasalazine use at randomization    n   ( % )
sulfonylurea use at baseline
sulfonylureas
sulfonylureasb
sulphonamides  urea derivatives
sulphonylureas only
sun - $nmbr$ ( $nmbr$ )
supplementary table $nmbr$ . change from baseline in urine albumin - to - creatinine ratio by hba $nmbr$ c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .
surgical repair of vsd or pda > $nmbr$ - year duration
suspected myocardial infarction
sustain
sustain $nmbr$
sustain $nmbr$ : semaglutide vs . placebo
sustain $nmbr$ : semaglutide vs . sitagliptin $nmbr$ mg
sustain $nmbr$ : semaglutide vs . exenatide er $nmbr$ . $nmbr$ mg
sustain $nmbr$ : semaglutide vs . iglar
sustain $nmbr$ : semaglutide add ‐ on to insulin vs . placebo
sustained decrease of > $nmbr$ % in egfr ®
sustained esrd  death due to kidney failure  or sustained decrease of > $nmbr$ % in egfr from baseline
sustained mucosal healingc
sustained mucosal healingc n / n ( % )
swollen - joint count ( of $nmbr$ joints assessed ) — no .
swollen joint count
swollen joint count ( $nmbr$ - $nmbr$ joints )
swollen joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd )
swollen joint count ( $nmbr$ — $nmbr$  per swollen joint )
swollen joint count ( $nmbr$ )  mean ( sd )
swollen joint count ( $nmbr$ joints )  mean ( sd ) ’
swollen joint count ( range $nmbr$ - $nmbr$ joints )
swollen joint count of $nmbr$ joints
swollen joints ( $nmbr$ - joint count )  mean ± sd
swollen joints > $nmbr$  n ( % )
symmetric t - wave inversions
symmetric t wave inversions
symptom - free days in the past $nmbr$ weeks ( % )
symptom bother
symptom duration  months
symptom onset - to - randomization
symptom onset to enrollment
symptom onset to hospital arrival  median ( iqr )  h
symptom onset to hospitalization
symptom onset to pci  h
symptomatic
symptomatic deep - vein thrombosis
symptomatic heart fail
symptomatic hypoglycaemia
symptomatic hypotension
symptomatic hypotension ( sbp < $nmbr$ mmhg )
symptomatic hypotension with sbp < $nmbr$ mm   hg
symptomatic ich
symptomatic infarct swelling
symptomatic localization - related
symptomatic pe
symptomatic remissionb n / n ( % )
symptomaticb
symptoms mean ( sd )
symptoms of atrial fibrillation in the $nmbr$ months before randomization — no . ( % )
symptoms onset to first balloon inflation  min
syncope
syndrome  n ( % )
sys : ns dia : < $nmbr$ . $nmbr$
systemic corticosteroids — no . ( % )
systemic corticosteroids  n ( % )
systemic embolism
systemic glucocorticoid use at randomization  n ( % )
systemic hypertension
systemic sle medications  n ( % )
systoiic biood pressure  mm hg
systolic blood pressure — mmhg
systolic blood pressure ( change from baseline )
systolic blood pressure ( median $nmbr$ . $nmbr$ )
systolic blood pressure ( mmhg )  mean ± sd
systolic blood pressure < $nmbr$ mm hg and diastolic
systolic blood pressure > $nmbr$ mm hg — no . ( % )
systolic blood pressure > $nmbr$ mm hg
systolic blood pressure > $nmbr$ mm hg  n ( % )
systolic blood pressure > $nmbr$ mm hg or diastolic
systolic blood pressure mmhg  mean ( sd )
systolic blood pressure  ( mm hg )
systolic blood pressure  mm hg ( sd )
systolic blood pressure  mm hg ^
systolic blood pressure  mm hq
systolic blood pressure  mm   hg
systolic blood pressure  mmhg *
systolic blood pressure  mmhg  mean ( sd )
systolic blood pressure ^
systolic bp
systolic bp ( mmhg ) *
systolic bp at baseline :
systolic bp  mm hg ( mean ) nyha class
systolic bp  mm hg  mean ( sd )
systolic bp  mm   hg  mean ( sd )
systolic bp  mmhg
systolic bp  mmhg  mean ( sd )
systolic pressure — mm hg
systolic pressure at ankle level ( mmhg )  mean ± sd
systolic pressure  mm hg
systolic  mean ( sd )  mm hg h
systolic  total
systolic  treated at baseline
t
t - jj ( $nmbr$ - $nmbr$ )
t - score at femoral neck
t - score categories lumbar spineb
t - wave inversion
t - wave inversion only
t ( n = $nmbr$  $nmbr$ )
t $nmbr$ . $nmbr$ mg
t wave inversion
t $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml )
t $nmbr$ lesion volume  mm '
t $nmbr$ d duration  years
ta
ta ( n = $nmbr$ )
table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela
table $nmbr$ . characteristics of patients treated with losartan and atenolol *
table $nmbr$ . characteristics of the patients at baseline . *
table $nmbr$ . selected baseline characteristics of the study patients . *
table_group
taci
tadalafil
tadalafil $nmbr$ mg n = $nmbr$
tadalafil $nmbr$ . $nmbr$ mg
tadalafil $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
tadalafil $nmbr$ . $nmbr$ mg n = $nmbr$
tadalafil $nmbr$ mg
tadalafil $nmbr$ mg ( n = $nmbr$ )
tadalafil $nmbr$ mg mean change ( sd )
tah ( n = $nmbr$ )
taking antihypertensive medication at baseline  no . ( % ) e
taking antihypertensive treatment at
taking calcium supplements at baseline  n ( % )
taking statins  n ( % ) a
tamong those enrolling via bnp stratum . the study - qualifying bnp or
tamsulosin
tamsulosin ( n = $nmbr$ )
tamsulosin ( w = $nmbr$ )  $nmbr$ / $nmbr$
tamsulosin $nmbr$ . $nmbr$ mg ( n = $nmbr$ )
tamsulosin $nmbr$ . $nmbr$ mg vs . placebo
tamsulosin $nmbr$ . $nmbr$ mg vs . $nmbr$ . $nmbr$ mg
tanezumab ( all doses combined )
tanezumab ( all doses combined ) + nsaida
tanezumab $nmbr$ mg
tanezumab $nmbr$ mg + nsaid
tanezumab $nmbr$ . $nmbr$ mg
tanezumab $nmbr$ . $nmbr$ mg + nsaid
target nail napsi score ( $nmbr$ – $nmbr$ scale )
target vessel
tass ’
tbp
tc ( mg / dl )
tc level  mean ( sd ) mg / dl
tc : hdlc
tcomparison of proportion of patients with nyha class lll / iv heart failure .
tcz - sc $nmbr$ mg every other week ( n = $nmbr$ )
tcz $nmbr$ mg / kg n = $nmbr$
tcz + mtx ( n )
tdi e ' ( septal ) ( cm / sec )
teaes in a $nmbr$ % of individuals
teaes leading to discontinuation of study drug
teaes of special interest
teaes reported by ≥ $nmbr$ % patients in the overall brv group    n   ( % )
teaes  cases per $nmbr$ - patient years ( ci )
temporal data and management strategy
temporary factors
temporary risk factor
tender - or painful - joint count ( of $nmbr$ joints assessed ) — no .
tender joint count
tender joint count ( $nmbr$ - $nmbr$  per tender joint )
tender joint count ( $nmbr$ - $nmbr$ joints )
tender joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd )
tender joint count ( $nmbr$ )  mean ( sd )
tender joint count ( $nmbr$ joints )  mean ( sd ) ’
tender joint count ( range $nmbr$ - $nmbr$ joints )
tender joint count of $nmbr$ joints
tender joints ( $nmbr$ - joint count )  mean ± sd
tenecteplase and pci ( n = $nmbr$ )
teriparatide ( n   =   $nmbr$ )
teriparatide n / n ( % )
terlile $nmbr$
terrible
tertiary
tertiary amines
tertiary end points
tertiary endpoints :
tertile $nmbr$ : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )
tertile of total cholesterol at baseline  mean ( sd )  mmol / l
test for interaction
test for interaction ( p value )
test for interaction between treatment and race
test for trend
testing order
testosterone ( nmol / l )
testosterone ( tt ) ( nmol / l )
testosterone level ( nmol / l )
tests for categoric
texcaps
tg ( mg / dl )
tg  triglycerides . * median values ( standard deviation for medians ) .
th ( $nmbr$ % )
th c
the american college of rheumatology ) .
the metabolic syndrome ^
the netherlands  australia  new zealand  and south africa
the plot shows hazard ratios and $nmbr$ % confidence intervals for the primary outcome  with patients stratified according to eight sub - groups prespecified in the statistical analysis plan . no heterogeneity was observed for these subgroups .
the square of the height in meters . patient ' s and physician ' s global assessment scores can range from $nmbr$ to $nmbr$ . scores for the western
the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .
therapies
therapy
therapy - fatigue ( facit - f  $nmbr$ - $nmbr$ )
therapy use
thiazide diuretic *
thiazide users
thiazolidinedione use at baseline
thiazolidinediones *
thiazolidinedionesc
thienopyridine alone
thienopyridine at baseline
thienopyridine at discharge
thienopyridine + dipyridamole
third yeart
this study
three - point mace
three or more lesions
thromboaspiration
thromboembolism
thrombolysis
thrombolytic agents
thrombus aspiration done per lesion †
thyroid disease
thyroid hormone
tia  n ( % )
ticagrelor $nmbr$ mg
ticagrelor $nmbr$ mg diabetes n = $nmbr$
ticagrelor $nmbr$ mg km %
ticagrelor $nmbr$ mg no diabetes n = $nmbr$
ticagrelor in ‐ hosp ( n = $nmbr$ )
ticagrelor pre ‐ hosp ( n = $nmbr$ )
tier $nmbr$ aes
time - to - first - infusion from hip surgery ( days )  n ( % )
time - to - first infusion
time ( sec ) *
time between index acs and randomization — days
time between index acs and randomization ( days )
time from acute coronary syndrome to randomization ( days )
time from end of fit  years ( meanisd )
time from fibrinolytic therapy to study - drug administration — no . / total no . ( % )
time from hospital admission to enrollment
time from hospitalization to randomization — hr
time from index acs event to randomisation ( days )
time from ld to pci  min  median ( q $nmbr$ – q $nmbr$ )
time from onset of pain to randomization — hr
time from onset of symptoms to presentation — hr
time from onset of symptoms to start of fibrinolytic therapy — hr
time from pah diagnosis months
time from parkinson ’ s disease diagnosis in months  mean ( sd )
time from presentation to randomization — hr
time from psoriatic arthritis diagnosis [ a ]  years
time from qualifying ecg to balloon inflation
time from ra diagnosis  years  median
time from randomization to cabg — hr
time from randomization to coronary angiography — hr
time from randomization to pci — hr
time from randomization to study - drug administration — hr
time from randomization to study - drug initiation — hr
time from sx onset to baseline ecg  min
time from symptom onset of ra  years  median
time from symptom onset to balloon inflation
time from symptom onset to enrollment
time from symptom onset to start of fibrinolytic therapy — hr
time from symptoms to randomization  h
time from  median ( iqr )  h
time in therapeutic range
time in therapeutic range  median ( iqr )  %
time in trial
time intervals
time point
time sample drawn ( h )
time since as diagnosis ( years )  mean ( sd )
time since as diagnosis ( years )  mean   ±   sd
time since asthma
time since asthma diagnosis [ years ]  median ( range )
time since asthma diagnosis years
time since bph diagnosis ( years )
time since cabg
time since diagnosis of ciu / csu ( years ) $nmbr$
time since diagnosis of ciu / csuf ( y )
time since diagnosis of copd  years
time since diagnosis of diabetes ( years ) ( median  iqr )
time since diagnosis of diabetes  mean ( sd )
time since diagnosis of diabetes  n ( % )
time since diagnosis of ln  years
time since diagnosis of pah years #
time since diagnosis of psa ( years )  mean ( sd )
time since diagnosis of sle  years
time since diagnosis of t $nmbr$ dm
time since diagnosis of t $nmbr$ dm  y  n ( % )
time since diagnosis of type $nmbr$ diabetes mellitus
time since diagnosis  years
time since end of fit  mean ( sd )  y
time since epilepsy diagnosis ( years )
time since first luts ( years )
time since first psoriasis diagnosis ( y )  mean ( sd )
time since ipf diagnosisa  mean years ( sd )
time since last dose of
time since most recent myocardial
time since onset ( h )
time since pd diagnosis  mean ± sd
time since primary diagnosis
time since prior alendronate use  n ( % )
time since psa onset  mean years ( sd )
time since psoriasis diagnosis  years $nmbr$
time since rheumatoid arthritis diagnosis  years
time since start insulin ( years )
time since start of fit  mean ( sd )  y
time since start of fit  years ( meanisd )
time to all - cause death up to end of the study
time to angiography — hr
time to death due to pah or hospitalization due to pah up to the end of the treatment periodd
time to first cv hospitalization or death from any cause
time to first exacerbation
time to first inhaled corticosteroid ( % )
time to first morbidity / mortality event up to the end of the treatment periodd
time to first oral or systemic corticosteroid ( % )
time to first sare * ( % )
time to randomization ( h )
time to rx
time to treatment  h
time  mean ( sd )  min procedure
timi - bleeding major / minor
timi ≥ $nmbr$
timi ≥ $nmbr$ and spoke
timi ≥ $nmbr$ and spoke and time ≤ $nmbr$ h
timi clinically significant
timi flow grade $nmbr$ of mi culprit vessel post ‐ pci
timi flow grade $nmbr$ of mi culprit vessel pre ‐ pci
timi flow ‡
timi major or
timi major / minor bleeding
timi minor bleeding
timi non - cabg major
timi risk score — %
timi risk score — no . / total no . ( % ) : c
timi risk score — no . / total no . ( % ) f
timi risk score > $nmbr$  %
timi risk score > $nmbr$  n ( % )
timi risk score category — no . ( % )
timi risk score *
timi risk score  n / n ( % )
timi risk scoret
tio
tio ( n $nmbr$ $nmbr$ )
tio $nmbr$ | ig ( n = $nmbr$ )
tio i $nmbr$ mcg ( n = $nmbr$ )
tion  os = overall satisfaction  qmax = maximal urinary flow rate .
tiotropium + olodaterol $nmbr$ / $nmbr$
tiotropium $nmbr$ meg ( n = $nmbr$ )
tiotropium $nmbr$ . $nmbr$ μ g ( n   = $nmbr$ )
tiotropium $nmbr$ . $nmbr$ pg
tiotropium $nmbr$ . $nmbr$   μ g ( n   =   $nmbr$ )
tiotropium $nmbr$ pg
tiotropium $nmbr$   μ g ( n   =   $nmbr$ )
tiotropium salmeterol no . of patients / total no .
tiotropium vs . salmeterol
tj ( $nmbr$ - $nmbr$ )
tj ( $nmbr$ % )
tjc  mean ( sd )
tk
tlmi risk score
tnf - failure patientsa
tnf - failurea
tnf - ir
tnf - na ï ve
tnf - naive patientsa
tnf - naivea
tnf antagonist - exposed
tnf antagonist - failure population ( n - $nmbr$ )
tnf antagonist - naive ' ’
tnf antagonist - naive subgroup ( n - $nmbr$ )
tnf antagonist - naive ®
tnfi - exposed †
tnfi - ir
tnfi - naive
tnfi - na ï ve
tnfi - na ï ve  n ( % )
tni ultrapositive ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$
tni ultrapositive  ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$
tobacco use  n ( % )
tobacco use  yes  n ( % )
tobacco user
tofacitinib
tofacitinib $nmbr$ mg bid ( n = $nmbr$ )
tofacitinib $nmbr$ mg bid ( n   = $nmbr$ )
tolvaptan
tolvaptan ( n = $nmbr$ )
tonic
tonic – clonic
took prior antihyperglycemic agent ( any )
tophi present  n ( % )
topical
topical non - prescription
topical prescription
toricoxib $nmbr$ mg n = $nmbr$ ) ( % )
totai mortaiity
total - c
total - hip bmd t - score
total ( n [ $nmbr$ )
total ( n $nmbr$ $nmbr$ )
total ( n   = $nmbr$ )
total ( n )
total ( n   =   $nmbr$ )
total ( v = $nmbr$  $nmbr$ )
total > atients
total $nmbr$
total aim ‐ high study
total asthma symptom score  mean ± sd ‡
total asthma symptom score  mean ± sdz
total back pain score ( $nmbr$ – $nmbr$   mm scale )  mean   ±   sd
total back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd
total basdai score  mean ( sd )
total basdai score  mean   ±   sd
total baseline insulin dose
total bilirubin > $nmbr$ x uln $nmbr$
total bilirubin  mg / dl
total bleeding
total bleeds
total by treatment
total c ( mg / dl ) *
total c / hdl - c ratio * *
total carmelina population
total cholesterol ( mmol / l )  mean ( sd )
total cholesterol ( sd )  mg / dl
total cholesterol level  mg / dl
total cholesterol  mean ( sd )
total cholesterol  mean ( sd )  mg / dl
total cholesterol  mg / dl  ^
total cholesterol  mg / dl  mean ( sd )
total cholesterol  mmol / l ( sd )
total cholesterol  mmol / l  mean ( sd )
total cholesterol  mmol / le
total cholesterol  mmol / lt
total cholesterol ^
total cigarette pack - years  mean ( sd )
total cohort
total daily dose of ics  mean  μ gc
total daily insulin dose ( lu / kg )
total daily insulin dose ( u / day )
total daily insulin dose  u
total daily insulin dose  units / kgt
total death
total deaths
total deaths  n
total events  n
total feet score
total gadolinium - enhancing lesion count . no . ( % )
total glucose mg / dl
total hands score
total hip ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd )
total hip bmd ( g / cm $nmbr$ )
total hip bmd t - score
total hip bmi ) t - score
total hip or knee replacement
total hipc
total ics dose at entry  / xg / d
total ige — lu / ml
total ige levelx ( iu / ml )  median ( range )
total ige  geometric
total included in combined analysis
total ipss
total length of implanted stents  mm  mean ( sd )
total macular volume  mean ( sd )  mm $nmbr$
total mayo score
total mortality all
total n
total n   =   $nmbr$
total n $nmbr$
total no . $nmbr$
total no . of events ( % of participants ) / total no . of participants
total no . of events / total no . of participants
total no . of events / participants
total number of events / participants
total number of patients
total phase $nmbr$ pooled ( n = $nmbr$ )
total psa ‐ modified shs
total randomised ( n )
total randomized
total randomized  n
total resolution of dactylitisb
total resolution of enthesitisc
total resolution of nail psoriasisd
total sample = $nmbr$ ( % )
total score ( $nmbr$ – $nmbr$ scale )
total score < $nmbr$
total score > $nmbr$
total score §
total scores ( total score range : $nmbr$ - $nmbr$ )
total sgrq mean total score ( sd )
total sgrq score
total study itt population ( n = $nmbr$ )
total subjects
total time of fondaparinux treatment before
total updrs score ( baseline )  mean ( sd )
total updrs score ( range  $nmbr$ — $nmbr$ ) y
total vdh - s score
total vdh - s score ( $nmbr$ - $nmbr$ ) ( n )
total !
total ! by baseline diabetic status
totalhdl cholesterol ratio
toward
tpasi $nmbr$
tpm - exposed
tpm - naive
tpm subgroup  n = $nmbr$
tr jet velocity ( m / sec )
trait
trandolapril
trandolapril ( n = $nmbr$ )
transaminases increased
transfemoral
transfusion
transfusion ≥ $nmbr$ units rbcs or whole blood
transfusions
transient
transient ischaemic attack — no . ( % )
transient ischemic attack ( % ) type of lacunar syndrome ( % )
transient st elevation
transradial
treated at baseline
treated at baseline  mean ( sd )  mm hg
treated at baseline  mm hg : sbp  mean ( sd )
treated for hypertension  %
treated lesions ‡
treated patients with baseline and $nmbr$ post - baseline ef ﬁ cacy measurement  bp value for treatment group comparison ( proactive intervention vs usual care ) was calculated based on a $nmbr$ - sample t test for continuous variables and chi - square test for categorical variables  cbp values were measured at baseline ( week $nmbr$ )  whereas information on all of the other variables listed was collected during screening . abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .
treated vessel ( s )
treated with atenolol ( n = $nmbr$ )
treated with laba  %
treated with losartan ( n = $nmbr$ )
treatment - by - subgroup interaction
treatment - by - subgroup interaction  p = $nmbr$ . $nmbr$
treatment ( de vs warfarin ) by thrombophilia interaction
treatment after randomization  in the single - dummy phase — days ]
treatment and parameter
treatment arm ( zoledronate ) ( % )
treatment at baseline
treatment at randomisation
treatment before catheterization
treatment before randomization — days
treatment before randomization  %
treatment by subgroup interaction
treatment comparison
treatment comparison ( mg / day ) t
treatment diff . vs tio ( $nmbr$ % ci )
treatment difference % ( $nmbr$ % cl )
treatment duration before randomization — days
treatment duration mean ( sd )
treatment during or after catheterization
treatment effect ( hr )
treatment for latent tuberculosis ^
treatment glargine
treatment group  on - treatment il - $nmbr$ threshold
treatment groups  n ( % )
treatment period index dvt : event
treatment randomization
treatment throughout study
treatment with any blood - pressure -
treatment with sulphonylurea + biguanide  n ( % )
treatment with sulphonylurea + biguanide  n { % )
treatment with sulphonylurea  n ( % )
treatment  n ( % )
treatment   ×   lipid interaction
treatments at randomisation
triacylglycerol  mmol / l  mean ( sd )
triacylglycerol  mmol / le
trial
trial $nmbr$
trial completers
triglyceride ( mg / dl ) $nmbr$
triglyceride level
triglyceride  mg / dl  mean ( sd )
triglycerides — mg / dl ^
triglycerides — mg / dl | |
triglycerides — mmol / l
triglycerides ( mmol / l ) ( median  iqr )
triglycerides ( mmol / l )  mean ( sd )
triglycerides ( sd )  mg / dl
triglycerides > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l )
triglycerides at baseline
triglycerides level  mg / dl
triglycerides mean
triglycerides  median ( iqr )  mg / dl
triglycerides  median ( q $nmbr$ : q $nmbr$ )
triglycerides  median ( qi  q $nmbr$ )  mmol / l
triglycerides  mg / dl  median ( q $nmbr$ : q $nmbr$ )
triglycerides  mmol / l  mean ( sd )
triglycerides  mmol / l ®
triglycerides  * mmol / l
troponin
troponin ( - )
troponin ( + )
troponin negative ( n = $nmbr$ )
troponin positive ( n = $nmbr$ )
trough fev  response ( l ) i
trough fev | response ( l )
trough fev $nmbr$
trough fev $nmbr$   response
trough fvc response ( l )
trough fvc response ( l ) !
trough seated dbp ( mmhg ) a
trough seated hr ( bpm ) a
trough seated sbp ( mmhg ) a
tt
ttf - fv
ttr ( warfarin arm only )
two - dimensional echocardiography
two - sided p - value for hetero - geneity
two lesions
two or more
two or more antihypertensive medications
two or more at baseline
type
type $nmbr$ collagen  mean ( sd )  ng / ml £
type $nmbr$ diabetes — no . ( % )
type $nmbr$ diabetes — no . ( % ) §
type $nmbr$ diabetes — no . { % ) §
type $nmbr$ diabetes meiiitus
type $nmbr$ diabetes mellitus
type $nmbr$ diabetes mellitus ' $nmbr$ '
type $nmbr$ diabetes mellitus  n ( % )
type $nmbr$ diabetes mellitusa
type $nmbr$ diabetes pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )
type $nmbr$ diabetes *
type $nmbr$ diabetes  no . ( % )
type $nmbr$ diabetes . n ( % )
type b $nmbr$ / c lesions  n ( % )
type ia
type ib
type ic
type ii diabetes
type of af
type of af  n ( % )
type of antihypertensive medication use among patients using antihypertensive medications  n ( % )
type of atrial fibrillation
type of atrial fibrillation - n ( % )
type of atrial fibrillation — no . / total no . ( % )
type of atrial fibrillation ( % )
type of atrial fibrillation ( n = $nmbr$ $nmbr$ )
type of atrial fibrillation  n ( % )
type of atrial fibrillation  no . / total no . ( % )
type of basal insulin  n ( % )
type of event :
type of hospital care
type of hospitalization
type of index event — no . ( % )
type of insulin
type of insulin therapy — no . ( % ) $nmbr$
type of intervention
type of lipid - lowering regimen
type of ml  no . ( % )
type of reference treatment strategy
type of surgery cabg
type of surgery cabg only
type of tnf antagonist failure  n ( % ) ' ’
type of tnf antagonist failure  n ( “ / o ) ”
type of tnf failure  n ( % ) b
type / no . of valves repaired / replaced mitral
types of antihypertensive medications at $nmbr$ year   †
types of antihypertensive medications at last visit   §
u . s . black patients
u . s . non - black patients
ua ( n = $nmbr$ )
uacr
uacr — mg / g  median ( iqr )
uacr ( mg / g  median [ iqr ] )
uacr   < $nmbr$   mg / mmol ∗
uacr   ≥ $nmbr$   mg / mmol ∗
uacr *  mg / g ( q $nmbr$  q $nmbr$ )
uacr  median ( iqr )  mg / g
uacr  mg / g  median ( $nmbr$ th − $nmbr$ th percentile )
uacr  mg / g  median ( iqr )
uacr  n ( % ) †
uacr  pg / mg
uas $nmbr$ {
uas $nmbr$
uc
uc ( n   =   $nmbr$ )
uc [ gemini $nmbr$ ] ‘
uc disease duration ( y )
uc disease durslion
uc history
ucl
udy entry
ufh only
ugt induction status : as randomizeda  n ( % )
ugt induction status : per aeda  n ( % )
uistekinumab
ulcer
ulcer  n ( % ) a
ulpasi $nmbr$
umec $nmbr$ . $nmbr$ | ig ( n = $nmbr$ )
umec $nmbr$ . $nmbr$ mcg ( n = $nmbr$ )
umec / vi $nmbr$ . $nmbr$ / $nmbr$
umec / vi $nmbr$ . $nmbr$ / $nmbr$ ( n $nmbr$ $nmbr$ )
umied
unacceptable side effects
unadjusted $nmbr$ - y risk per $nmbr$ population = se ( adjusted rate )
unadjusted hazard ratio ( $nmbr$ % ci )
unadjusted hazard ratio ( $nmbr$ % cl )
unadjusted hr ( $nmbr$ % ci ) for $nmbr$ sd increment
unadjusted hr ( $nmbr$ % ci ) for $nmbr$ standard deviation increment
unadjusted hr ( $nmbr$ % ci ) a
unadjusted model hr  $nmbr$ % ci  p value
unadjusted p value
unadjusteda beta ( se )
unclassified
uncontrolled on basal insulin
uncontrolled on oad ( s )
uncontrolled : acq - $nmbr$ > $nmbr$ . $nmbr$
uncover - $nmbr$
underlying disease
undetermined
undetermined etiology  n ( % )
undeterminedc
undiagnosed diabetes mellitus
undiagnosed diabetes mellitus  n = $nmbr$
unfractionated heparin — no . ( % )
unfractionated heparin ( n = $nmbr$  $nmbr$ )
unfractionated heparin only
unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ )
unfractionated heparin within $nmbr$ hr before randomization — no . / total no . ( % )
unfractionated only
unhappy
unified parkinson disease
united states ( n   = $nmbr$  $nmbr$ )
united states and canada
united states  canada
uniti - $nmbr$
uniti - $nmbr$ and uniti - $nmbr$ im - uniti
univariable
univariable or ( $nmbr$ % ci )  p value *
univariate logistic modela
unknown — no . { % )
unknown ( % )
unknown / missing
unprovoked vte n ( % )
unrelated to effectiveness
unstable
unstable angina ( n = $nmbr$  $nmbr$ )
unstable angina requiring hospitalization
unstable but no rest angina
untreated
untreated at baseline
untreated at baseline  mean ( sd )  mm hg
untreated at baseline  mm hg : sbp  mean ( sd )
upa $nmbr$ mg qd
upadacitinib $nmbr$ mg ( n = l $nmbr$ )
upcr  n ( % )
updrs iii ( motor )
updrs score
updrs total ( ii + iii )
updrs  part ii ( adl )
updrs  part iii ( motor )
uplift ® population
upper abdominal pain
upper gastrointestinal tract
upper limb
upper limbs
upper respiratory tract inflammation
upper tertile : > $nmbr$ . $nmbr$
ups score  mean ( sd )
ure
urgency episodes / $nmbr$ h
urgent peripheral revascularization
urgent revascularisation due to unstable angina
urgent revascularizati on
urgent revascularization because of unstable angina
urgent surgery
urgent vascular hospitalization
urinary acr
urinary acr ( mg / mmol )
urinary albumin - to - creatinine ratio — no . ( % ) §
urinary albumin - to - creatinine ratio §
urinary albumin : creatinine ratio ^
urine acr ( mg / mmol )
urine acr < median
urine acr > = median
urine acr geometric mean ( cv % )  a  b mg / g
urine albumin - to - ereatinine ratio
urine albumin / creatinine ( mg / mmol )
urine albumin / creatinine ratio  mg / mmol
urine p / cr
urine qmax  ml / s
urticaria
us n = $nmbr$
us site
us w = $nmbr$
usa ( n = $nmbr$  $nmbr$ )
usa / canada
use ( % )
use at baseline
use at baseline  n
use of ace inhibitors / arbs  n ( % )
use of anti - hypertensive agents  n ( % ) *
use of antiplatelet agents — no . / total no . ( % )
use of antiplatelet agents  n ( % )
use of aspirin at time of qualifying event ( % )
use of cgm ( yes )
use of cgm interaction test p - value ^ =
use of clopidogrel
use of diuretics  n ( % )
use of h $nmbr$ bloekers  n ( % )
use of high - dose inhaled glucocorticoid — no . { % )
use of ics at baseline  %
use of inhaled glucocorticoids at baseline
use of loop diuretics
use of low - dose aspirin ( < $nmbr$
use of low - dose aspirin ( < $nmbr$ mg daily )
use of medication for pah
use of medication from randomization through $nmbr$ hr — no . / total no . ( % )
use of methotrexate at randomization —
use of oral glucocorticoids
use of pci or thrombolysis within one day of randomization
use of proton inhibitors  n ( % )
use of statin at any follow - up visit ( % )
use of systemic glucocorticoid at random -
use of ticagrelor
use of verapamil or quinidine
used
user
using alendronate at baseline ( % )
using hrt or raloxifene at baseline ( % )
usteki
ustekinu
ustekinumab
ustekinumab ' ’ ( n = $nmbr$ )
ustekinumab $nmbr$ mg ( n = $nmbr$ )
ustekinumab combined
ustekinumab ® ( n = $nmbr$ )
usual care
utis
uveitis
v $nmbr$ ( n = $nmbr$
valdecoxib
valsartan n / n
value for nteraction
values are mean ± sd  median [ quartile range ]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .
values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group . † obesity was defined as body mass index $nmbr$ kg / m $nmbr$ . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criteria $nmbr$ as any $nmbr$ of the following : waist circumference $nmbr$ cm for men or $nmbr$ cm for women  triglycerides $nmbr$ mg / dl  high - density lipoprotein cholesterol $nmbr$ mg / dl for men or $nmbr$ mg / dl for women  mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg  fasting glucose $nmbr$ mg / dl . § by medical history . aliskiren  n $nmbr$  hydrochlorothiazide  n $nmbr$ .
values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index . † other forms of atherosclerosis are peripheral arterial disease  abdom - inal aortic aneurysm  symptomatic carotid artery disease  transient isch - emic attack  and stroke . ‡ family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged $nmbr$ years or female ﬁ rst - degree relative $nmbr$ years . § blood pressure $nmbr$ / $nmbr$ mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .
values were calculated using t tests for continuous variables and chi - square
values were reported for $nmbr$ patients in the spironolactone group and $nmbr$
valve repair / replacement only
valve repair / replacement with or without cabg
valve replacement / repair with or without cabg
valvular disease  mitral
valvular heart disease
valvular heart disease — no . ( % )
valvular heart disease  n ( % )
varespladib
variable ' ! '
variable demographic characteristics
variable_level
variables
variables *
variables .
variables $nmbr$
vascular access site †
vascular accidents  n ( % )
vascular death
vascular disease
vascular disease ( % of group )
vascular risk score — no . { % ) ^
vascular risk score |
vascular risk score *
vasodilator
vasodilator therapy
vasp pri - defined hpr ( % patients )
vdz n = \ $nmbr$
vdz n = $nmbr$
vdz / pbo [ n = $nmbr$ ]
vdz / pla n = $nmbr$
vdz / vdz [ n = $nmbr$ ]
vedolizumab cohort $nmbr$ ( n = $nmbr$ )
vedolizumab n = $nmbr$
vein bypass stented
verapamil ( n  % )
verapamil sr ( no . = $nmbr$ )
verifynow pru - defined hpr ( % patients )
versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ - $nmbr$ / $nmbr$ pg
versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg
vertebral fracture and / or t score - $nmbr$ . $nmbr$
vertebral fracture and / or t score s - $nmbr$ . $nmbr$
vertebral fractures at baseline
very elderly patients ( n - $nmbr$ )
very g ood / ex cellent
very good or excellent
very high
very high ( >   $nmbr$ xuln ) n   =   $nmbr$
very high vs . normal
very high vs . normalb
very severe ( itt ) ( n = $nmbr$ )
very severe copd
very severe  gold $nmbr$
vhd
vhd event rate / year ( n )
vi - $nmbr$ % ( - $nmbr$ %  $nmbr$ % )
vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )
vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % )
vi $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )
vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % )
vi $nmbr$   µ g
viidagliptin $nmbr$ mg daily + glimepiride
vildagliptin + metformin ( vldm )
vildagliptin $nmbr$ mg daily
vildagliptin $nmbr$ mg daily + glimepiride
visit
visit $nmbr$ blood pressures :
visit $nmbr$ dbp  mm hg
visit $nmbr$ sbp  mm hg
vital signs  mean ( sd )
vitamin c
vitamin d §
vitamin k antagonist experienced  n ( % )
vitamin k antagonist experiencedk ( n = $nmbr$ $nmbr$ )
vitamin k antagonist naive
vitamins
vka ( n   = $nmbr$ )
vka at randomization
vka experienced
vka naive
vka naive  n ( % )
vka naxve
vldl - c
vldm n = $nmbr$
voided volume  ml
voiding subscore
volume change  mm ^
volume depletion - related aes
volumetric bmd by qct
voluntary
vonoprazan $nmbr$ mg n = $nmbr$
vorapaxar
vorapaxar ( n = $nmbr$ )
vorapaxar no . ( $nmbr$ - y km % )
vorapaxar placebo
vorapaxar ( n = $nmbr$ )  n ( % )
vs . placebo
vs . warfarin
vte / vte - related deathsa  n / n ( % )
vte / vte - related deathsb  n / n ( % )
w europe
w hite
wafarin
wafarin event incidence / n
waist circumference — cmj
waist circumference ( cm ) : mean ± sd
waist circumference women : > $nmbr$ in ( $nmbr$ cm ) men : > $nmbr$ in ( $nmbr$ cm ) tc $nmbr$ c $nmbr$ mg / dl
waist circumference  cm  mean ( sd )
waist circumference .
waist / hip < median
waist : hip ratio
waisvhip > = median
walk for exercise
walk for exercise ( % )
walking
war
warf
warfarin % ( n / n )
warfarin ( % )
warfarin ( n - $nmbr$  $nmbr$ )
warfarin ( n = $nmbr$ )  n ( % / y )
warfarin ( s $nmbr$ % cl )
warfarin events / n ( % / y )
warfarin n = $nmbr$
warfarin n = $nmbr$ n / n ( % )
warfarin n / n  rate ( % )
we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' $nmbr$ % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .
we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * $nmbr$ % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .
week
week - $nmbr$ changea
week $nmbr$ — mg / liter
week $nmbr$ czp $nmbr$ mg q $nmbr$ w
week $nmbr$ czp $nmbr$ mg q $nmbr$ w ( n = $nmbr$ )
week $nmbr$ czp dose combined
week $nmbr$ czp dose combined ( n   =   $nmbr$ )
week $nmbr$ mayo endoscopy subscorea
week $nmbr$ mean ± sem
week $nmbr$ - baseline
week $nmbr$ — mg / liter ^
week $nmbr$ mean + sem
week $nmbr$ outcome
week $nmbr$ outcomes
week $nmbr$ overall population
week $nmbr$ responders  ( n = $nmbr$ )
week $nmbr$ ( before ee )
week $nmbr$ crp
week $nmbr$ ( non - ee responders )
week $nmbr$ mean ( sd )
week $nmbr$ % of patients
week $nmbr$ ( mmol / l )
week $nmbr$ ertugliflozin $nmbr$ mg vs placebo
week $nmbr$ ertugliflozin $nmbr$   mg vs . placebo
week $nmbr$ ertugliflozin $nmbr$ mg vs . placebo
week $nmbr$  % ( n )
week $nmbr$  % ( n ) #
week $nmbr$  % ( n ) # or for cana vs pbo ( $nmbr$ % ci ) | |
week $nmbr$  % ( n ) * *
week $nmbr$  % ( n ) ^
week $nmbr$  % ( n ) | | or for cana vs pbo ( $nmbr$ % ci ) §
week $nmbr$  % ( n ) §
week $nmbr$  % ( n ) $nmbr$
week $nmbr$  % ( n ) $nmbr$ or for cana vs pbo ( $nmbr$ % ci ) | |
week $nmbr$  % ( n ) j
week $nmbr$ *
week $nmbr$ * ’ ’
week $nmbr$ / et
week $nmbr$ a
week and
week o ( baseline ) mean 士 sd
week   $nmbr$
weekly iss {
weekly iss $nmbr$
weekly number of hives score {
weekly number of hives score $nmbr$
weekly size of largest hives score {
weeko mean + sem
weeks
weeks_measured
weight — kg cardiovascular history — no . ( % )
weight # $nmbr$ kg
weight ( kg ) ( mean ± sd )
weight ( kg ) bmi ( kg / m $nmbr$ )
weight ( kg ) *
weight ( kg )  mean ( s . e . )
weight ( kg )  mean   ±   sd
weight ( kg )  median ( m / n  max )
weight ( kg ) 十
weight ( kg ) a
weight ( kg }  median ( min  max }
weight ( median [ iqr ] )  kg
weight [ kg ]
weight < $nmbr$ kg  n ( % )
weight $nmbr$ +
weight $nmbr$ - $nmbr$
weight at baseline
weight at randomization ( kg )
weight category
weight group  no . ( % )
weight in kg ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] )
weight of < $nmbr$ kg  n ( % )
weight  kg ( mean ± s . d . )
weight  kg ( mean $nmbr$ sd )
weight  kg blood pressure  mm hg
weight  kg duration of pah  n ( % )
weight  kg mean ( sd )
weight  kg  mean ± sd
weight  kg $nmbr$
weight  mean ( sd ) ( kg )
weight  mean ( sd ) lbs .
weight  mean ( sd )  kgb
weight  mean ± sd kg
weight ^
weight < $nmbr$
west europe
western
western europe ( n   = $nmbr$  $nmbr$ )
western europe plus other
western europe  australia  new zealand
western europe  australia  new zealand  and middle east
western europe  australia  new zealand  middle eai
western europe  australia  new zealand  middle east
while
white ( n   = $nmbr$  $nmbr$ )
white ( n = $nmbr$  $nmbr$ )
white blood cell count  cellsx $nmbr$
white hispanic
white hispanic - n ( % )
white mtx ( n )
white non - hispanic
white non - hispanic - n ( % )
white or caucasian  n ( % )
white race — no . ( % ) y left ventricular ejection fraction — %
white race — no . { % ) ' i '
white race — no . { % ) - i -
white race — no . { % ) $
white race — no . { % ) t
white race ( n = $nmbr$ $nmbr$ )
white tcz + mtx ( n )
white  n ( % ) medical history  n ( % )
white  n / n ( % )
white  no . ( % )
white  non - hispanic
whiteb
who fc ii symptoms at baseline $nmbr$
who fc ii symptoms at baselinef
who functional class
whole cohort
with any stent
with aspirin ( n = $nmbr$  $nmbr$ )
with baseline crp level of > $nmbr$ mg / liter
with baseline vertebral fracture
with cerebrovascular disease
with ckd ( $nmbr$ )
with ckd intensive ( n = $nmbr$ )
with ckd standard ( n = $nmbr$ )
with concomitant ics
with des
with dm
with dm ( n proactive intervention ( n = $nmbr$ a )
with dyspnoea
with events ( % )
with higher classes indicating greater limitations on physical activity owing to
with highest bwa
with highest hba $nmbr$ cc
with ics  n ( % )
with long - acting j $nmbr$ - agonists
with lowest bwb
with lowest hba $nmbr$ cd
with metabolic syndrome
with mets
with prior mi / stroke ( n = $nmbr$ )
with rehospitalization  urgent coronary revascularization
with tamsulosin
with tiotropium
with treatment
withdrawals  n / n ( % )
withdrew consent
within $nmbr$ h after first procedure
without aspirin ( n = $nmbr$  $nmbr$ )
without baseline vertebral fracture
without cerebrovascular disease
without ckd ( $nmbr$ )
without concomitant ics
without dm
without dvt dvt alone
without dyspnoea
without hx of hf
without hypertension at baseline to hypertension
without metabolic syndrome
without mets
without psoriasis ( n = $nmbr$ )
without tamsulosin
wml load at follow - up mri stratified by baseline severity of wml load
womac function score
womac pain score
womac stiffness score
women ( % )
women ( n ( % ) )
women ( n = $nmbr$ ) events
women ethnic origin
women t
women taking estrogen
women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l )
women  qva $nmbr$ - sfc
womens
worldwide black patients
worldwide non - black patients
wrist
wt  second  median
x cr $nmbr$ . $nmbr$ x age
x ? = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$
x ? = $nmbr$ - l  p = $nmbr$ - $nmbr$
x ? = l - $nmbr$  p = $nmbr$ - $nmbr$
x $nmbr$  n ( % )
x $nmbr$ = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$
x $nmbr$ = $nmbr$ - l  p = $nmbr$ - $nmbr$
x $nmbr$ = $nmbr$  p = $nmbr$ - $nmbr$
x $nmbr$ years
xanthine
xanthines  b   n ( % )
xanthinesg
xho  p = o - $nmbr$
xi = ° - ° $nmbr$
xi = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$
xi = $nmbr$ . $nmbr$
xi = $nmbr$ - $nmbr$
xi = $nmbr$
xi = $nmbr$ - $nmbr$  p = $nmbr$ - l
xi = $nmbr$ - $nmbr$  p = o - l
xi = $nmbr$ - $nmbr$  p = $nmbr$
xi = $nmbr$ - l  p = $nmbr$ - $nmbr$
xi = l ’ $nmbr$  p = $nmbr$ - $nmbr$
xi = o - $nmbr$  p = o - $nmbr$
xi = oo  p = o - $nmbr$
yaa
year - $nmbr$
year from randomization
year of publication of primary results
year  n ( % )
yearl
years ( mean ± sd )
years ( sd )
years duration oa
years male gender  n ( % )
years modified hoehn and yahr stage  n ( % )
years of education *
years of education  mean ( sd )
years of follow - up  mean ( sd ) [ maximum ]
years since diagnosis
years since diagnosis of type $nmbr$ diabetes  n ( % )
years since diagnosis  mean
years since last gout flare
years since mi ( median
years since pd diagnosis  mean ± sd
years since symptom onset
years with gout
years with gout  mean ± sd
years with gouty arthritis
years )
years  n ( % ) smoking  n ( % ) current
yes ( % ) weight [ kg ] ( interaction : p = $nmbr$ . $nmbr$ )
yes ( any )
yes ( n  % )
yes vs . no
yes  $nmbr$ $nmbr$ y
yes  o $nmbr$ cm
yes  r $nmbr$ y
yes  z $nmbr$ cm
younger subjects ( aged < $nmbr$ years )
zoledronic acid
zoledronic acid ( n = $nmbr$ )
zoledronic acid arm
zt = $nmbr$
placebo - ezetimibe $nmbr$ / simvastatin $nmbr$ - fenofibrate $nmbr$ - ezetimibe $nmbr$ / simvastatin $nmbr$ / ezetimibe $nmbr$
l - dopa / carbidopa - l - dopa / carbidopa / entacapone
arb - arb / ccb
other - candesartan
benazepril / hydrochlorothiazide - benazepril / amlodipine
atenolol - losartan
amlodipine - amlodipine / valsartan
mycophenolate mofetil - cyclophosphamide
atorvastatin - pravastatin
placebo - abatacept $nmbr$ / $nmbr$ - abatacept $nmbr$ / $nmbr$
bivalirudin - heparin plus gpi
olmesartan / ccb - olmesartan / diuretic
comparator - linagliptin
placebo - linagliptin
placebo - dexlansoprazole
placebo - carisbamate $nmbr$ mg - carisbamate $nmbr$ mg
ezetimibe / simvastatin - double dose statin - rosuvastatin
stent / abciximab - stent / placebo
insulin lispro mix $nmbr$ / lispro mix $nmbr$ - insulin glargine / insulin lispro
ideglira - ideg - lira
placebo - ideglira
ideglira - ideg
budesonide - budesonide / formoterol
placebo - vonoprazan $nmbr$ - vonoprazan $nmbr$
fluticasone - fluticasone / salmeterol
febuxostat - febuxostat / lesinurad $nmbr$ - febuxostat / lesinurad $nmbr$
telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide
chlorthalidone - amlodipine - lisinopril
placebo - famotidine $nmbr$ - famotidine $nmbr$
air insulin - insulin glargine - air insulin / insulin glargine
olmesartan $nmbr$ - olmesartan $nmbr$ / hydrochlorothiazide $nmbr$ . $nmbr$
sdc $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml
hf symptomatic improvement
hf symptom unchanged
hf symptom worsened
cv death / hf hospitalization
vertebral fracture
nonvertebral fracture
mortality  shock or congestive heart failure within $nmbr$ days
main accord endpoint
fatal / nonfatal mi ( excluding silent mi )
cardiovascular death or nonfatal mi ( excluding silent mi )
cardiovascular death  nonfatal mi ( excluding silent mi )  or stroke
combined efficacy and safety endpoint
mean change from baseline bp at week $nmbr$
median change in atheroma volume  %
nonvertebral fractures
clinical vertebral fractures
complete clinical response at week $nmbr$
death or mi at $nmbr$ days
$nmbr$ - year mortality
net adverse clinical events at day $nmbr$
adas - cog
cdr - sob
adcs - adl
npi
proportion of > = $nmbr$ % responder rates
ldl - c concentration
non - hdlc concentration
hdlc - concentration
apolipoprotein a
apolipoprotein b
complete ulcer healing at week $nmbr$
major amputations at week $nmbr$
mean percentage of nights without heartburn
new or worsening vertebral fracture at $nmbr$ months
new vertebral fracture at $nmbr$ months
seizure reduction from baseline
apolipoprotein a - i
hba $nmbr$ c at week $nmbr$
primary endpoint at $nmbr$ days
primary endpoint at $nmbr$ months
dual i extension - end of trial hba $nmbr$ c
dual iv - end of trial hba $nmbr$ c
dual ii - end of trial hba $nmbr$ c
proportion of days without heartburn at week $nmbr$  percentage
first severe asthma exacerbation
change in fev $nmbr$ at week $nmbr$
serum ua < $nmbr$ mg / dl by month $nmbr$
control of sitting bp at week $nmbr$
rate of atrial fibrillation
combined $nmbr$ - year cvd
percentage of days without heartburn
bp goal at week $nmbr$
previous use of digoxin
cardiothoracic ratio
retinal severity change
serum uric acid  mg / dl
concomitant statin use
study protocol
concomitant mao - b inhibitor use
ckd at baseline
cvd  ckd
acei use
beta blocker use
nitrate use
sirolimus eluting stent
vessel disease
kilip class
time to randomisation from symptom onset ( h )
time from symptoms onset to $nmbr$ st balloon inflation ( h )
time from randomisation to $nmbr$ st balloon inflation ( h )
first medical contact
stent placement
previous mi and t $nmbr$ dm
baseline peripheral artery disease
fibrinolytic agent given
shock risk indext
aetiology
baseline $nmbr$ - min walk distance m
baseline who functional class
age at baseline years
diabetes and untreated hypertension
clinically evident vascular disease
ethnicity  location
alcohol intake  drinks / week
history of statin use
low - density lipoprotein  mg / dl
high - density lipoprotein  mg / dl
baseline bmd t score at femoral neck
prior treatment status
inclusion diagnosis
modified braunwald class
high - risk criterion
cadillac score
arterial access site
vessels with stenosis > $nmbr$ %
stent type implanted
heparin pre - randomization
p $nmbr$ y $nmbr$ inhibitor loading dos
p $nmbr$ y $nmbr$ inhibitor maintenance
primary management strategy
clinical dementia rating score
cholinesterase inhibitor use
apolipoprotein e carrier
prior exposure to levetiracetam
prior exposure to carbamazepine
prior exposure to topiramate
prior exposure to lamotrigine
thienopyridine use
intent to use gp iib / iiia
intent to use dti
troponin or ckmb value
timi score
investigator - reported hypoglycaemia
nocturnal heartburn severity
concurrent medication
antiepileptic drug type at baseline
cardiogenic shock
type of mi
target vessel diameter
onset of chest pain
received pci
acei or arb pre - randomisation
acei or arb post - randomisation
bb after randomisation
acei / arb and bb after randomisation
pulsed blood pressure
admission crcl
admission k  mmol / l
randomisation
nerd grade
asthma control
eosinophil count ( cells / microlitre )
baseline uric acid
disease stage
chronic heart failure class ii - iii
prior mi / stroke
cardiovascular status
egfr  ml / min ( mdrd )
diabetic retinopathy at baseline
type of reflux disease
number of symptom days per week
cardiac surgery type
baseline egfr
hiatus hernia
h . pylori infection
hypertension severity
> $nmbr$ or incident vitrectomy or photocoagulation
stage $nmbr$ ( cockcroft - gault )
stage $nmbr$ ( four - variable modification of diet in kidney disease )
western eu  australia  new zealand
eastern eu
< - $nmbr$ . $nmbr$
> - $nmbr$ . $nmbr$
yes  yes
yes  no
no  yes
no  no
< = $nmbr$
ii - iii
pci - hospital
non - pci hospital / ambulance
non - european
< $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$
ipah / fpah / drug and toxin
repaired congenital shunt
black  worldwide
non - black  worldwide
black  us
non - black  us
past or nonsmoker
> - $nmbr$ . $nmbr$ to < - $nmbr$ . $nmbr$
na ï ve
recent
inadequate
non - q - wave ml
no rest angina
rest angina
no antianginal drug
$nmbr$ antianginal drug
$nmbr$ antianginal drugs
intermediate risk
single vessel disease
at least one drug - eluting stent
all bare metal stents
prasugrel or ticagrelor
non - lad
pci procedure
non pci procedure
non europe
< mild
mild - < moderate
moderate - < severe
severe - very severe
enzyme inducing
non - enzyme inducing
< = $nmbr$ . $nmbr$ mm
> = $nmbr$ h
< = $nmbr$ ml / min
pre - hospital
in - hospital
< = $nmbr$ %
russia / ukraine / belarus
poor  tried previous glucocorticoid / non - laba
poor  tried previous glucocorticoid + laba
good  tried previous glucocorticoid + laba
good  tried previous glucocorticoid
> = $nmbr$ mg / dl
advanced
< = $nmbr$ . $nmbr$ %
established disease
risk factors only
pre - mixed insulin
yes  proliferative
yes  non - proliferative
yes  unknown
erosive reflux disease
gastrooesophageal reflux disease
> $nmbr$  < = $nmbr$
non - cabg or combined
tx
tx $nmbr$
amlodipione - chlorthalidone
lisinopril - chlorthalidone
famotidine $nmbr$ - famotidine $nmbr$
placebo - famotidine $nmbr$
air insulin - air insulin / insulin glargine
insulin glargine - air insulin / insulin glargine
placebo - vonoprazan $nmbr$
febuxostat - febuxostat / lesinurad $nmbr$
or_value
or $nmbr$
or $nmbr$ _value
